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Abstract 
Randomised controlled trials are considered the gold standard study design, as random 
treatment assignment provides balance in prognosis between treatment arms and 
protects against selection bias. When trials are subject to departures from randomised 
treatment, however, simple but naïve statistical methods that purport to estimate 
treatment efficacy, such as per protocol or as treated analyses, fail to respect this 
randomisation balance and typically introduce selection bias. This bias occurs because 
departure from randomised treatment is often clinically indicated, resulting in systematic 
differences between patients who do and do not adhere to their assigned intervention.  
There exist more appropriate statistical methods to adjust for departure from 
randomised treatment but, as demonstrated by a review of published trials, these are 
rarely employed, primarily due to their complexity and unfamiliarity. The focus of this 
research has been to explore, explain, demonstrate and compare the use of causal 
methodologies in the analysis of trials, in order to increase the accessibility and 
comprehensibility by non-specialist analysts of the available, but somewhat technical, 
statistical methods to adjust for treatment deviations. 
An overview of such methods is presented, intended as an aid to researchers new to the 
field of causal inference, with an emphasis on practical considerations necessary to 
ensure appropriate implementation of techniques, and complemented by a number of 
guidance tools summarising the necessary clinical and statistical considerations when 
carrying out such analyses. Practical demonstrations of causal analysis techniques are 
then presented, with existing methods extended and adapted to allow for complexities 
arising from the trial scenarios.   
A particular application from epilepsy demonstrates the impact of various statistical 
factors when adjusting for skewed time-varying confounders and different reasons for 
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treatment changes on a complicated time to event outcome, including choice of model 
(pooled logistic regression versus Cox models for inverse probability of censoring 
weighting methods, compared with a rank-preserving structural failure time model), 
time interval (for creating panel data for time-varying confounders and outcome), 
confidence interval estimation method (standard versus bootstrapped) and the 
considerations regarding use of spline variables to estimate underlying risk in pooled 
logistic regression.  
In this example, the structural failure time model is severely limited by its restriction on 
the types of treatment changes that can be adjusted for; as such, the majority of 
treatment changes are necessarily censored, introducing bias similar to that in a per 
protocol analysis. With inverse probability weighting adjustment, as more treatment 
changes and confounders are accounted for, treatment effects are observed to move 
further away from the null. Generally, Cox models seemed to be more susceptible to 
changes in modelling factors (confidence interval estimation, time interval and 
confounder adjustment) and displayed greater fluctuations in treatment effect than 
corresponding pooled logistic regression models. This apparent greater stability of 
logistic regression, even when subject to severe overfitting, represents a major 
advantage over Cox modelling in this context, countering the inherent complications 
relating to the fitting of spline variables. 
This novel application of complex methods in a complicated trial scenario provides a 
useful example for discussion of typical analysis issues and limitations, as it addresses 
challenges that are likely to be common in trials featuring problems with nonadherence. 
Recommendations are provided for analysts when considering which of these analysis 
methods should be applied in a given trial setting.  
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1. Introduction 
The focus of this thesis is an investigation into the issue of nonadherence to prescribed 
intervention in randomised trials, and a demonstration and comparison of statistical 
methods that may be used to appropriately adjust for such nonadherence. In particular, 
the following research questions will be explored: 
 What is the extent, nature, impact of and potential solutions for nonadherence 
in general practice and in randomised controlled trials? 
 What methods are available to adjust for such nonadherence in randomised 
trials and are these methods applied? 
 What are the assumptions made, limitations of and conclusions drawn from 
application of these methods in trials demonstrating various deviations from the 
treatment protocol? 
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Nonadherence to medical advice has been recognised as a widespread problem since 
the 1970s but its impact on clinical trial analyses and results is less well recognised. 
Failure to appropriately allow for changes to randomised treatment in trials may lead to 
biased results and misleading conclusions. 
Analysis methods must reflect the clinical research question of interest. When 
estimating the effectiveness of treatment policy (in other words, the effect of being 
assigned treatment) treatment changes can be ignored in the analysis, under the 
assumption that such treatment changes mirror what will happen in practice outside of 
the trial setting. Ignoring such treatment changes will, however, distort estimation of the 
efficacy (or biological effect) of treatment (in other words, the effect of treatment 
received).  
Randomised controlled trials (RCTs) are considered the gold standard study design, as 
random treatment assignment provides balance between treatment arms with respect to 
measured and unmeasured covariates that may influence prognosis. Simple but naïve 
statistical methods that purport to estimate treatment efficacy, such as ‘per protocol’ 
(PP) or ‘as treated’ (AT) approaches, fail to respect this balance produced by 
randomisation and typically lead to selection bias. This occurs because departure from 
prescribed or randomised treatment is often clinically indicated, resulting in systematic 
differences between those subgroups of patients who do and do not adhere to their 
assigned intervention.  
There exist more appropriate methods to adjust for departure from randomised 
treatment but these are rarely employed by trial statisticians, in part due to the fact that 
they are not widely known. This thesis will investigate their use in a number of 
expository trials.  
   
   
21 
 
In Chapter 2, the problem of nonadherence in general medical practice is described, 
followed by the implications of nonadherence for the design, analysis and interpretation 
of RCTs in Chapter 3. 
In Chapter 4, a number of expository RCTs are described in terms of the form and 
extent of nonadherence to randomised treatment that occurred and the resulting impact 
on trial analysis. Some of these trials will be used to illustrate the application of 
particular statistical methods to adjust for such nonadherence in this and subsequent 
chapters. 
In Chapter 5, an overview is provided of the statistical methods that may be used to 
adjust for nonadherence when analysing RCT data. The issue of confounding and 
selection bias, introduced with use of naïve but common methods of analysis such as 
PP or AT analyses, is discussed. An overview of causal methods is provided, 
introducing the concept of potential outcomes, and two methods appropriate for 
analysis of survival data (the rank preserving structural failure time model (RPSFTM) 
and inverse probability of censoring weights (IPCW)) are described in detail. In the 
spirit of the aims of the funding body (NIHR) supporting this studentship, this 
overview of statistical methods is provided as an aid to researchers who are new to the 
field of causal inference, and has thus been presented with an emphasis on practical 
considerations necessary to ensure appropriate implementation of techniques, with a 
particular focus on interpretation of methods, rather than technical detail. 
In Chapter 6, a review of recently published RCTs is presented, summarising the degree 
of nonadherence reported in RCTs and the extent to which trialists attempt to adjust 
for this nonadherence in their analysis.  
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In line with the remit of this PhD, Chapter 7 provides a clear description of the 
necessary practical and statistical considerations that are involved when implementing 
causal methodology, in order to clarify the process and enable other non-specialists to 
more easily carry out their own causal research. This chapter presents recommendations 
and guidelines to trial analysts in order to simplify and facilitate wider use of available 
causal estimation techniques, thus addressing potential barriers to the wider use of such 
methods by the trial community. In particular, a number of pictograms are provided to 
clarify the appropriate methods to use and statistical issues that must be considered, 
according to the particular trial scenario. 
The next three chapters demonstrate how to translate a clinical question of interest into 
an appropriate causal analysis procedure, particularly for trials with survival outcomes 
(which typically feature deviations from treatment protocol). These practical 
applications demonstrate how clinical considerations and data constraints must 
appropriately inform the statistical choices, not just as part of the modelling exercise but 
also in preparation of data. These issues are demonstrated in trials of contrasting 
complexity featuring different compliance issues.  
In Chapter 8, the RPSFTM is used to adjust for departure from randomised treatment 
in three trials (the honey trial, SANAD arm A and SANAD arm B); the applicability, 
appropriateness and limitations of applying this model are discussed for each trial 
setting. 
In Chapter 9, the IPCW model is demonstrated in the most complex of these trial 
settings (SANAD arm B). The IPCW methodology relies on the assumption of no 
unmeasured confounders (NUC), necessitating a variable selection process to determine 
which of the many measured covariates should be adjusted for in this model. 
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Considerations for this selection process include choice of threshold for inclusion of 
covariates, forward versus backward selection procedures and reliability of selection.  
The work in these chapters aims to investigate the impact of various statistical factors 
on treatment effect estimates when adjusting for treatment changes, including choice of 
model (survival versus pooled logistic regression (PLR) for IPCW, and IPCW versus 
RPSFTM), time interval (for defining time-varying covariates and outcome variables: 
monthly, fortnightly or weekly intervals), confidence interval (CI) estimation method 
(standard versus bootstrapped CIs), adjustment for time-varying confounding variables 
(seizure count, AE count and dose) and reason for treatment changes (to allow for the 
competing reasons of inadequate seizure control, unacceptable adverse events and 
personal choice). 
In Chapter 10, the IPCW and RPSFTM are compared in the context of the SANAD 
arm B, using the standard set of covariates determined by investigations described in 
Chapter 9, highlighting the challenges and limitations associated with each method. 
Chapter 11 concludes with a summary of the main findings of the thesis, ideas for 
further development of methods and recommendations for trialists and statisticians 
when analysing and reporting trial nonadherence. 
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2. Nonadherence in general 
clinical practice  
2.1. Introduction 
The aim of this thesis chapter is to describe the degree to which nonadherence is 
present and its impact in general medical practice. This will provide an important 
grounding for the purposes of this thesis, given that it is necessary to understand the 
issues relating to nonadherence in the context of routine healthcare before moving on 
to considering its impact in clinical trials. This chapter therefore summarises a review of 
the clinical research literature on adherence to prescribed intervention, including a 
description of the extent, nature and causes of nonadherence to prescribed treatment in 
general practice. 
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2.2. History of compliance research  
It has long been recognised that patients will often fail to follow medical advice, with 
the earliest record of nonadherence dating back to Hippocrates in 400 BC who is 
believed to have advised “keep watch also on the faults of the patients, which often 
make them lie about the taking of things prescribed”. The first record in modern 
medicine was by Robert Koch in 1882, who complained that non-adherent patients 
were ‘vicious consumptives, careless and/or irresponsible’ (1). 
Research into the area of nonadherence began in the early 1970s when, in 1972, David 
Sackett realised that poor response to treatment in hypertensive patients was likely to be 
due to non-compliance. The McMaster Workshop/Symposium on compliance with 
therapeutic regimens was held in 1974, and ‘patient compliance’ was included as an 
official Medical Subject Heading in the US National Library of Medicine in 1975. 
Sackett and Haynes’ landmark book “Compliance with therapeutic regimens’ was 
published in 1976 (2), providing the first, and most commonly cited, definition of 
medical compliance: “the extent to which a patient’s behaviours (in terms of taking 
medication, following diets, or executing lifestyle changes) coincide with health care 
providers’ recommendations for health and medical advice” (3). 
Over the next twenty years, more than 10,000 research papers were published 
investigating the issue of nonadherence (4). This extensive research has demonstrated 
that poor compliance with recommended medical intervention is a common problem, 
widespread across all areas of medicine, irrespective of disease type or severity (5, 6). 
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2.3. Types of nonadherence  
Specific manifestations of nonadherence vary according to the type and duration of 
prescribed intervention or medical advice. 
Adherence to prescribed drug treatment (referred to in this thesis as ‘medication 
adherence’) may be categorised into three phases relating to the start, execution and end 
of the treatment period, defined respectively by Vrijens (3) as initiation, implementation 
and persistence. Typical patterns of medication nonadherence include taking too much 
or too little (even none) of the prescribed course of medication, or taking medication at 
different times or intervals, or under contraindicated conditions, to those directed (7).  
Failing to initiate therapy (or ‘primary non-compliance’) occurs, for example, when 
patients receive a prescription but fail to have it made up at a pharmacy. During the 
implementation period, patients may not follow the correct treatment schedule by 
taking treatment at incorrect doses, times or intervals; the most common form of such 
nonadherence is delaying or omitting doses, referred to as ‘partial nonadherence’ (4, 8). 
Patients may also repeatedly stop and restart treatment, taking ‘drug holidays’ (stopping 
treatment for at least three days before restarting) or may improve compliance around 
the time of follow up appointments (known as ‘white-coat compliance’) (9). Premature 
cessation of prescribed treatment occurs, for example, when patients fail to obtain 
repeat prescriptions or simply decide to stop taking their treatment. 
Nonadherence may also result when patients endeavour to seek out, receive and 
persevere with other forms of treatment, especially those involving lengthy and complex 
processes. General forms of nonadherence to medical intervention carrying 
consequences from a population-wide, as well as a personal, perspective include delay in 
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seeking appropriate health care, refusing to participate in screening programmes and 
failure to attend medical follow up appointments (4, 9). 
2.4. Prevalence 
Compliance is typically higher with curative or short-term symptom-relieving, rather 
than preventative, treatments (10). As such, nonadherence to prescribed medication 
tends to be a greater problem with chronic rather than acute diseases, especially when 
the disease is asymptomatic or when nonadherence seems to present no obvious, 
immediate or drastic consequences. The likelihood of nonadherence in chronic 
conditions is also affected by the long term nature of treatment, along with the need for 
continual monitoring or follow up, all of which can present challenges to adherence. 
Haynes (11) gives the example of a hypertensive patient who must adhere not only to 
long-term treatment regimens but also to advice on lifestyle factors (weight, diet, 
exercise, stress) as well as attending numerous investigative and monitoring 
appointments, all potentially for the rest of their lives. Haynes (6) estimates that up to 
half of patients drop out of medical care completely within the first year of starting a 
treatment regime for chronic conditions, and of those who persist with treatment, one 
third do not take sufficient medication to achieve therapeutic benefit. 
As such, estimated adherence rates with long-term interventions for chronic diseases are 
typically lower (40-50%) than for acute illness or short-term interventions (70-80%) 
(12). Even lower compliance is observed for behavioural or lifestyle prescriptions (20-
30%), and only 10% of patients are believed to comply with advice on smoking or 
weight loss in the long term. Although approximately half of patients with chronic 
disease are believed to demonstrate some form of nonadherence, this estimate varies 
more widely in certain disease states; for example, non-compliance is typically low with 
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prescriptions of oral contraceptives (8%) but may be up to 70% for long term treatment 
of arthritis (6). 
In the past 60 years, disease burden has shifted from acute to chronic disease as modern 
medicine has advanced and life expectancy in developed countries has increased. 
Noncommunicable diseases, mental health disorders, HIV/AIDS and tuberculosis 
made up more than half of all global illness in 2001 and are expected to exceed two 
thirds of all illness by 2020 (5). This shift in disease profiles, along with the high rates of 
nonadherence associated with chronic disease, has led to increasingly significant 
worldwide consequences of nonadherence, both clinical and economic; the impact of 
these consequences has been recognised for decades, with non-compliance having been 
designated “America’s other drug problem” (13).  
2.5. Consequences  
 “Drugs don’t work in patients who don’t take them.”(14) 
In chronic conditions (such as diabetes, AIDS and asthma), patient’s disease may 
worsen as a direct consequence of inadequate compliance, with clinical consequences in 
terms of both decreased efficacy and increased toxicity. Medication nonadherence may 
result in more extreme relapses than when treatment is taken as recommended, and may 
decrease patients’ chances of responding to treatment in the long term. Patients may 
also risk adverse effects, rebound or recurrent first-dose effects (for example, when 
therapy is restarted after a drug holiday), accidents (for example, if ignoring advice 
regarding lifestyle changes necessary when taking medication) and treatment 
dependence (5, 15). 
Further repercussions on patient health may occur if undisclosed non-compliance leads 
physicians to make inappropriate decisions regarding treatment (16).  For example, 
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white-coat compliance may cause clinical confusion, as short-term responses to 
treatment (for example, blood pressure) measured at clinic visits may be normal, 
reflecting the patient’s improved compliance to treatment prior to appointments, but 
longer term outcomes may be poor due to general nonadherence otherwise (17). If 
clinicians are unaware of patients’ non-compliance, they may deem it necessary to 
(inappropriately) prescribe higher doses or more invasive or stronger, more toxic 
medication (18).  
Nonadherence in infectious disease carries both direct and indirect consequences. For 
example, underdosing of anti-infective drugs (caused by delayed or omitted doses, 
premature discontinuation of treatment or drug holidays in particular) can lead, not only 
to poor outcome on the part of individuals involved, but also to consequences affecting 
the wider population, such as drug-resistance caused by excessive microorganism 
replication in the presence of inadequate or intermittent doses (19, 20). 
Nonadherence to appropriate medication prescription impacts not only the health of 
individual patients but also the health care system and society as a whole (21). 
Economic consequences result not only because of wasted medication but also 
because of increased health care demands to deal with subsequent unnecessary health 
deterioration (21), manifested as disease exacerbation, crisis or relapse (5). The cost to 
the NHS of unused medication has been estimated at £100 million per year (21), while 
the overall cost of medication nonadherence in US is estimated at $100 billion per year 
(4). The burden on health care systems increases as a result of more frequent hospital 
admissions, increased length of hospital stay and increased expenditure on health care. 
One tenth of US hospital admissions are reported to be due to inappropriate use of 
medication (while between one and two thirds of all medication-related admissions are 
caused by poor medication adherence (14)), and nearly one quarter of admissions to 
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nursing homes are said to be caused by patients’ inability to manage their own treatment 
(4).  
The clinical and economic consequences of nonadherence vary according to the severity 
of the patient’s condition and their comorbidities. Failing to correctly follow treatment 
for a life-threatening disease, for example, incurs greater costs than nonadherence to 
treatment for a mild condition (22). Indirect costs result from patients’ reduced quality 
of life (5) and loss of productivity (18). Additional costs may result if apparent poor 
response to treatment (caused by undisclosed non-compliance) causes the clinician to 
prescribe an alternative more costly or complex treatment (18). 
2.6. Measurement of adherence  
Measurement of patient adherence has occurred since the time of Hippocrates, who 
noted whether or not patients had taken various prescribed potions when recording 
their effectiveness. Numerous direct and indirect adherence measurement methods 
exist, each featuring their own particular advantages and disadvantages.  
Direct measurement methods generally provide more accurate compliance information 
than indirect methods but they suffer from a number of disadvantages which preclude 
their use in long term compliance assessment, most notably being labour intensive or 
invasive. Although theoretically the most accurate measurement technique available, 
direct observation of therapy (observing a patient taking their prescribed drug) still 
provides opportunity for patients to hide medication in their mouth, rather than 
swallowing it, and is feasible only for monitoring single-dose or intermittent treatment 
of hospitalised patients rather than long term self-administered treatment (9, 14).  
Biochemical measurement in body fluids (blood, saliva or urine) of drug levels, 
metabolites or biological markers added to medication provides an alternative direct 
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method to assess medication adherence, but this too suffers from major disadvantages. 
Such measurements are subject to pharmacokinetic variation between patients (being 
affected, for example, by diet and rates of absorption and excretion) and thus may be 
misleading or highly variable, they may be unacceptably invasive or prohibitively 
expensive and not all medications can be readily measured in bodily fluids. Drugs level 
in body fluids may be distorted by timings of doses taken and in particular by white-coat 
compliance, as this improved compliance prior to a follow up visit will overestimate 
typical levels of compliance (1, 14). 
Indirect measurement measures tend to be more practicable, convenient and affordable 
but at the expense of accuracy.  
Patients are typically nervous about disclosing any deviation from their prescribed 
regimen and thus are likely to overstate their compliance when self-reporting (10, 20). 
Thus various commonly used patient self-reporting methods (such as interviews, 
treatment diaries or questionnaires) are all prone to intentional overestimation of 
adherence by the patient, as well as recall error. Diaries filled in concurrently may help 
to overcome the problem of inaccurate recall but are likewise easily distorted by 
patients; furthermore patients may resent the constant reminder of their disease that 
these diaries present and thus fail to complete them regularly. Given the reluctance on 
the part of patients to disclose adherence problems when faced with direct questioning 
or open discussions with their treating doctor, it is unsurprising that doctors have been 
shown to be poor at detecting nonadherence in their patients, typically doing so no 
better than chance (6, 23).  
Pill counts (or weighing) of returned pill bottles is another easy, inexpensive method of 
assessing compliance to longterm medication and has been the most common method 
of adherence assessment used to date in clinical research. This method provides an 
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indication of proportion of drug taken but captures no information on the timing of 
doses taken; furthermore it has been demonstrated to be entirely unreliable when 
compared with more objective methods, unsurprising given the opportunity for patients 
to simply discard or hoard any left-over medication (14, 23).  
Patients’ prescription refill dates may be obtained from supplying pharmacies’ records 
to inform on the regularity with which patients obtain prescribed medication, but such 
data only provide information on the supply, rather than intake of medication, and will 
be accurate only if a patient takes all of the dispensed medication and utilises a single 
pharmacy whose records are complete and up-to-date.  
A relatively new technology, first developed in 1977 and taking the form of a 
microprocessor incorporated into electronic monitoring devices fitted to treatment 
dispensers, has provided the most reliable indirect medication adherence data to date 
(17). Such medication event monitoring systems (MEMS, where “medication event” 
is defined as the set of actions needed in order to take a dose of medication) store time 
and date data when the relevant treatment dispenser (for example, medicine bottle, 
blister pack, inhalator or eye drop dispenser) is triggered.  
The detailed dose timing information obtained from MEMS has been used to test the 
reliability of other methods, demonstrating, for example, the unreliability of pill counts 
and other patient self-reporting methods. By recording the exact time and date of 
opening or activation of drug dispensers, MEMS data have provided valuable insight 
into the patterns of patients’ drug-taking, unearthing various typical manifestations of 
nonadherence such as drug holidays and white-coat compliance (17). Such data can also 
be input into pharmacokinetic/pharmacodynamic (PK/PD) models, as the dosing 
records allow prediction of the time courses of drug plasma concentrations and drug 
actions (15). 
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In providing a complete dosing history and thus allowing detailed comparison between 
prescribed and realised drug regimens, MEMS is considered to be the most accurate and 
useful single approach available for measuring medication adherence in clinic trials or 
adherence research (17). These devices are, however, prohibitively expensive and 
cumbersome for routine practice (5, 6). Furthermore, the account of treatment taking 
provided by such devices, although detailed, nevertheless only provides an indirect 
account of treatment timing rather than a direct measure of treatment ingestion. There 
is therefore the potential for patients to mislead (if they regularly activate the treatment 
dispenser at the correct dose times but then fail to actually take the intervention); 
although such behaviour would require substantial effort on the part of the patient and 
is therefore unlikely to be sustained over long periods (15), there is some evidence 
indicating such behaviour (in a cancer setting with self-administered chemotherapy) 
(16).  
Thus, even the most reliable methods for measuring patient’s self-administered 
treatment provide only an estimate of actual intake (5). The resulting lack of a gold 
standard measurement technique for measuring compliance has been cited as a major 
barrier to compliance research (4, 22). 
2.7. Causes 
Despite these difficulties in reliably measuring compliance, recognition of its impact and 
extent has prompted a huge amount of research into its causes. Traditionally patient 
factors have been considered the primary cause of non-compliance (14) but research 
has demonstrated that demographics (such as age, sex and social class) do not strongly 
predict compliance (9). Age impacts on a patient’s practical ability to comply, with 
elderly patients more like to suffer problems with memory, vision, mobility and 
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cognition; however elderly patients may also be more concerned and focused on their 
health than younger individuals so, with appropriate help, may be more likely to comply 
to prescribed regimens. Heterogeneous findings regarding educational levels have been 
reported; some studies have demonstrated higher compliance among those with higher 
education levels (because of a greater understanding of the disease and its 
consequences) while others suggest that a lower educational level will enhance 
compliance (because of a greater trust in clinical advice). Similarly, contradictory results 
have been reported for gender, ethnicity and marital status (18). Inconsistent results 
regarding demographic factors may be due to underlying correlations with variables 
relating to psychological influences or a patient’s cultural and socioeconomic 
background (18). 
Social and economic factors also play a role, along with the practical limitations 
presented by daily life. Employment status may impact on practical limitations on time 
due to work commitments or may provide insufficient funds to meet the cost long term 
treatment. The quality of health care provision from health care systems impacts on 
compliance, for example in terms of affordable medication, adequately trained and 
supported health care workers, continuity of care from the same provider, sufficiently 
long appointment times and convenient access to appropriate health care facilities (5, 
18).   
Social support may be required to overcome practical problems with compliance, or 
may help to reinforce positive attitudes to treatment and thus enhance patients’ 
motivation (18). On the other hand, patients who fail to comply with medication may in 
fact relish the increased care and attention received from health care professionals, 
friends and family as a result of the clinical consequences of their non-compliance, 
which will serve only to encourage their non-compliance further. 
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Treatment factors which impact on adherence include the convenience, duration, cost 
and complications involved. Dosing frequency and number of prescribed treatments 
both affect compliance, though greater problems are caused by the number of daily 
doses required rather than the number of different prescribed treatments (9). Invasive 
or complicated treatments will discourage compliance, and side effects of treatment may 
negatively impact a patient’s motivation and trust in the treatment or prescribing 
clinician (18).  
Disease factors, such as severity of symptoms, duration of disease and rate of disease 
progression, also impact on adherence. Long term illness typically leads to a greater 
probability of compromised compliance, although newly diagnosed chronic disease 
patients may demonstrate lower compliance rates than those who have had a disease for 
many years, perhaps because they feel no sense of urgency or have not yet experienced 
the adverse effects of living with the disease (18). Noticeable improvement of 
symptoms with treatment, or worsening of symptoms when treatment is discontinued, 
encourage compliance, while comorbidities may hinder compliance, especially 
depression, poor cognition and alcohol or drug abuse (5). Patients are naturally less 
likely to adhere when taking long-term preventative medication for asymptomatic 
conditions presenting no immediate risk than for conditions with life-threatening or 
serious consequences. Premature cessation of prescribed treatment, for example, occurs 
most often in asymptomatic disease when risk is not immediately obvious (for example, 
in hypertension) (19). 
Patient knowledge regarding disease and treatment is known to influence compliance 
rates (18). Patients need sufficient information on the impact of the prescribed 
treatment on the course of disease and the consequences of suboptimal treatment 
compliance and should be provided with written information to complement verbal 
   
   
36 
 
instructions. The quality of this information will impact on their likelihood of 
adherence, as patients may forget, not understand or simply ignore inadequate 
instructions.   
Indeed non-compliance is not always intentional; it may simply be due to ignorance or 
lack of understanding on the part of the patient. A patient may occasionally forget to 
take treatment (indeed, forgetfulness has been reported as the leading reason for poor 
compliance with long-term medication) (14, 24, 25), or may be more severely limited 
when following a prescribed treatment regimen, either by their mental or physical 
capability or because of inadequate financial or health care resources (21).  
Patient beliefs and their experience of their prescribed medication and medication as a 
whole is a very important determinant of compliance, and patients will balance their 
beliefs of the benefit and harms of treatment when deciding on how to take their 
medication. The Health Belief Model has been applied to the study of compliance, such 
that patients are believed to comply more readily if they believe they actually have the 
disease in question, that they will benefit from following the prescribed course of 
therapy or will otherwise be susceptible to consequences of the disease course (9). 
Patients make decisions regarding treatment compliance by, consciously or 
unconsciously, weighing up the health benefits gained from complying with treatment 
against the practical implications of compliance on their daily lives, taking into account 
cost, inconvenience or side effects (4).  
Psychological factors, such as embarrassment, anxiety or anger regarding disease or 
medicine-taking, fear of side effects, interactions with other treatments or developing 
addiction to long-term treatment, or poor motivation to persist with treatment or 
behavioural changes, will impact on a patient’s compliance status (26). Those who are 
not concerned by their ill-health will be less likely to comply, especially if the act of 
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taking regular medication presents physical or practical problems (1). Although disease 
severity has been shown to correlate with compliance, evidence suggests that a patient’s 
perception of their health status may in fact be more influential on compliance than 
actual disease severity (18). Negative beliefs about medication in general, for 
example that they are unnatural or harmful, or patients’ suspicions regarding chemicals 
or science, will impact on adherence. Patients may be in denial regarding their diagnosis 
or may wish to avoid the constant reminder of their illness presented by taking regular 
medication (10, 27). Nonadherence may be a coping mechanism, if patients are 
otherwise unable to express their fear, anger or frustration with their situation (12). 
The quality of communication between the patient and their clinician is cited as a key 
factor in determining compliance (12, 28) though it is difficult to measure, quantify and 
therefore adequately study the impact of precise factors relating to the patient-doctor 
relationship (9). It is acknowledged that clinicians often fail to inform patients of 
crucial information when initially prescribing treatments (29). Insufficient consultation 
time, or poor rapport, with prescribing clinicians may leave patients with unanswered 
questions (for example, regarding  diagnosis, absence of symptoms, expected adverse 
events, and expected delay from start, or duration, of treatment effect) (9).  
Prescribing practice varies amongst clinicians; thus, when confronted with conflicting 
dosing advice from different clinicians, patients may be inclined to instead rely more 
heavily on their own judgement. Blackwell (27) sums it up nicely: “…the physician will 
be expected to prescribe with only approximate accuracy, and the patient will be 
expected to comply with only modest fidelity. Thus mankind has been able to survive 
bleeding, cupping, leeches, mustard plasters, turpentine stupes, and Panalba.” As such, 
patients with chronic diseases often become “experts of their own disease” and, 
regardless of clinical advice, will adjust their treatment intake (e.g. dosing levels or 
   
   
38 
 
timing) according to perceived therapeutic or side effects in order to balance perceived 
benefit and harms, or to determine their own personal minimum effective dose of 
treatment (9). 
Thus extensive research into the causes of non-compliance has revealed numerous 
associated factors related to the patient, disease, treatment, health care provider and 
health care system (4, 5). However, despite suggestions of causal influence, none have 
demonstrated consistent or fully predictive association with compliance (9), due in part 
to the difficulties in accurately measuring and quantifying the complex interaction 
between these factors.  
2.8. Terminology 
“One of the most striking reasons for the lack of progress in compliance research is the 
absence of a crucial factor: the patient’s perspective.” (9). 
In spite of extensive research into its causes in the 1970s and 1980s, nonadherence 
continued to be a problem, with no apparent consistent predictors or solutions to the 
problem. As Becker commented “Patient non-compliance has become the best 
documented but least understood health related behaviour” (30). This research 
demonstrated not only the pervasive problem of discrepancy between prescribed and 
received interventions, but also of the moral limitations of the original term 
“compliance” (9). This traditional term has negative connotations, implying a 
paternalistic relationship between a doctor and their patient, whereby patients should 
submit to their doctor’s advice, and failure to do so is considered disobedience (9). 
Indeed, the Cambridge Dictionary defines compliance as “the act of obeying an order, 
rule, or request”. Furthermore, use of the term “non-compliance” has been cited as a 
potential tool by health care providers to label and discredit their patients (31). 
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Justified use of the term ‘compliance’ implies certain underlying assumptions which may 
not be realised in practice, namely that the clinician correctly diagnoses the patient’s 
condition and prescribes the most appropriate individually tailored treatment with clear 
instructions to ensure adherence. Although medication is usually prescribed by 
clinicians in good faith that it will provide the best help available to the patient, a 
clinician is unable to guarantee to a patient that the benefit of the prescribed treatment 
will indeed outweigh its harm; “compliance” with a prescribed treatment may therefore 
not be in a patient’s best interest. Rather than assuming a purely passive role, patients 
(especially those with long-term illness) may need to evaluate and make decisions 
regarding their treatment intake, in order to maximise benefits and minimise harms. 
Donovan (4) raises the point that recommended doses are based on average patient 
responses, but given the great variation between patients’ metabolism rates, it may 
therefore be necessary for individual patients to experiment with dosage and timings of 
treatment in order to find their optimal dose requirements. Thus when patients alter 
their drug intake levels, this may in fact be a “sensible and rationale response”.  
Therefore, with increased recognition of these multifactorial causes of non-compliance, 
including not only patient factors but also those related to the disease and drug itself, 
the treatment providers and health care system, there was a move away from using the 
term “compliance”. Indeed, researchers have long recognised the need to work with a 
“problem-solving approach” to encourage patients in developing strategies in working 
towards their own self-management of long-term condition and treatment (27), and that 
patients should be encouraged to assert their own needs, preferences and expectations 
as regards their treatment (12). Even Sackett’s landmark book on compliance (2) 
referred to the need for a “tailored consensual regimen” with consideration of practical 
problems encountered by the patient and the need to prevent any notion of blame when 
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assessing compliance behaviour (32), but this focus has only recently permeated into 
compliance research.  
Research in the 1990s therefore shifted from an assumption of an authoritative 
relationship between doctor and patient, introducing a new regard for the need to 
understand a patient’s motivations and attitudes towards treatment, and the importance 
of the patient as ultimate decision maker. Thus, in an attempt to move away from the 
blame associated with the term ‘compliance’, the term ‘adherence’ was introduced in the 
WHO document (5), defined as ‘the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider”. It was hoped that this term 
would better portray the notion of cooperation and partnership between patient and 
prescriber, the main difference with compliance being the need for the patient to agree 
to the prescribed course of therapy rather than simply passively following orders (9, 14). 
However, over time the term “adherence” became almost synonymous with 
“compliance” because of the persisting underlying implication of obligation on the part 
of the patient to follow the assigned treatment plan (with the Cambridge dictionary 
defining adherence as “behaving exactly according to rules, beliefs”).  
Recognition of this flawed terminology led members of the working party of the Royal 
Pharmaceutical Society to propose a new framework to replace the traditional 
“compliance” model. The term “concordance” was introduced, describing a situation 
where the health care provider works with the patient to determine the optimal course 
of treatment for the patient, with consideration of their personal needs and values, thus 
aiming for “agreement and harmony” between patients and prescribers (9). 
Concordance (defined in the Cambridge dictionary as “the state of there being 
agreement or similarity between things”) “signifies the practical and ethical goal of 
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treatment”, founded on the patient as decision maker with encouragement from an 
empathetic treatment provider (9). Other terms that have been used synonymously with 
concordance include ‘cooperation’, ‘agreement’ and ‘therapeutic alliance’, all of which 
suggest a ‘meeting of the minds’ of patients and health care providers (3) with mutual 
respect between doctor and patient for their (clinical and personal) contribution 
towards the treatment decision. Key to the notion of concordance is acceptance that 
“increasing compliance with prescribing instructions is not as important as meeting 
patients’ individual needs and priorities” (10). 
Concordance in practice 
The move towards concordance requires a shift from the traditional relationship 
between patient and clinician towards a more equal partnership with mutual respect for 
the respective personal and clinical expertise that each has to offer. Patients need to feel 
confident that disclosing their honest opinions about their difficulties with compliance 
or their treatment preferences will be received without judgement or reprimand. 
Concordance is particularly important when treatment is first prescribed or when 
changes are made to prescribed treatments (3) requiring prescribing clinicians to 
consider not only the effectiveness but also feasibility and acceptability of treatments 
(32). 
However, barriers to achieving concordance in practice are substantial, with limited time 
in initial and follow up consultancy appointments, spent mostly in discussion regarding 
diagnosis or symptom control (32), patients’ reticence to disclose their difficulties in 
following prescribed regimen and lack of perception on the part of clinicians to detect 
compliance problems.  
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Heath (33) feels that “patients need different information, not more of the same, and 
there is an urgent need for more honesty about the limitations of medicine and the 
uncertainties of medical knowledge”. Aronson (34) agrees, stating that “clinicians’ views 
about therapy can never be perfectly concordant with those of patients”, as patients are 
unlikely to be able to make a sound judgement based on complex medical information 
(35). Aronson feels that the idea of concordance is well-intentioned but is “not relevant 
to the interaction between a clinician and a patient (which is not a negotiation)”; instead 
clinicians should focus on providing clear communication and appropriate patient 
support, with recognition that patients then have a right to choose whether to follow or 
deviate from their clinical advice.  
2.9. Taxonomy 
A systematic literature review of papers on adherence terminology published in the first 
half of 2009 demonstrated use of more than ten different terms to describe departure 
from prescribed treatments, including “adherence”, “compliance”, “persistence”, 
“pharmionics”, “therapeutic alliance”, “persistency”, “patient irregularity” and 
“pharmacoadherence” (3). Vrijens reported inconsistency in the definitions of terms 
and found that these definitions did not provide guidance on how to measure or report 
these quantities, for example when trying to succinctly but adequately summarise 
multiple dimensions (e.g. timing, dosage and frequency) of longitudinal time-series data 
on patients’ dosing histories with single summary measures (36).  
The need for a standard and unambiguous taxonomy has been recognised; indeed, 
Vrijens et al (3) identified the need for clarification not only of the terminology used to 
describe the study of adherence, but also of the fundamental structure of adherence in 
relation to both the process and measurement of adherence, in order to “facilitate a 
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smooth transition from conceptual to operational definitions”. In their recent 
publication, they describe a foundation which clearly distinguishes between what they 
believe to be the three core elements of adherence research: ‘adherence to medications’, 
‘management of adherence’ and ‘adherence-related sciences’.  
 
Figure 1 (from (3)): Illustration of the process of adherence to medication (light 
blue) and the process of management of adherence (dark blue) 
The first component to this structure, ‘adherence to medications’, is defined as ‘the 
process by which patients take their medications as prescribed’ and consists of three 
stages, namely ‘initiation’, ‘implementation’ and ‘discontinuation’. Initiation occurs at 
the point at which the patient takes their first dose of prescribed medication, and 
discontinuation occurs when the patient takes their final dose. The implementation 
period extends between these two time points, with ‘persistence’ being defined as the 
length of time between first and final doses. Therefore medication nonadherence may 
be manifested by a patient failing to initiate prescribed therapy, failing to follow the 
prescribed course of treatment over the implementation period or discontinuing 
treatment prematurely. This terminology framework has been used through this thesis, 
particularly in the review of published trials. 
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The second element of adherence research, ‘management of adherence’, relates to the 
process by which patients are monitored and supported in their adherence to prescribed 
medication by family, friends, patient support groups or health care providers and 
systems. The final component, ‘adherence-related sciences’, encompasses the many 
disciplines (including, for example, medicine, biostatistics, biopharmaceutics and health 
economics) involved in furthering understanding of the causes and impact of the 
nonadherence process.  
One such relatively new adherence-related science is ‘pharmionics’, the study of how 
patients take medication that has been prescribed to them (‘what the patient does with 
the drug’) first introduced in 1987 to complement the two existing subdisciplines in the 
field of biopharmaceutics, namely pharmacokinetics (‘what the patient’s body does to 
the drug’) and pharmacodynamics (‘what the drug does to the patient’s body’).  
2.10. Summary measures 
Vrijens (36) discusses the limitations of terms such as ‘adherence’ and ‘concordance’ 
when measuring and analysing drug regimen compliance data, arguing that these 
“blanket” terms describe multidimensional processes but without physical dimensions 
and thus do not support quantitative analysis. Instead Vrijens proposes they be replaced 
by substituent measures, ‘initiation’, ‘compliance’ and ‘persistence’ in order to 
adequately summarise the differences between the actual and prescribed dosing 
regimens over the implementation period (the time over which the patient takes their 
prescribed treatment).  
Given that initiation and discontinuation are events occurring at a particular time point, 
while implementation refers to a continuous time period, these three phases of the 
‘adherence to medication’ process should be summarised separately and appropriately. 
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The definitions of typical summary measures used to describe these features of 
compliance are summarised in Table 1, along with a brief discussion of their potential 
limitations.  
Table 1 Recommended measures to describe features of medication adherence 
Feature Definition  Typical summary measures Limitations 
Initiation Time between 
receipt of 
prescription and 
first dose 
Initiation rate  
 proportion of patients 
starting prescribed treatment 
Potentially overly simplistic, 
providing no indication of the 
time between prescription receipt 
and starting treatment  
    
Compliance  Degree of 
correspondence 
between 
patient’s actual 
dosing history 
and prescribed 
dosing regimens 
Within-patient summary statistics 
of this period; e.g.  
 proportion of prescribed 
drug taken 
 number of drug holidays  
 proportion of days when 
correct dosage is taken  
 proportion of doses taken 
on time 
May be misleading in isolation 
(without further information on 
initiation or discontinuation) 
e.g. reporting average percentage 
of dose taken provides no 
information on the continuity of 
therapeutic action 
    
  Therapeutic coverage  
 proportion of patients who 
are exposed to a (minimal 
clinically important) 
therapeutic dose for a 
minimum percentage of 
time 
Typically difficult to justify choice 
of thresholds (for dose and time) 
required in order to define 
measure 
Requires detailed temporal dose 
data (e.g. from electronic 
monitoring device) 
    
Persistence Time between 
first dose and 
treatment 
discontinuation 
Discontinuation rate 
 proportion of patients 
stopping treatment per unit 
time 
Potentially overly simplistic, 
providing no indication of the 
length of time spent on treatment  
 
Quantification of the implementation period is often particularly complicated, as it is 
necessary to compare two time-series: the prescribed drug dosing regimen versus the 
patient’s actual drug dosing history (3). It is common to report within-patient summary 
statistics of this period, but such summary measures cannot fully describe the 
longitudinal implementation period and in isolation, without further information on 
initiation or discontinuation, may be misleading. Patients who take a similar proportion 
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of prescribed drug over the course of a trial, for example, may demonstrate very 
different profiles relating to initiation, discontinuation and implementation (3).  
In the absence of temporal dose data (from electronic monitoring devices), it is not 
possible to supplement these summary measures; if, however, longitudinal dose data are 
available, a rather more informative summary measure which takes into account some 
important properties of the drug is ‘therapeutic coverage’ (defined as the proportion of 
patients who are exposed to a (minimal clinically important) therapeutic dose for a 
minimum percentage of time), but justification for the chosen thresholds of these 
properties may be difficult (37). 
It is not possible or appropriate to define a universal definition of compliance across all 
clinical areas, given the disparate requirements in different clinical settings. The 
assessment of compliance is necessarily disease- and treatment-specific; as such, the 
most appropriate specific definition of non-compliance will depend on clinical features 
(such as the severity, comorbidities and consequences of disease) and the therapeutic 
objective of therapy, as well as (in the case of drug therapy) the duration of action of the 
prescribed drug relative to pattern of non-compliance manifested (known as ‘drug 
forgiveness’) (17).  
2.11. Solutions and initiatives  
Various methods have been implemented in an attempt to improve adherence but with 
only limited success, primarily as they have generally focused only on patient-related 
factors rather than addressing the multiple causes of non-compliance (1, 5). The most 
effective methods have involved a combination of multiple adherence interventions and 
therefore have typically been expensive, complex and labour intensive (14). Generally, 
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however, there has been a marked lack of research into methods to improve adherence 
(38). 
Thus, the prevalence and wide-reaching consequences of nonadherence, along with 
increasing recognition of the need to work with the patient to achieve concordance 
rather than unrealistically expecting the patient to follow whatever is prescribed for 
them, has led to a number of prominent initiatives seeking solutions to the problem. 
The global WHO initiative “Adherence to Long-term Therapies Project” was 
launched in 2001. The resulting report, entitled “Adherence to Long-term Therapies: 
Evidence for Action”, was aimed at health care professionals, managers and policy 
makers, and promotes strategies to improve worldwide adherence rates for chronic 
disease therapies (5). 
The Expert Patient Task Force was set up in 1999 in recognition that patients and 
health care professionals each have their own area of knowledge and expertise with 
respect to treatment of chronic disease (the clinician providing knowledge on diagnosis, 
disease, prognosis, treatment options and probable outcomes, while the patient adds 
expertise on their illness experience, values, preferences and practical considerations), 
suggesting the value of them working together in developing self-management 
programs (or Expert Patient Programs) in order to increase patient’s knowledge, 
confidence and motivation to manage life with a chronic condition. 
The Task Force for Medicines Partnership was created in 2002 by the Department 
of Health to promote the principles of concordance in order to improve health 
outcomes and patient satisfaction in the NHS. Practical initiatives were developed to 
encourage medication adherence, including the introduction of the Motivation for 
Medicines Service (pharmacy based adherence support service to support patients newly 
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prescribed long term medication), Medication Reviews (annual meetings for patients 
taking long term medication with a pharmacist, nurse or doctor in order to discuss 
practical problems or ask medical questions, with the aim of resolving patient’s 
problems with adherence and thus improving effectiveness of medication and reducing 
waste) and other patient adherence support programmes (such as the repeat 
prescription service and the introduction of telephone or online helplines for those 
prescribed certain medicines). Training packages were developed to enable health care 
professionals to develop concordant consultation skills in order to support patients with 
taking medication. 
The ABC (Ascertaining Barriers for Compliance: policies for safe, effective and cost-
effective use of medicines in Europe, http://abcproject.eu/index.php?page=project) 
project was launched in 2009 with the aim of improving patient compliance in Europe. 
Particular aims of the project were to standardise taxonomy of, and identify causes of 
non-compliance, research current compliance management techniques, assess the 
effectiveness of compliance enhancing interventions and develop policy 
recommendations to promote compliance within European health care.  
The ESPACOMP (European Society for Patient Adherence, Compliance, and 
Persistence) association was established in 2009 to promote study into, and ultimately 
provide research information to patients, health care providers, policy makers and 
pharmaceutical researchers on, the reasons for, and clinical and economic 
consequences, of patients’ nonadherence to prescribed medication. 
NICE guidelines (Clinical Guidelines and Evidence Review for Medicines Adherence: 
involving patients in decisions about prescribed medicines and supporting adherence) 
were published in 2009 (21), providing recommendations on increasing patient 
involvement in decisions about medicines and supporting patients in medication 
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adherence: “Patient involvement and adherence are central to medicine-taking yet these 
areas are less well researched than medicines themselves.” The guidelines recognise the 
potential for harm, as well as benefit, from prescribed medication and thus proposed 
initiatives aimed at providing patients with informed choice and supporting them in 
their role as primary decision maker. 
2.12. Summary  
This review of the clinical literature has highlighted that the problem of nonadherence 
with prescribed intervention is widespread and ubiquitous, affecting all areas general 
medical practice, from secondary prevention measures (detecting and treating disease 
that has not yet become symptomatic, for example screening programmes) to 
recommended behavioural interventions and prescribed medical treatments. The wide 
reaching clinical and economic consequences of nonadherence have prompted 
extensive research into its causes, extent and impact spanning more than four decades. 
However, despite these efforts, the prevalence of non-compliance to long term 
treatment has remained stable, with between one third and one half of patients 
demonstrating some form of non-compliance. Recognition that patients are increasingly 
more informed on their illness and medication, often in the case of chronic illness 
becoming experts in their own disease, and are more willing to take responsibility for 
their own health care, has led to a shift in focus from the traditional concept of 
compliance, which implies negative consequences if a patient does not follow the 
prescription of an (assumedly appropriate) intervention by a paternalistic authoritative 
doctor. This assumption makes no allowance for a patient’s circumstances, beliefs, 
values or expert knowledge of their own disease (especially in the case of chronic 
illness), or for the fact that evidence for efficacy of prescribed treatments (e.g. from 
clinical trials) is based on average responses (rather than on individual’s needs) 
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potentially from small, homogenous groups of patients (and thus may not be 
generalisable to general populations) or indeed for the possibility of incorrect or 
harmful treatments or diagnosis. The term “adherence” was therefore introduced, 
aiming to imply more of a shared decision-making relationship with the patient being 
considered an equal partner with the prescribing clinician, but the assumption that the 
patient should follow the determined course of treatment persisted still. As such the 
concept of “concordance” was founded, along with a number of initiatives providing 
guidance to health care providers and policy decision makers on how to improve 
patient’s treatment experience by involving them in the decision making process.  
However, for successful implementation of a concordant relationship, treatment 
providers must have the humility to accept the validity of each patient’s view and make 
the effort to present a more accepting approach to patients, while patients must be 
convinced of the value of moving from passive acceptance (or unspoken rejection) of 
the authority of the clinical profession towards a more active decision-making role 
requiring openness and honesty. In addition, there exist other substantial barriers to 
achieving concordance in practice, in particular limited time in initial and follow up 
consultancy appointments and patients’ reticence to disclose (and lack of perception on 
the part of clinicians to detect) compliance problems. Furthermore, ethical problems are 
introduced when patients’ preferences do not match clinical opinion of the optimal 
course of treatment.  
2.13. Conclusions 
This literature review has highlighted that nonadherence is common across much of 
general clinical practice, most notably in the long term treatment of chronic disease, 
with multifactorial causes and substantial economic and clinical consequences. Inherent 
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difficulties in defining and measuring compliance have historically presented major 
barriers to research into the impact of compliance on patient outcomes. The 
introduction in recent years of a standard taxonomy to describe the multidimensional 
features of compliance has provided a clearer framework on which to base the 
measurement and reporting of compliance, and an increasing appreciation for the need 
to work with patients in achieving concordance in order to lessen the impact of 
nonadherence has led to a number of high profile initiatives. Nevertheless, despite these 
efforts, deviation from prescribed intervention continues to feature heavily in medical 
practice. The next chapter will describe how such issues translate into complications in 
the context of clinical trials.   
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3. Nonadherence in randomised 
controlled trials 
“There could not be worse experimental animals on earth than human beings; they 
complain, they go on vacations, they take things they are not supposed to take, they lead 
incredibly complicated lives, and, sometimes, they do not take their medicine.” (39) 
3.1. Introduction 
The literature review of the previous chapter revealed the widespread and continuing 
problem of nonadherence in general medical practice. In this chapter, focus shifts 
towards the issue of nonadherence to randomised treatment in trials, in particular how 
such nonadherence may be manifested in trials and its impact on design and analysis. 
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3.2. Trial design features 
The randomised controlled trial (RCT) is considered the gold standard study design for 
clinical research, providing the strongest form of evidence available from a single study 
(40, 41). The strengths of the RCT lie in its design features, most notably 
randomisation, blinding and allocation concealment. These design features serve to 
maximise a trial’s internal validity by preventing any biases or confounding, such that 
any differences between treatment arms in terms of outcome can be directly attributed 
to treatments (42).  
Randomisation prevents the introduction of bias which may occur during the 
treatment allocation process if, consciously or unconsciously, recruiting clinicians or 
patients are able to influence choice of treatment, leading to systematic allocation of 
patients with generally poor or good prognoses to the different treatment groups (40). 
In order to protect against such biases, randomisation necessarily involves two 
processes: not only the use of a random allocation sequence (thus preventing any 
predictability of future treatment allocations given knowledge of previous allocations) 
but also the concealment of each treatment allocation until it is actually assigned to the 
trial participant (known as “allocation concealment”).  
Assuming sufficient numbers of recruited patients, randomisation will therefore provide 
baseline comparability between treatment groups, both in terms of known and 
unknown prognostic factors, ensuring fair group comparisons. Additionally, in 
providing an ‘ignorable’ assignment mechanism, randomisation provides a valid 
basis for hypothesis testing (43, 44), allowing the use of probability theory to determine 
the likelihood that the observed differences between treatment groups have arisen 
purely by chance (41). 
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Allocation concealment may, depending on the trial, be extended beyond the point of 
randomisation, such that one or more parties (patients, clinicians, assessors or analysts) 
remain unaware of treatment allocations during the entire trial period, a design feature 
known as “blinding”. Blinding prevents bias occurring when preconceived ideas or 
experience of treatments affect judgment or decisions made during the trial. For 
example, blinding may reduce the probability of co-intervention bias (when additional 
treatment is given to one treatment group only) or diagnostic-suspicion bias (when the 
analysis or interpretation of results is influenced by knowledge of treatment). 
Knowledge of treatment group can also influence decisions made during outcome 
assessment or statistical analysis, for example, on patient withdrawals, outcomes and 
time points to analyse and report. Thus, although patient and/or clinician blinding is 
not always practical, it may be possible to conceal treatment assignment from those 
evaluating and analysing outcomes in order to avoid measurement bias and ensure 
objectivity in statistical analyses (44-46).  
Blinding may be achieved by use of a placebo, an inert substance which appears 
identical to the active treatment under study; in the case of active-controlled trials, 
treatment assignment may be masked using placebos for both treatments, providing a 
“double dummy”. Use of a placebo is necessary to distinguish the placebo effect 
(caused by expectation of treatment) from the true effect of treatment (47). 
These design features which serve to increase internal validity do so, however, at the 
expense of a trial’s external validity. In aiming to ensure robust, valid conclusions, such 
constraints render the trial a somewhat artificial clinical environment, compromising the 
generalisability of its results to the wider population of interest. In particular, features 
(such as the nature of the patient-clinician relationship, and their individual preferences) 
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which typically influence a patient’s response to treatment or likelihood of compliance 
may be altered by randomisation and blinding (48). 
Thus, although generalisability (external validity) of trial results is generally based on the 
assumption that the sample is generalisable to the target population, this may not be the 
case. Trial participants may be typically more motivated and interested in the treatment 
than others with the same condition, and this greater medical awareness may mean they 
are more likely to comply with treatment instruction (37). More generally, by influencing 
their behaviour, trial conditions may also impact on a patient’s likelihood of 
nonadherence, altering patterns and rates of nonadherence in the trial compared to 
those that would typically be expected in practice. In general, trial adherence rates are 
usually considered to be higher than those displayed by the general public, despite the 
fact that trial participants may face greater barriers to adherence than those being 
treated in a usual care setting. For example, the trial treatment protocol may be rather 
more involved or demanding, and may be accompanied by more intense follow-up or 
invasive assessments than would be experienced in general practice, all of which can 
hinder participation (11).  
Conversely, the extra contact with health care professionals provided by the trial setting 
may, in itself, provide patients with incentive and encouragement to persevere. Blinding 
may also help to reduce problems with patient drop out, as knowledge of treatment 
allocation may cause disappointment and subsequent patient withdrawal, if they 
perceive their allocation is the inferior treatment. On the other hand, blinding, especially 
by use of placebo, may mean patients are less likely to persevere with treatment, given 
the possibility that they are receiving a dummy drug. Furthermore, patients’ uncertainty 
about the efficacy of a drug being tested in the trial setting may mean that trial 
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participants are less likely to persevere with unpleasant side effects of treatment than 
those who are confident of the efficacy of their treatment.  
Patients may fear embarrassment if they report side effects or withdraw from treatment 
that turns out to be a placebo; indeed, empirical evidence has shown that patients are 
more likely to report side effects or withdraw from treatment if the trial involves an 
active control treatment rather than placebo (49). Similarly, a clinician blinded to 
treatment allocation may proceed more cautiously (for example with dose escalation), 
perhaps monitoring the patient’s response and symptoms more closely than usual (46). 
Thus, unnatural trial conditions may affect a trial participant’s behaviour, which is turn 
may distort their (perceived, reported or actual) trial outcomes, thus potentially limiting 
the reliability and generalisability of the trial’s overall conclusions.  
3.3. Aim of trial 
The impact of such differences from real life presented by the trial setting will depend 
on the aim of the trial. Ultimately the purpose of any trial will be to provide an estimate 
of some aspect of the intervention’s usefulness in achieving its therapeutic goal in the 
population being studied: the estimate of interest may be the treatment effectiveness 
(aiming to mirror how it will be used in practice) or efficacy (use under ideal 
circumstances as prescribed). The importance of a trial’s external validity will therefore 
depend entirely on its research question, which may be broadly classified as either 
pragmatic or explanatory. 
3.3.1. Efficacy trials 
‘Explanatory’, ‘efficacy’ or ‘experimental’ trials aim to determine the biological or 
pharmacological efficacy of an intervention, in order words whether or not it produces 
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the expected result under ideal circumstances (48), with the primary purpose of 
furthering scientific knowledge (50). Efficacy, also referred to “proof of principle” (51) 
or “method-effectiveness” (52), measures the effect of the treatment actually 
administered.  
Haynes (11) defines an efficacy trial as one whose aim is to determine whether a 
“treatment does more good than harm to those who take it”, whereas an effectiveness 
trial assesses this in those to whom it is offered. As such, a trial which aims to 
demonstrate the explanatory effect of treatment requires highly controlled conditions; 
thus explanatory trials tend to be designed to prevent blurring of the treatment effect by 
extraneous factors.  
In seeking to determine whether a treatment works in terms of biological processes, an 
explanatory trial will therefore typically restrict patient eligibility criteria to ensure 
recruitment of those thought most likely to respond and adhere to study treatments, 
potentially incorporating pre-randomisation screening using a placebo (thus assuming 
that non-compliance is a general characteristic of the person rather that the drug) to 
weed out non-compliant individuals (32, 44). Thus, such trials typically involve a 
homogeneous population without concomitant medical conditions who have 
demonstrated a degree of compliance prior to recruitment into the trial and are 
therefore likely to remain in the study (42). As such, patients recruited into an 
explanatory trial may not be wholly representative of the general population of interest. 
3.3.2. Effectiveness trials 
The purpose of a “pragmatic” or “effectiveness” trial, on the other hand, is to ascertain 
whether a treatment which has previously been shown to be efficacious actually works 
in real life conditions. Pragmatic trials are therefore said to measure the effectiveness of 
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an intervention and to inform choices between treatments (50). Effectiveness is also 
known as “proof of practice” (51) or “use-effectiveness” (52) because it measures the 
benefit observed under the usual conditions of use. The participants of a pragmatic trial 
will therefore tend to be more representative of the entire intended target population, 
and as such may demonstrate varying degrees of compliance and be taking concomitant 
medications for other medical conditions (42). 
Effectiveness of treatment incorporates not only the true efficacy of treatment but also 
the compliance with the treatment, and thus regardless of the actual efficacy of 
treatment, effectiveness of treatment will decrease as compliance decreases (47). The 
pragmatic estimate inherently includes the effect of the acceptability to the patient, 
which is regarded as an inseparable part of the evaluation of treatment effectiveness 
(53). 
Schwartz and Lellouch (54) were the first to make a “distinction” between explanatory 
and pragmatic trials.  Schwartz explains that treatments are administered within a 
particular context (mode of administration, side effects (and the consequential 
treatments), diet, auxiliary care, associated treatment). An explanatory approach requires 
that these contextual factors are balanced across randomised groups in order that the 
only difference between groups is the exact treatment received. In a pragmatic trial, 
however, optimal levels of these factors are set separately for each treatment group in 
order to inform a choice between two treatment modalities, such that these contextual 
factors become part of the treatment package. 
Although trials may be broadly classified as pragmatic or explanatory, efficacy and 
effectiveness are not discrete, independent quantities, but instead exist on a continuum, 
precluding any sensible dichotomisation (48). Rarely will a trial adopt an entirely 
pragmatic or explanatory approach; for example, even the most pragmatic trial design 
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will typically include collection of more outcome data than in usual practice (55). The 
degree to which a trial demonstrates evidence of efficacy or effectiveness should 
therefore be measured on a sliding scale; there are potential characteristics that help to 
distinguish pragmatic and explanatory elements of a trial and a number of tools exist for 
determining where on this continuum a trial lies. 
Gartlehner et al (48) proposed the use of a simple, validated tool composed of seven 
criteria to distinguish explanatory and pragmatic trials, namely the population and care 
facilities, eligibility criteria, principal outcomes, treatment modality and study duration, 
adverse event assessment, sample size considerations and analysis population. 
Alternatively, the PRECIS (PRagmatic-Explanatory Continuum Indicator Summary) 
wheel is based on ten domains (outcomes, patient adherence, practitioner adherence, 
primary analysis, eligibility criteria, flexibility of experimental/control interventions, 
practitioner expertise with interventions, blinding) and is intended to aid researchers in 
designing trials in line with their purpose (55).  
Trial design features therefore determine the balance between efficacy and effectiveness, 
ideally at a point which provides satisfactory internal and external validity relative to the 
trial aims. However, a satisfactory level of interval validity is required in order to achieve 
external validity (48); thus all trials require at least the basic elements of trial design, 
such as randomisation and allocation concealment, to ensure validity of its conclusions. 
As such, the setting of even the most pragmatic of trials will inevitably be artificial in 
some respects. 
3.4. Manifestations of treatment nonadherence in trials 
One such inevitable difference between a patient’s clinical care in a trial and in practice 
is the requirement to follow the trial protocol, which contains specific details on patient 
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recruitment, treatment regimens, assessment, outcomes, follow up and analysis, 
providing a clear reference to permit accountability and reproducibility of the trial’s 
design, conduct and analysis. Compared with a regular clinical setting, an added 
dimension to the problem of nonadherence arises in clinical trials because of the 
required adherence of both trial participants and treatment providers to the potentially 
stringent trial protocol.  
Thus subjects may never receive their allocated treatment, may receive the intended 
treatment but comply only partially, or may change during the course of treatment from 
one treatment arm to another. As in general clinical care, premature termination of (or 
non-persistence with) treatment is a common problem in trials of long term patient-
administered treatments, potentially exacerbated by overly demanding treatment 
regimens, treatment side effects, deterioration in patient’s condition or lack of perceived 
benefit (56). Similarly, partial non-compliance occurs when patients deviate from 
randomised treatment protocol, for example forgetting to take occasional doses or 
taking drug holidays. Thus trial participant nonadherence may take the form of 
premature participant withdrawal from the study (commonly referred to as withdrawal 
of consent or participant discontinuation of the study) or discontinuation of treatment, 
either permanently (often referred to as withdrawal from treatment) or temporarily 
(treatment interruptions). Other forms of nonadherence include failing to follow 
treatment protocol as regards timing or dosage of randomised treatment, or failing to 
initiate allocated treatment at all.  
Furthermore, in a trial setting, “adherence” comprises more than the patient simply 
following a prescribed treatment regimen or therapeutic intervention; it also includes 
cooperation on the part of treatment providers and assessors in following the 
procedures as specified in the treatment protocol. Clinician nonadherence typically 
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occurs when, based on their own experience and judgement (relating to side effects or 
efficacy of treatments) or in response to changes in the patient’s state or other 
intervening complications, clinicians may make changes to a patient’s prescription from 
those stipulated by the treatment protocol (57). For example, treatment providers may 
deviate from protocol when administering or prescribing treatment, by changing the 
type, dose or schedule of drug prescribed or failing to deliver treatment according to the 
procedure specified in the protocol (for example, during a surgical operation).  
“Crossover” between randomised treatment arms, also known as “contamination” or 
“intrusion” (58), may occur for reasons entirely unrelated to a patient’s prognosis or 
condition (for example, as a result of dispensing errors). More commonly, patient 
preference or interference on the part of the clinician, due to differential expectation of 
treatments, may result in immediate switches to the alternative treatment arm following 
randomisation. However, it may be necessary to permit switches to alternative 
treatment arm immediately following randomisation for practical reasons (for example, 
if the randomised intervention is not feasible). Treatment crossover to the alternative 
trial treatment, or non-trial treatments, during the course of the trial may also be 
permitted or encouraged in the treatment protocol for medical reasons, for example 
following disease progression, intolerable side effects or lack of efficacy. Indeed time to 
treatment withdrawal may well be a primary outcome of interest (53, 59). 
Contamination may occur simply as a result of being recruited into a trial. For example, 
receipt of the extra attention or information about the aim of a trial may induce a 
certain therapeutic effect, especially in behavioural intervention trials; Simon (60) 
describes patients in the placebo arm of a depression trial who experienced benefits 
simply as a result of the extra contact with trial staff. Contamination may also result 
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when active treatment is readily available to those in the control group, for example, 
over the counter at a pharmacy (11). 
The pattern and nature of departures from randomised treatment exhibited in a 
particular trial will depend on the form of randomised treatments being compared. 
Thus, participant compliance may be all-or-nothing (when treatment is given at a single 
time point or when treatment changes only occur prior to initiation of treatment, rather 
than during the course of treatment) or partial, fluctuating in a time-dependent manner 
(for example, when patients occasionally forget to take a dose of medication or take 
longer drug holidays). Levels of adherence may be constant or change quantitatively 
over the course of the trial. Treatment changes may take a variety of forms; treatment 
switches may take place in one treatment arm only (for example, when control patients 
are given the option switch to the experimental treatment on disease progression) or 
may be very complex (for example, when all patients are permitted to switch to the 
alternative trial treatment or external non-trial treatments). 
Furthermore, in a trial setting, adherence is required, not only in relation to the 
provision of treatment but all other aspects of trial design, including the follow up 
assessments necessary to permit outcome determination and appropriate inclusion of 
the patient in the trial analysis. As such, in addition to previously discussed 
manifestations of treatment nonadherence, nonadherence to the follow up protocol in a 
trial setting may also occur if a patient fails to provide or receive outcome assessments. 
Missing outcome data may occur for technical or practical reasons or because of loss to 
follow up. Patient withdrawal from treatment often coincides with premature 
withdrawal from the trial, as outcome data are often collected at the time of treatment 
delivery (for example, when patients receive treatment and provide follow up 
information at the same clinic visit).  
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3.4.1. Deviation from follow up protocol: missing outcome data  
Manifestation of nonadherence in a trial setting therefore generally takes the form of 
deviation from randomised treatment regimen, as defined in the treatment protocol 
(thus referred to herein as “deviation from treatment protocol”) or absence of outcome 
data (or “deviation from follow up protocol”).    
Missing outcome data may be indicative of undetected nonadherence to treatment 
assignment in a trial, because failure to adhere to assigned treatment protocol is often 
associated with subsequent failure to provide follow up information. Therefore 
treatment protocol deviations may also be manifested as (or masked by) absence of 
outcome data, which is generally caused by withdrawal of patient consent, loss to follow 
up (LTFU) or missing assessments. Patients may become unavailable for follow up or 
withdraw their consent to taking part in the trial for reasons related or unrelated to their 
condition or treatment. For example, a patient’s condition may improve (leading to a 
perception that they no longer require treatment) or worsen (such that they believe the 
treatment is detrimental) or they may simply move away for non-medical reasons. 
Outcome data can be assumed to be missing completely at random (MCAR) if the 
reason for missingness is entirely unrelated to the patient’s characteristics or outcome at 
the time of drop out, for example when a patient’s medical notes go missing. In such a 
case, the missing outcomes can be considered as a random selection from all trial 
participants’ outcomes and therefore their exclusion from analysis will not distort trial 
conclusions.  
If, on the other hand, missingness is related to certain factors which have been 
observed and recorded prior to drop out (for example, if the patient’s condition 
improves or deteriorates significantly), the outcome data are said to be missing at 
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random (MAR) for all such patients; the assumed dependence between the missing 
and observed outcome data in patients with these characteristics can be used to predict 
or appropriately account for these missing outcomes. 
When missingness is related to some unobserved event occurring following an individual’s 
final follow up (for example, a sudden unexpected disease relapse), data are said to be 
missing not at random (MNAR). The probability of bias resulting when such data are 
excluded from analysis cannot be assessed or ruled out, because of a lack of information 
on the reason for missingness; as such, the missing outcome data cannot be modelled or 
predicted without risk of bias. 
Access to information on the reasons for missing data is therefore vital in order 
to determine how best to approach the analysis of missing outcomes, because 
without explicit records on the reasons for missingness, it is not possible for analysts to 
test whether data are MAR or MCAR. However, as previously discussed, given that 
outcome determination in a trial setting often occurs at the same time as receipt of 
treatment, discontinuation of treatment typically coincides with loss to follow up; this is 
particularly problematic given that treatment discontinuation is typically related to a 
patient’s clinical condition (60).  
Missing outcome data may therefore cause bias, even in the case of an analysis carried 
out according to randomisation (an intention to treat, ITT) analysis (40). A typical 
complete case (or “respondent-based”) analysis which excludes patients with 
missing outcomes, or censors at the point of termination of follow up, will be unbiased 
only if the reason for missing outcome is unrelated (entirely or within prognostic factor 
group) to the risk of the outcome at the point of loss to follow up (in other words, 
MCAR or MAR respectively), such that the average prognosis of those without follow 
up information does not differ between randomised groups (60). This is typically 
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unlikely to be the case, as loss to follow up is often related to a patient’s state; 
furthermore, it is usually difficult to verify whether or not it is true, given that missing 
outcome determination typically coincides with complete loss to follow up relating to all 
other patient factors. As such, the strict definition of an ITT analysis requires complete 
follow up on all patients (61). 
Thus any exclusions, whether due to poor compliance or lack of missing data will 
potentially put into jeopardy the balance provided by randomisation: even if it is 
possible to demonstrate that groups remain balanced in terms of measured prognostic 
factors following such exclusions, this will not be sufficient to show balance on all 
factors. Even when rules for exclusion of participants are stated in advance (in statistical 
analysis plan or protocol), this does not preclude bias occurring, because no account is 
taken of the possible association between the reason for exclusion and outcome.  
3.5. Complications in analysis  
Nonadherence to any aspect of the trial protocol will present a challenge when 
analysing data. The chosen method of analysis is crucial to the interpretation of results 
from a trial, especially when dealing with deviation from protocol. In particular, 
deviation from treatment protocol will impact on the interpretation of trial analyses 
because the underlying assignment mechanism (randomisation), which forms the basis 
for unbiased hypothesis testing, no longer reflects the actual treatment received in some 
capacity.  
The decision on how to approach analysis in the presence of such deviations is 
therefore crucial to the interpretation of trial results. If analysis is naively carried out 
according to treatment received rather than randomised allocation, the advantages of 
randomisation are lost such that the trial results and conclusions are potentially 
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rendered invalid. However, if all deviations are ignored in analysis and analysis is carried 
out according to randomisation, inference can be made only on the effectiveness of the 
treatment policy or prescription, rather than on the biological efficacy of treatment actually 
received. The most common alternative approaches to analysis are considered in the 
next section.  
3.6. ITT, PP and AT analyses  
Analysis in the face of treatment protocol deviations may therefore take a number of 
forms. 
Analysis according to randomisation, in other words according to how the patient was 
intended to be treated (hence the term “intention to treat”, ITT), ignores any such 
deviations, such that patients are simply analysed according to their randomised 
allocation regardless of whether they received or deviated from this allocation. In 
retaining randomised allocations, an ITT analysis maintains the balance afforded by 
randomisation, thus preventing selection bias and assuring a sound basis for statistical 
hypothesis testing. In the presence of any deviation from assigned treatment, however, 
the interpretation of such an analysis is limited to an assessment only of the 
effectiveness of treatment policy or of the treatment prescription, rather than a causal 
estimate of treatment received. 
When the efficacy of treatment received is also of interest, alternatives to ITT are 
required, as inclusion of non-adherent participants in ITT analysis generally diminishes 
the estimated treatment effect and thereby resulting in a biased assessment of treatment 
efficacy (61). Analysts must however be mindful of the potential for bias resulting when 
analysing according to anything other than randomised allocations. A simple but 
statistically naïve method of analysis may involve analysis of patients in their 
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randomised group only if (or during the period during which) they follow their 
randomised allocation, thus excluding or censoring (terminating the time at which the 
participant was included in the analysis as being “at risk” of the event of interest at the 
point of deviation from the treatment protocol, which is possible when undertaking a 
survival analysis for an outcome which is time to some event) patients who deviate 
from randomised treatment protocol (hence the term “per protocol” (PP) analysis).  
Exclusion of participants from analysis in this way affects both the internal and external 
validity of a trial (62). A patient’s ability or willingness to persevere with treatment is 
highly likely to be correlated with their condition and other lifestyle factors; indeed, 
non-compliant patients have been shown to have worse prognosis than compliers in 
their respective randomised group, even when administered with placebo (9). As such, 
by excluding some definition of “non-compliant” participants, a PP analysis will affect 
the generalisability of a trial, as those who persevere with treatment protocol represent a 
non-random sample of the original group of trial participants.  
Furthermore, such an analysis is likely to introduce selection bias and thus also affect 
the internal validity of a trial, because the various treatment protocols being compared 
will present different challenges to adherence. This is especially likely when the 
definition of “compliance” varies between treatment arms, reflecting the different 
adherence requirements of the treatment packages. As such, the residual compliant 
subgroups of each randomised group are unlikely to be comparable. Therefore, unless it 
can be demonstrated that the average prognosis of those who deviate from treatment 
protocol does not differ between randomised groups, a PP analysis will likely upset the 
balance provided by randomisation, casting doubt on the validity of its conclusions (60).  
However, given that those intermediate confounding factors which influence a patient’s 
compliance status as well as their prognosis (and hence outcome) typically remain 
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unmeasured (and may arguably even be unmeasurable), it is often impossible to 
compare the profiles of these factors between groups. Therefore, even if the baseline 
characteristics, and rates and reasons for treatment withdrawals or changes, appear 
relatively similar between treatment arms, it is not possible to ascertain whether the 
compliant subgroups remain balanced with respect to unmeasured prognostic factors. 
The results of any such PP analysis are therefore highly likely to be unreliable because 
of these hidden confounding or selection effects (63).  
Exclusion of patients due to deviation from treatment protocol reduces the statistical 
power of a study by reducing the sample available for analysis. A variation on (but one 
even more flawed than) PP analysis used to overcome this problem of reduced power is 
analysis according to treatment received (or an “as treated” analysis). As treated (AT) 
analyses, whereby patients are analysed according to the (predominant) treatment 
received, are never likely to be valid as randomisation is disregarded entirely (57).  
3.6.1. Healthy user bias 
This (so called “healthy user”) bias associated with compliance analyses is supported by 
evidence demonstrating that those with better compliance behaviour tend to have better 
clinical prognosis that those with poor compliance, regardless of treatment received (e.g. 
active or placebo treatment). This effect has been demonstrated in varying clinical 
setting with disparate drug regimens, independently of whether or not there is an 
apparent clinical effect of drug (or of a drug/compliance interaction), suggesting 
generalisability of this phenomenon. (64)  For example, in the Coronary Drug Project 
Research Group (65), non-compliers in the placebo group experienced nearly double 
the mortality rate compared to compliers (28% versus 15%, respectively), and in the 
Beta Blocker Heart Attack Trial, poor adherers had an increased risk of death whether 
they were taking active treatment (OR=3.1) or placebo (OR=2.5) (66). 
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Epstein (64) discusses potential reasons for this apparent relationship between 
compliance and outcome: first, the psychological impact of complying with medical 
instruction may actually enhance the wellbeing of the patient, either solely because of 
the placebo effect (expectation that the drug will work leads to improvement in a 
patient’s condition) or because of the mediating effect of patients’ changes in habits or 
actions which result from the positive feelings towards taking treatment (for example, if 
such positivity leads patients to alter other lifestyle habits which in turn influence their 
outcome). Secondly, the relationship between compliance and outcome may be 
spurious: either because of the method in which compliance information is collected 
(for example, if those faring better are more likely to provide compliance data or be 
labelled as “compliant”) or if a patient’s ability or likelihood to comply is determined 
directly by their prognosis (either physically or psychologically) or their innate 
personality traits (which in turn affect their outcome), and thus the apparent 
relationship between compliance and outcome merely reflects the underlying link 
between prognosis and outcome. Finally, the relationship between compliance and 
outcome evident in both treatment and placebo groups may be caused by different 
mechanisms – for example, in the active treatment group, this association may be due to 
the true effect of drug, whereas in the placebo group, other factors (such as those listed 
above) may have improved compliant patients’ outcomes – though it may seem unlikely 
that these different mechanisms would lead to similar results between non/compliers in 
both randomised groups. 
Thus, although it may tempting to base any validity of such a comparison on assessment 
of any differences in baseline factors between compliers and non-compliers, an 
apparent similarity in baseline prognostic factors is not sufficient to justify such an 
assumption. Indeed, analysis exploring the relationship of baseline prognostic factors 
   
   
70 
 
with compliance in a number of trials demonstrates that adjustment for important 
prognostic factors often fails to explain for the variation in treatment effect attributable 
to compliance features (65, 67, 68). 
3.7. Analysis beyond ITT 
Analysis according to ITT provides an unbiased estimate of treatment effectiveness, but 
only in terms of the conditions under which the trial was conducted and only if 
complete outcome data are collected on all randomised patients. As such, there may be 
may be a number of reasons why it may be necessary to consider analysis methods 
beyond ITT. 
The choice of trial analysis should be determined according to the aim of the study and 
the ultimate research questions of interest. In many trials, the effectiveness of treatment 
will be of interest to ascertain whether the intervention being studied actually works in 
practice. Indeed, analysis according to randomisation is generally regarded as the most 
appropriate for primary trial analyses, as it mirrors the trial design and maintains all the 
advantages of randomisation (69).  
However, it has long been recognised that trial results will inevitably be somewhat 
artificial; Bradford Hill in 11th edition of Principles of Medical Statistics wrote: “at its 
best … a trial shows what can be accomplished with a medicine under careful 
observation and certain restricted conditions. The same results will not invariably or 
necessarily be observed when the medicine passes into general use; but the trial has at 
the least provided background knowledge which the physician can adapt to the 
individual patient.” Furthermore, ITT analysis will only be appropriate if the level of 
acceptability of treatment in a trial is generalisable to its future use in clinical practice: if 
non-acceptability in the trial setting is due to uncertainty about randomisation or 
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consent to trial procedures, then any problems regarding patient acceptability of 
prescribed treatment in the trial will not be relevant to clinical practice (53).  
As such, it could be argued that ITT analyses from even the most pragmatic of trials 
may not even adequately estimate effectiveness, and thus such analyses are not 
providing answers to anyone’s questions. This argument may be extended to suggest 
that instead a trial should provide an estimate of true efficacy, undiluted by the issues 
and complications presented by trial conditions, which can then be adapted to mirror 
alternative and more realistic projected situations. Indeed, it is arguable that efficacy is 
more useful to medical decisions than effectiveness; thus trials should be designed and 
analysed to provide causal estimates to inform clinical judgment (52). As such, it may 
arguably useful to collect and report information on the levels of treatment adherence in 
all trials, in order to facilitate accurate interpretation of the trial results and potentially to 
enable compliance-adjusted analyses. 
Trials designed with explanatory aims tend to impose conditions with the aim of 
minimising adherence problems, for example by recruiting only patients who have 
demonstrated a commitment to compliance (identified perhaps using a pre-
randomisation placebo screening period) and by specifying restrictions on treatment 
changes in the treatment protocol. However, the prevalence of treatment nonadherence 
observed in treatment practice will inevitably be carried into even the strictest 
explanatory trial setting. In addition, some trial features which aim to maximise validity 
of results may in fact impact negatively on adherence. For example, in the case of a 
blinded trial, if a participant thinks there is a chance they may be on control treatment, 
they may be less inclined to persevere, particularly if they have previously received the 
control treatment without success; in practice, however a patient may be more likely to 
persist with a novel treatment, given the associated expectation of their known 
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treatment. Therefore analysis of even the strictest explanatory trial will likely need to 
feature treatment protocol deviations that must be adjusted for in order to accurately 
estimate treatment efficacy. 
Similarly, a trial may necessarily have a pragmatic design for practical, ethical or 
recruitment considerations, but the causal estimate of treatment may nevertheless be of 
primary interest. For example, treatment switches between randomised treatments may 
be permitted or encouraged in the protocol for reasons such as inefficacy (for example, 
on disease progression), toxicity or other adverse effects. Although such treatment 
changes are not technically deviations from treatment protocol, switches from original 
randomised treatment will dilute the ITT treatment effect as an estimate of treatment 
efficacy, because of merged treatment experience of the randomised groups. Therefore, 
depending on the research question, it may well be of interest to factor out such 
treatment changes in a causal analysis. 
3.7.1. Differing research perspectives 
As such, even when ITT is considered the primary analysis, there may be interest in 
secondary causal analyses, especially because of the typical mix of explanatory and 
pragmatic traits within a single trial, thus warranting several different analyses (70). 
Indeed, Godwin et al (42) advocate the collection of compliance information in both 
pragmatic and explanatory trials, but for different reasons: in an explanatory trial, 
compliance may be expected to be high, given the use of a homogenous population 
likely to comply with treatment and particular efforts typically often employed to 
maximise adherence to treatment protocol. If compliance data are collected and a high 
level of compliance is observed, the results of the ITT analysis will closely estimate the 
efficacy of treatment within that patient population. In a pragmatic trial, it is important 
to collect compliance data, in order to ascertain whether an intervention will be adhered 
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to in practice; if not, even a highly efficacious treatment may be rendered ineffective. 
However Godwin suggests that efforts to encourage adherence in a pragmatic trial 
should not exceed what would be given in usual clinical practice, in order to ensure a 
realistic level of compliance among the trial participants and thus externally valid results.   
Therefore, even when ITT is considered the primary analysis, it is often appropriate to 
at least measure and report on, if not adjust for, compliance. The chosen method of 
analysis will depend entirely on the focus of the particular research questions of interest. 
The focus of the research question will in turn depend on the perspective of the party 
interested in the causal estimate. 
Patient perspective 
Adjustment for treatment deviation is important, not least for motivated patients who, 
when offered a new treatment will primarily want to know the long term and 
unadulterated treatment effect of treatment taken as directed, rather than the population 
average distorted by nonadherence. This will be especially important from a patient’s 
point of view if the treatment changes or withdrawals are due to patient choice rather 
than side effects (71). Indeed, such interest in treatment efficacy is becoming 
increasingly important, as patient decisions based on informed choice in health care 
become more widespread (72). 
Public health planning 
The compliance rates or patterns observed in a trial are not guaranteed to reflect those 
in general practice. First, trial participants recruited into a trial may differ from the 
general target population, in obvious and less obvious ways. Recruitment of 
homogeneous patient groups according to strict eligibility criteria makes trial results less 
generalisable, but so too might the subconscious motivation provided by inclusion in 
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the trial. Even when trials participants’ characteristics appear representative of their 
patient group, publication of positive trial results may increase patient’s confidence in 
the drug when the trial is complete, thus impacting positively on compliance rates in 
general medical practice, compared with possible suspicion of trial patients aware of the 
unproven treatment efficacy (73). Indeed, if the treatment is widely publicised as a 
promising treatment, in practice patients may be encouraged and motivated to persevere 
such that the benefit seen in practice mirrors that of the true efficacy, rather than 
effectiveness, of the treatment in the original trial (74). In such cases, it would be of 
interest to adjust for these various compliance rates in order to obtain a more realistic 
estimate of treatment effectiveness in practice. 
Furthermore, the policy of treatment change implemented in a trial (for example, the 
factors determining treatment changes) may differ from that used in practice. Although 
treatment switches will be necessary in clinical practice, the specific standard or non-
trial second-line treatments that patients switch to in the trial setting may be obsolete by 
the time the trial results are published. An ITT treatment effect will relate only to the 
patterns and types of treatments used in the trial, which may be different to those 
expected in practice, adding to the argument for additional efficacy analyses to 
supplement ITT analysis. 
Likewise, results that are generalisable to one community or setting may be less so in 
others with different resources or policies; as such, for the purpose of public health 
planning, it may be of interest to policy makers to obtain adjusted trial treatment 
effects assessing efficacy in a different setting which exhibits different patterns of 
compliance (73). 
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3.7.2. Anticonservative ITT estimation 
Furthermore, although it is generally accepted that ITT provides a conservative estimate 
of treatment effect (by providing an estimate that is potentially closer to the null effect 
than the truth, thereby ensuring the true treatment effect is not exaggerated), this is not 
always true. In the case of the most common trial design, which aims to ascertain 
whether one treatment is superior to another and is thus called a superiority trial, a 
conservative estimate would mean that the treatment effect (e.g. the estimate of the 
difference in the effect of treatments) would be smaller than in truth, and thus is not 
exaggerating the true treatment effect. However depending on the pattern of deviations 
from treatment protocol, this may or may not be the case. For example, if the pattern of 
treatment changes makes the treatment experience of the two randomised treatment 
arms more similar than they would be if everyone had followed the treatment protocol 
(for example, if some patients switched to the alternative trial treatment), then in 
ignoring these treatment departures, the ITT treatment effect estimate would reflect this 
greater similarity in the treatment experience and would indeed provide a conservative 
estimate. However, if the pattern of treatment changes in the trial results in an 
exaggerated difference between the treatment experience of the randomised arms, the 
ITT estimate will be biased away from the null, providing an anticonservative estimate 
of treatment efficacy. This would occur if patients from the more efficacious treatment 
arm were able to switch to a non-trial treatment which was in fact even more 
efficacious, thus making the observed difference between treatment arms even greater 
than it would be if this type of switch had not occurred. The direction of bias may be 
difficult to predict particularly if numerous options are available to patients, for example 
when patients receive second-line treatments on cancer progression. 
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ITT is generally accepted as providing a conservative assessment of treatment efficacy, 
as non-compliance on the whole leads to greater similarity between treatment arms than 
originally intended (for example, when treatment switches occur between trial 
treatments or when premature discontinuations of treatment occur in both treatment 
arms) and as such, the inclusion of non-compliers leads to a diminished treatment effect 
compared to the true efficacy of one treatment relative to the other. However, there are 
a number of analysis scenarios for which this diluted treatment effect renders ITT an 
anti-conservative method of analysis.  
Equivalence trials 
When a trial is designed to demonstrate equivalence between two treatments, or non-
inferiority of a certain treatment (as opposed to the standard superiority trial, designed 
to demonstrate that one treatment is superior than its comparator), the merging of 
treatment experiences of the different randomised treatment arms resulting from the 
inclusion of non-compliers in analysis will lessen the observed difference between 
treatment outcomes, thus increasing the probability that the null hypothesis (of a 
difference between treatments) will be rejected; in other words, ITT increases the 
probability of falsely concluding equivalence (or non-inferiority) between treatments.     
Harms analyses  
For similar reasons, the analysis of harms outcomes using an ITT approach is not 
recommended, as a diminished treatment effect in a harms analysis will be anti-
conservative, making a harmful treatment more likely to be accepted as harmless. As 
stated by Lewis (75), “a pure ITT approach to the analysis of safety simply adds to the 
risk of failing to identify potential safety problems, and is therefore never advocated”. 
Instead, the ICH GCP guidelines (61, 76) suggest that analysis of harms data should be 
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according to treatment received, in other words all participants who received at least 
one dose of a treatment should be included in that treatment group for harms analyses, 
though there is no consensus on this issue (62). 
In particular, ITT analysis may distort the risk of harms that may be expected in 
compliant individuals. By averaging across all patterns of compliance in a trial, an ITT 
analysis will underestimate harms in patients who exhibit certain incorrect dosing 
patterns (for example, when drug holidays cause drug resistance or rebound or 
recurrent first-dose effects) while overestimating risk in the majority of patients who 
take the drug correctly (caused by a minority of patients who seriously deviate from 
treatment prescription) (20). If variable dosing patterns can cause serious harm, then 
disregard of non-compliance when considering the causes of such adverse events may 
lead to an incorrect conclusion regarding the safety of the intervention when taken as 
prescribed.  
3.7.3. Statistical issues 
There are numerous other statistical reasons why compliance information should be 
collected in order to allow analyses beyond ITT. 
Power 
The dilution effect of non-compliance in an ITT analysis affects the power of 
superiority trial analyses to a surprising degree. For example, a trial where only half of 
trial recruits were fully compliant may need up to five times as many to be recruited as 
for a trial with complete compliance (11) to achieve necessary power. As such, 
projections of anticipated compliance rates should be accounted for in sample size 
calculations; likewise, however, the potential role of compliance in diminishing 
power of the ITT analysis should also be investigated: if adherence to treatment 
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protocol is assumed to be high and is therefore not measured as part of the trial, the 
lack of an observed treatment benefit may simply be due to the dilution of the true 
treatment effect caused by poor adherence to the randomised treatment rather than due 
to true inefficacy of treatment (11). Adjusting for compliance may provide more realistic 
confidence interval limits for an observed treatment effect (68).  
Meta-analysis  
Another argument for reporting adherence information in trial publications is the need 
to consider variation in adherence rates across trials in a systematic review. Without 
consideration of the degree of compliance expected in a trial, the true efficacy of 
treatment may be masked by incorrect treatment-taking patterns; thus consideration of 
compliance in statistical analyses may also help to explain variations in treatment effects 
over time or between different participant subgroups or indeed between trials in a 
meta-analysis (MA) (73). Differences in compliance rates between trial settings will 
cause heterogeneity between ITT analyses, as ITT estimates mix the true efficacy with a 
measure of patient acceptability and compliance. Therefore, given that undiluted 
estimates of true efficacy are likely to be more constant across trials than ITT results, 
estimation of undiluted treatment efficacy may therefore help to reduce variability 
between trial results in a MA (77). Therefore, even when compliance adjustment is not 
relevant for trial aims, it is nevertheless important for trialists to report on the extent of 
non-compliance in their trial, using clinically relevant measures of compliance, such that 
potential meta-analysts can interpret any heterogeneity with respect to reported levels of 
compliance.   
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3.7.4. Drug development 
Despite the prevalence of adherence problems in practice and the impact of adherence 
on treatment effectiveness, adherence to treatment has largely been ignored in the 
development of new treatments (22). This has been blamed on the unreliability of 
compliance measurements typically used in trials (for example, pill counts and 
biochemical measurements of drug, both of which may give distorted indications of 
longterm adherence) and the suspicion on the part of regulatory bodies regarding bias 
that may be introduced with any causal analyses that do not mirror randomised 
allocation. Indeed, Urquhart (22) argues that trial statisticians’ reliance on ITT has 
fuelled this problem further. In addition, it may not be regarded in the interest of 
pharmaceutical companies to disclose adherence information regarding with their 
products, for fear of highlighting patient non-acceptance of, or difficulties with, 
treatment.  
It is imperative, however, for compliance to be considered when policy makers are 
choosing between treatment options. A treatment found to be efficacious in strict trial 
conditions may not necessarily demonstrate treatment effectiveness under usual 
conditions of care. Thus one treatment may be deemed preferable to an alternative 
simply on account of patient acceptance, for example because of less frequent dosing, 
less invasive administration methods or combinations preparations (reducing the 
number of separate medicines taken) (78). Indeed, Urquhart  (22) discusses how 
modern drug development rarely leads to a first ever treatment for previously 
untreatable conditions, but instead tends to identify treatments that may serve as 
alternatives to already available treatment modalities, increasing the importance of 
considering qualities such as patient acceptability and adherence. 
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Drug labelling 
Adjustment for treatment changes is particularly pertinent as regards drug labelling, 
which is informed primarily from clinical trial data. Given the evidence for drug 
underdosing in general practice among patients with chronic diseases, it is not unlikely 
that drug trials will also suffer from such underdosing, leading to a diluted average ITT 
treatment effect relative to the full-dose effect, known as the ‘dilution effect’ (22). Drug 
labelling based on ITT results from clinical trials may therefore mislead those patients 
who intend to follow the treatment course as prescribed as to the likely drug outcomes 
(15, 22).  
Cost-effectiveness analyses  
Factors relating to adherence are also particularly pertinent for public health planning, 
given their impact on cost of treatment in actual practice. Nonadherence impacts on 
health care economics by its association with various related costs, for example, those 
associated with initial drug acquisition and utilisation of health care resources to deal 
with consequences of nonadherence; indeed, costs resulting from nonadherence may 
outweigh those related directly to the original treatment provision. For example, 
reduced efficacy of a treatment following nonadherence to the prescribed regimen may 
incur substantial additional costs due to requirements for extra clinical consultations, 
monitoring and testing, and hospitalisation; treatment costs may also increase because 
of unnecessary increases in dosage or switching to alternative (usually more expensive) 
drugs. Thus, a more expensive treatment may work out cheaper than its alternatives 
simply because of fewer adherence problems. As such, compliance should always be 
considered in health economic evaluations of drug cost-effectiveness (78), for example 
by exploring the impact of changes in non-compliance rates on trial cost-effectiveness 
analyses (69). 
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Pharmacokinetic and pharmacodynamic modelling  
Compliance data may also be useful in pharmacokinetic and pharmacodynamic 
modelling. Pharmacokinetics (PK) may be simply defined as what the body does to the 
drug (in terms of the extent and rates of absorption, distribution, metabolism and 
excretion) as opposed to pharmacodynamics (PD) which may be defined as what the 
drug does to the body. PK/PD modelling combines these two disciplines to model the 
time course of the drug concentration and action in the body, for example through the 
use of dose-response curves. In providing exact information on both timing and 
quantities of doses, MEMS provide the required input parameters for PK/PD 
modelling, whereby the dosages of drug taken into the body over time are related to the 
drug concentration and action in the body. Availability of MEMS data therefore avoids 
the need to rely on the unrealistic and untestable assumption that all patients necessarily 
followed the treatment schedule according to prescription (22, 37). Furthermore, 
information on when doses were ingested along with biochemical measures of drug 
absorption allows assessment of potential variation between individuals in associations 
between these factors (23). 
Pharmacogenetic modelling 
Compliance information is also relevant for pharmacogenetic (PG) modelling. 
Genetic testing may be used to inform personalised treatment choices for patients by 
determining for a particular individual the appropriate dose of treatment (as in (79)), or 
by predicting the likelihood of treatment efficacy (as in (80)) or the risk of adverse drug 
reactions or toxicity (as in (81, 82)). Information on treatment discontinuations and 
compliance may be input into a PG model to identify patients for whom a certain 
treatment is particular efficacious and who therefore may be encouraged to persevere 
with treatment despite unpleasant side effects. Alternatively, PG modelling may use the 
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genetic profile of patients to identify those more able to tolerate adverse drug reactions, 
thus increasing their benefit-harm ratio and warranting prescription of otherwise overly 
toxic drugs (83).  
3.8. Introduction to causal estimation 
If trials are carried out perfectly, with perfect randomisation and blinding, full follow up 
and complete adherence on the part of all patients and treatment administrators, 
analysis according to randomisation will provide an unbiased estimate of the causal 
effect of treatment as received compared to control. However, as discussed in this 
chapter, complications often arise in trials as a result of nonadherence to treatment or 
follow up protocols, leading to changes to treatment or incomplete data. Before 
considering, in subsequent chapters, some examples of real-life trials exhibiting such 
compliance issues, this chapter will conclude with an explanation of why such 
deviations may cause problems when aiming to estimate efficacy of treatment. 
In particular, this chapter ends with a discussion of the definition and difference 
between associational and causal effects, and how causal effects are most easily defined 
using a potential outcomes (counterfactual) framework. A brief introduction to the use 
of causal diagrams, which provide a pictorial aid to clarify the relationship between the 
treatment, outcome and other covariates associated with the particular causal scenario, 
will help to clarify the issues of confounding and selection bias and reveal how naïve 
methods (such as PP or AT analyses) introduce such biases.  
Initially, therefore, it is necessary to provide an introduction to causal estimation and 
the framework within which such parameters may be estimated, beginning with the 
definition of a cause and an explanation of the difference between associational and 
causal inference.  
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3.8.1. Definition of a cause 
The notion of cause dates back at least as far as Aristotle, who defined four types of 
causes (the material cause (that out of which the thing is made), the formal cause (that into 
which the thing is made), the final cause (that for which the thing is made) and the efficient 
cause (that which makes the thing), the last of these being that most relevant to statistical 
inference, while Locke in 1690 defined both the cause (“that which produces any simple 
or complex idea”) and its effect (“that which is produced”) (84). 
There are two necessary conditions for the definition and estimation of the effects 
produced by a certain cause (logically referred to as “causal effects”).  
Firstly, the effect of a particular cause can only be meaningfully defined in relative terms 
to another cause. In other words, it takes at least two causes (or two versions or levels 
of a cause) to define an effect; thus in experimental studies, the treatment under study 
must always be compared to a relevant control condition, such that “experiments 
without control conditions are simply not experiments”. Indeed, stating that “A causes 
B” inherently implies a comparison of the effect of A on B to some condition not 
involving A (84). 
Secondly, the key notion that distinguishes a “cause” from an attribute or characteristic 
is the potential for all units in the population of interest to be exposed to all levels of the 
cause being compared. In other words, before a unit has been assigned a certain level of 
the cause, it must be technically possible to define and observe, in principle, every level 
𝑎  of the causal factor 𝐴  under consideration; no outcome 𝑌𝑖(𝑎)  can be a priori 
“counterfactual” for any individual 𝑖 (85). Thus Holland (84) explains how statements 
regarding the effect of an individual’s traits (such as sex, race, eye colour) can only 
describe observational associations rather than be given causal interpretation. To 
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understand why this is so, it is necessary to consider the fundamental difference 
between causal and associational analyses.  
3.8.2. Distinction between causal and associational analysis 
In order to understand the difference between associational and causal analyses, it is 
vital to appreciate the difference between the underlying causal model and the process 
of observation (84). Thus consider a comparison of exposure to experimental (𝐴 = 1) 
versus control treatment (𝐴 = 0) on outcome 𝑌. An individual’s observed outcome 𝑌𝐴𝑖 
may differ from their underlying unconfounded potential outcome under each potential 
treatment assignment (𝑌0𝑖  or 𝑌1𝑖 ), as their observed outcome may be influenced by 
factors other than just treatment received. Therefore, the association between treatment 
received and observed outcome may be contaminated by selection and confounding 
factors and thus may not reflect the true underlying causal relationship between 
treatment received and true potential outcome, the observed data (𝐴𝑖 , 𝑌𝐴𝑖) may therefore 
differ from the underlying causal variables (𝐴𝑖, 𝑌0𝑖 , 𝑌1𝑖). 
As such, in providing information only on the observed association between variables, 
results from standard statistical analysis methods (for example, regression or 
stratification methodologies) can only be interpreted in terms of descriptive statistics 
rather than providing any evidence of causality (84).  
Such methods are used to estimate population parameters from which study samples 
are selected, and thus may be used to provide information on the observed relationship 
between variables by considering their joint distribution. For example, if 𝑃(𝑌 = 𝑦, 𝐴 =
𝑎)  denotes the proportion of individuals 𝑖  in the population for which 𝑌𝑖 =  𝑦  and 
𝐴𝑖 =  𝑎, parameters estimated from this joint distribution simply describe the observed 
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relationship between variables at a single point in time; for example, the conditional 
distribution of 𝑌 given 𝐴 
𝑃(𝑌 = 𝑦|𝐴 = 𝑎)  =  
𝑃(𝑌 = 𝑦, 𝐴 = 𝑎)
𝑃(𝐴 = 𝑎)
 
describes how the distribution of 𝑌  changes with 𝐴 . A typical parameter from this 
distribution may be obtained by regressing 𝑌  on 𝐴 , providing the conditional 
expectation (or average) of 𝑌 given 𝐴, 𝐸(𝑌|𝐴 = 𝑎), i.e. the expected value of 𝑌 given a 
specific value of 𝐴.  
In contrast, statements regarding causality cannot be defined from a joint distribution 
alone. This is due to the potential bias arising when comparing different treatment 
effects observed in distinct sections of the population, as underlying inherent 
differences between individuals in each treatment group may distort the comparison.  
The definitions of, and reasons for, these forms of bias are most easily depicted and 
defined through the use of causal diagrams.  
3.9. Causal diagrams 
Causal diagrams are a form of directed acyclic graph providing a visual representation of 
causal or associational relationships between variables, first used by Wright (1921) to 
convey the direction of the causal relationship in equation modelling.  
A directed acyclic graph (DAG) is made up of nodes (indicating measured or 
unmeasured variables) and directed edges (arrows between nodes). A DAG is called a 
causal DAG when the arrows have direct causal interpretation (i.e. arrows represent 
structural rather than merely associational relationships) and all common causes of each 
pair of variables are included on the graph. Causal DAGs (cDAGs) are necessarily 
acyclic (because a cause cannot affect itself, which would be implied from a cyclic 
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graph) and directed (because causal effects are by definition directional, from cause to 
effect). 
Wright demonstrated how a causal diagram could be used to clarify the fact that the 
equation Y = βA + c, intended to indicate the strength of the relationship between A 
(exposure or cause) and Y (outcome), could not meaningfully be rearranged to suggest 
that Y influences A i.e. A = (Y − c)/ β, given that the causal diagram accompanying 
such an equation indicates the direction of the causal relationship with an arrow from A 
to Y. 
Hernan (86) summarises the theory underlying cDAGs, summarising the three causal 
structures by which apparent associations may be produced between treatment actually 
received (adopted treatment 𝐴) and outcome (𝑌):  
i) treatment received (𝐴) and outcome (𝑌) may share a common cause (𝑈), 
leading to potential apparent association even when neither 𝐴 causes 𝑌 (or 
vice versa) (common cause) (as per figure below) 
 
ii) treatment received (𝐴) and outcome (𝑌) may have a common effect (𝐶), 
such that they will be conditionally associated when the association measure 
is calculated within levels of the common effect 𝐶  (conditioning on 
common effects) as per figure below, where square around  𝐶  indicates 
conditioning on certain value of 𝐶 . In fact, the conditional association 
between 𝐴  and 𝑌  may occur more generally, within strata of a common 
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effect 𝐶 of two other variables – one of which is either 𝐴 (or a cause of 𝐴) 
and the other which is either 𝑌 (or a cause of 𝑌). 
 
iii) the treatment received (𝐴) may in truth cause outcome 𝑌 (cause and effect), 
thus the apparent association can be attributed entirely to the causal effect 
of 𝐴 on 𝑌. 
 
Note that these three causal structures do not include the arising of association simply 
by chance, because, in contrast to causal associations, such chance associations will 
diminish with increasing sample size. 
Thus evidence of an association between two variables does not necessarily indicate a 
true causal relationship; instead apparent associations may arise due to a common cause 
or conditioning on common effects of the variables. Furthermore, categorisation into 
these three causal structures provides a basis on which to distinguish between the types 
of bias that arise when associational parameters are interpreted as causal measures, in 
particular differentiating between “confounding” and “selection” biases: the term 
“confounding bias” typically arises when exposure and outcome share a common cause 
(structure i), whereas “selection bias” occurs when analysis is conditional on common 
effects of exposure and outcome (structure ii).  
Perfect randomised trial 
In the case of a perfect randomised trial, with no confounding of treatment assignment 
or nonadherence to assigned treatment, successful blinding and complete follow up, an 
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individual’s actual treatment received ( 𝐴 ) perfectly reflects their randomisation 
allocation (𝑍), which is assigned independently of all underlying prognostic factors (𝑈). 
Thus, given that 𝐴 and Y share no common causes and no conditioning is made on 
their common effects, the association measure (∆) between 𝐴 and 𝑌 is not affected by 
bias and can be interpreted as the causal effect measure. 
 
Imperfect adherence to randomised treatment  
However, in the case of a randomised trial with imperfect adherence to treatment 
assignment, analysis according to adopted treatment (𝐴) is confounded if there are 
underlying prognostic factors (𝑈) which influence both an individual’s likelihood of 
taking treatment and their outcome, as 𝐴 and 𝑌 share a common cause (as per structure 
i above).  
 
Missing outcome data 
Furthermore, selection bias may occur if the trial is subject to missing data, even with 
complete adherence to assigned treatment; a so-called “differential loss to follow up” 
bias occurs when missing outcome data typically occur for reasons related to both 
prognosis and treatment (86). For example, side effects associated with treatment may 
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lead to censoring (if patients are too ill to attend follow up visits), as represented by 
arrow from 𝑍(= 𝐴)  to 𝐶  (denoting conditioning on censoring status) in the figure 
below. Furthermore, a patient’s underlying condition and prognosis (𝑈) (mediated by 
their observed symptoms 𝑋) may affect their likelihood of follow up (as demonstrated 
by arrows from 𝑈 to 𝑋, and from 𝑋 to 𝐶). Thus, the association between 𝐴 and 𝑈 via 𝐶 
means that, even when treatment does not affect outcome (evident by the lack of an 
arrow from 𝐴  to 𝑌 ), when analysis is conditional on follow up ( 𝐶 ), an apparent 
association between treatment and outcome may result, arising solely because  𝐶  is a 
common effect of a cause of the outcome (the underlying condition and prognosis, 𝑈) 
and of the treatment received (𝐴). 
 
Therefore, even in the case of full adherence to treatment assignment, trials may still be 
subject to selection bias because of differential loss to follow up. A similar selection bias 
occurs in the case of a per protocol (PP) analysis of a trial with imperfect compliance, 
where selection into the analysis set is determined according to compliance status 
(denoted again by 𝐶  in the diagram above), if such compliance is related to any 
underlying prognostic factors (𝑈) as well as being related to the assigned treatment 
protocol (𝑍 ≠ 𝐴). This selection bias introduces a non-causal association between 𝑍 
and 𝑌 such that the PP analysis cannot be granted causal interpretation. 
An as treated (AT) analysis attempts to deal with the loss of power associated with PP 
analyses, by allocating patients entirely according to their adherence rather than 
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randomisation. Even in the case of purely random nonadherence, this analysis removes 
any balance afforded by randomisation, and therefore reflects an entirely observational 
comparison, given that randomised allocation is ignored entirely. As such, the simple 𝐴-
𝑌 association measure will be confounded in the same way as for observational studies, 
if underlying reasons for exposure to treatment are related in any way to prognosis (i.e. 
if treatment exposure (𝐴) and outcome (𝑌) share common causes). 
PP and AT analyses are therefore only valid under a simplistic exchangeability 
assumption, namely that those who do and do not comply are comparable, such that 
comparison between these groups is not subject to confounding or selection effects; 
only then will exclusion (or censoring) of those who deviate from randomised treatment 
(in the case of PP), or analysis according to treatment receipt (in the case of AT), not 
introduce bias. In other words, without appropriate adjustment for selection bias or 
confounding, PP and AT implicitly assume that non-compliance occurs completely at 
random (87). However, as demonstrated by the cDAG for a trial with imperfect 
compliance, given the likelihood of some unmeasured and unknown confounders, it will 
not be possible to account for the so-called “back-door” path (between 𝑈, 𝐴 and 𝑌) 
when estimating the causal effect (of 𝐴 on 𝑌) without invoking additional assumptions. 
3.9.1. Problems associated with hidden bias or time-dependent 
confounding 
Ten Have (88) distinguishes between two forms of (selection) bias, overt and hidden, 
which are attributed to observed and unobserved confounders, respectively. When 
aiming to estimate causal effects, standard statistical methods such as covariate 
adjustment in a regression model or propensity score analysis may be used to adjust for 
overt bias, given availability of known confounders, but these methods cannot address 
hidden bias.  
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Furthermore, standard adjustment for measured confounders may introduce bias if 
these confounders are time-dependent rather than fixed baseline measures. In the case 
of dynamic treatment regimens, common in epidemiological studies and trials where 
treatment is continuously being reassessed and varied according to evolving patient 
response, time-varying factors such as disease severity and adverse events will not only 
be affected by previous treatment received, but may also influence future treatment 
decisions and patient outcome. As such, these time-dependent confounders act 
simultaneously as confounders and intermediate (mediator) variables and cannot be 
adjusted for unbiasedly using standard methods. The reason for this (as demonstrated in 
the cDAG below) is that, in adjusting for confounding, selection bias is introduced.  
 
By way of explanation, consider the trial scenario indicated in the cDAG above, where 
initial treatment ( 𝐴0 ) impacts on symptoms ( 𝑋1 ) which are used to decide on 
subsequent treatment ( 𝐴1 ). Unbiased estimation of the effect of overall treatment 
(𝐴 = 𝐴0 + 𝐴1) requires adjustment for 𝑋1 to remove confounding bias in estimating 
the effect of 𝐴1 (caused by common cause 𝑈 of 𝐴1and 𝑌), but in doing so, stratification 
(or regression, depending on the functional form of the covariates 𝑋1 ) introduces 
selection bias for the estimation of the effect of 𝐴0 (due to conditioning on 𝑋1, which is 
a common effect of 𝐴0  and 𝑈). Thus, standard methods to adjust for confounding 
factors affecting treatment decisions removes confounding at the expense of 
introducing selection bias (86). 
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Thus, given the inability of standard methods to adjust for unmeasured (hidden) or 
time-dependent confounding likely to be present in both trials and observational 
studies, alternative methods are required to provide unbiased estimation of causal 
contrasts of interest. Furthermore, estimation of treatment effectiveness may be subject 
to selection bias due to missing outcome data, such that the most basic ITT analysis 
(according to randomisation) may be rendered invalid. As such, causal methodology will 
be relevant in both pragmatic and efficacy trials subject to any form of deviation from 
treatment or follow up protocols.  
3.10. Discussion 
The complications introduced by nonadherence in the general medical setting (as 
described in Chapter 2) are compounded further in trials by the added dimension of 
necessary adherence by both the patient and the treatment provider to the treatment 
regimen specified in the trial protocol. Even the most pragmatic of trials require clear 
specification of the treatment practices followed in the trial to allow reproducibility, 
provide transparency and provide a basis for treatment evidence. Thus, the need to 
follow even a relatively flexible treatment protocol will necessarily limit the level of true 
concordance achievable in a trial setting (44). Serebruany (35) suggests that an element 
of concordance can be incorporated into a clinical trial context simply by the doctor 
explaining the possible adverse reactions that the patient may experience, in order to 
minimise treatment discontinuation, but concludes that the “impact of the concordance 
model on clinical trials is unclear and requires further consideration”. Trialists would 
need to give detailed explanation of how ‘concordance’ affected treatment protocol, 
which would require detailed collection and succinct summaries of treatment patterns. 
Incorporating the spirit of concordance, with its evolutionary and particularly 
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unpredictable nature, is therefore even more challenging in a trial setting than in general 
clinical practice.  
In this chapter, it has become evident that the nature and extent of nonadherence 
manifested in a trial will impact on trial conclusions, as a result of complications in 
statistical analysis when patients’ outcome data are excluded or missing due to 
ineligibility, missing assessments or deviations from treatment protocol. However, even 
in trials of a predominantly pragmatic nature, there may be numerous reasons to 
consider the extent, and impact on analysis, of such deviations from protocol. Before 
considering methods to appropriately account for nonadherence, in the next chapter, 
we will consider real-life examples of some such trial scenarios where it may be of 
interest to look beyond ITT for answers to alternative research questions of interest 
beyond the effect of treatment as randomised. 
3.11. Recommendations 
Although ITT analysis is an important part of any trial, there is a potential danger that 
the spirit of ITT could be interpreted as an indication that collecting or reporting data 
on the degree of adherence to treatment protocol is unimportant. However even when 
there is no intention to formally investigate the relationship between treatment uptake 
and outcome, reporting information on the degree of intervention received is arguably 
important in order to assess the degree to which the intervention is even reaching the 
targeted population. Otherwise it may not possible to judge whether an unfavourable 
observed effect of treatment, for example, may be in part due to non-receipt rather than 
ineffectiveness of treatment, and if due to non-receipt of intervention, whether steps 
could be taken to improve uptake of treatment to potentially enhance treatment effect. 
Indeed, an ITT analysis can only provide information on the effectiveness of the 
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intervention as it was implemented in the trial (for example, the trial policies on 
treatment changes) and according to the level of adherence observed in the trial. In 
reality, the implementation of the intervention in clinical practice may differ, and 
adherence rates may improve (or diminish) directly because of dissemination of results 
from the trial itself and resultant changes in expectation of the intervention amongst 
users and clinicians. Thus even the interpretation of the effectiveness of an intervention 
may be limited from an ITT analysis. Collecting information on adherence and 
treatment changes that occurred in the trial could potentially allow subsequent statistical 
investigation into the impact of changes to administration of treatment or adherence 
rates on the treatment effect (89). Even in the case of so-called “large, simple trials” 
where emphasis lies on collection of limited data from a very large number of 
participants (90), collection of adherence information from just a small random 
subsample of patients may add to the clinical interpretation of trial results without 
greatly increasing the burden on participants or trial staff.  
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4. Expository trials 
demonstrating nonadherence  
The previous chapter demonstrated how the problem of nonadherence in general 
clinical practice translates into problems in randomised trials, causing complications for 
analysis and interpretation of trial results. Before future chapters explore in more detail 
how deviation from protocol affects analysis and subsequent interpretation of 
conclusions drawn from trial data, and potential methods to appropriately account for 
such deviations, this chapter will present a number of expository trials demonstrating 
issues relating to various forms of departure from randomised treatment, thus providing 
examples of when it may be appropriate to consider estimation methods beyond ITT.  
Trials will be described in term of their interventions, patient populations and the 
particular forms of treatment deviations that occurred, with a focus on how these 
treatment deviations relate to the trial research question and their subsequent impact on 
trial conduct, data collection and analysis.  A number of these trials will be used later in 
   
   
96 
 
the thesis to illustrate the application of particular statistical methods to adjust for such 
nonadherence.  
4.1. Introduction  
This exposition includes seven trials from six different clinical areas, including HIV, 
cancer, epilepsy, community infant care, wound care and (two trials in) coronary heart 
disease (CHD). Treatment duration varies; the majority of the trials had a longitudinal 
treatment period, either medium term (wound care and cancer) or long term (epilepsy, 
HIV, hypertension and CHD), but there is also an example of short term treatment 
(community care). There are examples of trials which include treatment changes that 
were necessary and expected and thus were incorporated into the trial protocol (HIV, 
epilepsy, CHD and cancer); in contrast, other trials experienced treatment changes that 
were unplanned and undesirable, either as a result of treatment switches requested by 
patients or administered by external clinical staff (because of a belief that one treatment 
was superior (wound care)), logistical difficulties in distributing treatment (community 
care) or nonadherence to treatment dose or schedule by participating patients (CHD). 
Most of the trials considered analysis that accounted for changes in prescribed treatments 
rather than adherence by randomised participants, as patient adherence data were 
generally not collected.  
The majority of the trials reported primary outcomes that captured time to some event, 
which is not surprising given the longitudinal nature of most of the trial treatments, but 
two trials included binary outcomes (one of which was the original primary outcome 
(community care) and the other which was included as a simplification of the 
complicated primary time to event outcome (epilepsy). All but one (cancer) of the trials 
are complete and have previously been published.  
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4.2. Trials  
4.2.1. Vitamin A 
The simplest trial in terms of both the types of treatment deviation and primary 
outcome is the vitamin A trial, first published by Sommer et al (91). This was a cluster 
randomised trial carried out in 450 villages in rural Indonesia, half of which were 
randomly assigned to the treatment arm and the remaining were designated as control 
villages. Preschool children in the treatment arm villages were given two large oral doses 
of vitamin A six months apart, and children in control villages did not receive any 
treatment. The primary outcome was mortality rate between four and twelve months of 
age. 
Deviation from randomised treatment in the vitamin A trial did not occur as a result of 
a lack of cooperation on the part of the participant; instead non-receipt of trial drug 
occurred as a direct result of the failure of the trial drug distribution system to reach a 
substantial proportion of those randomised to receive treatment: 20% (2419/12,094) of 
those children randomised to the treatment arm did not receive vitamin A.  
Table 2: Table I from (91) 
Study group  Received 
treatment  
Number of 
children 
Number of 
deaths 
Mortality  
(per 1000) 
Control - 11,588 74 6.4 
Treatment  - 12,094 46 3.8 
 Yes 9675 12 1.2 
 No 2419 34 14.1 
 
Information on those who did and did not receive treatment was captured, and thus it 
was possible to calculate the mortality rate among those allocated to treatment who did 
and did not actually receive vitamin A (1.2 per 1000 versus 14.1 per 1000 respectively) 
among those randomised to receive treatment. This initial comparison suggests that the 
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selection of patients in ‘compliant’ and ‘non-compliant’ groups is not simply a random 
process, and the reason why infants did not receive treatment (failure on the part of the 
distribution system) provides an explanation for this: Goetghebeur (92) points out that 
those infants who did not receive the treatment tended to be those living in a more 
difficult environment with less access to health resources. Thus the non-compliant 
subgroup had a higher baseline risk of mortality and were thus more likely to have died, 
irrespective of whether or not they received treatment. 
This propensity for a more successful outcome among those who comply with 
treatment compared with those who don’t comply with treatment does not, in itself, 
lead to a biased comparison between treatment groups. Bias arises only when 
differences between the two treatment groups, in terms of the mechanisms which lead 
to non-compliance, result in differential selection processes for compliant subgroups, 
such that the resultant compliant subgroups in the two treatment arms are not 
comparable (91).  
However, this fact is also evident when one compares the mortality rate among the 
non-compliant subgroup of the vitamin A group to that observed in the group of 
infants who were randomised to not receive vitamin A. As children in the control arm 
were not administered with any placebo treatment, non-compliers in the active 
treatment received the same “intervention” (no treatment) as those in the control arm. 
Thus if one were to suppose that compliance to intervention was entirely random, the 
mortality rates between the control arm and non-compliers in the treatment arm would 
be expected to be broadly similar. However a comparison of these mortality rates 
demonstrates a mortality rate among non-compliant treatment arm infants (1.41%) 
which is more than twice the mortality rate of the overall control arm (0.64%). As 
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Sommer points out, this suggests that simply being able to access the vitamin A 
treatment strongly predicts the risk of mortality.  
A simple ITT analysis, comparing the treatment groups as randomised, regardless of 
compliance with the randomised intervention, provides an estimate of the relative risk 
(RR, defined as the risk of death among the treatment arm divided by the risk of death 
in the control arm) of death, giving an indication of the so-called “programmatic 
effectiveness” of the vitamin A distribution. Using data from Table 2, the estimate of 
this relative risk is 0.38/0.64 = 0.59 (95% CI= 0.41, 0.86), thus implying that the 
vitamin A distribution programme used in the trial resulted in approximately a 40% 
reduction in childhood mortality.  
However, given that a substantial proportion of the treatment arm did not receive 
Vitamin A simply because the trial treatment distribution system failed to reach them, 
causal analysis beyond ITT (such as that carried out by Sommer and Zeger) are 
necessary in order to estimate the biological action of vitamin A in preventing 
childhood mortality. This question of treatment efficacy is of particular interest in this 
case because, if vitamin A was proved to be efficacious, the treatment distribution 
method used in the trial would not be used in practice to provide supplementation to 
the Indonesian population. Instead a completely different method of circulation, such 
as fortification of a common daily food, would be used to reach the general population. 
As such, Sommer argues that by estimating the biologic efficacy of vitamin A 
supplementation, along with a likely rate of successful delivery of the actual method 
chosen for vitamin A distribution, the effectiveness of the chosen program could be 
determined; this would be a more useful measure than the effectiveness of the trial 
distribution program, which would not be used in practice. 
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Thus Sommer and Zeger (47) first proposed a method of analysis to estimate what they 
refer to as the ‘biologic efficacy’ of treatment, as opposed to the ‘programmatic 
effectiveness’ of treatment. As the use of a placebo was not permitted in this trial, it is 
not possible to ascertain which of the control children would have complied with 
placebo intervention. Such information is not, however, necessary for the method of 
analysis proposed by Sommer and Zeger, and the reason for this is that the compliant 
subgroups of the two randomised groups would not necessarily be comparable anyway. 
This is due to the fact that the compliance selection process is likely to differ between 
the two treatment arms, because the difference in treatment protocol between the two 
arms is likely to present a different challenge to adherence, thus resulting in compliant 
subgroups that have been selected by different processes and hence do not provide a 
valid or fair basis for comparison (47).  
Instead Sommer and Zeger propose a comparison of outcomes among those who 
would have complied with active treatment if randomised to receive it. Although such a 
subgroup is directly observed in the vitamin A group, it is not possible to directly 
ascertain which patients would have complied with active treatment in the control arm, 
and thus it is necessary to compare the outcome among those observed to be compliant 
in the active treatment arm with an inferred control subgroup who would have complied 
with active treatment (47). The causal effect estimated using their proposed method (to 
be presented and discussed in the next chapter) was later referred to as the CACE 
estimate (complier average causal effect) and relates to the efficacy only among those 
who would comply with treatment.  
4.2.2. CPD trial 
The Coronary Drug Project (CDP) was a randomised, double-blind, placebo-controlled, 
six-arm trial that was carried out to evaluate the long term efficacy and safety of lipid-
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influencing drugs in the secondary prevention of coronary heart disease (CHD) among 
middle aged males who had experienced a myocardial infarction within the previous 
three months (65). Participants were randomly assigned to the placebo arm (2789 men) 
or to an active treatment arm (each of which contained approximately 1100 men), and 
were followed up at four-monthly visits for a minimum (maximum) of 5 years, or until 
death. This summary of the trial focuses on only one active treatment arm (clofibrate) 
versus placebo. The primary outcome was all-cause five-year mortality rate. 
Nonadherence to treatment protocol in the CDP occurred as a result of patients failing 
to take the correct dosage of their randomised treatment. Following the initial titration 
phase, patients in each treatment arm were required to take nine tablets daily (three 
tablets three times per day). Clinicians recorded any changes to prescribed medication at 
each four-monthly visit, along with their assessment of the patient’s adherence to the 
drug regimen since their previous clinic visit. This assessment was made by counting or 
estimating how many capsules had been returned by the patient at each visit, along with 
information obtained from a discussion with the patient about whether they had 
experienced any problems in remembering to take (or side effects resulting from taking) 
their medication. This information was used to calculate the cumulative percentage 
adherence over the first five years of follow up (or until death, if this occurred before 
the end of five years follow up). Patients were divided into ‘compliant’ and ‘non-
compliant’ subgroups according to whether or not they took at least 80% of their 
prescribed medication. 
The adherence data used here was necessarily determined by clinician from interview 
with patient and pill counts, neither of which are methods that are considered 
particularly reliable (15). The adherence data suggested that one third of the patients 
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(33.5% (357/1065) in the clofibrate group and 32.7% (882/2695) in the placebo group) 
failed to take at least 80% of their prescribed medication.  
Overall clofibrate did not appear to affect mortality when compared to placebo: five-
year mortality in the clofibrate group was 20.0% compared to 20.9% in the placebo 
group. Given this negative result and the relatively complicated patient-administered 
treatment (3 x 3 tablets daily) and high prevalence of non-compliance (defined as taking 
less than 80% of prescribed medication over the course of the first five years of 
treatment), the study investigators and external parties became interested in whether the 
ITT result may have masked a true effect of treatment among those who received 
clofibrate as intended.  
Table 3 Mortality rates according to adherence level.  
Note that this table only includes those patients for whom cumulative adherence rate was available. 
 Treatment group 
 Clofibrate Placebo 
 Number of 
patients  
% mortality  
(SE) 
Number of 
patients  
% mortality  
(SE) 
Adherence      
<80% 357 24.6 (2.3) 882 28.2 (1.5) 
≥80% 708 15.0 (1.3) 1813 15.1 (0.8) 
Total 1065 18.2 (1.2) 2695 19.4 (0.8) 
 
An initial inspection of the difference in mortality rates between ‘compliers’ and ‘non-
compliers’ in the clofibrate group seems to support this hypothesis: the mortality rate 
among ‘compliers’ (15.0%) was substantially lower than among ‘non-compliers’ (24.6%). 
However a similar examination of the placebo group demonstrates a similar pattern: the 
mortality rate among placebo ‘compliers’ (15.1%) was almost identical to that of 
clofibrate ‘compliers’ and was nearly half that among those who did not comply to their 
placebo medication schedule (28.2%). Bearing in mind that those who did and did not 
comply with their placebo medication schedule were receiving the same “treatment” 
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(assuming that any placebo effect associated with compliance to prescribed treatment 
would have a minimal effect on the objective outcome mortality), this would suggest 
that the behaviour of patients as regards compliance with medication seems to be 
strongly related to their baseline risk of mortality. It would appear that there are 
confounding factors associated with compliance that affect outcome, such that those 
who are able or willing to comply with taking either intervention as prescribed tend to 
be less likely to experience the event.  
These simple summaries according to adherence levels immediately demonstrate the 
dangers of using a patient response factor such as adherence to select patients for 
inclusion in analysis. A number of comparisons between subgroups defined according 
to adherence can be made; for example, comparing the mortality rate of only those with 
good adherence in the two treatment arms (15.0% in the clofibrate arm versus 15.1% in 
the placebo arm), comparing the mortality rate of only those with poor adherence in the 
two treatment arms (24.6% in the clofibrate arm versus 28.2% in the placebo arm),  
comparing the mortality rate for good adherers in the clofibrate group (15.0%) against 
the placebo group as a whole (19.4%), or comparing the outcome among poor adherers 
in the clofibrate group (24.6%) against the placebo group as a whole (19.4%). Indeed 
the investigators conclude that “one can justify almost any conclusion, depending on 
the analysis chosen” (65). 
The CDP investigators assessed whether adjustment for differences in baseline factors 
between those with ‘good’ and ‘poor’ adherence in the placebo group helped to explain 
the difference in mortality rates between these subgroups. Although poor adherers 
tended to have a somewhat higher prevalence of some of the baseline risk factors when 
compared with good adherers, adjustment for 40 of these variables explained only a 
small proportion of the difference between these subgroups: the adjusted five-year 
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mortality rates were 16.4% (compared with 15.1% unadjusted) for good adherers and 
25.8% (28.2% unadjusted) poor adherers.  
Thus it is evident that the available baseline data did not capture the characteristics 
which were both predictive of outcome and associated with adherence. The baseline 
factors that were measured in this trial reflected clinical rather than behavioural or social 
measures, and it is possible that clinical factors may be less useful in explaining 
compliance behaviour. Without knowledge of which factors simultaneously influence 
adherence and outcome, it is not possible to ascertain the selection processes which 
have resulted in the compliant subgroups in each treatment arm and thus whether or 
not these subgroups provide a fair basis for analysis. Thus this trial provides a 
straightforward example of why analysis according to subgroups defined by compliance 
behaviour is not valid. 
4.2.3. MRC hypertension trial 
The MRC hypertension trial (93) was a randomised single-blind placebo-controlled trial 
set up to assess the long term efficacy of two antihypertensive drugs (diuretic or beta-
blocker) compared with placebo in prevention of cardiovascular (CV) events and 
mortality in elderly patients. 
Given the long term nature of the treatment protocol, the need to monitor and control 
each patients’ blood pressure, and the known possible side effects of the prescribed 
active treatments, the trial protocol permitted changes to treatment from that to which 
patients were originally allocated. These protocol-permitted treatment changes reflected 
what would typically occur in clinical practice. 
The nature of the treatment change depended on the underlying cause: if a patient’s 
blood pressure persistently exceeded their target level, the dose of their (active) 
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randomised drug would be increased, and if this also did not achieve acceptable blood 
pressure control, the patient would be prescribed an additional drug (initially the 
alternative active trial drug). If this too was unsuccessful, a treatment external to the trial 
would be prescribed. If their blood pressure continued to be unacceptably high, the 
patient was managed outside of the trial protocol, but information on prescribed 
treatment and outcomes continued to be collected.  
If a patient was experiencing unacceptable side effects on active randomised treatment, 
the randomised treatment would cease to be prescribed and an alternative treatment 
(commonly the other active trial drug) may have been given instead.  
Other less common treatment changes included discontinued prescription of the 
randomised treatment when it was felt by the prescribing clinician to be unnecessary, or 
withdrawal from the study by patients for reasons which may have been associated with 
risk (for example, dislike of the trial treatments or assessments) or unrelated to risk (for 
example, if a patient moved away).  
Note that the treatment changes recorded in the MRC hypertension trial relate only to 
changes to prescribed treatment. Information on patient adherence to prescribed 
treatment was not recorded, and thus could not be factored into the analysis. It is 
worthy of note that patient nonadherence may have had a similar magnitude of causal 
effect as changes to prescribed medication, but it was not possible to investigate this 
here. 
When analysing those who were lost to follow up, it was possible to obtain their 
mortality data by Office of National Statistics “flagging”, but it was unknown what 
treatment changes occurred following withdrawal. Such “loss to treatment follow up” 
(so-called by White (68) as these patients were not lost to event follow up, as time and 
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cause of death was ascertainable for all patients through flagging) was not an 
insignificant factor: White states than 21% of person years, and 41% of deaths, 
occurred in subjects who were lost to treatment follow up (defined as the period 
following withdrawal or 190 days after a subjects’ last follow up visit). 
Patients randomised to receive beta-blocker were more often prescribed supplementary 
drugs than those randomised to diuretic treatment, and this group experienced 
significantly more withdrawals than the diuretic group, both for reasons related to side 
effects and because of inadequate blood pressure control. A larger proportion of the 
beta-blocker group also discontinued their randomised treatment: including those who 
were lost to follow up, almost two thirds of the beta-blocker groups stopped their 
randomised treatment compared to approximately half of the diuretic group (cumulative 
percentages of those who stopped their randomised treatment, including those lost to 
follow up, were equal to 63% in the beta-blocker group and 48% in the diuretic group). 
The ITT analysis of the MRC hypertension trial appropriately addressed the primary 
question of interest, namely whether there was any difference in the effectiveness of the 
treatment policies of starting treatment with one randomised intervention, followed by 
any treatment changes that became necessary. The effectiveness of the active treatments 
in preventing stroke and other CV events was apparent from the ITT analysis, as the 
risk of these events was significantly reduced in the active treatment groups compared 
with the placebo groups. When the two active treatment groups were compared directly 
in an ITT analysis, it was unexpectedly found that the rate of coronary events (and of all 
CV events) was significantly lower in the diuretic group compared with the beta-blocker 
group. 
In light of the frequency of treatment changes that occurred in this trial, and the 
relatively high proportion of follow up time that was spent not taking randomised 
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treatment, it was naturally of interest to the trial investigators to investigate whether, 
and how much of, the unexpected ITT difference between the active treatment groups 
was in fact be due to differential rates of treatment changes that occurred in the 
different randomised groups.  
White adjusted for changes in prescribed treatment in this trial using both naïve (68) 
and randomisation-based (89) methods (to be introduced in the next chapter). These 
analyses demonstrate the need for an understanding of the subtleties of the particular 
disease or treatment being studied before one can confidently produce and interpret 
findings from a causal analysis. Effective communication between the statistical analysts 
and the clinical experts for a particular trial is of paramount importance to ensure such 
nuances are not overlooked in the analysis, and to prevent statistical anomalies or biased 
interpretation of trial results. 
4.2.4. Concorde  
The Concorde trial was designed to compare two treatment policies with zidovudine 
(ZDV) among patients with asymptotic HIV disease. ZDV was known to be efficacious 
in delaying death when treating symptomatic HIV disease, but it was unknown whether 
treatment with ZDV earlier in the disease process would delay the onset of AIDS-
related complex (ARC) or AIDS, or whether it could be potentially harmful due to 
increased toxicity. Thus patients were randomised either to start ZDV immediately 
following randomisation (immediate group) or to delay treatment with ZDV until the 
onset of symptomatic HIV disease (ARC or AIDS). The trial was double-blind; patients 
in the deferred group were administered with placebo from randomisation until they 
presented with symptoms of the disease, at which point they started to receive active 
ZDV treatment (94).  
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The treatment protocol intended patients to receive blinded treatment (active ZDV in 
the immediate group or placebo in the deferred group) until the point of disease 
progression, at which point they were to be prescribed open label ZDV without being 
unblinded to their original allocation. However, there were deviations from this 
intended schedule for a number of reasons. Some patients experienced a delay in 
starting their active or placebo treatment (though this was usually a relatively short 
period of delay). Patients could choose to stop taking their blinded medication, and this 
occurred usually because of adverse events or for personal reasons. In these cases of 
early cessation of treatment, patients were not unblinded to their original treatment and 
they were prescribed with open label ZDV if and when they presented with disease 
progression. If patients developed clinical or immunological deterioration (before 
disease progression) they stopped their blinded treatment and usually started open label 
ZDV within a few days. 
Major changes were made to the treatment protocol one year into the recruitment 
phase. Although the original protocol specified that patients in the deferred group 
should not start active ZDV treatment until the onset of ARC or AIDS, the protocol 
amendment permitted subjects in the deferred group to begin taking open label ZDV 
before the onset of ARC or AIDS if they persistently presented with low CD4 cell 
counts. Another change which affected both treatment groups was introduced as part 
of this amendment, namely that patients with low CD4 cell counts were to be treated 
with primary PCP prophylaxis. (PCP is an opportunistic infection that affects AIDS 
patients, and recurring attacks of PCP may be fatal (95).) These changes brought the 
treatment protocol in line with what had become regarded as best clinical practice since 
the protocol had been originally devised.  
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A substantial proportion of patients experienced treatment changes in this trial. 
Approximately one third of each group stopped blinded therapy for reasons other than 
clinical deterioration; another one third of patients stopped open label ZDV treatment. 
A higher proportion of deferred group patients (48%) than immediate group patients 
(37%) started open label ZDV and these treatments tended to be started earlier in the 
deferred group. 
There were three related survival outcomes of primary interest: time to disease 
progression (ARC or AIDS) or death, time to AIDS or death, and time to death. The 
ITT results from this trial suggested a potential benefit of early treatment with ZDV in 
preventing disease progression (to ARC, AIDS) or death (HR (95% CI) = 0.89 (0.75, 
1.05), no effect on prolonging time to progression to AIDS or death (HR (95% CI) = 
1.01 (0.82, 1.24), and a possible detrimental effect on overall survival (HR (95% CI) = 
1.26 (0.93, 1.70)), but none of these results were statistically significant. 
However, the amendments to the treatment protocol were a cause for concern: 
although it was recognised that the treatment protocol amendment was necessary to 
update the trial to standards of best clinical practice, the decision to allow 
commencement of treatment in the deferred group to a time point earlier than originally 
intended led to complaints that this had resulted in an unfair assessment and a diluted 
effect estimate of treatment with ZDV. The ITT analysis of the trial appropriately 
assessed the comparison of the treatment policies as implemented in the trial, but given 
the change to original protocol, this did not assess the treatment policies as they were 
originally intended to be implemented in the trial. 
Thus, when the ITT results of the Concorde trial were published, providing no 
statistically significant evidence of a clinical benefit of starting ZDV prior to 
presentation of symptomatic HIV infection, the question arose whether these 
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discouraging results could have been caused by a diluted effect of starting ZDV 
treatment early in the asymptomatic phase of HIV disease, as a result of the change of 
treatment protocol leading to earlier starting of ZDV among the deferred group than 
had originally been intended.  
Premature cessation of blinded or open label treatment, whether for clinical or personal 
reasons, would be expected to occur naturally when ZDV treatment was prescribed as 
part of normal clinical care. Thus this aspect of deviation from the randomised course 
of treatment was not considered to distort the interpretation of the trial, and 
accordingly the causal analysis did not attempt to factor out these treatment changes.  
White (94) used this example to demonstrate the need to sensibly decide on the scenario 
that one wishes to simulate when adjusting for treatment changes: this is a clinical issue 
which must be determined in light of which treatment changes are inherently intrinsic 
to the treatment and disease pathway, and which changes would be usefully factored out 
in order to answer certain research questions. Once the relevant research question of 
interest has been carefully specified, this will then logically (if not easily) translate into a 
model that would reflect this adjusted scenario.  
For example, in this trial, White points out that it that it would not be interesting or 
informative to factor out cessation of treatment that occurred when patients 
experienced side effects, as this is an expected course of events. Also, given that it was 
already known that ZDV was efficacious in treating advanced disease, it would not be 
sensible to simulate a comparison between the immediate group as treated against an 
altered deferred group who never received ZDV treatment, as this would not enhance 
clinical knowledge beyond what is already known of ZDV efficacy. 
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Instead the desired alternative treatment scenario of interest is that which would have 
occurred under the original treatment protocol, so that patients in the deferred group 
would not have received treatment prior to disease progression or death, but other 
treatment changes would have been expected as observed in the trial (for example, 
cessation of treatment due to side effects). Thus it was of interest to adjust only for the 
earlier start of ZDV in the deferred group, which could have contributed to the 
observed non-significant results by diluting the difference between randomised groups. 
This was particularly likely given that decisions to start open-label ZDV treatment in 
this trial were very strongly related to prognosis (74). 
Thus this analysis sought to answer a well-defined question: what would the results have 
been if no participant in the deferred treatment arm had started ZDV before 
progression, but other treatment changes (such as stopping an active treatment after a 
side effect) were as observed? 
Following on from an initial naïve analysis of these trial data using time dependent 
treatment covariates to simulate an AT survival analysis (68), White instead advocates 
and demonstrates use of a randomisation-based survival model (to be introduced in the 
next chapter), which also relates the event time to a time-dependent covariate but which 
is based on groups as randomised (rather than on the biased basis of actual treatment 
received) (89).  
4.2.5. PACIFICO 
PACIFICO is a randomised two-arm trial comparing two forms of chemotherapy for 
fitter older patients with follicular lymphoma, in order to assess which treatment is 
optimal in terms of efficacy in controlling the spread of the disease balanced against the 
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toxicity to patients associated with these types of treatment. This trial is currently still 
recruiting patients. 
The PACIFICO treatment protocol specifies that cycles of inpatient chemotherapy be 
delayed, and potentially ceased entirely, if patients experience excessive toxicity. This is 
a pertinent issue in this trial, given the aim of balancing efficacy with tolerability of 
treatment, and detailed instructions are provided in the protocol regarding these 
permitted changes to the treatment. Clinicians are required to record details of the dose 
and time of treatment cycles in the trial case report forms (CRFs) to ensure that they 
follow the treatment protocol in this regard. However any deviations from the 
instructions given in the protocol are likely to reflect differences that will occur in real 
clinical care, and thus are accepted as an integral part of the variation of treatment 
according to patient’s needs and symptoms.  
The trial chemotherapy also involves patient-administered home therapy. Patients are 
asked to record in a daily diary the date, time and doses of self-administered treatment, 
also noting any occurrences when the absorption of the treatment may have been 
compromised (for example, if vomiting occurred soon after treatment was taken), 
though this is not expected to occur often. Patients are generally expected to comply 
closely with the doses and schedule of prescribed home chemotherapy as far as possible 
as they are keen to halt spread of cancer; furthermore, they are a relatively fit and able 
group who would not be expected to experience the typical logistical or memory 
problems that may be associated with self-administered treatment by the elderly. 
The treatment changes that are, however, of particular interest in terms of causal impact 
in this trial are those relating to alternative treatment choices made at the point of 
disease progression; interest in the impact of this pattern of treatment changes at this 
stage of disease is typical of late-stage cancer trials. When patients are being treated for a 
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cancer that may later progress or relapse, it is often an ethical requirement to permit in 
the trial protocol a switch to alternative treatments when their disease worsens, which 
may or may not include the other trial treatment. In PACIFICO, the treatment protocol 
recognises the need to offer and experiment with other treatments if a patient’s disease 
progresses, and thus the date, time and nature of these alternative treatments are 
recorded.  
The primary outcome in trials where such treatment changes are expected is usually 
chosen to be progression-free survival (PFS) or relapse-free survival (RFS), defined as 
the time from randomisation to progression (or relapse) or death, whichever occurs 
first. Such an outcome is not affected by switches at progression or relapse, as the 
switches occur after the event of interest and thus have no causal impact. Determining 
date of progression, however, is potentially complicated and subjective, and may not 
necessarily translate into a survival advantage.  
The traditionally more common outcome of overall survival (OS) would, however, be 
affected by such treatment changes, as merging of the treatment experience in the two 
arms following progression or relapse is likely to cause diminished treatment effects on 
OS. Despite the fact that such treatment changes are often seen in clinical practice, 
there may be a number of reasons for interest in obtaining a clean estimate of overall 
survival (OS). OS is objective and is usually the most important outcome for the 
patient, as well as being of primary interest for health economics and policy decisions.  
Debate regarding PFS versus OS 
Analysis of OS is often confounded by uncontrolled post-progression (or relapse) 
therapy, which is increasingly common thanks to the growing number of active anti-
cancer agents. This has led to the use of PFS as a surrogate outcome for OS, as 
   
   
114 
 
treatment switches generally occur after the point of progression and, as such, time until 
progression is less heavily affected by changes from randomised treatment. However 
the use of PFS as primary outcome has its own disadvantages. 
Disease progression is a categorical outcome first developed by WHO to describe 
changes that occur to a tumour during therapy, rather than as a measure intended to 
infer meaningful clinical benefit (96). Although potentially useful in early phase trials as 
an indication of potential treatment response, the use of PFS in phase III trials is 
controversial for a number of reasons. 
Sharma (83) highlights how the debate regarding the most appropriate clinical endpoints 
in oncology trials, and in particular whether trials should be allowed to base their 
conclusions on shorter-term outcomes like PFS rather than ultimate long term 
outcomes such as OS, was sparked by the controversial fast track approval of the 
bestselling cancer drug Avastin. The license for sale of this drug was granted by the 
FDA based on trial results which suggested PFS, but not OS, improvement associated 
with the drug; however, following two subsequent trials which demonstrated no such 
improvement and which furthermore suggested a greater side effects profile, the FDA 
later rescinded its approval for the use of Avastin in metastatic cancers because of 
concerns that the drug’s side effects outweighed its benefits, while the European 
Medical Agency reaffirmed its approval. The use of PFS is therefore argued to simply 
provide a means of lowering of the bar for declaring efficacy of new drugs, which in 
turn offers little in the way of meaning for patients.  
Although there are a number of advantages when using PFS in place of OS (as 
progression usually occurs well before death, thus requiring smaller numbers and 
shorter follow up times, and progression is not confounded by effects of subsequent 
follow up therapies), there are a number of limitations associated with PFS.  
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Firstly, the practical implications in defining PFS are not straightforward; the theoretical 
definition of PFS is the time from defined origin (such as date of randomisation) to 
tumour progression or death. However, in practice, progression is usually identified via 
some form of imaging assessment, involving some subjective judgment on the part of 
assessors (often their treating clinician), especially in the case of equivocal or 
uncertainties in interpretation of radiologic assessments. As such, there are a number of 
biases and sources of measurement variability that may arise in obtaining the date of 
progression (for example, when times of evaluation differs between the treatment arms 
or when the knowledge of treatment received in some way affects a patient’s recorded 
response or progression status) (97). 
In particular, given that progression is not as objective an outcome as mortality, there 
are multiple factors which may introduce variability or bias into the assessment of 
progression (97). Thus, in order to make determination of time of progression as 
objective as possible, it is necessary that patients undergo regular and frequent 
assessments, which must be balanced and determined exactly equally for both treatment 
arms, to prevent any biases arising due to timing or prompting for such assessments. In 
order to protect from likely bias that may be introduced when subjective decisions are 
made by assessors or clinicians when determining progression (especially when factors 
such as “clinical deterioration” are included in the definition), blinding of clinicians and 
assessors is of great importance; however, this is not always possible given the disparate 
forms of treatment (for example in terms of treatment schedules and modalities). 
Alternatively the assessment of progression may be made by an independent imaging 
review group.   
There are other potential concerns when using PFS in place of OS as a primary 
outcome. Firstly, it has been demonstrated that PFS is not a reliable surrogate for OS in 
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a number of cancers; only two tumour types have evidence providing support for the 
surrogacy of PFS for OS (96). Indeed Booth provides biological reasons why a certain 
treatment may demonstrate advantages in terms of PFS without impacting on OS. 
Furthermore, PFS is more likely to be affected by missing outcome assessment data and 
informative censoring than OS, as definition of progression relies heavily on the 
availability of the necessary assessment outcome data.  
Change to treatment protocol 
Another potentially interesting aspect of this trial with regards to treatment changes 
involves an important change to treatment protocol that occurred partway through the 
recruitment period. During the course of the trial, concerns regarding excess life-
threatening toxicity due to one component (FC) of the experimental treatment were 
raised as a result of external evidence from another trial. As such, a “lighter” regimen 
(FC-lite) was introduced for all future patients recruited to PACIFICO. This 
amendment to treatment protocol would likely affect the treatment comparison for 
both primary outcomes, as fewer cycles and/or reduced dose of FC treatment will 
impact both on efficacy and tolerability of this treatment. Thus it would be of interest 
to estimate the causal effect of treatment adjusting for this protocol change, in order to 
attempt to answer the original question of interest. 
Thus, causal analyses for the PACIFICO trial would focus on two main questions: first, 
what the treatment efficacy would be if all patients had not received alternative therapies 
on disease progression, and secondly what the treatment effect would have been if all 
patients randomised to receive FC had received the original (rather than the lighter) 
dose as per the original trial protocol.  
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4.2.6. Honey  
Robson et al (98) carried out an open label RCT comparing wound healing rates in 105 
patients randomised to receive either conventional wound dressings or dressings treated 
with a medical grade honey. Treatment and follow up continued until wound healing up 
to a maximum of 24 weeks, and the primary outcome was time to wound healing. The 
aim of the study was to compare a medical grade honey with conventional treatments 
on the rates of wounds healing by secondary intention (rather than by direct 
intervention, such as surgery). 
Despite its relatively straightforward treatment protocol, this trial was subject to a 
number of deviations from treatment protocol and complications in follow up, 
including switches between trial treatments, switches to (known and unknown) non-trial 
treatments, LTFU and death during the course of treatment (a competing risk). 
These treatment changes occurred for a number of reasons. In cases of deterioration of 
the wound, it was ethically necessary to allow patients to receive more extreme forms of 
treatment and as such some trial patients ceased randomised treatment and started 
receiving antibiotics or received surgery or radiotherapy as appropriate. Although 
information on these non-trial treatments were recorded whenever possible, the change 
of patient care often resulted in missing follow up information. When patients withdrew 
from the trial prematurely, or were moved to another hospital, it is likely that they 
continued to receive some form of conventional treatment, but treatment and follow up 
data were not available. 
Expectation about honey treatment also lead to treatment switches from randomised 
conventional arm to honey. There had been considerable amounts of publicity 
regarding the use of honey in wound care by the time the trial was opened, as honey 
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was not at the time available on NHS prescription. This expectation, but lack of 
availability of honey (except in a clinical trial setting such as this one where the honey 
was provided by the manufacturers), initially created a recruitment incentive for both 
patients and clinical staff. However, this anticipated efficacy of honey treatment, 
coupled with the unblinded nature of the trial, frequently lead to disappointment when 
patients were not allocated to receive honey. 
Patients recruited to the trial had typically been unsuccessfully treated with various 
forms of conventional dressings for their offending wound prior to recruitment into the 
trial. As such, given their natural expectation of honey and likely frustration with 
previous conventional treatments, along with the logistical impossibility of blinding 
patients to their randomised allocation (as patients necessarily were able to see and feel 
the applied dressing), patients were prone to disappointment when they were not 
allocated to receive honey. This lead to premature discontinuation of the trial by those 
who could not muster sufficient interest to continue attending the more frequent than 
usual clinic visits required for trial follow up. And occasionally, from the more bold 
discontented patients randomised to conventional treatment, there was the request to 
switch to honey treatment from the outset, which was granted in one case. 
Treatment switches also occurred because of decisions of clinical staff external to the 
trial who were keen for their patients to receive honey, especially those younger fitter 
patients who would be expected to make good progress with honey treatment.  
In contrast, some patients believed that honey treatment was causing additional pain to 
their wound which, as a result of their unblinded treatment, lead to a request to 
discontinue honey treatment and switch to conventional treatment.  
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Death during the course of the trial resulted in irretrievably censored treatment and 
follow up data. Patients requiring care for wounds healing by secondary intention are 
typically relatively elderly and frail, and as such a number of the recruited patients died 
during the course of follow up. Given that death precludes any subsequent occurrence 
of the event and causes of death may be related to deterioration of the wound being 
treated by the randomised treatments (and thus censoring at the time of death would 
potentially be informative), this event is defined as a “competing risk” and introduces 
complications for analysis. 
Missing outcome data often accompanied the treatment changes in this trial. When 
patients withdrew consent from further trial treatment and follow up, either because 
they were discontented with their treatment, progress or with the trial follow up 
requirements, it was not possible to obtain information on the rate of wound healing. 
When the course of treatment was altered because the worsening severity of their 
wound necessitated a more extreme treatment choice, or when the patient moved 
hospital, outcome follow up was not possible on a practical level.   
Although it was ethically necessary to allow patients to receive alternative or more 
powerful treatment if they experience side effects or wound deterioration, the primary 
aim of this trial was to ascertain the biological efficacy of honey treatment when 
compared to the best standard care. As such, it is of interest to estimate the causal effect 
of honey treatment compared with conventional dressings in the absence of any 
treatment changes.  
4.2.7. SANAD 
The SANAD trial was an unblinded randomised comparison of a number of Standard 
And New Antiepileptic Drugs primarily among patients presenting with newly 
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diagnosed epilepsy (although some patients who had unsuccessfully been treated with 
an anti-epileptic drug (AED) previously (not including any of the trial treatments) or 
who had relapsed following withdrawal of treatment after a period of remission were 
also recruited). Patients were enrolled into one of two arms of the SANAD trial: 
Arm A of the SANAD trial was designed to compare the efficacy and safety of five 
antiepileptic drugs (AEDs) (carbamazepine (CBZ), lamotrigine (LTG), gabapentin, 
oxcarbazepine and topiramate) in terms of seizure control, tolerability, quality of life 
(QoL) and health economic outcomes (99), and was intended for patients for whom the 
standard treatment CBZ was considered to be most appropriate (usually presenting with 
focal epilepsy).  
Arm B of the SANAD trial compared (sodium) valproate (VPS), lamotrigine (LTG) and 
topiramate (TPM) (100), and was intended for those for whom the drug valproate was 
considered more appropriate (most of whom had generalised epilepsy).  This multi-way 
randomisation is the first complication affecting both arms of this trial, simply because 
many of the causal methods which can be applied to investigate or adjust for treatment 
changes will struggle to contrast more than two groups.  
The second complication of this trial design was the need to balance efficacy and safety: 
thus if a drug was shown to be superior in terms of tolerability (side effects), it was 
deemed necessary only to demonstrate non-inferiority of the treatment’s efficacy in 
terms of seizure control. The need to employ methods to determine non-inferiority (or 
equivalence) is complicated when treatment deviations occur, because as discussed in 
Chapter 3, ITT analysis is anticonservative in this case. Thus there was a need for 
estimation methods beyond ITT and PP, as neither of these methods are unbiased in 
this setting.  
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The third complication of the SANAD trial was the lack of blinding. As mentioned in 
the discussion of the honey trial, knowledge of which treatment has been prescribed can 
have an impact of the expectations and motivation of patients and clinicians alike. 
AEDs are known to often cause unpleasant side effects; a lack of blinding may mean 
that patients or clinicians are consciously or subconsciously looking for emergence of 
such symptoms and are therefore more likely to act on these side effects than they 
would be if they did not know which treatment was being prescribed. Furthermore, the 
inevitable disappointment if a hoped-for treatment is not prescribed may affect a 
patient’s morale and potentially impact on their general health. Both of these 
consequences of open label prescribing may lead to more frequent decisions to switch 
treatments than if treatment allocation had been masked. 
Changes to prescribed treatment are common in epilepsy, because the clinician must 
tailor the prescription to meet the individual’s needs. The optimum dose of each drug 
varies between individuals, and must provide a balance between maintaining seizure 
control but limiting side effects to a tolerable level. This is achieved by a titration phase, 
in which the dose of the originally prescribed drug is increased or decreased in 
gradations until a balance between efficacy and tolerability is achieved. If a drug is not 
acceptable to a patient following such a titration phase, it may be necessary for an 
additional AED to be prescribed (if, for example, the original drug is not controlling 
seizures) or for the original drug to be dropped entirely and replaced with a different 
AED (if, for example, the original drug is leading to unacceptable side effects even at a 
low dose).  
Thus the treatment protocol in SANAD was chosen to be entirely pragmatic, mirroring 
the ethical requirements for treatment changes that are part of everyday clinical care. 
The treatment protocol did not specify the initial dose of each randomised treatment, or 
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the rate of titration to reach the optimal dose of each trial drug. Instead decisions 
regarding dose and choice of alternative treatments were left to the discretion of the 
treating clinician.  
Treatment changes were further complicated by the typical need for a loading phase 
(when starting a new treatment) or a withdrawal phase (when stopping a treatment) in 
order to slowly increase or reduce prescribed treatment doses, rather than simply 
ceasing treatment straight from, or starting treatment at, a potentially optimum 
maintenance dose. This meant that when a treatment switch took place, there were 
often overlapping periods when two AEDs were taken simultaneously, with the 
duration of this overlap varying considerably between patients. 
Another complication of the SANAD treatment experience was the fact that some 
patients were still taking other treatments at randomisation. These patients were usually 
being withdrawn from a non-trial AED which had failed to prevent seizures, and the 
sometime lengthy withdrawal phase of this drug therefore overlapped with prescription 
of the randomised treatment. 
Thus patients in SANAD could experience a number of different treatment changes 
and complications during their trial follow up, including changes to prescribed 
treatment dose, complete withdrawal from randomised treatment, addition of other trial 
(or less commonly non-trial) treatments to aid seizure control, switching to another trial 
(or non-trial) treatment or a continuing short term prescription of another treatment 
still being taken at randomisation.  
This trial is therefore similar in a number of ways to the MRC hypertension trial 
mentioned previously. As in the MRC trial, the SANAD treatment protocol recognised 
that changes to prescribed treatment would be necessary, with treatment failure (change 
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to prescribed treatment) generally occurring in this clinical area for two competing 
reasons: either as a result of inefficacy of treatment (indicated by inadequate seizure 
control, ISC) or intolerability of treatment (due to unacceptable adverse events, UAE).  
The relevance of the issue of changes to prescribed treatment in epilepsy is borne out 
by the fact that one of the primary outcomes in SANAD was time to treatment failure 
(defined as the time from randomisation to cessation of randomised drug (whether due 
to ISC or UAE or both) or time to addition of a supplementary AED, whichever 
occurred first). ISC typically resulted in addition of an alternative treatment, most 
commonly one of the other trial AEDs, whereas UAEs led to cessation of randomised 
treatment and prescription of an alternative treatment.  
Both of these causes of treatment failures are related to dose but with opposite 
directions of association. Dose is related not only to the efficacy with which a certain 
treatment will prevent further seizures, but also to the likelihood of adverse reactions: as 
dose increases, the efficacy of treatment is expected to increase, but so too will the 
likelihood of unpleasant side effects. Thus it was necessary to analyse time to treatment 
failure using methods allowing for competing risks: a blanket analysis of time to 
treatment failure, without regard for the underlying cause, could lead to a masking of 
treatment effects as a result of cancelling out of the opposite effects of treatment by the 
two competing causes of treatment failure (198). 
The second primary outcome was time to 12 month remission (T12mR), defined as the 
time from randomisation to reaching a 12 month period free of seizures. This outcome 
is of great practical importance to patients, as one year’s remission is required before a 
patient regains the right to their driver’s license. However, as we shall see in future 
chapters, it is a rather complicated non-standard summary of repeated events data. 
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Time to first seizure (TFS) was one of a number of secondary outcomes. Although this 
outcome may initially seem a sensible and obvious choice for a more straightforward 
primary efficacy outcome (than T12mR), it does not necessarily provide a fair 
comparison of treatments, given that seizure control is going to be related to some 
degree to the initial dose of treatment. When clinicians prescribe a drug that is well 
known to them, they are likely to be more confident in increasing the treatment dose as 
part of the titration phase and thus may achieve higher doses of drug more quickly than 
when they are prescribing a newer drug with a less familiar side effect profile. Thus the 
comparison of TFS across treatments may be confounded to some degree with the 
familiarity of the drug, in favour of older treatments, as seizure control depends 
substantially on the initial drug dose.  
Indeed any treatment comparison in terms of seizure control is likely to be influenced 
by this dosing issue; however, dose is likely to have a more direct impact on this 
outcome than on T12mR, which depends more on a sustained delay of seizures and is 
thus less affected by the initial dose. 
Also, as in the MRC hypertension trial, the dose data collected in SANAD related only 
to prescribed treatment rather than patient compliance. Thus, any causal inference from 
these data is necessarily interpreted in terms of the explanatory effect of treatment that 
would be observed if there had been no prescribed changes to randomised treatment. 
Ideally this causal research question would also relate to the effect of compliance with 
randomised treatment schedule; indeed the effect of participant non-compliance with 
prescribed treatment, especially given the side effects associated with treatment, may 
have had a causal impact equal to or greater than that of actual treatment prescribed, 
but without the necessary adherence data, this theory cannot be investigated. 
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In the same way that mortality information was available (via flagging) when a patient 
had incomplete treatment follow up data as a result of premature discontinuation in the 
MRC hypertension trial, and patients in the Concorde had missing treatment 
information despite continuing to be followed up for outcome information, SANAD 
patients for whom treatment follow up data were missing or sparse nevertheless tended 
to be followed up for seizures. In such cases it was necessary to assume, as in the MRC 
trial, that no treatment changes had occurred unless they were specifically recorded. 
When treatment changes occur prior to achieving remission, the assessment of each 
randomised AED is distorted and it becomes unclear which AED should be attributed 
with success or failure in achieving remission. It is therefore of interest to assess the 
impact of uninterrupted use of each AED in achieving remission; thus the causal 
question of interest in terms of estimating treatment efficacy in this trial is as follows: 
What is the relative benefit of each drug in achieving a minimum T12mR, in the 
absence of any changes to prescribed treatment other than changes of dose of 
randomised treatment? Potential analyses investigating this (and variations of this) 
causal research question are explored in more detail in Chapters 8 to 10. 
4.2.8. Magnetic 
In the MAGNETIC trial (101), over 500 children presenting to A&E with a severe 
asthmatic attack were randomised to receive three doses of magnesium or placebo 20 
minutes apart. The primary outcome was asthma severity score at 60 minutes following 
randomisation (ASS60). Treatment deviations occurred in the timing and number of 
doses received: 24 (10%) in the magnesium group and 29 (12%) in the placebo group 
received doses that were more or less than 20 minutes apart (with a maximum margin 
of error of 5 minutes). Such deviations in terms of timing are arguably going to occur in 
clinical practice, given the pressured A&E setting, and thus it would not be sensible to 
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factor out such deviations. It may, however, be reasonable to expect greater control 
over the number of doses given in practice, and thus one could argue that it would be 
of clinical interest to estimate treatment efficacy that adjusts for the cases where less 
than three doses of treatment (as specified by the treatment protocol) were 
administered. There were seven (3%) of such cases in the magnesium arm and 12 (5%) 
in the placebo arms. 
As will be discussed in the next chapter, adjustment for dose deviations could be 
implemented using instrumental variable (IV) regression, with randomisation as the 
exogenous variable; endogenous variables would be actual number of doses of active 
treatment received along with other baseline characteristics that are considered to 
correlate with number of doses received but which do not directly influence the 
outcome. Note that the number of active doses of treatment received would be set as 
zero for all patients in the placebo arm, regardless of their adherence to the treatment 
protocol. Thus the only patients for whom adjustment was required in the case were the 
seven patients in the magnesium arm who received less than three doses.  
Unfortunately six of these seven patients withdrew from the trial prior to collection of 
the primary outcome. The likelihood of missing outcome data among patients who 
deviate from treatment protocol is not unusual. It does however mean that it is not 
possible to use any form of adjustment for deviation from dose protocol without 
imputing values for the missing outcome data (of those who received less than three 
doses in the magnesium arm). 
The authors of the HTA report (102) presented three sensitivity analyses investigating 
the impact of missing outcome data generally (not just among those with treatment 
protocol deviations). The reasons for missing data were recorded, and were most often 
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due to withdrawal from trial or a serious adverse event. The primary ITT analysis 
assumed that the outcome data were missing at random.  
The first sensitivity analysis imputed an ASS60 score of 0 if the recorded reason for 
missing data related to a good clinical status (for example, withdrawal due to 
improvement in condition, as was the case in three children), and imputed a value of 9 
if withdrawal was due to poor clinical status (as was the case for one child). When the 
reason for missingness was unknown or was unlikely to be related to clinical status, the 
outcome data were left as missing. These imputations did not affect the statistical 
significance of the outcome. 
The second sensitivity analysis involved multiple imputation to create five sets of 
imputed values, the average and corresponding variance of which were used to create 
the final data set and adjusted mean differences of ASS60 between the two treatment 
groups. Again the difference in group outcomes remained statistically significant. 
Finally a joint modelling analysis of the time to withdrawal (T0, T20, T40 or T60, with 
those who did not dropout prior to T60 being censored at T60) and the longitudinal 
ASS data was performed to account for the non-ignorable nature of the missing 
outcomes. The results suggest that those who dropped out from the magnesium group 
did so because of an improvement in condition, whereas those who withdrew from the 
placebo were experiencing a worsening of scores prior to dropout.  
Thus an informed adjustment for the reduced dose that was received by seven of the 
magnesium group patients would be likely to further increase the difference between 
the magnesium and placebo groups. However given that these patients are such a small 
percentage (3%) of the magnesium group, it is unlikely that such an adjustment would 
make any appreciable difference to the conclusions. 
   
   
128 
 
4.3. Discussion 
This exposition of nonadherence in trials has demonstrated how treatment receipt may 
differ from randomised allocation for a number of reasons, including logistics, changes 
to trial protocol and (especially in the case of long term treatment regimens) patient 
and/or clinician choice. Changes to prescribed treatment may be necessary for clinical 
reasons, for example when patients are experiencing toxicity or adverse reactions. 
Furthermore, when faced with chronic disorders, patients themselves will often seek 
their own optimal course of treatment to fit in with their individual practical and 
medical needs. When clinicians are willing to work with patients to find this optimal 
course of treatment, concordance may be achieved between patient and clinician; 
however, this adaptive flexible approach to treatment introduces complications for 
randomised trials, in a similar way to all other treatment deviations from original 
randomised treatment. The potential for very different treatment experiences across 
patients within the same randomised group prompts the question of how any useful 
causal interpretation may be obtained from trials featuring such treatment deviations.  
The approach to causal analysis therefore begins with identification of the particular 
causal research question of interest, which must differentiate treatment deviations or 
characteristics that are accepted as inherent within the treatment process (and thus 
should not be factored out in analysis) from those that do not reflect the intended 
treatment experience (and thus would usefully be adjusted for in analysis). Thus, by 
ignoring those treatment switches which correspond with the intended trial scenario (for 
example, clinically indicated changes in treatment prescription due to side effects) while 
adjusting for other deviations that do not reflect the scenario of interest (such as 
changes to trial protocol, patient nonadherence or logistical difficulties with treatment 
delivery), causal analysis may in fact provide estimation of treatment effects which are 
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conceptually intermediate between efficacy and effectiveness of treatment (73). As will 
be discussed further in future chapters, the approach taken to the causal question will 
therefore vary depending on the perspective of the interested party; for example, highly 
motivated patients’ interpretation of which treatment changes should be accounted for 
(in order to provide a realistic efficacy estimate) may well differ from those of policy 
makers (perhaps interested in pragmatic effectiveness of treatment in a setting that 
varies somewhat from that presented in the trial), and therefore their corresponding 
causal questions will reflect different handling of treatment deviations. Once defined, it 
is then necessary to consider how to translate this question into causal contrasts prior to 
undertaking analysis; this issue will be discussed and demonstrated in future chapters. 
4.4. Conclusion 
The literature review of the previous chapter and description of expository trials in this 
chapter have demonstrated how treatment deviation may manifest itself in a variety of 
clinical trial settings, and that, despite the best efforts of trialists, the problem of 
deviation from treatment protocol is to some extent inevitable and will not be resolved; 
indeed changes to treatment are sometimes necessary features of the protocol.  
Given that it is often important to estimate (some aspect of the) effect of treatment as 
received rather than simply as randomised, there is a need for appropriate alternative 
statistical methods which overcome the inadequacies of commonly employed methods 
such as PP or AT analyses, in order to provide unbiased estimates of such causal 
effects, defined by the causal question of interest. The next chapter therefore 
summarises a review of the statistical literature regarding potential methods to adjust for 
treatment deviations, using a number of the trials described in this chapter to illustrate 
methods. 
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5. Statistical methods to adjust 
for deviation from 
randomised treatment 
protocol  
5.1. Introduction 
Following the brief introduction to causal analysis and causal diagrams provided at the 
end of Chapter 3, this chapter will present an overview of causal methods to estimate 
treatment effects for a range of outcome measures and varying complexity of 
compliance patterns and associated patient-level covariates, with a particular focus on 
methods to analyse time to event (TTE) outcomes, as such outcomes are often 
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particularly relevant in trials with longitudinal treatment and follow up periods which 
are typically most likely to suffer from complications due to nonadherence or loss to 
follow up. 
In keeping with the practical focus of this PhD, this overview of statistical methods is 
written with the intention of being a guide for researchers, directing them to the most 
appropriate causal method to use, according to their particular trial and compliance 
scenario. Thus technical details will be kept to a minimum; instead discussion will focus 
on application, highlighting important issues that researchers should consider as part of 
the causal estimation process. The key statistical methods discussed in this chapter will 
be illustrated in this and following chapters using a number of the expository trials 
introduced in Chapter 4. 
5.2. Potential outcomes framework 
Having considered in Chapter 3 the definition of a causal effect and how biases may be 
introduced using associational statistical methods due to unmeasured or time-varying 
confounding, it may now be apparent that causal effects can in fact only be defined in 
terms of comparing, for each individual, their potential outcomes resulting from each of 
the relevant treatment conditions while holding all other factors constant, such that any 
outcome difference can then be attributed solely to the differential exposures rather 
than to any potential selection or confounding effects. Such a within-patient contrast 
cannot of course ever be directly observed (in other words, it is a latent comparison) 
because only at most one of the conditions can be observed for a given individual at a 
particular time. Even crossover trials (which aim to estimate within-patient effect 
estimates by randomising patients to receive both the treatment and control treatment 
in sequential treatment periods separated by a suitable washout period) are unable to 
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provide true causal contrasts, as time (and thus potentially other factors) differs between 
the different treatment exposures periods.  
5.2.1. Counterfactuals  
When comparing potential outcomes for a given individual, all outcomes except that 
corresponding to the actual treatment received are said to be counterfactual (i.e. they are 
entirely hypothetical and cannot be observed) while that which is observed is said to be 
factual (85). The entire collection of all possible outcomes, both actual and 
counterfactual, for the target population is called the set of potential outcomes (103). 
The notion that a causal relationship is necessarily described in terms of a within-patient 
difference between outcomes under counterfactual conditions (i.e. comparing the effect 
on outcome of one form of treatment with what would have happened under an 
alternative form of treatment) is not new. In 1748, the philosopher Hume stated “we 
may define a cause to be an object followed by another… where, if the first object had 
not been, the second never had existed.”; in hypothesizing about what would have 
occurred under conditions contrary to those that occurred in reality, this statement is 
termed “counterfactual conditional” (103). However, it took another 175 years before 
this idea of comparing actual and counterfactual outcomes for the same individual was 
first formalised by Neyman (in 1923), who introduced the idea of multiple prospective 
outcomes under differing treatment conditions in the context of randomised 
agricultural experiments. His notation (relating to multiple plots and seed varieties) and 
terminology (“potential yield”) has since been applied to randomised trials, providing a 
crucial basis for design, analysis and interpretation of studies investigating causal 
relationships (85).  
   
   
133 
 
5.2.2. Barriers to the use of causal estimation methods 
Methods based on the potential outcomes (PO) framework are relatively new and 
continue to be developed, with particular methods varying according to (outcome and 
compliance) data and focus of the causal question. However a number of barriers, both 
historically and in present day, have undermined the use and acceptance of causal 
analysis techniques by mainstream statisticians.  
One important proposed reason for the apparent resistance to wider use of causal 
estimation methods based on the PO framework is the requirement of underlying 
additional, but untestable, assumptions to allow inference on a causal rather than merely 
associational basis. This is due to the need to consider multiple, partially latent, 
counterfactual outcomes for each individual, which not only underpins the difference 
between associational and causal estimation, but also, in the words of Holland (84), is 
the “fundamental problem of causal inference”, given that it is impossible to observe 
more than one outcome for each individual at a particular time point. The apparent 
impossibility of this task does not render causal analysis entirely futile, but instead 
requires that additional assumptions are made.   
Causal assumptions are often treated with scepticism, despite often being more 
plausible than the underlying (but perhaps unappreciated) assumptions required for 
valid interpretation of naïve associational analyses according to treatment receipt (for 
example, PP analysis assumes the simplest but least plausible assumption that subjects 
who do and do not comply with their assigned treatment protocol are comparable with 
regard to prognosis). Pearl (104) argues that this reticence to accept causal, in contrast 
to associational, analyses may be due to the fact that assumptions which underlie 
associational analyses, such as those regarding probability density functions or 
conditional independence between variables, are somewhat less transparent than causal 
   
   
134 
 
assumptions regarding how one variable may cause another, and therefore the latter 
tend to be more open to counterargument.  
Another potential barrier to the use of causal estimation is that, in contrast to those 
relating to associational relationships, assumptions associated with causal relationships 
cannot be expressed using usual statistical notation. Given that all causal analyses are 
conditional on a given set of assumptions beyond those of standard associational 
methods, clear notation is important in order to allow judgment of whether these 
assumptions are credible. For example, statistical dependence between outcome 𝑌 and 
adopted treatment 𝐴  (expressed as 𝑌|𝐴 ) cannot be distinguished from causal 
dependence using standard statistical notation alone. Thus, supplemental explicit 
notation has been developed to facilitate differentiation between associational 
inferences and causal claims or assumptions, as well as to clarify the notion of 
counterfactuals, both in terms of outcomes and treatment receipt.  
Such a causal “language”, however, has developed only relatively recently. Although 
Neyman introduced the concepts relating to causal analysis in the 1920s, half a century 
passed before Rubin (105) and Holland (84) helped to reignite interest in causal 
techniques by clarifying the notation for counterfactual or potential outcomes which 
underlie causal inference. The importance of Neyman’s innovative notation was that it 
allowed causal effects to be expressed independently of any particular probability model 
(85). For example, it became apparent that when carrying out causal analyses, it was 
possible to consider counterfactual outcomes as functions of treatment received and 
counterfactual treatment receipt variables in terms of randomisation assignment. 
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5.2.3. Notation and definition of typical causal estimands 
Using such notation, the causal contrast can be expressed as a relative measure (for 
example, a relative risk or odds ratio for a binary outcome) or absolute difference (for 
example, difference in means of a continuous variable) (103). Assuming a simple 
scenario, where outcome or response (𝑌 ) is to be compared under two conditions 
(experimental (𝐴 = 1) versus control (𝐴 = 0) treatment) without interference between 
units (in other words, the effect of treatment on an individual does not vary according 
to treatment received by other individuals), the causal effect for a given individual 𝑖 can 
be defined in terms of a contrast between their (potentially unobserved or 
counterfactual) responses under the two conditions, for example the absolute difference 
𝑌1𝑖 − 𝑌0𝑖 (106).  
In other words, to describe a causal estimate, one needs not one (𝑌𝑖) but two (𝑌1𝑖, 𝑌0𝑖) 
response variables for each individual, denoting their response had they been assigned 
to treatment or control respectively (84). Note that this notation can be extended to a 
situation where treatment is received repeatedly over time, such that 𝑌?̅?𝑖  denotes the 
(potentially counterfactual) outcome that would have been observed if subject 𝑖  had 
followed treatment regimen 𝑎 for their entire follow up period, say up to time 𝑘 (0 ≤
𝑡 ≤ 𝑘) i.e. ?̅? =  {𝑎1, 𝑎2 … 𝑎𝑘: 0 ≤ 𝑡 ≤ 𝑘}. The causal contrast comparing continuous 
treatment to no treatment would then be written as 𝑌(?̅?=1̅)𝑖 − 𝑌(?̅?=0̅)𝑖 = 𝑌1̅𝑖 − 𝑌0̅𝑖  
(107). 
Furthermore, given that the treatment a participant receives is assumed to be influenced 
by their randomised treatment allocation, again assuming binary treatment receipt, the 
two potential treatments that a patient may receive can be indexed according to whether 
they were assigned to experimental (𝑍𝑖 = 1) or control treatment (𝑍𝑖 = 0), i.e. 𝐴𝑖(𝑍𝑖 =
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1) = 𝐴1𝑖;  𝐴𝑖(𝑍𝑖 = 0) = 𝐴0𝑖 . (Note that the subscripts denoting individual 𝑖  can be 
dropped without ambiguity, given that outcomes values are assumed to be 
independently and identically distributed over the entire sample being studied.) 
Given that it is impossible to observe both potential outcomes for a given individual, 
rather than attempting to determine the causal effect of treatment for a particular 
individual 𝑖  (known as the individual causal effect (ICE) and defined by the 
difference Δ𝑖 = 𝑌1𝑖 − 𝑌0𝑖 ), it is instead sensible to estimate some form of average 
causal effect (ACE) for the population of interest. For example, the average within-
patient causal difference 𝐴𝐶𝐸 = 𝐸(𝑌1𝑖 − 𝑌0𝑖) is (by usual laws of probability) equal to 
the difference in averages 𝐸(𝑌1𝑖) − 𝐸(𝑌0𝑖) =  𝐸(𝑌1) − 𝐸(𝑌0) between the treatment 
and control observations for all units in the population of interest. If one can assume a 
constant effect of treatment on all units, the ACE as an estimate of the underlying true 
constant treatment effect is relevant and informative for all individuals (84).  
5.2.4. Underlying assumptions  
However, given that outcome data are available for only a small sample rather than all 
of the population, it is necessary to accept certain assumptions before the ACE, or any 
other causal parameter, can be estimated.  
If treatment assignment is randomised and adhered to perfectly, randomisation provides 
independence between outcome and allocation of treatment; thus, under the 
assumption that the sample is generalisable to the target population, the outcome data 
𝐸(𝑌𝑗) =  𝐸(𝑌|𝑍 = 𝑗)  can be used to estimate this average quantity ACE 
by  𝐸(𝑌|𝑍 = 1) − 𝐸(𝑌|𝑍 = 0) = 𝐸(𝑌1) − 𝐸(𝑌0) , a result first demonstrated by 
Neyman (85). However any selection process which violates the independence between 
allocation of treatment and outcome (such as that typically introduced by deviation 
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from randomised treatment or by observational rather than experimental assignment of 
treatment) invalidates this estimation (84). 
As such, the underlying treatment assignment mechanism is of fundamental 
importance. The causal methods to be discussed presently rely on randomisation to 
provide balance on all baseline variables (including all potential random variables and 
thus counterfactual outcomes) between groups. Methods for observational studies rely 
on the assumption that the randomisation balance can be simulated by conditioning on 
all relevant variables which confound the a priori independence between treatment 
allocation and outcome, invoking the so-called strong ignorability assumption (where 
“strong” implies an unconfounded and therefore causal interpretation), also known as 
the assumption of no unmeasured confounders (NUC), such that the relationship 
between the potential outcomes and received treatment can be assumed to be 
independent, given adjustment for all such confounders. In the case of dynamic 
treatment regimens, the sequential ignorability assumption would be required, 
adjusting for relevant (time-varying) covariates at each time point, to simulate sequential 
randomisation of treatments at each time  𝑘  (107, 108). This assumption can be 
interpreted as, conditional on all pertinent baseline and time-varying confounders, those 
who do and do not change treatment at time 𝑡 have the same probability of outcome, 
such that the decision on whether to change treatment is independent of underlying 
untreated outcome given these variables.  
Formally, randomisation ensures that the probability that an individual with potential 
outcome 𝑌0 and 𝑌1 is assigned a certain treatment is a constant that does not depend on 
their potential outcomes 𝑌0 and 𝑌1, such that 𝑃(𝑍|𝑌0, 𝑌1) = 𝑃(𝑍) ∀ 𝑌0, 𝑌1, whereas the 
NUC assumption states that the probability of assignment is independent of all missing 
( 𝑌𝑚𝑖𝑠)  and observed ( 𝑌𝑜𝑏𝑠 ) outcomes, and can be assumed to be random once 
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conditioned on observed covariates 𝑋 , i.e. 𝑃(𝑍|𝑋, 𝑌𝑜𝑏𝑠, 𝑌𝑚𝑖𝑠) = 𝑃(𝑍|𝑋) ∀  𝑌𝑚𝑖𝑠, 𝑌𝑜𝑏𝑠 
(109). 
Another basic assumption commonly invoked for causal analysis, necessary to allow 
statistical inference based on the assumption that individuals’ observations are 
statistically independent, is the stable-unit-treatment-value assumption (SUTVA), which 
assumes that a full set of potential outcomes exist for each person (even though only 
one is observed) which are independent of outcomes and treatment status of all other 
subjects (110). Note that the SUTVA differs from the usual assumption of identical 
independent distributions of outcomes (i.e. that the outcome of an individual is 
unaffected by outcomes of other participants) required for standard statistical analysis, 
as it relates to stability of treatment received as well as outcome status. This assumption 
is necessary for the notation 𝑌𝑖𝑘 to be sufficient in denoting the outcome of unit 𝑖 with 
treatment 𝑘 ; otherwise, notation would need to include information on treatment 
received by all other units and the basic assumption of statistical independence between 
subjects (necessary for all statistical inference) would also fail (111). The SUTVA means 
that the observed outcome for unit i will equal one of the potential outcomes for that 
unit, no matter how the treatment was received (63). 
This assumption also incorporates the notion of treatment stability, i.e. that each level 
or form of treatment is given to different units in an identical manner (so that there are 
no hidden versions of treatments), or equivalently that even if the treatment delivery 
varies slightly from individual to individual, the effect (i.e. potential outcomes) will be 
consistent. This assumption is required in order that the following equality will always 
hold: 𝑌𝑖 = 𝑌1𝑖 ∗ 𝐴𝑖 + 𝑌0𝑖 ∗ (1 − 𝐴𝑖) (112). 
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The SUTVA may be contravened in studies of infectious disease or when behavioural 
interventions are affected by interaction between individuals (85) or in cluster 
randomised behavioural or educational trials where participants may observe or 
influence each other’s outcomes. Treatment stability may not hold in cases where 
natural variation occurs in the treatment process, for example when the rapport 
between therapist and individual affects the delivery of treatment for psychological 
disorders, or when clinicians’ expertise influences the quality of surgical or medical 
treatment, or when practitioners’ experience with one patient influences their 
subsequent treatment of another patient. In practice, some treatment variation is likely 
to occur, but such heterogeneity is assumed to remain within a reasonable range (113). 
The exclusion restriction (ER) is a commonly employed assumption which implies no 
direct effect of treatment assignment, such that the offer of treatment itself has no 
influence on outcome, but instead any effect of randomisation on outcome is entirely 
due to its effect on treatment receipt. An alternative interpretation is that a patient who 
receives treatment will experience the same outcome whether or not they were 
originally randomised to receive it (114). In a continuous compliance setting, this 
assumption may be considered a “zero dose-response” assumption, such that without 
treatment, assignment will have no effect (115). The exclusion restriction is so called 
because the assignment mechanism is assumed to influence outcome “exclusively” 
through its effect on actual treatment received (112).  
The exclusion restriction is likely to hold in double-blind trials (116) where the 
psychological effect of treatment assignment is (theoretically) negligible, but when 
participants are aware of the treatment they have been allocated to, there is potential for 
a strong placebo effect (or expectation of treatment) and thus this assumption may not 
hold. Unblinded behavioural intervention studies may be particularly prone to 
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invalidation of this assumption, given that the impact of being assigned a certain 
behavioural intervention may affect an individual’s outcome for reasons other than the 
intervention itself (for example, due to changes in a patient’s mood or motivation levels, 
or because of an underlying rapport with therapist). Furthermore, the exclusion 
restriction will not hold if additional treatments or extra medical attention tend to be 
given in a certain treatment arm. 
Before moving on to consider various approaches to causal methods which make these 
assumptions, it is worthy to note that, in making explicit the nature of relationships 
between variables and the underlying implicit assumptions regarding these relationships 
required for causal inferences, cDAGs implicitly demonstrate a number of key features 
of the causal techniques to be discussed.  
5.2.5. cDAGs demonstrate underlying features and assumptions of 
causal techniques 
First it is interesting to discover that the graphical representation of a trial with 
imperfect compliance using a cDAG implicitly depicts two such key assumptions that 
are often required in order to allow causal interpretation. 
Pearl (104) points out that the underlying causal assumptions are encoded in a cDAG 
by the missing rather than the indicated links in a causal diagram; the existence of an 
arrow in the diagram suggests the potential for a causal connection (of unknown 
strength) between variables, whereas a missing arrow indicates a definite lack of causal 
link. Therefore, the randomisation (or independence) assumption is demonstrated by 
the lack of any common causes of 𝑍 with any other factor; as such, assignment 𝑍 can be 
assumed to be entirely independent of any underlying prognostic factors 𝑈.   
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Secondly, lack of a direct arrow between randomisation 𝑍 and outcome 𝑌 indicates that 
assignment 𝑍 has no direct influence on outcome 𝑌 except through the actual treatment 
received 𝐴 (or equivalently, the effect of randomisation on outcome is entirely mediated 
by treatment exposure). This depicts the ER assumption, as it excludes the assignment 
mechanism variable Z from being a determining argument of the (𝐴, 𝑌) association.  
Along with these two assumptions (randomisation and ER), this cDAG introduces 
another important feature of causal analysis, namely that of instrumental variables. 
The depiction of an arrow from 𝑍 to 𝐴 indicates that there is a potential correlation 
between 𝑍 and 𝐴; if it can be assumed, not only that the effect of randomisation is 
entirely mediated by treatment receipt (in other words, the ER assumption holds) but 
also that randomisation has a positive effect on treatment exposure (such that 
randomisation to experimental treatment leads to a greater probability of receiving that 
treatment than randomisation to control treatment), randomisation is said to fulfill the 
role of an instrumental variable (IV) in this context.  
Exploitation of randomisation as an IV is a common feature of the various causal 
techniques to be introduced in this chapter. The idea behind IVs is to avoid correlation 
between an endogenous variable (like compliance) and the error terms in a regression 
model, by substituting this endogenous variable (so called because, in a model 
regressing outcome on treatment received, treatment received would be correlated with 
the error terms; such endogeneity would render biased coefficients of the mediator) 
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with another “instrumental” variable (say, randomised treatment) which is correlated 
with the original predictor (compliance) and with outcome, but which does not directly 
affect outcome. Thus, the problem of hidden confounding may be circumvented by 
assuming a priori that randomisation per se has no direct effect on outcome, but rather 
its impact on outcome is entirely via treatment received (as per the ER assumption), 
which then (in conjunction with the assumption of random allocation) leads naturally to 
the use of randomisation allocation as an IV. Typically IV methods use a two-stage least 
squares (2SLS) process to estimate these coefficients, whereby the outcome is regressed 
on the predicted values of the mediator variable (obtained by first regressing this 
endogenous mediator variable (treatment received) on the IV (randomisation)), thus 
providing unbiased estimation coefficients of the effect of the original mediator variable 
on outcome. 
The use of randomisation as an IV is implicit in many causal methods, but is most 
commonly associated with the more traditional method involve structural equation 
modelling.   
5.3. Traditional causal estimation: SEMs 
Traditionally, causal estimation has been approached through the use of structural 
equation modelling (SEM), where “structural” refers to the underlying structure of the 
causal relationship (as opposed to mere association) as demonstrated in a cDAG.  
Introduced by Wright in the 1920s, this method has been developed and used since the 
1960s, primarily by sociologists and economists. SEM is very similar to classical 
simultaneous equation modelling, with features such as an underlying linear structure, 
constant coefficients and reliance on error terms to encompass the effect of missing 
variables (117). The focus of this regression approach is to estimate direct and indirect 
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(for example, through adherence) effects of treatment on outcome using instrumental 
variable (IV) techniques but with implicit reliance on a number of assumptions, firstly 
that the functional forms assumed by the model are correct, and secondly that there are 
no missing influences (𝑈) on the outcome. In other words, conditional on the included 
covariates (𝑋), there remains no confounding between mediator (treatment adherence) 
and outcome (thus invoking the NUC, or strong ignorability, assumption). 
In general, SEM has not been widely accepted by statisticians as a causal estimation 
method because of a number of important inadequacies: first, the lack of transparency 
regarding underlying assumptions (expressed, for example, in terms of correlation 
between error terms) makes it is difficult to interpret, assess or communicate the validity 
of results and implications of the model results. Furthermore, given the likelihood of 
hidden or time-varying confounding bias, SEM is often viewed with suspicion because 
of a lack of confidence that full information has been collected on all confounding 
variables in order to satisfy the NUC assumption.  
More recently, however, newer causal inference methodologies have been developed, 
with explicit underlying assumptions and clearly notated causal contrasts, thus allowing 
researchers to more easily understand the implications of the underlying assumptions 
and how the causal contrasts relate back to the research question of interest. Indeed, the 
most important difference between available approaches to causal estimation lies in 
their transparency with respect to their underlying assumptions, affecting the ability of 
researchers to interpret and evaluate the validity of each method. 
These newer methods, to be discussed in the next section, are based on the PO 
framework but are not entirely unrelated to SEMs; indeed SEMs are actually implicitly 
based on the assumption of POs, although this is not obvious, while the use of 
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common assumptions (such as randomisation, or NUC, and ER) means that modern 
methods often also rely on randomisation as an IV (118).  
5.4. Causal estimation methods 
Having established the notation and assumptions required for causal methods based on 
the PO framework, two approaches to such estimation are now introduced, both of 
which are highly suited to trial data, as they rely on the randomisation assumption of 
balance between groups in terms of underlying untreated (or control) outcomes. The 
first approach employs this assumption to estimate treatment efficacy (i.e. effect of 
actually receiving treatment) for all patients, while the second estimates the effect of 
randomisation (i.e. the ITT effect of being assigned treatment) within a (latent) 
“complier” subgroup. 
Other methods, originally developed for observational studies, rely on the assumption 
that all time-varying confounders between treatment receipt and outcome are known 
and measured, such that appropriate adjustment for these factors removes the selection 
bias associated with analysis by treatment received. Such methodology can be applied to 
randomised trials, and will be introduced following the discussion of the two 
randomisation-based approaches involving comparison of potential outcomes. 
5.4.1. Principal stratification approach (CACE) 
Continuing to assume only (time-fixed) binary (rather than quantitative or time-varying) 
compliance and a binary treatment contrast, the potential outcomes framework 
provides a basis for classifying individuals according to their underlying potential 
compliance status under each randomised treatment.  
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The principal stratification (PS) approach is based on stratifying the population into 
latent subgroups (principal strata) based on this potential compliance behaviour and 
then fitting (unbiased) ITT estimates (known as principal effects) within these 
principal strata.  
A patient’s principal stratum is considered to be a characteristic of the subject, 
effectively representing their underlying willingness to become exposed to the various 
treatments being contrasted. This characteristic is considered a baseline covariate, which 
is therefore unaffected by randomisation allocation, and as such can be used as a 
stratifying variable without introducing bias (unlike for other confounders measured 
after randomisation) (119). As such, methods based on PS can be thought of as latent 
class models, whereby the problem of deviation from randomised assignment is avoided 
by considering the (unconfounded) estimation of effect of treatment assignment (i.e. 
ITT effect estimate) within categories of patients according to their principal 
compliance status. The challenge presented by this approach is that an individual’s 
status is never fully observed (i.e. it is latent) because it refers to their compliance 
behaviour on both possible treatments, whereas it is possible to observe only their 
observed compliance to their assigned treatment. As such, it is necessary to invoke 
additional assumptions in order to categorise patients into one of the possible principal 
compliance classes (119). Hence in this approach, counterfactuals enter with respect to 
definition of compliance class, defined assuming all-or-nothing compliance. 
5.4.2. Compliance classes 
The (latent) compliance classes can be defined by cross-classifying each patient 
according to the treatment that they would receive under each possible randomised 
allocation, in order words cross-classification of 𝐴0 and 𝐴1, where 𝐴0 = 0 (𝐴1 = 1) if a 
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patient, when randomised to control (experimental) treatment, would adhere and 
actually take control (experimental) treatment; 𝐴0 = 1 if instead they would instead take 
experimental treatment when randomised to control and 𝐴1 = 0 if instead they would 
take control treatment despite receiving allocation to experimental treatment. 
The table below shows how this cross-classification provides the definition of the 
underlying compliance classification status (𝐶) of each individual: 
Table 4 Compliance classification 
Treatment received when randomised to control arm  
 
Control treatment 
(𝐴0 = 0) 
Experimental treatment 
(𝐴0 = 1) 
Treatment received when randomised 
to experimental arm 
  
Control treatment (𝐴1 = 0) Never taker (𝑁) Defier (𝐷) 
Experimental treatment (𝐴1 = 1) Principal complier (𝑃𝐶) Always taker (𝐴) 
 
In other words, an always taker (𝐴) takes experimental treatment regardless of their 
randomised allocation ( 𝐴𝑍 = 1 ∀ Z ), a never taker ( 𝑁 ) will always takes control 
treatment (𝐴𝑍 = 0 ∀ Z) and a defier (𝐷) will always take the opposite treatment to that 
which they were randomised (𝐴𝑍 = 1 − 𝑍 ∀ Z). A principal complier (𝑃𝐶) is defined 
as an individual who would always take the treatment to which they were randomised 
(𝐴𝑍 = 𝑍 ∀ Z).  
The term “principal complier” is used in preference to “complier” in order to 
distinguish between those who have simply been observed to comply with their 
randomised allocation only and those who would comply with either randomised 
allocation. Those observed to comply with experimental arm allocation may be always 
takers or principal compliers, whereas those observed to comply when randomised to 
control treatment may be never takers or principal compliers. As such, observed 
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compliance status alone does not provide full information on a patient’s underlying 
principal stratum. More formally, given that, for each individual, we are able to only 
observe their compliance status 𝐴𝑧𝑖 under their randomly assigned treatment 𝑧𝑖 , their 
compliance status  𝐴(1−𝑧𝑖)  is unobserved and therefore their underlying compliance 
class is unknown.  
Once these compliance classes have been identified, unbiased causal estimation is 
thereafter achieved by estimating the (unbiased) effect of assigned treatment (i.e. 
according to randomisation) only in the subgroup of principal compliers who would 
comply with whatever treatment they were randomised to (and thus distinct from 
observed compliers). Given that no deviation from randomisation occurs in this 
subgroup, analysis according to randomisation equates to analysis according to 
treatment received for this subgroup of patients, and thus this effectiveness estimate 
can be granted causal interpretation.  
Thus the PS approach involves estimation of ITT within latent compliance classes 
known as principal strata. The resulting (unbiased) ITT estimate of treatment 
effectiveness calculated within the principal strata of potential compliers can be 
interpreted as a measure of treatment efficacy relating to such patients, known as the 
complier average causal effect (CACE).  This is because, for this universally 
compliant subgroup, treatment received is always equal to randomised treatment; as 
such analysis according to randomised treatment (ITT analysis) within this group of 
patients equates to (unbiased) analysis according to treatment receipt. However, rather 
than relating to the entire population, the CACE is therefore generalisable only to the 
(unobservable) subgroup of patients who would naturally comply with their assigned 
treatment. 
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5.4.3. CACE vs PP vs AT: how PO formulation clarifies deficiencies 
The key to PS methods is using the potential framework to define patients’ potential 
compliance status, thus revealing the distinction between a principal complier 
(compliance under both treatments) and an observed complier (compliance under the 
treatment actually assigned). Little (109) demonstrates how the PS formulation can be 
used to clarify the biases introduced by naïve analysis methods such as PP or AT.  
Using the notation 𝑌(𝑍 = 𝑗) = 𝑌𝑗  to denote a patient’s potential outcome when 
randomised to treatment 𝑗, the CACE estimate is denoted as 
Equation 1 
𝐶𝐴𝐶𝐸 = 𝐸(𝑌1 −  𝑌0|𝐶 = 𝑃𝐶) 
where the conditioning on 𝐶 = 𝑃𝐶 is identical to conditioning on  𝐴1 = 1 and 𝐴0 = 0. 
The CACE is a valid causal effect because it is a summary measure of individual-level 
effects (𝑌1 −  𝑌0) in a subpopulation of interest, namely compliers. 
In contrast, AT analysis, which classifies subjects by the adopted treatment 𝐴(𝑍) = 𝐴𝑍, 
estimates 
𝐴𝑇 = 𝐸(𝑌𝑍|𝐴𝑍 = 1) −  𝐸(𝑌𝑍|𝐴𝑍 = 0) 
This estimate does not carry causal interpretation, as it is not an average of individual-
level causal effects; instead it compares outcome averages for different groups with 
different characteristics. In particular, it compares the average outcome of those 
adopting experimental treatment (namely all always-takers, principal compliers who 
were assigned experimental treatment and defiers who were assigned to the control 
treatment) with the average outcome of those adopting control treatment (namely 
compliers randomised to receive control treatment, defiers randomised to experimental 
treatment and never-takers who were assigned either treatment).  
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Similarly, PP analysis, in estimating 
𝑃𝑃 = 𝐸(𝑌𝑍|𝐴1 = 1) −  𝐸(𝑌𝑍|𝐴0 = 0) 
is not an average of individual-level causal effects. In comparing only those subjects 
who actually adopted their assigned treatments, a PP analysis compares the outcomes of 
those who were assigned and received experimental treatment (compliers and always-
takers assigned to experimental treatment) with the outcomes of those who were 
allocated to and received control treatment (that is, compliers and never-takers 
randomised to control treatment). In order for the PP analysis to be valid, unrealistic 
assumptions are required: the mean outcome for those who comply with experimental 
treatment is assumed to be the same both for compliers in the experimental arm and 
always takers from both treatment arms, and similarly the mean outcome for those who 
comply with control treatment is assumed to be constant, regardless of whether they are 
non-compliers from the experimental arm or never takers from both treatment arms: 
i.e. outcome is unrelated to compliance: 𝑌 ⊥ 𝐶|𝐶 = 𝑁 𝑜𝑟 𝑃𝐶, 𝑍 = 0 and 𝑌 ⊥ 𝐶|𝐶 =
𝐴 𝑜𝑟 𝑃𝐶, 𝑍 = 1 (109). 
5.4.4. Heuristic derivation of CACE: assumptions required  
Although CACE in Equation 1 above is simply the ITT estimate among the class of 
“compliers” and thus a valid causal estimand, it is not immediately apparent how it can 
be estimated, given that underlying principal compliance status (𝐶) of individuals is not 
known (109). The answer lies in being able to assume certain plausible restrictions. 
Indeed, the heuristic derivation of the CACE estimate provides a useful platform for 
demonstrating the relevance and use of the assumptions most commonly applied in 
causal analysis. 
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In particular, in order to estimate the CACE, a number of standard assumptions 
(SUTVA, ER and randomisation) are required, along with two further restrictions 
(monotonicity and non-zero compliance). The following explanation of CACE 
estimation demonstrates how and why these assumptions are implemented. 
First note that, assuming randomised allocation of treatments, the usual ITT estimate is 
equal to  
𝐼𝑇𝑇 = 𝐸(𝑌1 −  𝑌0) 
which, by the usual laws of probability, equates to   
𝐼𝑇𝑇 = 𝐸(𝑌1 −  𝑌0)
= 𝐸((𝑌1 −  𝑌0)|𝐶 = 𝑃𝐶) 𝑃(𝐶 = 𝑃𝐶)
+ 𝐸((𝑌1 −  𝑌0)|𝐶 ≠ 𝑃𝐶) 𝑃(𝐶 ≠ 𝑃𝐶) 
Note next that, if the exclusion restriction holds, the ITT treatment effect (i.e. 
difference in outcome between randomisation to treatment and control arms) in never-
takers and always-takers will always equal zero. This follows because the exclusion 
restriction states that randomisation has no effect beyond that of treatment received; 
thus, given that, in these compliance subgroups, treatment receipt does not vary with 
randomisation, the difference in potential outcomes for never- and always-takers will 
always equal zero; i.e. 𝑌0 = 𝑌1 if 𝐴0 = 𝐴1. 
The next assumption required is that of monotonicity, which implies that there are no 
defiers (subjects who would always take alternative treatment to that randomised) This 
assumption is named ‘monotonicity’ because treatment assignment is assumed to work 
in one direction only, such that 𝐴1𝑖 ≥ 𝐴0𝑖∀𝑖  or equivalently 𝑃(𝐴1𝑖 ≥ 𝐴0𝑖) = 1 . If 
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these two assumptions hold, it can be noted that the second term of the equation above 
is equal to zero, because  
𝐸((𝑌1 − 𝑌0)|𝐶 ≠ 𝑃𝐶) 𝑃(𝐶 ≠ 𝑃𝐶) 
= 𝐸((𝑌1 − 𝑌0)|𝐶 = 𝐴) 𝑃(𝐶 = 𝐴) 
+𝐸((𝑌1 −  𝑌0)|𝐶 = 𝑁) 𝑃(𝐶 = 𝑁) 
+𝐸((𝑌1 −  𝑌0)|𝐶 = 𝐷) 𝑃(𝐶 = 𝐷) 
and 𝐸((𝑌1 −  𝑌0)|𝐶 = 𝑁) = 𝐸((𝑌1 −  𝑌0)|𝐶 = 𝐴) = 0 (by ER) and 𝑃(𝐶 = 𝐷) = 0 
(by monotonicity). Thus  
𝐼𝑇𝑇 = 𝐸(𝑌1 −  𝑌0) = 𝐸((𝑌1 − 𝑌0)|𝐶 = 𝑃𝐶) 𝑃(𝐶 = 𝑃𝐶) = 𝐶𝐴𝐶𝐸 ∗ 𝑃(𝐶 = 𝑃𝐶) 
As such, the CACE estimate is simply the ITT estimate (of the difference in outcome 
between randomised groups) divided by the proportion of principal compliers (which, 
in the final assumption of this analysis (namely, the non-zero compliance assumption), 
is taken to be positive; in other words, it is assumed that there exists at least one 
individual in the trial who would always comply with their randomised treatment 
allocation). Although unknown, this proportion can be estimated very simply and 
unbiasedly if one invokes the randomisation and monotonicity assumptions. In Table 4, 
it may be noted that the observed proportion of patients randomised to the 
experimental treatment arm who actually receive this treatment (denoted here as 𝑝1) is 
an unbiased estimate of the combined (population) proportions of compliers and 
always-takers; similarly the proportion ( 𝑝0 ) of control arm patients who adopt 
experimental treatment is an unbiased estimate of the population proportion of always-
takers (as there are assumed to be no defiers). As such, the true proportion of compliers 
𝑃(𝐶 = 𝑃𝐶)  can be estimated by the difference in the observed proportions of 
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experimental and control arm patients who receive experimental treatment (𝑝1 − 𝑝0), 
which is equal to the ITT difference (i.e. when analysing according to randomisation) of 
experimental treatment receipt.  
Therefore, under the above stated conditions, the CACE estimate is simply a ratio of 
two ITT effects: the ITT effect (of randomisation) on outcome divided by the ITT 
effect (of randomisation) on treatment receipt. For example, with observed mean 
outcomes, ?̅?0 and ?̅?1, from the control and experimental treatment groups respectively, 
the CACE estimate is given as  
Equation 2 
𝐶𝐴𝐶𝐸 =  
?̅?1 −  ?̅?0
𝑝1 −  𝑝0
=
𝐼𝑇𝑇 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝑜𝑢𝑡𝑐𝑜𝑚𝑒
𝐼𝑇𝑇 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑟𝑒𝑐𝑒𝑖𝑝𝑡
 
The use of assumptions (namely SUTVA, randomised assignment, exclusion restriction 
and monotonicity) in this derivation of CACE links it to IV estimation, as 
randomisation satisfies the necessary conditions of an IV in this setting. As such, this 
ratio is sometimes called the instrumental variable (IV) estimator and was 
demonstrated by Angrist (117) to be equivalent to the IV estimand.  
Newcombe (53) was the first to describe PS (IV) methods to adjust for non-compliance 
from randomised treatment, demonstrating the equation above for a continuous 
outcome. Newcombe described the link between the explanatory (CACE) and 
pragmatic (ITT) estimates of treatment effect in terms of an attenuation factor 
(difference between the proportions in each randomised group who receive 
experimental treatment, or equivalently the difference between group proportions 
receiving control treatment), and pointed out that counterintuitively, this attenuation 
factor depends, not on the sizes of the selection biases associated with deviation from 
assigned treatment but instead only on the frequency of such deviations.    
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5.4.5. Demonstrate method for binary outcome: Sommer 
Sommer and Zeger (47) then demonstrated a similar idea adjusting for binary non-
compliance with a binary outcome, their methodology having been motivated and 
illustrated by the Vitamin A trial (described in Chapter 4). Given that children in the 
control arm of this trial were not given the option of active treatment (such that only 
two PS exist in this setting: by definition, patients are not able to be always-takers or 
defiers), their method (later referred to CACE) relates to assessing outcome among 
those who would have complied with active treatment if randomised to receive it.  
As such, patients are assumed to either be principal compliers or non-compliers (with 
active treatment). Although such a subgroup is directly observed among those 
randomised to vitamin A, it is not possible to directly ascertain which patients would 
have complied with active treatment in the control arm, and thus it is necessary to 
compare the outcome among those observed to be compliant in the active treatment 
arm with an inferred control subgroup who would have complied with active treatment. 
Thus, as with all causal methods, their analysis relies on a number of untestable but 
potentially plausible assumptions (with the degree of plausibility needing to be assessed 
according to the particular clinical setting).  
The derivation of their CACE estimate, given in terms of the relative risk (𝑅) of death 
among those children who would receive treatment if allocated to it, is demonstrated 
here as an example of how these assumptions are applied in practice, highlighting issues 
that may need similar consideration by researchers wanting to apply such methods. 
(Note that the original article displayed an incorrect formula without derivation – as 
such, these workings have been included here to demonstrate my own work and 
understanding of the concepts).  
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Table 5: Table IIa in (91) 
Control group: principal compliers  Treatment group: principal compliers 
 No Yes Total   No Yes Total 
Alive 𝑚00 𝑚01 𝑚0∙  Alive 𝑛00 𝑛01 𝑛0∙ 
Dead 𝑚10 𝑚11 𝑚1∙  Dead 𝑛10 𝑛11 𝑛1∙ 
Total 𝑚∙0 𝑚∙1 𝑀  Total 𝑛∙0 𝑛∙1 𝑁 
 
Using Sommer’s notation given in Table 5, the relative risk estimate can be expressed as 
Equation 3 
?̂? =  
𝑛11 𝑛01 + 𝑛11⁄
𝑚11 𝑚01 + 𝑚11⁄
 
However, given that we do not know which control patients would have complied with 
active treatment, it is not possible to observe 𝑚01 and 𝑚11, so these values must be 
estimated using the two key assumptions, namely randomisation and ER. 
By the randomisation assumption, we assume that 
𝑚.0
𝑀
=  
𝑛.0
𝑁
 (given that randomisation 
balance allows us to assume that the proportion of patients who would comply with 
active treatment is assumed to be equal between groups), such that  
Equation 4 
𝑚00 + 𝑚10
𝑀
=  
𝑛00 +  𝑛10
𝑁
 
𝑚00 +  𝑚10 =  𝑀[
𝑛00 +  𝑛10
𝑁
] 
By the ER assumption, we assume that 
𝑚10
𝑚00+𝑚10
=  
𝑛10
𝑛00+𝑛10
 (because, in the absence of 
treatment, the probability of outcome is assumed to be independent of randomised 
allocation), such that 
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𝑚10 = [𝑚00 + 𝑚10][
𝑛10
𝑛00 + 𝑛10
] 
Substituting in from Equation 4 
𝑚10 = 𝑀[
𝑛00+ 𝑛10
𝑁
][
𝑛10
𝑛00+𝑛10
] = 𝑛10
𝑀
𝑁
 
Thus Equation 4 becomes  
𝑚00 =  [𝑛00 +  𝑛10]
𝑀
𝑁
−  𝑛10
𝑀
𝑁
=  𝑛00
𝑀
𝑁
 
 
Thus we can calculate estimates of 𝑚01 and 𝑚11 as follows: 
Equation 5 
?̂?01 =  𝑚0. − ?̂?00 =  𝑚0. − 𝑛00
𝑀
𝑁
 
Equation 6 
?̂?11 =  𝑚1. − ?̂?10 = 𝑚1. − 𝑛10
𝑀
𝑁
 
In order to estimate the relative risk among compliers, given in Equation 3, 
?̂? =  
𝑛11 𝑛01 + 𝑛11⁄
𝑚11 𝑚01 + 𝑚11⁄
 
?̂? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑚01 + 𝑚11
𝑚11
] 
Using the estimated values of ?̂?01 and ?̂?11 given in Equation 5 and Equation 6, we 
obtain 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
?̂?01 + ?̂?11
?̂?11
] 
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?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
(𝑚0. − 𝑛00
𝑀
𝑁) + (𝑚1. −  𝑛10
𝑀
𝑁) 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑚0. + 𝑚1. − (𝑛00+ 𝑛10)
𝑀
𝑁 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑚0. + 𝑚1. − (𝑛00+ 𝑛10)
𝑀
𝑁 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑀 − 𝑛.0
𝑀
𝑁 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑀 (1 −
𝑛.0
𝑁 ) 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛01 + 𝑛11
] [
𝑀 (
𝑁 − 𝑛.0
𝑁 ) 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  [
𝑛11
𝑛.1
] [
𝑀 (
𝑛.1
𝑁 ) 
𝑚1. −  𝑛10
𝑀
𝑁
] 
?̃? =  
𝑛11
[𝑚1.
𝑁
𝑀 − 𝑛10]
 
Note that this (corrected) formula appears in (47). 
A more intuitive set of calculations may be given as follows. First, the compliance 
information in treatment arm and the balance produced by randomisation is used to 
estimate the number of children in the control who would be non-compliant. Given 
that the proportion of non-compliant patients is assumed to be equal in the two 
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randomised groups i.e. 
𝑚.0
𝑀
=  
𝑛.0
𝑁
, the number of children in the control who would be 
non-compliant is assumed to be equal to the proportion of non-compliers in the 
treatment arm multiplied by the number of patients in the control arm, i.e. 𝑚.0 =
𝑀 
𝑛.0
𝑁
. Thus in this example, 𝑚.0 = 11,588 ∗
2419
12,094
=  2317.8.  
The inferred number of control children who would comply with intervention is 
therefore equal to 𝑚.1 = 𝑀 − 𝑚.0 = 11,588 −  2317.8 = 9270.2. 
Under the ER assumption, the mortality risk of the non-compliers in the control groups 
is assumed to be equal to the mortality risk among non-compliers in the treatment arm 
(as neither of these groups receive any treatment) i.e. 
𝑚10
𝑚.0
=  
𝑛10
𝑛.0
 and thus 𝑚10 =
 𝑚.0
𝑛10
𝑛.0
= 2317.8 ∗
34
2419
= 32.6. 
Thus, by definition, the number of non-compliant control children expected to survive 
is equal to 𝑚00 =  𝑚.0 − 𝑚10 = 2317.8 − 32.6 = 2285.2, and thus the number of 
compliant control children expected to die and survive can be calculated by subtracting 
the expected number of non-compliant children who will die and survive, respectively, 
from the known number of control children who died and survived, respectively. 
𝑚01 =  𝑚0. − 𝑚00 = 11,514 − 2285.2 = 9228.8 
𝑚11 =  𝑚1. − 𝑚10 = 74 − 32.6 = 41.4 
Table 6 
 Control compliance    
Treatment 
compliance 
 
 No Yes    No Yes  
Alive 2285.2 9228.8 11,514  Alive 2385 9663 12,048 
Dead 32.6 41.4 74  Dead 34 12 46 
Total 2317.8 9270.2 11,588  Total 2419 9675 12,094 
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Thus the estimated risk reduction among compliers can be calculated as 
?̃? =  
𝑛11 𝑛01 + 𝑛11⁄
𝑚11 𝑚01 + 𝑚11⁄
=  
12 9675⁄
41.4 9270.2⁄
=  0.277 
Thus the causal effect of treatment among compliers can be interpreted as leading to a 
risk of mortality among those who take treatment equal to just 28% of the risk among 
those who do not take treatment, i.e. treatment is estimated to reduce the risk of 
mortality by more than 70%.  
5.4.6. Interpretation of CACE 
The attractive simple nature of PS methods must be weighed against their inherent 
limitations, the first being the implicit restrictions on interpretation of the CACE 
estimate.  
It is imperative to appreciate that the resulting CACE estimate applies only to the 
(theoretical) subgroup of “principal compliers”, the exact interpretation of which must 
be determined in the light of the trial setting. Rather than relating to the entire 
population, the CACE is therefore generalisable only to the (unobservable) subgroup of 
patients who would naturally comply with their assigned treatment.  
As such, the CACE relative risk estimated above must be viewed in light of the barriers 
leading to (principal) non-compliance in the vitamin A trial. This causal effect of 
treatment relates only to those who would have had the ability to receive treatment if 
they were allocated to the treatment arm, and therefore cannot be generalised to those 
who were not able (often for logistic reasons) to receive treatment (principal non-
compliers). Given that it was evident that children who were unable to receive 
treatment tended to have worse baseline health, if the effect of treatment varies 
according to the baseline mortality risk, it may not be appropriate to use the CACE to 
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generalise the treatment effect to the entire population. However, as pointed out by 
Sommer, there are no data available from this trial to test whether such an interaction 
exists. 
Furthermore, Sommer points out that this reduction includes both the biologic impact of 
vitamin A and any placebo effect of having active treatment (compared to no treatment). 
Without a placebo, it is not possible to differentiate between these two effects and thus 
it is not possible to isolate the biological impact of treatment. However, such an effect 
would also be included in the ITT estimate of any trial that does not involve a placebo, 
and given that the outcome is entirely objective, one would expect the placebo effect to 
be minimal. 
Although interpretation of any CACE estimate is limited in that it relates only to the 
(unidentifiable) PS consisting of participants who would “comply” (as defined by trial 
conditions) in future, such an estimate is likely to be of particular interest to motivated 
patients and their treating clinicians. Furthermore, PS estimates from all the different 
compliance classes may be combined as a weighted average, assigning weights to each 
PS estimate, depending on (and assuming availability of) reliable estimates projecting 
the likely compliance profile in the population to which the results are to be generalized, 
thus providing an overall estimate of the likely average treatment effect for the whole 
general population. This weighted average may be of particular interest for policy 
makers who want to determine the benefit if all potential individuals were assigned 
treatment and is likely to be more reliable than the usual ITT effect estimate, which is 
realistic only when the population compliance patterns match those demonstrated in the 
trial (112).  
However, Shrier (113) points out that a patient’s PS membership may differ between 
trial and real-life conditions. For example, if participants in the control arm are not able 
   
   
160 
 
to receive active treatment in the trial setting, the latent subgroup of always-takers is 
assumed not to exist, whereas in practice the active treatment may be freely available, 
such that, in practice, patients may be categorized into different principal strata to those 
available in the trial. Indeed Shrier (113) describes how the real-life conditions under 
which a treatment is available may alter a patient’s PS: if treatment is free and readily 
available, a patient may be an always-taker, whereas if it is expensive or difficult to 
access, they may be a never-taker; if affordable or available with a small degree of effort, 
they may be a principal complier; as such, if it is plausible that a patient’s underlying 
compliance status may change with conditions (for example, in terms of treatment 
availability and patient motivation), differences between trial and real-life settings may 
render even the basic (rather than overall weighted) CACE ungeneralisable.  
5.4.7. Limitation to PS methods 
The other, most notable, limitation of PS methods is the requirement for binary 
compliance classification. Although, in theory, PS estimation embraces a broad class of 
models which includes general forms of non-compliance (such as time-dependent, 
continuous or multivariate), they are unbiased generally only for binary non-compliance 
and binary treatment comparisons, and thus at most four latent compliance classes 
(depending on the restrictions imposed by the trial design on whether control (or 
experimental) arm patients are able to receive the alternative treatment). For example, as 
in the vitamin A trial, if the trial treatment protocol prevents control patients from 
receiving experimental treatment (such that non-compliance only occurs among 
experimental arm patients who either do or do not receive experimental treatment), 
only two compliance classes actually exist, as patients do not have the opportunity, 
within the trial setting, to be always-takers or defiers. 
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Any extension to PS methods, for example to allow for partial compliance or 
comparison of (compliance with) more than two treatments, add to the complexity of 
models by requiring more principal compliance categories (for example, where 
compliance-type is defined by the time at which an individual would stop treatment if 
randomised to treatment) and more complicated assumptions in order to ensure 
identifiability of the causal estimates (69). For example, Sommer suggests that their 
method could be extended to allow more than two categories of compliance or 
continuous compliance by imposing some parametric structure on how the probability 
of outcome depends on compliance in the control group (for example, by assuming a 
logistic regression model that expresses likelihood of outcome for the control group as 
a function of compliance). Goetghebeur (115) demonstrates this by estimating causal 
effect for ordered binary categories (ordinal) under the assumption of a monotone 
dose-response relationship between treatment received and outcome. However, in 
general, methods to accommodate partial or time-varying treatment adherence require 
complex assumptions and are not fully developed (113). 
Furthermore, although model-based extensions to PS methodology are possible (for 
example, allowing for missing outcome data ((120-123) or including covariates for 
model-based estimation (124) using maximum likelihood (125) or Bayesian techniques 
(126, 127), inference using such models tends to be particularly sensitive to 
distributional assumptions, and still necessarily rely on classification of compliance into 
discrete (usually binary) compliance categories. 
This is a major limitation, given that trials most likely to be subject to treatment 
nonadherence are often those with long-term treatment and follow up schedules, 
adherence to which may not be adequately summarised using binary compliance classes. 
A further disadvantage is that in such trials, interest typically lies in assessing TTE 
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outcomes (thus capturing more information on the temporal aspect of treatment effect 
on outcome) rather than simpler binary or continuous outcomes; however, PS 
methodology has not been extended to analysis of such survival outcomes.  
These limitations lead us to now consider the second approach to estimation of causal 
effects using the PO framework, which was not only developed originally for use with 
TTE outcomes but also which can adjust for more flexible measures other than simply 
binary compliance.  
5.5. Efficacy-based: structural modelling 
The alternative causal methodology to PS based on the PO framework is that of 
structural modelling. Models for the distribution of potential outcomes are called 
structural (meaning causal) because of the underlying structure (as depicted in a 
cDAG) in a causal relationship, rather than mere association between variables.  
Structural models (SMs) make no assumption regarding the relationship between 
compliance and outcome, but instead model the relationship between observed and 
underlying untreated outcomes in terms of the relevant compliance measure (for 
example, cumulative dose of drug taken or time to treatment deviation) with estimation 
based on the assumed balance between randomised groups in terms of baseline 
(untreated) outcomes. As such, the concept of POs facilitates causal estimation using 
these models by defining the (potentially latent) subject-specific untreated outcome as 
the reference, against which the observed (treated) data may be modelled with explicit 
estimation of the causal parameter (73). 
Thus in contrast to the CACE estimate, which relates only to those patients who would 
naturally comply with their assigned treatment, a structural model provides a causal 
estimate relating to the entire population. However, the validity of such an estimate may 
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be equally questionable, if it is not feasible to believe that everyone in the population 
could be induced to comply. 
Compared to PS methods, this more general modelling approach to causal estimation 
means that SMs are able not only to incorporate more flexible measures of compliance 
but also to accommodate survival outcomes. Indeed after the concept of structural 
modelling was first introduced by Robins (128), SMs were developed by Robins and 
Tsiatis (129) specifically for TTE outcomes, in order to address the problems associated 
with adjustment for time-varying treatments using standard methods of survival analysis 
when treatment changes are typically indicative of patient prognosis. 
5.5.1. Standard survival methods 
Analysis of survival outcomes, which record the time from randomisation to the 
outcome event of interest (for example, time to disease progression or death) is 
complicated by the need to allow for censoring when follow up occurs prior to 
observation of the endpoint of interest, such that individuals are included in analysis 
only until the time at which their follow up ceases.  
Standard survival analysis methods assume uninformative censoring (i.e. censoring 
occurs completely at random), such that those who prematurely cease follow up can be 
considered a random sample of those remaining in the trial and thus censored at the 
point of loss to follow up without introduction of bias. One such method is the Cox 
proportional hazards (PH) model, the most commonly used model for survival 
outcomes which avoids the need for any distributional assumptions of underlying 
survival times by simply estimating the relative hazard (or hazard ratio, HR) between 
treatment groups, which is assumed to remain constant over the trial follow up period 
(under the proportional hazards (PH) assumption).  
   
   
164 
 
For example, in order to investigate the effect of a binary treatment 𝑍, the basic Cox 
model ℎ(𝑡) = eβZℎ0(𝑡) relates a patient’s (unspecified) underlying hazard ℎ0(𝑡) with 
their observed hazard ℎ(𝑡) at time 𝑡 through an estimated treatment HR eβ (expressed 
in terms of an exponential variable, given that such a ratio is necessarily positive). 
However, given that changes to treatment are unlikely to occur randomly with respect 
to a patient’s prognosis, censoring patient’s analysis at the point at which deviation from 
randomised treatment occurs (as in an “on treatment” (OT) version of a PP analysis) 
will not appropriately protect against bias. 
Similarly, an AT adjustment for a time-varying treatment covariate ?̅?(𝑡) (a summary 
measure such as cumulative dose or time spent on treatment until time 𝑡, or actual 
treatment received at time 𝑡 ) in a time-varying Cox model will reflect only the 
associational rather than causal relationship between treatment and outcome, given that 
the estimated HR eα  fails to distinguish between causal and potential selection (or 
confounding) effects (130). 
ℎ(𝑡) = eαA̅(𝑡)ℎ0(𝑡) 
Furthermore, attempts to adjust for time-varying confounders 𝑋(𝑡) (which are not only 
affected by prior treatment but which also influence future treatment choices as well as 
outcome) will not help to remove such biases, given that, in removing some of the 
effect of treatment received, the resulting treatment effect estimates would reflect 
neither the overall (unadjusted) nor direct (causal) effect of treatment on outcome (130). 
Indeed, in adjusting for such time-varying confounders (TVCs) which are also affected 
by prior treatment, further bias is introduced, as the TVC lies on the causal pathway 
between treatment exposure and outcome (at a particular time 𝑡); therefore explicit 
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control for this confounder will distort the treatment effect estimate, as the effect of 
treatment on the outcome acting via the confounder will be removed (131, 132). 
5.5.2. Accelerated failure time model 
An alternative standard survival model which is less common, but may be especially 
useful when the PH assumption does not hold, is the accelerated failure time model 
(AFTM). In contrast to the Cox PH model in which factors are assumed to affect the 
likelihood of the outcome occurring at a particular time point, the explanatory variables 
in an AFTM are assumed to act multiplicatively on the time scale, thus instead affecting 
the rate at which an individual proceeds along the time axis (133). If 𝑆0(𝑡) and 𝑆1(𝑡) 
denote a patient’s probability of surviving beyond time 𝑡 on control and experimental 
treatments, respectively, the relationship between these times, assuming an AFTM with 
(again necessarily positive) acceleration factor (so-called because of its effect on the rate 
at which lifespan is used up), 𝑒𝛽, would be denoted 𝑆1(𝑡) = 𝑆0(𝑡/𝑒
𝛽). Thus 𝑒𝛽 < 1 
(i.e. 𝛽 < 0) would imply an acceleration in time to event with experimental treatment 
compared to control, such that, with a positive (negative) event, such as healing (death), 
𝑒𝛽 < 1 implies the experimental (control) treatment is preferable (74). 
5.5.3. Rank-preserving structural failure time model 
The structural version of the AFTM was introduced by Robins (129); this model is 
structural in the sense that it makes a direct within-patient (rather than between patient) 
comparison of their observed (𝑌𝑖) and (potentially latent) untreated survival times (𝑌0𝑖). 
The structural AFTM is also known as the rank-preserving structural failure time model 
(RPSFTM), “rank-preserving” because, if the untreated event time for individual 𝑖 is 
less than that for individual 𝑗, the predicted treated event time for individual 𝑖 would 
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also be less than that for individual 𝑗 (thereby implying an assumption of no treatment-
covariate interactions)(74). 
The acceleration factor (AF) is estimated using a process called G-estimation, based on 
the assumption of balance produced by randomisation between treatment groups in 
terms of patients’ (potential) untreated survival times 𝑈0𝑖. The model assumes that an 
individual’s observed survival time 𝑌𝑖 is related to their underlying baseline survival time 
𝑈0𝑖 through an AF 𝑒
𝛽 assumed to vary with treatment received 𝐴𝑖(𝑡) (130).  
𝑈0𝑖(𝛽) = ∫ 𝑒
𝛽𝐴𝑖(𝑡)  
𝑌𝑖
0
𝑑𝑡 
Thus the RPSFTM relates observed outcome 𝑌𝑖  to 𝑌0𝑖  (counterfactual or potential 
outcome that would have been observed without treatment) through treatment effect 
𝑒𝛽 (hence structural as it relates potential outcomes on the same individual). 
Assuming discrete intervals of time, and binary treatment receipt (i.e. 𝐴𝑖(𝑡) is a binary 
time-dependent variable denoting receipt of experimental ( 𝐴𝑖(𝑡) = 1 ) or control 
(𝐴𝑖(𝑡) = 0) treatments over time), where a patient’s observed survival time 𝑇𝑖 can be 
expressed in terms of the amount of time spent on experimental (𝑇1𝑖) and control (𝑇0𝑖) 
treatments, where 𝑇𝑖 = 𝑇0𝑖 + 𝑇1𝑖  (134), the relation between treatment receipt and 
underlying untreated outcome can then be simplified as 
𝑈0𝑖(𝛽) = 𝑇0𝑖 + 𝑒
𝛽𝑇1𝑖 
such that the counterfactual (untreated) survival time 𝑈0𝑖 can be interpreted as the sum 
of time spent on control treatment and the time spent on experimental treatment 
multiplied by the AF 𝑒𝛽 (135). Thus, an AF equal to 𝑒𝛽 implies that every unit of time 
spent on experimental treatment would equate to 𝑒𝛽 units of time on control treatment. 
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Thus 𝑒𝛽 < 1  (i.e. 𝛽 < 0 ) would imply an acceleration in time to event with 
experimental treatment compared to control (treatment decreases event time), whereas 
𝑒𝛽 > 1  (i.e. 𝛽 > 0 ) would imply deceleration in time to event with experimental 
treatment compared to control (treatment extends event time). The optimal value of  𝛽 
is determined using an unusual test procedure known as G-estimation.  
5.5.4. G-estimation 
Given the reliance on unobserved counterfactuals, the acceleration factor 𝑒𝛽 cannot be 
estimated using usual methods for associational models. Instead, a method known as G-
estimation is employed, based on the assumption that the untreated survival times 𝑈0𝑖 
can be considered a baseline feature unaffected by post-randomisation treatment or 
confounding, which on average will differ only randomly between the randomised 
groups, i.e. 𝑈0 ⊥ 𝑍 . Thus, in exploiting the expected independence between the 
underlying untreated outcome and randomisation (the IV) under the randomisation and 
ER assumptions, G-estimation is the general version of IV estimation for time-varying 
treatments.  
Causal estimation is based on finding a value of the treatment effect parameter (𝛽) that 
attains baseline balance in terms of potential untreated outcome 𝑈0𝑖  between 
randomised groups (69).  
In practice, G-estimation is carried out on a trial and error basis, testing a range of 
proposed values of the acceleration 𝑒?̂?  factor to determine which achieves the best 
balance between randomised groups in terms of their (estimated) values of 𝑈0𝑖(?̂?). By 
specifying a plausible range of values for 𝛽, and intervals within this range, the user 
defines a grid over which to carry out a search for the optimal value of ?̂? (134). 
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Balance between randomised groups is assessed, for each ?̂? , according to the test 
statistic 𝑍(?̂?) corresponding to the hypothesis that ?̂? = 𝛽, whereby the point estimate 
of ?̂?  is chosen as that for which 𝑍(?̂?)  is closest to 0 (indicating equality between 
treatment arms in terms of 𝑈0𝑖(?̂?)).  The hypothesis test used for this procedure is 
usually the same as that used for the original ITT analysis, for example the log rank test, 
Wilcoxon or Cox model; given the nonparametric nature of these tests, 𝑍(?̂?) is a step 
function; thus in practice, values of  ?̂? are plotted against corresponding 𝑍(?̂?) values in 
order to identify ?̂? for which 𝑍(?̂?) is equal to 0. Similarly, the 95% CI for ?̂? consists of 
all values which fail to reject the null hypothesis at 5% (i.e. CI limits for  ?̂? are those for 
which the hypothesis test p-value is equal to 0.05) (136). It may be useful to consult 
graphical displays of 𝑍(?̂?) against ?̂? to check that a unique value of ?̂? exists, and its 
associated confidence limits are estimable (134). For example, if no values of 𝑒?̂?rejects 
the null hypothesis at the 5% level, the upper CI limit will not be estimable. 
In order to check whether the estimation procedure has worked well, it is useful to 
compare the HR estimated between control group and experimental group 
counterfactual survival times (in other words, the HR between the groups adjusted as if 
none of the patients had received experimental treatment): if the estimation procedure 
has worked well, this value should be very close to 1. This can be further investigated by 
checking that the KM graphs of these modelled counterfactual event times for each 
group are similar. 
G-estimation preserves ITT p-value 
Given that 𝑈0𝑖(0) = 𝑇𝑖 , the hypothesis 𝛽 = 0  simply corresponds to the null 
hypothesis of the ITT analysis, as by definition the test of 𝛽 = 0 is the straightforward 
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test of 𝑇 ⊥ 𝑍, thus demonstrating how G-estimation preserves the p-value associated 
with ITT analysis (leading to the term “randomisation-based efficacy estimator” 
(RBEE) (69). This in turn means that the 95% CI for 𝛽 will include 0 if and only if the 
ITT analysis is not significant at the 5% level. 
5.5.5. Assumptions  
It is generally not possible to identify the RPSFTM causal parameter without making 
some assumptions that are themselves non-identifiable (129). Firstly, use of a RPSFTM 
implies the (untestable) assumption that the underlying acceleration model is correct.  
Assumptions underlying G-estimation are that randomisation must have adequately 
balanced the alternative treatment arms with respect to prognostic characteristics, and 
that the effect of randomisation is mediated entirely by treatment receipt (such that 
those who receive a given duration of treatment will experience the same treatment 
effect, regardless of whether or not they were randomised to receive that treatment), i.e. 
the ER assumption. Given that, despite randomisation, the potential remains for 
important differences at baseline in small and larger trial, it is possible to adjust for 
baseline covariates within an RPSFTM analysis, in order to improve baseline balance 
and increase power (135). 
Furthermore, the treatment effect (relative to the duration of treatment) is assumed to 
be constant regardless of the point at which treatment is received (known as the 
“common treatment effect” assumption). For example, in a trial where treatment 
switches occur for clinical reasons, the treatment effect is assumed to be the same for 
those who were randomised to receive treatment (and thus received treatment from 
randomisation) as for those who only began treatment when switching was clinically 
indicated (for example, from time of disease progression). This may be unlikely in 
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reality, given that the treatment effect for those receiving treatment at a more advanced 
stage in their disease may vary from that experienced when treatment is given earlier 
(137). 
Similarly, the constant treatment effect (which gives rise to the title “rank-
preserving”) implies that the effect of treatment is constant between individuals.  
Although it is possible to use multiple parameter versions of the RPSFTM in order to 
relax the assumption of a constant treatment effect by incorporating more than one 
treatment covariate, these models typically suffer from a lack of power and do not 
deliver meaningful causal estimands (94, 95, 138). For example, inclusion of 𝑝 >
1 covariates as in the equation below would require a 𝑝-dimensional test statistic 𝑍(𝜓), 
so that, if 𝑝 = 2, the point estimate could be determined as the value at which both the 
logrank and Wilcoxon tests are zero. However these estimates are likely to be unstable 
and unreliable (89).  
𝑈𝑖(𝜓) =  ∫ exp [∑ 𝛽𝑗𝑋𝑖𝑗(𝑡)
𝑝
𝑗=1
] 𝑑𝑡
𝑇𝑖
0
 
It is also possible to adjust for baseline covariates in order to allow more precise 
estimation of causal effects, but given that each selection of included predictors will 
alter the resulting causal estimand, it is important to consider this choice carefully. 
Goetghebeur (139) demonstrates methods to check (both graphically and quantitatively) 
whether a baseline covariate can be omitted from a model. 
White (94) demonstrates how parameter estimates can be used to construct the data sets 
which, according to the accelerated life model, would have been observed under an 
alternative treatment scenario, and how this ‘counterfactual’ dataset can be used to 
estimate a ‘corrected’ hazard ratio. The causal AF estimand can be used to construct 
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the corresponding counterfactual dataset that, under the assumption of accelerated life 
model, would have been observed under the “corrected” treatment scenario. These 
counterfactual data can then be used to estimate the “corrected” HR, if it can be 
assumed that the survival times follow a Weibull distribution ℎ(𝑡) = 𝜙𝛾𝑡𝛾−1 (where 𝜙 
denotes the scale parameter and 𝛾 the shape parameter) (140), as this model provides 
direct correspondence between the accelerated lifetime model and Cox model, such that 
the RPSFTM estimand 𝛽 can be expressed in terms of the Cox parameter 𝜃, as 𝛽 =
𝜃
𝛾⁄ . Therefore if one can assume the exponential distribution (𝛾 = 1), the HR (𝑒
𝜃) and 
AF (𝑒𝛽) will be equal.  
Rank preserving 
When analysing RPSFTMs, it is generally necessary to apply certain key assumptions, 
namely the randomisation, SUTVA and exclusion restriction assumptions. Additional, 
(or variations of these) assumptions may be required for a particular analysis, depending 
on the degree of extrapolation required (for example, if one is interested in estimating 
the causal effect not only in those who received treatment but also to those who do not 
receive the treatment) or complexities presented by the nonadherence scenario.  
For example, when the exclusion restriction assumption is not plausible, it is not 
possible to estimate the causal treatment effect using SMs without invoking alternative 
no interaction assumptions, which differ subtly from the exclusion restriction in terms 
of the use and definition of “randomisation allocation”. For the no interaction 
assumption, 𝑍 defines different but observed groups of subjects (i.e. as a conditioning 
argument) whereas for the exclusion restriction, 𝑍  defines different (potential) 
randomisation conditions for the same individual (112). Again, this assumption may not 
be realistic: for example, if switches occurs early on for those who, due to underlying 
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disease state or psychological reasons, are unable to tolerate side effects or perceive 
treatment inefficacy, these underlying traits may lead to different treatment effects from 
those who were originally randomised to receive treatment. 
5.5.6. Censoring 
A major limitation of the RPSFTM is that censoring that is non-informative (on the 
original T-scale) may become informative on the U-scale through its inherent 
association with treatment received (89). Consider the uninformative censoring time 𝐶𝑖 
for individual 𝑖 (which is assumed to be known for all individuals whether or not their 
event time was censored; for example, a fixed maximum follow up time for all patients, 
or an individual maximum follow up time for each patient based on the difference 
between their date of entry and the final date of follow up, i.e. when censoring occurs 
for administrative purposes). The censoring time (𝐷𝑖) for 𝑈0𝑖(𝛽) is therefore  
𝐷𝑖(𝛽) = ∫ 𝑒
𝛽𝐴𝑖(𝑡)  
𝐶𝑖
0
𝑑𝑡 
which, through its dependence on treatment received 𝐴𝑖(𝑡), may in turn depend on 
prognosis.  
White (141) explains how this censoring introduces selection bias on the counterfactual 
scale: in restricting analysis to subjects with known death times, analysis becomes 
conditional on having an observed survival time less than time 𝐶𝑖, and this survival time 
(and hence the probability that it is less than 𝐶𝑖  and hence observed rather than 
censored) is assumed to be affected by treatment; a positive or negative treatment effect 
may increase or decrease the probability that the survival time of an individual is 
censored, and where treatment crossover occurs, treatment received is likely to be 
associated with prognosis (142). Thus for those individuals who had an unfavourable 
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treatment history (for example, control group patients who did not cross over onto a 
beneficial new treatment, or control group patients that did crossover onto a 
detrimental new treatment) and experienced events a short time before 𝐶𝑖 , a more 
optimal treatment path may have delayed their event such that it was not observed (i.e. 
if event had been delayed until after 𝐶𝑖) and as such it would not have been included in 
analysis. White’s proposed solution to remove the dependence of censoring time 𝐷𝑖(𝛽) 
on 𝐴𝑖(𝑡), in order to allow unbiased estimation of the causal parameter, is to restrict 
analysis to those whose survival time would have been observed whether they had been 
treated or untreated, in other words by recensoring at the minimum of all possible 
censoring time over all possible evolutions of 𝐴𝑖(𝑡)  in participant 𝒊 ’s allocated 
treatment group: 
𝐷𝑖
∗(𝛽) = min
𝐴
𝐷𝑖(𝛽) 
In particular, if 𝐴𝑖(𝑡) could have been always 0 and could have been always 1, then  
𝐷𝑖
∗(𝛽) = min(𝐶𝑖, 𝐶𝑖𝑒
𝛽) 
such that if 𝑌0𝑖 > 𝐷𝑖
∗(𝛽), then 𝑌0𝑖 is replaced by 𝐷𝑖
∗(𝛽) and its censoring indicator is 
replaced by 0. This method requires therefore that a potential recensoring time 𝐶𝑖  is 
provided for each individual (for example, as a fixed maximum follow up time for all 
individuals or a maximum follow up time for each individual based on the difference 
between their date of entry and the final date of follow up).  
The disadvantage to this recensoring approach is the obvious need to ignore some 
follow up data, with the impact of recensoring depending on the magnitude of the 
acceleration factor and the distribution of event times (141). Recensoring will be 
particularly problematic if the treatment effect is not constant over time; in the case of a 
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treatment-time interaction, recensoring of events that occur late in follow up will distort 
the overall estimated treatment effect, due to over-representation of earlier compared to 
later events. As such, White (89) warns that recensoring can lead to distorted 
conclusions if results are taken at face value without further consideration of the 
plausibility of the proposed causal effects, especially if the effect of treatment is not 
constant over time. Furthermore, the changes to original data due to recensoring 
introduce a undesirable difference between the RPSFTM and original ITT analysis (74). 
Alternative solutions to the problem of recensoring include specifying a relationship 
between 𝑈0  and 𝐴𝑡  (but this may well lead to bias if this parametric model is 
misspecified) or using a method based on inverse probability weighting (89), to be 
introduced in the next section. Generally, the need to recensor observations is one of a 
number of limitations associated with SMs; in the next section, the advantages and 
disadvantages of this methodology will be discussed in relation to the alternative 
randomisation-based PS techniques. 
5.5.7. Limitations of SM/advantages over PS techniques 
SM offer greater flexibility than PS methods in terms of the compliance measure or 
summary of treatment received included in the model, which in turn means a more 
accurate reflection of the causal contrast of interest. Thus binary, ordinal and 
continuous measures of compliance can be accommodated in SM via an appropriate 
functional form for the treatment received variable in the model.  
Furthermore, the flexibility of structural models allows extensions to include covariates 
and investigation of potential interactions between treatment group and baseline 
covariates (as demonstrated by Robins (143)); therefore these models are useful for 
assessing whether or not the effect of received treatment is modified by baseline 
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covariates. Inclusion of baseline covariates can also reduce the variance associated with 
the causal parameter, as long as the covariates are correlated with both the outcome and 
treatment compliance (144). 
However, SM is generally limited to valid estimation of only one causal parameter, 
which limits the scope of investigation especially for trials with multiple forms of 
treatment deviation. When aiming to estimate more than one structural parameter, it 
would be theoretically possible to include baseline predictors of compliance in order to 
ensure identifiability; in particular (𝑘 − 1) baseline covariates are required in order to 
identify 𝑘 parameters but these parameter must be good predictors of both compliance 
and outcome (144); in practice such estimation is not stable or reliable (94). 
Additionally, given the reliance on an underlying model structure, SM requires 
assumptions that once again cannot be empirically validated (114). In particular, a 
structural model for the effect of treatment received on outcome (for example, in terms 
of a linear function of duration or cumulative dose of treatment) requires the correct 
specification of dose-response relationship. Robins (145) demonstrated however, that 
although these models require specification of such assumptions, they are relatively 
robust to model misspecification and will provide unbiased model estimates and 
standard errors even if the functional relationship between outcome and covariates 
differs to that assumed by the model. Goetghebeur (139) demonstrates graphical 
methods to assess the appropriateness of the assumed structural model. 
Finally, in respecting randomisation (as demonstrated in section 5.5.5), estimated causal 
effects using SMs will, by definition, have the same significance level as original ITT 
effect. Even with incorrect model specification, this approach guarantees valid tests of 
the null hypothesis (of no effect of treatment) (112). This may be considered an 
advantage (given that interpretation may be unclear if the compliance-adjusted analysis 
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suggested greater statistical significance than the original ITT analysis) or a limitation (if 
there is a need to regain the power lost due to deviation from randomised treatments) 
(94).  
Limitations of the RPSFTM in particular, such as the need for recensoring to overcome 
the problem of informative censoring on the counterfactual survival time scale and the 
implications of the common treatment effect, will be addressed in detail by considering 
application of this method to a number of the expository trials introduced in Chapter 4.  
However the RPSFTM is only one of a whole class of structural models developed for a 
variety of outcomes and compliance scenarios in both trial and observational settings. 
5.5.8. History of SM for alternative outcomes  
An alternative structural AFTM proposed by Robins (131), for observational data, 
adjusts for time-varying covariates (rather than confounders) as an alternative to the 
Cox PH model with time-dependent covariates, both of which may be applied, for 
example, in the case of changing exposure to environmental factors over time. Robins 
and Greenland (95) extended these methods for a trial setting, thus making use of 
randomisation as the IV through G-estimation and therefore circumventing the reliance 
on the assumption of NUC for identification of the causal parameter. 
Robins (145) then presented the theory behind the general class of structural nested 
mean models (SNMMs) for causal estimation in the setting of a repeated continuous 
outcome, where nested structural models are necessary when treatment exposure and 
confounders vary over time (118). With repeated outcomes (or survival times split into 
discrete time periods and analysed sequentially using pooled logistic regression, PLR), 
the basis of structural nested models is that patients contribute to each discrete follow 
up period for which they remain under follow up (i.e. prior to censoring or event 
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occurring in the case of survival outcome), such that the trial is considered as a 
sequential randomised trial, each ‘trial’ comprising of subjects who remained ‘at risk’ 
(uncensored) at the end of the previous ‘trial’, each of which is nested within the 
previous trial (130). This approach addresses the bias introduced by time-varying 
confounders, as each nested ‘trial’ can be treated independently to all previous ‘trial’ 
periods.  
Robins (145) proposed general methods (for various outcome types) to estimate effect 
of treatment received using structural mean models (SMMs). SMMs are a special case of 
SNMMs for single measure rather than repeated measure outcomes; in the case of a 
singly measured linear outcome, it is possible to estimate the causal parameter using 
linear regression rather than through the iterative process proposed by Robins for the 
general form of SNMM with repeated outcome measures (144).  
Robins described additive (and multiplicative) SMMs to adjust for treatment deviations, 
where the causal parameter is expressed as the difference (ratio) of the expected 
observed and untreated (relevant control condition) outcome as a linear (exponential) 
function of unknown parameters, potentially adjusting for baseline covariates. Examples 
of additive (multiplicative) SMMs include linear (log-linear or logistic) SMMs which 
contrast linear models for the difference in means (log-ratio of means or log-odds-ratio 
of success in exposed subsets of the population) of observed and untreated (potential) 
outcomes (146). These methods were investigated further by Fischer-Lapp (144) and 
Ten Have (147) for situations where control group patients are and are not 
(respectively) allowed to switch to experimental treatment, focusing on the effect 
estimate for those who actually took treatment. Without a constraint ensuring that the 
probability of treatment success is bounded between 0 and 1, valid estimation of the 
causal parameter in logistic SMM was not achievable until Vansteelandt (148) 
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introduced the idea of generalised SMMs, allowing generalisation to incorporate any 
monotone, continuously differentiable link function (thus allowing for non-linearities by 
replacing the linear or log-linear links) and incorporating an associational model to 
appropriately constrain the predicted probability from logistic SMMs. 
Robins (149) introduced analogous structural nested models (SNMs) for estimating 
causal effects of time-dependent treatment in observational settings, which without the 
advantage of randomisation are identifiable only under the assumption that all relevant 
confounders have been accounted for (via NUC assumption), once again addressing the 
problem of time-varying confounding via the use of ‘nested’ observation periods. SNMs 
estimate the magnitude of causal effect of a final brief exposure of a time-dependent 
treatment given in an observational setting at time 𝑡  as a function of past time-
dependent treatment and prognostic factor history. 
In a trial setting, however, the balance provided by randomisation can be exploited such 
that the causal parameters for linear or log-linear SMMs, as well as RPSFTM, can be 
estimated by G-estimation.  
As with this structural modelling approach, which may be applied to observational 
settings under the assumption of NUC (in place of randomisation), the next causal 
estimation method to be discussed can be used in both observational and trial settings. 
Indeed, it was originally developed for use in observational studies, but has since been 
adapted and applied to randomised data as an alternative method to adjust for treatment 
deviations. In contrast to the nested approach of SNM, these observational-based 
methods allow for time-dependent confounders by indirectly adjusting for such 
variables via the use of inverse probability weighting. 
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5.6. Observational methods 
The basis of the previous two approaches for randomised trial data is that potential 
outcomes and compliance are independent of randomisation; this independence may in 
fact be true only after conditioning on covariates, in other words by the NUC 
assumption (110). Furthermore, the randomisation-based methods discussed in the 
previous section are generally only useful when adjusting for limited forms of treatment 
deviations in order to estimate a single treatment effect (for example, experimental 
versus control therapy) for trials with only two randomised arms. When the causal 
research question requires estimation of multiple treatment effects (for example, in an 
active-controlled trial with several randomised treatment arms, or in the case of an 
equivalence trial where patients may terminate treatment altogether rather than simply 
switch between treatments, requiring independent estimation of both treatment effects), 
these randomisation-based estimation procedures tend to be imprecise and unreliable 
(73). In such cases, it may be helpful to employ alternative methods, developed 
originally for use in observational studies which rely on the NUC assumption. 
Indeed, the distinction between randomised and observational settings tends to blur as 
follow up lengthens and hence potential for treatment deviations increases (87). It is 
therefore natural to consider methods originally intended for observational settings for 
application in trial settings, while remembering that trial data have the advantage of 
randomisation as an IV (although the strength of this IV weakens with increased 
treatment deviations over time). Thus the final approach to be considered for causal 
estimation is an observational approach based on the concept of propensity score 
weighting.  
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5.6.1. Inverse probability weighting 
An individual’s propensity score is their probability of receiving treatment (at a 
particular time) conditional on pertinent measured confounding variables, usually 
estimated by regressing treatment received (usually a binary measure, therefore using 
logistic regression) on all such confounders. This propensity score can then be used as a 
covariate in a regression model or to stratify or match treatment and control subjects, 
thereby eliminating bias caused by this set of confounding covariates, when assignment 
mechanism can be assumed to be unconfounded after conditioning on these observed 
confounders (119).  
However, as demonstrated by the cDAG in section 3.9.1, when covariates vary over 
time and are affected by previous treatment, as well as influencing future treatment and 
outcome, they are known as time-dependent confounders and cannot be adjusted for 
using usual methods (such as regression or standard methods involving propensity 
score matching). Instead unbiased estimation may be achieved a method known as 
inverse probability weighting (IPW), which uses propensity scores to simulate a pseudo-
population where causal association between treatment received and outcome can be 
inferred, by excluding or artificially censoring follow up when patients deviate from 
treatment conditions being assessed. The selection bias introduced by this artificial 
exclusion or censoring is addressed by weighting the remaining (uncensored) patients by 
the inverse of their probability of remaining uncensored. These probabilities are 
determined conditional on all factors that jointly predict outcome and treatment change, 
thus removing dependence between outcome and censoring. Thus the assumption of 
NUC (or of sequential randomisation) is key, as is that of positivity (that the 
probability of remaining on treatment is above zero for all possible covariate 
combinations at each time point) in order to ensure weights (inverse of these 
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probabilities) are estimable throughout follow up. Under these assumptions, in this 
simulated pseudo-population, treatment can be considered to be randomly assigned 
conditional on past covariate history and the treatment effect on outcome is the same as 
it would be in the original (unweighted) study population (111). This indirect adjustment 
for time-dependent confounders through their effect on an individual’s probability of 
receiving treatment at any particular time point avoids the confounding and selection 
biases that result when time-dependent confounders are included directly as variables or 
via propensity scores in the model. 
The reasoning behind this methodology is that, if one is able to determine all factors 
that jointly predict treatment change and outcome, weighting up the analysis of time to 
outcome (by the probability of remaining uncensored), while censoring at the point of 
any treatment change, assigns appropriate weight to individuals with the same 
characteristics of those previously censored. Given the assumption that all predictors of 
the outcome have been included in the weight-determining model, this weighting provides 
a pseudo-population that mimics the same likelihood of occurrence of outcome events 
that would have been observed if none of the patients’ follow up had been censored 
due to treatment changes. 
5.6.2. Model type 
Like SM, IPW methods are flexible and vary according to whether the compliance 
measure is binary (i.e. all-or-nothing, as required for PS methods), quantitative (for 
example, a summary continuous measure such as dose) or time-varying (such as time to 
withdrawal from randomised treatment). The exact method used will depend, not only 
on the compliance measure, but also on the outcome type. 
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In a trial setting where compliance is recorded using a binary variable (receipt/non-
receipt of randomised intervention), IPW methods can be used to adjust for selection 
bias that would be introduced in PP analyses due to informative exclusion of patients 
who did not receive their assigned treatment. With binary compliance, an individual’s 
propensity score reflects the impact of an individual’s time-invariant (i.e. baseline) 
covariates on their probability of receiving assigned treatment, which is estimated by 
logistic regression (of the binary treatment receipt variable) on all such confounding 
baseline variables. The corresponding inverse weights, known as inverse-probability-of-
treatment weights (IPTW), are then applied on a patient-specific basis in the outcome 
model. 
When treatment receipt and outcome are time-varying (for example, in a trial with a 
survival outcome where compliance is defined by time to withdrawal from randomised 
treatment), time-varying weights (indicating inverse probability of remaining on 
randomised treatment, and thus uncensored, at each time point) may be calculated using 
a time-varying Cox (or pooled logistic regression, PLR) weight-determining model; the 
inverse of these patient-specific time-varying probabilities (known as inverse-
probability-of-censoring weights, IPCW) are then applied as time-varying weights for 
each individual’s contribution (while they remain uncensored) in the Cox (or PLR) 
outcome model.   
Similarly, if outcome is recorded at the end of follow up as a binary or continuous 
response to treatment, and time-varying (binary) treatment is recorded at discrete time 
intervals, the overall weight for each individual can be calculated by multiplying the 
probability of receiving treatment at each discrete time point (estimated by logistic 
regression, regressing on all important baseline and time-varying covariates). Under the 
assumption of conditional independence, it is unnecessary to allow for correlation from 
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observations on the same subject, because of full conditioning on treatment history; in 
other words, all patients included in analysis at time 𝑡  are known not to have 
experienced treatment change prior to this point, such that their history is 
uninformative (and therefore there is no need for clustered standard errors). These 
patient-specific overall IPTW are then applied to each individual’s observations when 
carrying out logistic or normal linear regression (of binary or continuous response 
variables, respectively) including in the estimation sample only those patients who fully 
complied with their randomised assignment.  
When compliance is recorded using a continuous measure (such as cumulative dose 
received), however, the more general approach of IPW estimation using MSMs is 
required to accommodate the underlying dose-response relationship. 
5.6.3. MSMs 
The class of marginal structural models (MSMs), originally developed by Robins (111) 
for observational studies, uses the PO framework to estimate causal effects while 
simulating ignorable treatment assignment mechanisms using inverse probability 
weighting (IPW) techniques. Similarly to SNMs, MSMs are based on regression 
modelling using the PO framework, for example employing linear or logistic regression 
for continuous or binary outcome data (respectively) to model the relationship between 
treatment and outcome, in terms of the within-patient difference between a patient’s 
observed and (potentially latent) untreated baseline outcome. However, in contrast to 
the nested approach of SNM, MSMs (and associated IPW) methods allow for time-
dependent confounders by indirectly adjusting for such variables via the use of IPW, 
thus rendering the treatment receipt exogenous (which, in the context of cDAGs, 
would be demonstrated by a lack of any arrows into the (potentially time-varying) 
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treatment variable, except potentially from previous treatment); this is achieved by 
creating a pseudo-population in which treatment history has the same causal effect of 
treatment history as in the original population but prognostic factors do not predict 
treatment. Valid causal estimation is then achieved by simply applying standard 
regression models to the weighted population (111). Thus these models are both 
structural and marginal, as they model the structural (or causal) effect of treatment on the 
marginal distributions of the counterfactual outcomes, 𝑌?̅?  (rather than their joint 
distribution, as no account is taken for correlation between different potential 
outcomes).  
The IPCW method is therefore a special case of MSM which can be applied with 
randomised trial data where compliance to randomised treatment is measured as time to 
“deviation” from randomised treatment (with “deviation” defined according to the 
research question of interest). Both MSMs and IPCW methods relate to individual-
based treatment contrasts, but IPCW methods compare only two potential treatment 
histories; for example, in the case of a randomised two-arm trial (experimental versus 
control treatment) subject to treatment changes, the IPCW would compare treatment 
with experimental (identified from the weighted experimental treatment arm, censored 
at treatment change) versus treatment with control (identified from the weighted 
control treatment arm, censored at treatment change).  
Alternatively, MSMs can be used when binary treatment receipt varies over the course 
of the trial, such that the time following first treatment change is not ignored in analysis; 
instead the observed time-varying treatment covariate is included in the model (as in a 
standard time-varying treatment model). However, the bias introduced by use of this 
time-varying treatment covariate is countered again by the use of inverse probability 
weights. However, in this case, weights are calculated equal to the inverse probability of 
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receiving actual observed treatment at time 𝑘, known as inverse probability of treatment 
weights (IPTW). Thus, if at each time point 𝑘 , patient may receive experimental 
treatment (𝐴 = 1) or control treatment (𝐴 = 0) and estimated probabilities (𝑝𝑖𝑘) reflect 
the chance that individual 𝑖 receives experimental treatment, at any time point at which 
they receive control treatment, the IPTW would be equal to 1/(1 − 𝑝𝑖𝑘) rather than 
1/𝑝𝑖𝑘. 
Furthermore, MSMs are able to compare a wider range of potential treatment histories 
(for example, the effect of being treated for 𝑑 days) by modelling causal effects across 
potential treatment histories; in other words, by making a comparison of counterfactual 
outcomes resulting from different potential treatment histories in the same individual 
(for example, assuming a causal effect of 𝑑 days of treatment equates to 𝛽𝑑), where 
estimation of outcomes under each potential treatment history is obtained by weighting 
the data according to each patient’s corresponding IPTW. Thus, in an MSM, it is 
necessary to specify an appropriate functional form of relationship between dose and 
outcome, which again must reflect the causal question.  
Different versions of MSM can be applied, depending on the form of the outcome 
variable, such as linear or log-linear (or logistic) models for continuous or binary (with 
log or logit links, respectively) outcomes. In assuming a certain functional form (for 
example, linear) for the relationship between treatment received and outcome, 
information from those who did not fully comply with treatment is utilised to provide 
an estimation of the dose-response relationship.  
5.6.4. IPW method in practice 
The use of IPW methods in practice requires a number of analysis steps, which, given 
the pertinence of TTE outcomes when considering causal estimation techniques, will be 
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described below for survival outcomes, under the assumption that compliance is 
recorded as a time-vaying binary measure (or as time to deviation from randomised 
assignment), thus requiring IPTW (or IPCW) estimation respectively. 
It is necessary first to define the exact treatment regimens to be contrasted, in particular 
identifying the point at which deviation from these treatment regimens is considered to 
have taken place. In the case of IPCW, this definition of “treatment deviation” is then 
used to artificially censor individuals when they deviate from their original regimen. For 
IPTW models, this definition distinguishes between time spent on experimental and 
control treatment, thus informing the binary treatment receipt variable. It is then 
necessary to identify all important baseline and time-varying confounders that are 
considered to impact, not only outcome, but also the likelihood that an individual will 
“deviate” in this way from their assigned treatment allocation.  
In order to adjust for bias associated with this artificial censoring (in the case of IPCW 
modelling) or use of time-varying treatment covariate (in the case of an MSM with 
IPTW modelling), a weight-determining (WD) Cox (or logistic) model is used to 
calculate the time-varying (or time-fixed) probability that each patient is censored (or 
excluded), adjusting for all identified important predictors of treatment deviation. The 
estimated probabilities derived from the WD model are then used to calculate IPCW (or 
IPTW) for each patient at each time point. The time to event outcome is then assessed 
(using a relevant model corresponding to type of outcome data) in the population of 
patients weighted by their IPCW (or IPTW) until the time they were artificially censored 
due to treatment deviation (or, in the case of binary compliance, only in those who 
received randomised treatment).  
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5.6.5. Qualities of weighted pseudo-population  
This pseudo-population with 𝑤𝑖𝑘 copies for each “compliant” patient 𝑖 at time 𝑘, has 
two important properties which allow valid estimation of causal estimate: first, covariate 
history does not predict the status of treatment change at time 𝑘  and secondly the 
causal effect in this pseudo-population is the same as that of the original population 
(111). Thus it is valid to use standard regression techniques (such as ordinary time-
dependent Cox or linear regression) in this population to obtain unbiased causal 
estimates (136). 
Heuristically, it may be appreciated that weighting the observation for (uncensored) 
individual 𝑖 by 𝑊𝑖𝑘 at time 𝑘 essentially allows for the loss at or before time 𝑘 of the 
(𝑊𝑖𝑘 − 1) individuals who shared the same values of all confounding factors (𝑋𝑖0, ?̅?𝑖𝑘) 
as individual 𝑖 at time 𝑘) but who were artificially censored at time 𝑘. Given that, under 
the assumption of NUC, these (𝑊𝑖𝑘 − 1) individuals are also assumed to share the 
same (time to event) outcome as individual 𝑖, the estimated parameter in the weighted 
population is equivalent to that which would have been observed in the original 
population but without treatment deviation, and as such may be granted causal 
interpretation.  
In other words, the causal effect of treatment estimated from the pseudo-population is 
equal to that in the original population if no-one had been informatively censored, 
under the assumption that censoring occurs at random given covariate history. Thus 
when exclusion or artificial censoring of patients is applied to those who (or at the times 
when patients) deviate from their assigned treatment, weighting of the remaining 
patients creates a pseudo-population of patients who exhibit the same causal risk of 
event but who did not undergo changes to their treatment. 
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5.6.6. Need for stabilised weights 
Weights are referred to as inverse probability weights because the denominator of the 
weight is essentially the probability that the individual complies with their randomised 
treatment (at time 𝑘, in the case of time-varying compliance).  
However, given that the chance of treatment deviation increases over time, and as such 
the probability that a patient remains (artificially) uncensored decreases over time, the 
inverse of this probability can become very large, leading to very high weights for 
certain patients with prolonged follow up and extreme values of time-dependent 
prognostic factors strongly associated with outcome. These patients will dominate the 
weighting analysis by contributing large number of copies to the pseudo-population, 
leading to unstable parameter estimates with large variability. Using large samples of 
patients helps to cut down on occurrence of such sampling fluctuations, but in addition 
Robins and Finkelstein (150) recommend using a “dampening” numerator to stabilize 
the weights, equal to the probability of being censored at time 𝑘 dependent on baseline 
covariates only.  
Whereas unstabilised weights are simply the inverse of the conditional probability of 
having remained uncensored until time 𝑡 conditional on baseline and time-dependent 
covariates, stabilised weights are the conditional probability of having remained 
uncensored until time 𝑡 given baseline covariates, divided by the conditional probability 
of having remained uncensored until time 𝑡  given baseline and time-dependent 
covariates. The stabilised weight will be equal to 1 for all 𝑡 if the history of the included 
prognostic factors for failure does not impact upon the hazard of censoring at 𝑡, such 
that there would be no informative censoring and treatment switching would be at 
random.  
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Thus, in an IPCW model, the stabilised weight for individual 𝑖, 𝑊𝑖𝑘 = 0 at the time at 
which patient deviates from their assigned treatment (i.e. such that they are then 
dropped from analysis); otherwise their (stabilised) weight is denoted  
𝑊𝑖𝑘 =
Pr(𝐶𝑖𝑘 = 0|𝑋𝑖0)
Pr(𝐶𝑖𝑘 = 0|𝑋𝑖0, ?̅?𝑖𝑘)
 
where 𝐶𝑖𝑘 indicate whether individual 𝑖 has been artificially censored (due to treatment 
deviation) (𝐶𝑖𝑘 = 1) or remains under observation (𝐶𝑖𝑘 = 0) at time 𝑘, 𝑋𝑖0 are fixed 
baseline covariates, 𝑋𝑖𝑘  are time-varying covariates at follow up time 𝑘 , assumed to 
influence both treatment crossover and final outcome and ?̅?𝑖𝑘 is the history of these 
relevant time-varying covariates up to follow up time 𝑘. 
5.6.7. IPW methods to adjust for LTFU  
As well as adjusting for treatment deviation, IPW methodology may be used to account 
for bias introduced by informative loss to follow up; for example, when (complete case) 
pseudo-ITT analyses are carried out, the bias caused by missing outcome determination 
can be removed using IPW methods, assuming that data are available on all time-
varying determinants of loss to follow up. Furthermore, it is possible to adjust for 
treatment deviation as well as loss to follow up in the same analysis, by simply 
multiplying a patient’s time-varying “treatment deviation” weights by the corresponding 
“loss to follow up” weights to obtain overall weights (based on assumption of 
conditional independence) (151). 
5.6.8. Considerations regarding use of IPW methods 
There are a number of important limitations that must be considered when using IPW 
techniques.  
   
   
190 
 
First, the correlation introduced by the use of IPWs renders normal standard errors 
invalid; as such, robust variance estimation or bootstrapping is required for confidence 
interval estimation.  
IPWs are unestimable if there are levels of any covariates that ensure (in order, where 
the probability equals one) that treatment switching will occur (152). Indeed, IPW 
methods require that there remains a reliable pool of uncensored patients on which to 
base weight estimation at each time point and for each combination of confounding 
covariates. If the probability of treatment deviation for any such combination is 
especially high (or low), the stabilised weights will be subject to wild fluctuations, in turn 
leading to unreliable causal estimates.  
And finally, but perhaps most importantly, especially in the context of randomised 
trials, is the assumption of NUC. In order for IPW methods to be implementable, it is 
vital for data to be available on all potential confounders (in other words, those baseline 
or post-randomisation, potentially time-varying, variables that both predict treatment 
change and outcome). It is never possible to be entirely confident that all data on all 
confounders have been collected and correctly allowed for; indeed it is highly unlikely 
for the NUC assumption to be entirely true, but IPW methods will work well even 
when this assumption is only approximately true (142), provided no important 
confounders have been omitted from the model.  
However, the NUC assumption may represent a key limitation of the IPCW, 
particularly in a trial context. IPW methods were developed for observational studies 
which are typically more suited to the longitudinal data collection process required to 
meet this assumption. In contrast, datasets collected for trials are typically much smaller 
than those for observational studies, and key (time-varying) predictors of treatment 
switching are often not collected in trials (for example, reasons for patient switching 
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preferences). Personal or psychological traits which affect a patient’s ability to comply 
(and in turn affects their outcome) may be very difficult to record reliably longitudinally, 
especially in the strict setting of a randomised trial (while observational studies may 
provide more scope for long term follow up of such factors). Moreover, data collection 
on such indicators is often stopped during follow up for practical reasons (for example, 
upon treatment discontinuation or disease progression), thus further hampering the 
applicability of the IPCW method. Overall, when data on predictors are sparse, the 
NUC becomes less plausible and the IPCW method becomes less stable (142). 
5.7. Considerations regarding choice of adjustment method 
Having introduced the reader briefly to the field of causal analysis, it is useful to reflect 
briefly on the requirements and limitations of each method, in order to ensure 
appropriate application and interpretation, as well as to guide researchers in their choice 
of causal methodology.  
Table 7 Main differences between causal analysis approaches 
1. Key to causal analysis is appreciation of the PO framework, which underlies most 
causal estimation techniques.  
2. Traditional SEMs are disadvantaged by lack of transparency regarding underlying 
assumptions and the likely problem of hidden bias and time-varying confounding.  
3. Principal stratification techniques are straightforward to apply in simple, all-or-
nothing compliance scenarios but cannot be extended easily to allow for (more 
usual) time-varying treatment deviation or survival outcomes.  
4. Structural models provide a more flexible approach to causal analysis, 
accommodating more general compliance measures and using a nested approach to 
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adjust for time-dependent confounding, but are restricted to causal estimation of 
single causal effects and thus cannot be used to adjust for more than one form of 
treatment deviation.  
5. The assumption of NUC underlies the observational-based approach of MSMs 
(and associated IPCW methods), which account for time-dependent confounding 
by the use of inverse probability weighting; thus the key requirement for unbiased 
IPW estimation is availability of data on all relevant confounders, which may 
present a particular challenge in trial settings.  
5.8. Conclusion  
The overview of statistical methods to adjust for deviation from treatment protocol in 
randomised trials and observational studies summarised in this chapter has revealed a 
number of available approaches to causal estimation, with a particular focus on survival 
analysis methodologies, given that settings typically associated with treatment deviations 
(such as the necessarily dynamic treatment regimens in the treatment of cancer or 
longterm treatment for chronic disease) often use TTE outcomes to assess treatment 
efficacy. Having determined that such methodologies exist, a review of recently 
published trials is summarised in the next chapter, in order to determine the extent to 
which such treatment deviations actually occur in trials and whether trialists are aware 
of the available causal analysis methods in order to appropriately adjust for such 
treatment changes. The thesis will then move on to explore in more detail the 
practicalities and challenges arising from the application of the two key methods 
identified in this review of causal methods for adjustment for deviations to randomised 
trials when analysing survival outcomes, namely the IPCW and RPSFTM. 
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6. Review of nonadherence in 
published RCTs  
6.1. Introduction 
In previous chapters, it has been demonstrated that nonadherence is a problem in 
general clinical practice as well as trials, with specific examples given of departure from 
randomised treatment in (a select group of) trials and a discussion of the resultant 
complications in trial conduct and analysis and potential statistical methods to 
appropriately handle such departures in analysis. This chapter now describes a review of 
recently published RCTs carried out with the aim of determining the extent to which 
nonadherence occurs in randomised trials, as well as the degree to which trialists 
appreciate the importance of the issue of nonadherence, in terms of the quality of both 
their reporting of nonadherence and use of appropriate methods to adjust for such 
treatment deviations.   
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6.1.1. Reporting of adherence information  
It is well recognised that clinical trials often fail to report important features of design 
and analysis that are necessary to ascertain the methodological quality of the trial (153-
159). Lack of adequate trial reporting led to the development (and two further updates) 
of the CONSORT (Consolidated Standards of Reporting Trials) statement (41, 160, 
161), which aimed to improve reporting of trial methodology and results by providing 
authors with a checklist of items recommended for inclusion in trial publications. 
CONSORT recommends reporting “for each group the numbers of participants who 
were randomly assigned, received intended treatment and were analysed for the primary 
outcome.... Knowing the number of participants who did not receive the intervention as 
allocated or did not complete treatment permits the reader to assess to what extent the 
estimated efficacy of therapy might be underestimated in comparison with ideal 
circumstances.” Use of CONSORT flow diagrams to illustrate patient flow through the 
trial has become increasingly common (162), but the information presented in the flow 
diagram may not be detailed enough to ascertain the true extent and nature of any 
nonadherence to treatment protocol that have occurred in a trial. 
6.1.2. Aims 
As such, this review aimed to ascertain  
1) the extent and nature of nonadherence to randomised treatment reported in 
published trials, 2) how such nonadherence is handled in statistical analyses of benefit 
and harms outcomes, and 3) how well such nonadherence, and the statistical methods 
to deal with it, are reported in published RCTs. 
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6.2. Methods 
6.2.1. Terminology 
In this review, the term “nonadherence to randomised treatment” is used to indicate 
any deviation on the part of patient or treatment provider to the trial treatment 
protocol, or any treatment change agreed with medical staff but not permitted by the 
trial protocol. Protocol-permitted treatment changes can also present problems of 
interpretation but these were not considered here. For example, discontinuation of 
randomised treatment for safety reasons as specified in the protocol, or premature 
stopping of a trial according to a predefined stopping rule, were not be considered as 
examples of deviations from treatment protocol in this review. 
For the purposes of assessing adequacy of trial reporting, the definitions given by 
Vrijens (3) for the three quantifiable phases of patient adherence to prescribed 
medication (initiation, discontinuation and implementation) were extended for use in a 
clinical trial setting, where the intervention could be nonpharmacological and where 
adherence to treatment protocol can be influenced by treatment providers when 
administering or prescribing treatment as well as by participants, because of the required 
adherence to the trial treatment protocol. 
Thus adherence is defined as the degree of correspondence between a participants’ 
intended randomised treatment prescription and their actual history of treatment 
received over the course of the protocol-specified treatment period, and is split into the 
following phases: initiation of randomised treatment occurs when the participant begins 
their randomised intervention and discontinuation is defined as the permanent cessation 
of randomised intervention, with the intervening time being defined as the implementation 
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period. Persistence is defined as perseverance with randomised treatment as per the trial 
protocol until the end of the protocol-defined treatment period.   
Given that adequacy of trial reporting on adherence to treatment protocol depends on 
the duration and complexity of trial specific interventions, trials were classified 
according to whether the trial interventions were given at a single or multiple time 
points. Trials with treatment given at multiple time points (referred to as “longitudinal 
treatment periods”) were divided into “short term intervention trials” involving 
treatment given at a few discrete time points (for example, single daily dose over the 
course of a week) or continuously over a short period of time (for example, infusion 
given for one hour), and “long term intervention trials”. 
6.2.2. Benefits versus harms outcomes 
Analyses of harms data are particularly affected by departures from treatment protocol 
because of the anticonservative nature of ITT analyses for harms outcomes. Therefore 
it was of interest to investigate the handling of benefit and harms outcomes separately 
in this review; as such, outcomes were categorised according to whether they were 
assessing benefits or harms.  
Outcomes related to harms (for example, mortality or a composite cardiovascular 
outcome – including events such as stroke, myocardial infarction and death) but which 
were likely to be caused by the disease itself rather than side effects of the treatment 
(and therefore the purpose of the drug was to prevent such events) were categorised as 
benefit outcomes. 
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6.2.3. Key points to be reported  
In order to judge the quality of trial reporting, and statistical handling of treatment 
protocol nonadherence, it was important to identify key points that should be explicitly 
reported in each publication. Table 8 presents recommendations for explicit reporting 
of information relating to adherence to treatment protocol.  
All trials should report the number of randomised participants and the number of 
participants who initiated their randomised intervention. Longitudinal treatment period 
trials were also expected to have reported on treatment persistence: in the interest of 
conservative assessment of adequacy of reporting, short term intervention trials were 
required only to have reported on the number of patients who completed intervention 
(or the number who discontinued randomised intervention prematurely). Long term 
interventions are, however, more likely to result in treatment interruptions or 
deviations, so patients who were still taking treatment at the end of the protocol-
determined treatment period may not have been fully adherent to the treatment 
schedule for the whole duration of treatment. Thus publications of trials with long term 
interventions were judged according to whether they had supplemented their reporting 
of the number of participants who persisted with intervention according to the 
treatment protocol (or conversely the number of participants who prematurely 
discontinued randomised intervention) with some measure of participant and/or 
treatment provider adherence to treatment protocol (as appropriate, depending on 
whether administration of treatment was by the participant or the treatment provider) 
over the implementation period.  
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Table 8 Recommendations for explicit reporting of information relating to adherence to treatment protocol 
Quoted justification is taken from CONSORT 2010 elaboration document (41) unless stated otherwise. 
 Report for all trials          Report according to treatment duration Report reasons for Justification 
  Single (one-off) 
intervention 
Short term 
intervention 
Long term 
intervention 
  
1. Randomisation 1 Randomised     “Crucial count for defining trial size and assessing whether a 
trial has been analysed by intention to treat”; necessary to 
determine whether all trial participants received treatment and 
were included in analysis. 
2. Adherence to treatment protocol      
a. Initiation  1 Initiated (or 
received) 
randomised  
intervention 
1 Initiated 
randomised 
intervention 
1 Initiated 
randomised  
intervention 
Those not initiating 
randomised 
intervention 
“Knowing the number of participants who did not receive the 
intervention as allocated or did not complete treatment 
permits the reader to assess to what extent the estimated 
efficacy of therapy might be underestimated in comparison 
with ideal circumstances.” b. Completion/ 
Persistence2 
  1 Completed 
randomised 
intervention  
1 Persisted with 
randomised  
intervention as 
required by 
treatment protocol  
Those who did not 
complete / persist 
with randomised 
intervention 
c. Adherence 
over treatment 
period 3 
      
i) Method  Description of method used to measure 
adherence over treatment period (and of an 
additional method to check reliability if trial 
involves participant-administered 
intervention) 4 
 If participant compliance data are collected, the reliability of 
the method used to record compliance should ideally be 
checked by use of another method (for example, treatment 
diaries backed up by counts of remaining tablets at the end of 
each course of treatment) (14) 
ii) Justification for 
definition  
 Justification for any reported definition of 
adherence (for example, if a threshold is used 
to define adequate adherence) 4 
 “If patients are to be divided into “compliant” and 
“noncompliant” groups, the division should ideally be made 
on the grounds of the relationship of the compliance level to 
the therapeutic response or outcome” (11)  
iii) Results  Measure of participant and/or treatment 
provider adherence with  randomised 
intervention (as appropriate) 4  
Any participant or 
treatment provider  
nonadherence 4   
 
       
       
3. Analysis       
a. Analysed 1 Analysed     Any exclusion of 
participants from 
analysis  
“Attrition as a result of loss to follow up, which is often 
unavoidable, needs to be distinguished from investigator-
determined exclusion for such reasons as ineligibility, 
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 Report for all trials          Report according to treatment duration Report reasons for Justification 
withdrawal from treatment, and poor adherence to the trial 
protocol... Participants who were excluded after allocation are 
unlikely to be representative of all participants in the study.” 
b. Analysis set 
composition 
How analysis sets 
differ from 
randomised groups 
   Any difference 
between analysis sets 
and randomisation 
groups 
“Erroneous conclusions can be reached if participants are 
excluded from analysis, and imbalances in such omissions 
between groups may be especially indicative of bias.” 
1 Report numbers of participants in each randomised intervention group satisfying condition listed in each cell. 
2 Persistence is defined as perseverance with prescribed treatment until the end of the treatment period. 
3 Adherence is defined as a measure of the degree of correspondence between prescribed treatment and actual treatment received by participant. 
4 Note that, depending on the complexity of treatment, it may not be necessary for trials with short term intervention to report on adherence over the treatment period. 
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Methods used to assess participant or health care provider adherence to treatment 
protocol should be described, and clinical justification given for any definition used to 
define adherence. Ideally clinical trials involving participant-administered intervention 
should use a reliable measure, and ideally a combination of measures, to accurately 
record participants’ adherence data (14). Therefore, publications of such trials with a 
long term intervention period in this review were judged according to whether they 
collected and reported details of the methods used to assess, and check reliability of, 
participant adherence.  
It was also recorded whether any explanation was given regarding the use of any 
adherence threshold to split participants into “good” and “poor” compliers. Although 
such dichotomisation is not recommended (20), any threshold used to create such 
groups should be specified in the protocol; otherwise, there may be suspicion that an 
optimal adherence cut-off has been selected on the basis of the results to allow the most 
favourable adherence rates to be reported, as the “definition of non-compliance is 
malleable and could be inadvertently manipulated for benefit of investigators” (35).    
Analysis sets for both benefits and harms outcomes should be defined explicitly, with 
reasons given for the exclusion of any patients from analysis. If there is any difference 
between the defined analysis sets and the intervention groups as randomised, this 
should be stated clearly and any potential resultant bias should be discussed. 
6.2.4. Missing data 
The issue of missing outcome data is related to non-compliance, as the reason for 
missing data may well be related to nonadherence to treatment: those who withdraw 
from treatment may also withdraw from follow up (68). Thus when trialists apply 
methods to overcome the problem of missing data, this may be viewed as an attempt to 
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also deal with the issue of non-compliance, especially if outcome data are missing 
entirely as a result of treatment cessation. Thus it was noted, as part of this review, 
whether trialists reported missing outcome data and any methods used to adjust for this 
missingness.  
In particular, it was noted whether sensitivity analyses were performed, whereby missing 
outcome values are imputed assuming various missingness patterns (for example, 
MCAR or MAR, i.e. dependent on cofactors), recommended as a method to assess the 
robustness of conclusions from complete case analyses (163).  
6.2.5. Selection of reports 
A search of Medline (using terms randomi$ed controlled trial$ or controlled trial$ or 
controlled clinical trial$ or RCT$) was carried out in order to identify trial reports 
published in the British Medical Journal (BMJ), Journal of the American Medical 
Association (JAMA), Lancet and New England Journal of Medicine (NEJM) during 
2008. Of the 698 articles obtained from the initial search, 281 (49 from BMJ, 53 from 
JAMA, 84 from Lancet and 95 from NEJM) remained following deletion of duplicates, 
comments, systematic reviews and meta-analyses. A sample of 100 trial reports were 
randomly selected from these articles, 16 of which were from the BMJ, 20 from the 
Lancet, and 32 each from the Lancet and NEJM. 
6.2.6. Secondary publications 
Five of the selected studies were secondary publications of recent trials (original 
publications were in NEJM, American Journal of Medicine and Neurology). In these 
cases, for the purposes of reporting adherence data, the combination of both the 
primary and secondary publications of the same trial were considered as the unit of 
analysis. 
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6.2.7. Data extraction 
Characteristics of the trial publications were recorded using a piloted, standardised 
form. In cases of any doubt or ambiguity, the paper was reviewed by a second reader. 
Scrutiny of each trial publication allowed determination of 
 whether a CONSORT flow diagram was presented, and if so, what level of 
detail regarding deviation from treatment protocol was provided 
 whether procedures were put in place to ascertain and improve patient 
compliance with the treatment protocol 
 whether patient-related adherence data were collected and whether any attempt 
was made to check on the reliability of methods used to record compliance (for 
example, treatment diaries backed up by counts of remaining tablets at the end 
of each course of treatment)  
 the extent and nature of nonadherence to treatment protocol that was reported 
in the trial 
 method of benefit analysis used (for example, ITT or PP) and its 
appropriateness, given the aims, design and hypothesis of the trial 
 whether harms analyses appropriately allow for departures from treatment 
protocol (for example, when patients did not receive their allocated treatment or 
switched treatments) 
 any methods used to specifically adjust for, or examine effects of, departures 
from treatment protocol  
 extent of missing outcome data and methods to deal with missing data  
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6.3. Results  
6.3.1. Characteristics of RCTs 
The characteristics of the 100 randomly selected randomised controlled trials are shown 
in Table 9. The vast majority (92%) of the studies in the sample included a superiority 
hypothesis only. Ten trials were randomised at a cluster, rather than individual, level. 
Only one of these was a drug trial; the remaining involved nonpharmacological 
interventions. Sixty nine trials involved a drug treatment; the majority of which were 
labelled as (or characteristic of) phase III trials, and 44 (63.7%) of these drug trials used 
a placebo for the control arm. Only one nonpharmacological trial (which aimed to 
investigate various aspects of the placebo effect using placebo acupuncture) involved a 
placebo. 
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Table 9   Characteristics of 100 randomly selected RCT articles 
Characteristic Number (=%) 
Journal  
BMJ 16 
JAMA 20 
Lancet 32 
NEJM 32 
Hypothesis  
Equivalence 1 
Non-inferiority 7 
Superiority 92 
Design  
Cluster 10 
Parallel  90 
(of which factorial) (11) 
Blinding  
None 29 
Single 16 
 Investigator only                           1 
 Assessor only                                13 
 Laboratory staff only                     2 
Double 55 
 Patient and investigators1          26 
 Patient and assessors                   2 
 Investigator and assessors                    1 
 Statistician and assessors                                    1 
 Laboratory staff and assessors                       1 
 Patients, investigator and assessors2                 22 
 Patients, statistician and assessors             2 
Prespecified statistical analysis plan  
Stated 15 
Not stated 85 
Intervention type3  
Nonpharmacological intervention 35 
 Surgical     3 
 Behavioural    14 
 Device    7 
 Model of care/guidelines       7 
 Other        4 
Drug 69 
 Phase I or II                             4 
 Phase III4                                  65 
Control intervention  
Active intervention 55 
Placebo 45 
1 Note that this includes 12 placebo trials which were described as “double-blind” but did not explicitly state that the patient and 
investigators were blinded. 
2 Note that this includes two placebo trials which were described as “double-blind” but did not explicitly state that the patient and 
investigators were blinded. 
3 Four trials involved two types of intervention. 
4 Forty-nine of these did not specifically state “phase III” but were powered and controlled comparisons indicative of phase III. 
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6.3.2. Extent and nature of reported nonadherence to treatment 
protocol  
Ninety-eight publications reported at least one form of departure from treatment 
protocol (see Table 10). Direct comparison of the extent of departure from treatment 
protocol across trials is not straightforward, as trials differed greatly in terms of type and 
duration of intervention, definitions used to define nonadherence and level of reporting. 
However the distribution of percentage of patients displaying some form of deviation 
from treatment protocol (or the average degree of nonadherence in a single trial), based 
on information reported in the trial publications, can also be seen in Table 10. 
Table 10 Reported forms of nonadherence from protocol 
Number (=%) 
Reported some form of nonadherence to treatment protocol1 98 
Participants who did not initiate allocated treatment 39 
Participants with incomplete treatment (among those who initiated allocated treatment) 78 
Participants who switched trial treatments 12 
Participants who started open label treatment (not as per protocol) 7 
Participants who started disallowed/non-trial treatment 4 
Evidence of contamination between treatment groups 3 
Other forms of nonadherence to treatment dose/schedule 23 
Nonadherence on the part of treatment providers  12 
Did not report any nonadherence to treatment protocol 2 
  
Percentage of patients experiencing/displaying some form of nonadherence to 
treatment protocol  
 
None reported 2 
0-5% 23 
5-10% 10 
10-20% 22 
20-30% 11 
30-50% 12 
>50% 9 
>0% but unclear2 11 
1 Trial publications may have reported the number of participants in more than one of the categories 
listed. 
2 For example, trial report states only that the treatment providers were not adherent to some degree, or 
unable to distinguish withdrawal from treatment for legitimate reasons (for example, death or treatment 
changes permitted by protocol following adverse events) from withdrawal due to nonadherence. 
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6.3.3. Quality of reporting on departures from treatment protocol  
The vast majority of trial reports (96%) included a CONSORT flow diagram. Table 11 
summarises the quality and completeness of reporting on randomisation, adherence to 
treatment protocol and analysis in the CONSORT flow diagrams and the text. All 100 
trials stated the numbers randomised, but only 58 publications stated how many 
patients actually initiated their allocated treatment. All trials provided some information 
on the number of participants included in analysis of the primary outcome, but this 
information was not always provided for secondary outcomes, particularly when a large 
number of outcomes were analysed. Forty-three trial reports included an explicit 
explanation of the composition of the analysis sets used for benefit outcomes, 48 trials 
labelled the analysis sets (47 “ITT” and 1 “PP”) without further explanation of how the 
analysis sets were composed, and no details on the composition of benefit outcome 
analysis sets were given in the remaining nine trials. 
Table 12 provides a breakdown of persistence and adherence information reported in 
the 88 studies with longitudinal treatment periods. The majority (81, 92%) provided 
some information on treatment completeness, but this was sometimes incomplete or 
vague.  
Overall, reporting of treatment initiation and completeness was judged to be adequate 
in only 7 (11%) of 66 trials with long term interventions (requiring reporting of 
treatment initiation, persistence and some measure of adherence over the 
implementation period) and 8 (36%) of 22 trials with short term interventions (requiring 
reporting of treatment initiation and completion). Reporting of treatment receipt was 
judged to be sufficient in 10 (83%) of 12 trials with a one-off treatment. 
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Table 11 Reporting of key points in 100 trial reports 
 Report for all 
trials 
Report according to treatment duration 
  Single (one-off) 
intervention 
(n=12) 
Short term 
intervention 
(n=22) 
Long term 
intervention 
(n=66) 
1. Randomisation 100 (100%) - - - 
2. Adherence to treatment protocol 
a. Initiation - 10 (83%) 15 (68%) 
 
33 (50%) 
 
b. Completion/ 
Persistence 
- - 12 (55%) [17 
(77%)]1 
 
31 (47%) [51 
(77%)]1 
c. Adherence over implementation period 
i) Method - - 1 (50%)2 21 (47%)2 
ii) Justification for 
definition 
- - 0 (0%)3 0 (0%)3 
iii) Results - - 5 (23%)4 
 
22 (33%) [28 
(42%)]4 
3. Analysis     
a. Number analysed  100 (100%)5 - - - 
b. Analysis set 
composition 
43 (43%) [91 
(91%)]6 
- - - 
1 Number (%) of trials that fully reported [partially reported] on persistence or completion of randomised treatment. 
 2 Number of short term (2) or long term (45) intervention trials with patient-administered treatment (2) is used as 
denominator for %.  
3 Number of short term (1) or long term (18) intervention trials with patient- administered treatment that reported 
adherence definition is used as denominator for %.  
4 Number (%) of trials that fully reported [partially reported] some measure of nonadherence on the part of patient or 
treatment provider. 
5 Number (%) of trials that reported the number included in analysis of primary outcome.  
6 Number (%) of trials that fully reported [partially reported] analysis set composition; partially reporting trials stated 
that analysis was by “intention to treat” (n=47) or “per protocol” (n=1) but did not explicitly explain composition of 
analysis sets. 
 
Thirty-three trials with intervention given at multiple time points reported information 
on treatment interruptions (two trials) or a measure of average adherence over the 
treatment period, on the part of the participant (28 trials) and/or treatment provider 
(four trials; one trial reported on adherence of both the participant and treatment 
provider), but six of these reported this information for the whole trial or combinations 
of intervention groups rather than by individual intervention group. Reported measures 
included the percentage of patients who achieved a particular arbitrary level of 
adherence in terms of the proportion of doses received or the proportion of time 
patients were supplied with randomised drug over the course of the trial.  
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Table 12 Breakdown of persistence and adherence reporting in 88 trials with longitudinal intervention periods 
  Short term intervention 
(n=22)  
Long term intervention 
(n=66)  
Total 
Persistence      
Fully reported1  12 31 43 
Partially reported only2  5 20 25 
Partially reported, including reporting the number of participants who:    
 Withdrew 1 3 4 
 Withdrew consent 1 2 3 
 Lost to follow up (during treatment) - 3 3 
 Lost to follow up (unclear whether during treatment) 1 1 2 
 Discontinued due to certain event(s)3 - 6 6 
 Completed study 3 8 11 
 Discontinued study - 2 2 
 Completed different aspects of treatment protocol (reported separately)4 - 2 2 
 Completed treatment in trial overall (not by treatment group) 1 1 2 
     
Not reported  5 15 20 
    
Adherence over implementation period    
Fully or partially reported, including reporting2 5 
 
22 (6) 
 
27 (6) 
 
 Average measure of participant adherence 5  2 20 (6) 22 (6) 
 Average measure of adherence on part of treatment provider 3 1 4 
 Treatment interruptions - 2 2 
     
Not reported  17 38 55 
     
     
Overall reporting     
Some reporting x 19 
 
62 81 
 Persistence reported only (fully or partially) 14 34 48 
 Adherence reported only (fully or partially) 2 11 13 
 Both persistence and adherence reported (fully or partially)  3 17 20 
     
Not reported   3 4 7 
1 Reported the number of participants still taking treatment at end of treatment period, or the number who “completed” treatment, or who discontinued or withdrew from randomised intervention 
prematurely 
2 Trial publications may have reported on one more than one of the categories listed. 
3 Reported numbers discontinuing only for one reason (e.g. adverse events). 
4 Unable to discern how many participants received entire intervention.  
5 Figure in brackets indicates number of publications reporting adherence measure for overall trial or combinations of intervention groups, not by individual intervention group. 
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6.3.4. Ambiguities in trial reports 
Commonly used terms in CONSORT flow diagrams alluding to nonadherence (or 
adherence) to treatment protocol such as “discontinued”, “completed study protocol”, 
“withdrew”, “protocol deviations” and “loss to follow up” do not provide explicit 
information on completeness of treatment unless accompanied by clarification on 
timing or treatment actually received. For example, the term “withdrew” can indicate 
withdrawal from treatment only, withdrawal from further follow up or withdrawal of 
consent regarding inclusion of a patient’s data in the study. In 13 (62%) of the 21 trials 
that included the term “withdrew” in the flow diagram, it was not possible to ascertain 
whether the participants who “withdrew” had actually initiated treatment before 
withdrawing. Similarly, the timing of withdrawal was not clear in 8 (38%) of the 21 trials 
that described participants who “withdrew consent” in the flow diagram.  
Fifteen (18%) of the 85 trials with a longitudinal treatment which presented a flow 
diagram referred to the number of participants who “received” when they meant 
“initiated” treatment; this could potentially mislead readers as use of the word 
“received” may be incorrectly interpreted as receipt of the entire intervention.  
Three trials with a long term intervention period referred in the CONSORT diagram 
(and 4 more referred in the text) to the number of patients who “completed” treatment 
when it would have been more accurate to report this figure as the number “still on 
treatment at end of treatment period/trial follow up”, as completion of treatment may 
imply complete adherence to, as well as persistence with, randomised intervention 
throughout the treatment period. 
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6.3.5. Methods to check adherence 
Less than half (22, 47%) of the 47 trials with participant-administered treatment 
mentioned checking adherence, and only 5 of these assessed reliability of the adherence 
data using a second method. The most common methods to ascertain participant 
adherence involved counting (or weighing) pills (11 trials) or participant self-reporting 
(10), even though these methods are not considered to be reliable (14). More accurate 
methods such as medication events monitoring systems (MEMS) or measurement of 
drug metabolite or marker in bodily fluids were not used, except in one trial (which used 
blood tests and laboratory assays).  
As shown in Table 13, of the 69 trials that included a drug intervention, 17 (24.6%) 
included a definition of compliance (or non-compliance). All but three of these 
definitions were based on the percentage of prescribed medication received by the 
individual. Four trials simply described these as average percentages for the treatment 
groups separately (three trials) or for the entire trial population overall (one trial), while 
ten other trials specified a percentage cut-off rate indicating good compliance. The most 
common cut-offs were two thirds (three trials) or 80% (three trials) of treatment 
received, but other cut-offs included 50%, 60%, 75% and 100%. Three drug trials based 
their definition of compliance on factors other than simply the percentage of 
medication taken.  
Trials of nonpharmacological interventions also reported on compliance, but the 
complex nature of the interventions and pragmatic trial designs meant that less 
straightforward and potentially ambiguous definitions of compliance were more 
commonly reported than in drug trials. Definitions of compliance on the part of the 
participant in nonpharmacological trials were much less common than in drug trials: 
only two (5.7%) of the 35 trials that involved nonpharmacological interventions defined 
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compliance on the part of the participant. One defined good compliance as attendance 
of at least five out of six possible therapy sessions, and the other defined adherence as 
having undertaken at least 80% of the required blood monitoring.  
Nonadherence is not only an issue at the participant level, as treatment providers may 
also be unable or unwilling to adhere to treatment protocol. Twelve trials which 
involved administration of treatment by personnel other than just the participant 
mentioned an assessment of whether the treatment providers were adherent to the 
protocol. Most of these twelve trials simply discussed the fact that aspects of delivered 
treatment had been recorded (for example, using case report forms or program content 
checklists, videotaping treatment sessions, or recording information on a study web 
server) and thus it was determined that treatment providers had deviated from 
randomised treatment protocol in some manner. Two cluster trials discussed the rate of 
acceptance, participation or implementation of treatment guidelines by site staff. 
Table 13   Definition of compliance in drug trials 
 Number (% of 69 drug trials) 
  
Reported definition of compliance 17 (24.6) 
Based on percentage of medication received                           14 
 Reported percentage of medication consumed 4 
 By treatment group  3 
 For trial overall 1 
 Cut-off used to define good/poor compliance  10 
 50%  1 
 60% 1 
 2/3 3 
 75% 1 
 80% 3 
 100% 1 
  
Based on discontinuation of medication                                 3 
 Non-compliance defined as discontinuation of medication for any time period1 1 
 Percentage of time at risk that the participant spent in receipt of trial drug 
(<75%, 75-90%, >90%)2 
1 
 Split into full/partial/total non- compliance based on timing of multiple 
courses of drugs3 
1 
1 Documented discontinuation of trial drug for specific reasons rather than sporadic failure to 
take treatment. 
2 Based on evidence of collection of trial drug rather than actual consumption 
3 Dependent not only on the cooperation of the participant but also of the treatment provider, as 
the drugs were administered during outpatient visits. 
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6.3.6. Analysis populations 
A benefit analysis was carried out in all trials.  Nine trials did not define any benefit 
analysis populations, and two additional trials defined analysis populations but did not 
label them as ITT or PP.   
Of the 91 trials that defined some benefit analysis population, 73 carried out analysis on 
one population set only (67 ITT, two modified ITT, two PP and two unlabelled 
populations), 15 analysed two populations (12 ITT/PP combinations, one 
ITT/modified ITT and two modified ITT/PP combinations) and three analysed three 
populations (one ITT/modified ITT/PP and two ITT/PP/PP compliant 
combinations). 
Eight-seven trials included what was referred to as an ITT or “modified” ITT analysis. 
Of the 83 “ITT” analyses presented, 15 excluded patients if they did not initiate 
randomised treatment (and an additional three excluded treatment protocol violators), 
four included only eligible participants, and seven specifically stated that they only 
included those with a certain amount of follow up. In the six trial reports which stated 
that a “modified” ITT population would be analysed, specified requirements included 
receipt of treatment (five reports), availability of a certain amount of follow up data 
(four reports), complete follow up (one report) and eligibility of participants (one 
report). 
Of the 19 trials that specified a PP population, only one did not specify any details of 
the composition of the population, while one specified that participants would be 
analysed “as treated”. Fourteen of these 19 trials included a requirement of some degree 
of compliance with treatment protocol, but none provided any clinical justification for 
the threshold of received treatment used to define “compliance”.  
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Table 14 Analysis populations 
Benefit analysis 
population1 
Number (=%) 
“ITT”  83 
 No details        47 
 “Included all randomised individuals”                                   11 
 “Analysed as randomised, irrespective of adherence”             10 
 Other2      15 
      Included requirement of "≥1 dose/received  
     treatment”                                          
12 
 Included requirement of "at least one 
assessment/were followed up/                           
      excluded those who died" 
5 
 
 Included only eligible patients                        1 
 Included only those with complete follow up 1 
  
“Modified ITT” 63 
 Included requirement of "≥1 dose/received treatment"                                
Included requirement of “at least one assessment/ 
primary outcome data available”                                                           
Included only eligible patients 
Included requirement of complete follow up        
 
5
4 
 
1 
1 
“PP” 193 
 No details 1 
 “As treated” 1 
 Included compliance with treatment: 14 
 ≥1 dose 2 
 complete adherence 6 
 taking some proportion of the drug 6 
 Included only eligible patients                       3 
 Included requirement of “compliance with protocol”  7 
 Included requirement of data available/complete 
follow up 
 
5 
“PP compliant” 2 
 Included only those who used intervention, did not 
violate treatment protocol and had outcome data 
available; censored follow up when interruption in 
treatment 
 
1 
 
 
 Censored follow up when proportion of drug taken fell 
below 60%, or stopped trial medication and started 
non-trial medication to treat condition 
 
1 
Unlabelled 2 
 Included those who received ≥1 dose of assigned 
study drug 
1 
 Included those who completed all follow up      
 
1 
 
No details of population 9 
1 Some trials defined more than one efficacy analysis population. 
2 Some of these trials fitted more than one of the “other” categories.       
3 Some of these trials fitted more than one of the listed categories.     
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6.3.7. Handling of departure from treatment protocol in statistical 
analyses 
Of the 98 trials that reported some form of nonadherence to treatment protocol, 51 
(52%) reported some form of analysis method to handle such nonadherence in the 
analysis of benefit outcomes (see Table 15). Forty-six trials adjusted for treatment 
protocol deviations by carrying out analysis based on PP analysis (total not shown in 
Table 15), by censoring or excluding participants who had violated the treatment 
protocol in some way, but half of these analyses were labelled as ITT or modified ITT 
analyses. Only one trial (164) aimed to address the bias introduced from potentially 
informative censoring of patients at the point of deviation from treatment protocol, by 
weighting their censoring by the inverse of their estimated probability of adhering, as 
advocated by Robins (150). Other analysis methods that dealt with departures from 
randomised treatment included treating discontinuation of treatment (or starting 
disallowed or rescue medication) as a treatment failure in analysis (three trials), AT 
analyses (analysing participants according to the actual treatment received regardless of 
randomisation allocation) (three trials) and analysing outcomes concerned with time to 
discontinuation of trial drug (four trials). 
Of the 20 trials where adjustment for nonadherence was explicitly compared to other 
analyses, four trials reported that adjustment for nonadherence resulted in more 
extreme treatment effects; in the remaining 16 trials it was not reported to have made a 
substantial difference to conclusions. 
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Table 15 Statistical methods addressing nonadherence to treatment protocol 
 
                                               Number (%2)  Definition of analysis se Number 
  
Reported a statistical method addressing nonadherence to treatment protocol1                                       51 (52)  
Variant of PP  
 Primary PP analysis described as “PP”                      18 
 Included only those participants who received full randomised intervention  8 
Included only those participants who received at least one dose of randomised intervention 2 
 Minimum degree of adherence required 53 
 Included only those taking treatment at particular time during trial 1 
 Excluded participants if they started disallowed medication 1 
 Censored participants at time of stopping treatment  1 
 
 Primary PP analysis described as “ITT” or “modified ITT” analysis 23 
 Included only those participants who received full randomised intervention 1 
Included only those participants who received at least one dose of randomised intervention 16 
 Included only those participants who received the single treatment  3 
 Excluded participants if they deviated from treatment protocol 3 
 
 Sensitivity analysis                       12 
 Included only those participants who received full randomised intervention 4 
 Excluded participants if they received disallowed treatments 2 
 Minimum degree of adherence required 24 
 Censored participants at the point of deviation from treatment protocol  45 
 
 IPCW6 method 16 
 Subgroup analysis 27 
 Unlabelled analysis  18 
AT analysis  3 
Discontinuation of treatment analysed as treatment failure  3 
Time to treatment discontinuation included as trial outcome  4 
  
Did not report a statistical method to address nonadherence to treatment protocol                     47 (48)  
1 Nine trials carried out two methods of analysis, two trials carried out three methods and one trial carried out four methods. 
2 Number of trials reporting some form of nonadherence (98) is used as denominator for %. 
3 Adherence thresholds used were 60%, 2/3, 75%, 80%, and 90%. 
4 Adherence thresholds used were 2/3 and 5/6. 
5 Censoring times: time of starting disallowed intervention, when participants reported taking less than 2/3 of their medication in the past year, when received treatment out of trial, or censored following 6 month 
lag after receiving less than 80% of drug. 
6 Censored when received <80% of drug, weighted by the inverse probability of each participant’s estimated adherence probability. 
7 Analysis split into two groups (according to whether participants had taken more or less than 50% of the prescribed medication) in one trial and into three groups (according to the proportion (>90%, 75-90% 
or <75%) of their time at risk that they were supplied with drug) in other trial. 
8 Included if received at least one dose of treatment.  
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6.3.8. Harms outcomes 
Of the 69 trials that presented a harms analysis, 43 (62%) did not define the specific 
population set that was used in this analysis (see Table 16). Of the 26 trials that 
specifically defined a harms analysis population, the majority (18, 69%) specified that 
analysis was based on actual treatment received and included all patients who had 
received at least one administration of study agent, but only one study specifically stated 
that participants who received the alternative treatment rather than that allocated to 
them would be included in the alternative treatment group for this analysis. The 
remaining 43 trials that did not define a specific harms analysis population most 
commonly appeared to analyse the harms outcomes according to the specified benefit 
analysis population (31 ITT, two PP). 
Table 16 Harms analysis populations in 69 trials that presented harms analyses 
 Number (%1) 
Harms analysis population specifically defined in 
methods 
26 (38) 
Defined harms 
analysis population 
Based on actual treatment received (i.e. including all 
patients who had received at least one administration 
of treatment) 
18 
 ITT 5 
 All who started allocated treatment 2 
 All who completed allocated treatment 1 
 
Harms analysis population not specifically defined in 
methods 
43 (62) 
Inferred harms 
analysis population 
Stated “safety population” without further definition 1 
 Apparently analysed as per efficacy outcomes 33 
 ITT definition 31 
 PP definition  2 
 No details given of harms or benefit analysis population 9 
   
1 The number of trials with harms analyses presented (69) is used as the denominator for %. 
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6.3.9. Missing data 
The distribution of the percentage of patients with missing primary outcome data 
(excluding 26 trials with a time to event primary outcome, where censoring was applied 
when follow up was terminated prematurely) can be seen in Table 17. In 12 trials, there 
did not appear to be any missing primary outcome data. In a further three trials there 
was mention of how the trialists dealt with missing data, but it was not clear what 
percentage of participants did not have primary outcome data available. 
Table 17   Percentage of participants with missing primary outcome data 
(excluding 26 trials with time to event primary outcome) 
 Number (=%) 
Percentage of participants with missing primary outcome data  
None 12 
0-5% 15 
5-10% 16 
10-20% 20 
20% 8 
Unclear but >0% 3 
 
Of the 62 trials that reported missing primary outcome data, 29 (46.8%) trials did not 
attempt to account for the missing data and carried out complete case analyses only; 
simple imputation techniques were used in 26 trials (41.9%) of trials (either in the 
principal or sensitivity analyses) and more complicated techniques, such as maximum 
likelihood or multiple imputation, were implemented in 10 (16.1%) trials (see Table 18). 
Of the methods implemented to account for missing data, the most common were last 
observation carried forward (LOCF) and assignment of the worst possible outcome to 
all participants with missing outcome data (for example, assuming treatment failure or 
non-response). Other methods included multiple imputation and maximum likelihood 
methods, pattern-mixture models, Markov chain Monte Carlo imputation, assuming no 
change from baseline and repeated measures analysis of covariance. 
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Nineteen trials described the profile of the missing outcome data either by comparing 
characteristics of those who did or did not have missing outcome data or by comparing 
rates of missing outcomes between treatment arms.  
Table 18   Methods to adjust for missing outcome data 
 Number (=% unless otherwise stated) 
Adjustment for missing primary outcome 
data 
 
Not applicable 38 
 No missing data 12 
 Time to event outcome 26 
Complete case analysis only1 29 (46.7) 
   
Principal analysis1 25 (40.3)2,3 
 LOCF 10 
 Assumed worst possible outcome4 9 
 Assumed no change from baseline 2 
 Multiple imputation 3 
 Maximum likelihood  2 
 Markov chain Monte Carlo imputation 1 
 
Sensitivity analysis1 9 (14.5)3,5 
 LOCF 2 
 Assumed worst possible outcome4 3 
 Assumed best possible outcome 1 
 Pattern-mixture model 2 
 Multiple imputation 3 
 No details given 1 
 Other6 1 
Adjustment for missing secondary outcome 
data  
Principal analysis 19 
 LOCF 10 
 Assumed worst possible outcome2 4 
 No change from baseline 1 
 Multiple imputation 1 
 Maximum likelihood  1 
 Markov chain Monte Carlo imputation 1 
 Repeated measures analysis of covariance 
 
1 
Sensitivity analysis 27 
 Assumed worst possible outcome 1 
 Assumed best possible outcome 1 
 Multiple imputation 1 
1 Number of trials with missing primary outcome data (where primary outcome is not time to event) (62) is used as 
denominator for %. 
2 Two trials used two methods to adjust for missing data in principal analyses of primary outcome. 
3 One trial adjusted for missing data in principal and sensitivity analyses of the primary outcome.  
4 For example, assumed to be a treatment failure/non-response.  
5 Four trials carried out two sensitivity analyses of the primary outcome. 
6 Estimated total number of events that would have occurred if follow up had been complete for all participants, and 
then assigned half of the extra events to each treatment group. 
7 Two sensitivity analyses of secondary outcomes were carried out in the same trial. 
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6.3.11. Protocol permitted changes to treatment 
Protocol permitted changes to treatment were not considered as treatment deviations 
for this review. However, given that it may be necessary to factor out such treatment 
changes when considering certain causal research questions, it was of interest to note 
that the treatment protocols of 15 trials in this review permitted modifications to the 
dose of trial treatments or temporary or permanent cessation of treatment (in the event 
of certain adverse effects), which lead to necessary deviations from the optimal 
treatment dose. Six other trials introduced changes to the treatment protocols during 
the course of the trial. These included the introduction of additional concomitant 
treatments to both arms of the trial, dropping of a treatment arm (in a three arm trial), 
dropping of a lead-in treatment phase, replacing one treatment with another and 
modifications of the specified treatment dose as a result of external evidence. Two 
cancer trials permitted patients in the control arm to switch to the intervention 
treatment on disease progression or relapse, and one trial permitted participants to 
begin taking open-label treatment.  
Only three of these 15 trial reports investigated the effect that the change, or permitted 
modifications, to treatment protocol had on the observed efficacy of the treatment. For 
example, in one trial (165), the protocol was amended part way through the study 
permitting a lower initial treatment dose (at the discretion of the investigator) because 
of safety concerns. A sensitivity analysis was carried out excluding those participants 
who received an initial dose lower than was originally permitted in treatment protocol. 
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6.4. Discussion  
6.4.1. Reporting of adherence information  
In this review of published trials, although the vast majority of RCTs were subject to at 
least one form of nonadherence to treatment protocol (most commonly incomplete 
treatment or non-receipt of allocated treatment), often even the most basic adherence 
information on initiation, completion and premature discontinuation of treatment was 
not presented in some trials. Perhaps most remarkable was the fact that forty-two 
percent of the publications did not explicitly state how many patients actually initiated 
their randomised treatment. The template for the CONSORT flow diagram suggests 
that, in the treatment allocation box, trialists should report the number of participants 
who “received” allocated intervention, and in the follow up box, they should then 
report the number who “discontinued” intervention. However, except in the case of 
trials with treatment given at a single time point (only 12% of the trials in this review), it 
would be less misleading and more accurate to ask trialists to report the number of 
participants who “initiated” rather than “received” intervention, as “initiated” is 
unambiguous but “received” may be interpreted either as initiation or as receipt of the 
entire study treatment. Indeed, in the 2010 CONSORT elaboration document, the table 
which details the information required in the flow diagram (table 3) states that the 
treatment allocation box should include the number of participants who “completed” 
treatment as allocated, rather than “initiated” or at least “received”.  
The absence of any explicit reporting of the number of participants who initiated 
intervention may lead readers to assume that all randomised participants at least started 
their randomised intervention. Indeed Vrijens (3) states that, in the context of clinical 
trials of prescribed medication, given that the first dose of a randomised medication is 
usually administered on site following informed consent, “it is often assumed that 
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initiation is implicit for all included patients”. However more than one third (26, 38%) 
of the 69 drug trials in our review included participants who did not initiate their 
randomised intervention. 
Other inadequacies in reporting (related to departures from treatment protocol) were 
evident in this review. For example, none of the 13 trial reports that specified a cut-off 
to define adequate adherence included an explanation for the choice of threshold. As 
discussed by Vrijens (20), the use of “ad hoc” threshold values, such as the “often-used 
but never pharmacometrically justified” adherence criterion of taking at least 80% of 
prescribed doses to define sufficient and insufficient exposure to drugs needed to 
achieve satisfactory therapeutic results, is unacceptable as such a threshold will depend 
on a wide range of underlying drug-, disease- and formulation-specific 
pharmacodynamics. 
In the case of pragmatic trials with nonpharmacological interventions, especially those 
randomised at the cluster level with intervention administered by health care providers 
rather than by the patient, it was often difficult to determine which participants received 
the full intervention as per protocol. For example, some trial reports implied that 
treatment providers were either unwilling or unable to follow the treatment protocols 
fully, but it was not possible to ascertain the extent to which this affected the treatment 
of individual patients. Also, with some complex interventions, it was sometimes difficult 
to define when patients were “on” or “off” treatment, especially when use of, and the 
level of use, of the intervention was optional. Indeed, of the eight trials that failed to 
provide any information on treatment persistence or adherence, all had pragmatic 
designs and all but three were cluster trials with nonpharmacological interventions. 
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6.4.2. Incomplete reporting of exclusions from analysis  
The reporting of methodological features of RCTs has historically been shown to be 
less than optimal, with numerous reviews providing evidence that authors of trial 
publications often fail to include details on the important features of design and analysis 
(154, 158, 159). In particular there is increasing evidence that trialists provide inadequate 
information on the exclusion of participants from analysis (153, 155, 157, 166, 167).   
Schulz et al (166) investigated the association between methodological quality and 
evidence of biased treatment estimates in 250 RCTs (published between 1955 and 1992) 
from 33 meta-analyses from the Cochrane Database, and found that inadequate 
methodological approaches to trial design are associated with bias, particularly with 
respect to poor allocation concealment. They unexpectedly found, however, that those 
trials that reported excluding participants after randomisation did not yield exaggerated 
treatment effect estimates compared with trials that explicitly reported, or “gave the 
impression”, of no exclusions (the vast majority of which were not explicit). They noted, 
however, that of those trials report that gave the impression that no exclusions had 
occurred, few explicitly stated that no exclusions had occurred. Thus they conjectured 
that this phenomenon may have be resulted simply because those trials demonstrating 
higher methodological quality (for example, using adequately concealed allocation) were 
similarly likely to demonstrate better reporting quality (by clearly reporting on the 
exclusion of randomised participants), whereas those involving poorer methodology 
were less likely to openly report excluding participants.  
A similar review by Schulz (167) of obstetric and gynaecology trials published in 
1990/1991 provided more evidence of this “exclusion paradox”. Schulz categorised 
trials according to whether the trial publication explicitly stated that there were some or 
no exclusions or where there were “no apparent exclusions” (when they simply reported 
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analysing the same number of participants as were randomised, thus implying that no 
exclusions had occurred). They found that those trials with reported exclusions and 
those which explicitly reported no exclusions were more likely to have implemented 
adequate methods of allocation concealment than those with no apparent exclusions, 
and thus “paradoxically, trials that reported exclusions seemed generally of a higher 
methodological standard than those that had no apparent exclusions”. Thus Schulz 
suggests that when there is a no mention of exclusions (or a lack of exclusions) in a trial 
publication, exclusions may nevertheless have taken place, leading to an “unsettling 
irony… some of the more biased trials might be mistakenly interpreted as unbiased, 
while many of the less biased trials may be interpreted as biased” (168).  
Although the trials in both of Schulz’s review are not current, and it is hoped that 
reporting of trials has improved in recent years following acceptance of the CONSORT 
statement (160, 169), the finding in our review that only 58% of studies explicitly report 
how many patients initiated randomised treatment suggests reporting could be 
improved further. Furthermore, although the number randomised and analysed (at least 
for the primary outcome) was reported in all of the trials in our review, given the 
findings by Schulz, without explicit mention of exclusions, this does not guarantee that 
the number analysed was equal to the total number initially randomised. 
For example, the wording in the text of a few trial reports in our review regarding the 
number of randomised participants was slightly ambiguous and may be suggestive of 
the exclusion of certain participants from the trial report. This seemed especially likely 
when the description of the number randomised was conjoined with another descriptive 
characteristic of the participants, for example “883 HIV-infected, treatment-naive 
patients were randomised and analysed for efficacy” (170) or “A total of 579 people 
were randomised and completed the baseline questionnaires” (171).  
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6.4.3. Assessment of participant adherence in drug trials 
Despite the fact that collection of participants’ adherence data is now considered to be 
an important aspect of clinical trials and use of a combination of measures is 
recommended to improve accuracy of adherence data (14), less than half of the trials 
involving participant-administered treatment mentioned checking adherence, and less 
than one third of these assessed reliability of the adherence data. The most common 
methods to ascertain adherence involved counting pills (either directly or by weighing 
medication bottles) (11 trials) or questioning the participant (in person or through 
questionnaires or diaries) (11 trials), even though these methods are not considered to 
be particularly reliable (14). It is of interest to note that more accurate methods such as 
medication events monitoring systems (MEMS) or measurement of drug metabolite or 
marker in bodily fluids are not typically used (only one trial used blood tests and 
laboratory assays to assess adherence), even in the large scale and high quality trials 
which are published in the four journals included in this review. 
Trial-specific definitions of compliance or adherence were common, especially in the 
case of drug trials with long term intervention periods, where compliance was usually 
defined as the proportion of prescribed drugs that were actually taken by the 
participant. One quarter of drug trials (17/69) in this review defined compliance, based 
most commonly on the percentage of medication received (14) but also on 
discontinuation of medication (3). Ten trials defined good or poor compliance based on 
cut-offs on the percentage of medication received, but none of these thresholds were 
justified.  
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6.4.4. Trials of nonpharmacological interventions 
Trials of nonpharmacological interventions reported on participant compliance far less 
commonly than in drug trials, and the complex nature of the interventions and 
pragmatic trial designs meant that less straightforward and potentially ambiguous 
definitions of compliance were more commonly reported than in drug trials.  
Checking compliance with treatment protocol on the part of treatment provider (rather 
than just the participant) is especially important in trials of nonpharmacological 
interventions. This is particularly true for those which are randomised at the level of the 
treatment provider (cluster trials), and this was evident in this review, as proportionally 
more of those randomised at a cluster level specifically mentioned that adherence of 
treatment providers was monitored compared to those randomised at the individual 
level (55.6% versus 26.9% respectively).  
The compliance data reported regarding adherence by treatment providers to the trial 
protocol on administration of nonpharmacological interventions were not, however, 
always very clear or transparent, and it was not easy to determine the degree of impact 
that the reported nonadherence would have had on trial participants. Most of these 
twelve trials simply discussed the fact that aspects of delivered treatment had been 
recorded (for example, using case report forms or program content checklists, 
videotaping treatment sessions, or recording information on a study web server) and 
thus it was determined that treatment providers had deviated from randomised 
treatment protocol in some manner. Two cluster trials discussed the rate of acceptance, 
participation or implementation of treatment guidelines by site staff. 
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6.4.5. Statistical methods to deal with departures from treatment 
protocol  
Although more than half (51/98, 52%) of the trials that were subject to nonadherence 
to treatment protocol implemented a statistical analysis method to deal with such 
nonadherence when analysing benefit outcomes, these were most commonly based on 
variations of PP analysis (46) and very few recognised, or sought to address, the 
potential for bias introduced when excluding or censoring patients at the point of 
deviation from treatment protocol. Only one trial (164) addressed the potential bias 
caused by censoring of patients at the point of deviation from treatment protocol, using 
the IPCW method (150), while another trial (172) provided justification for the decision 
to exclude participants who had not received the allocated intervention, citing 
Fergusson (173) and stating that the “omission [of such patients] would be equally 
distributed between groups, would be unrelated to treatment assignment, and would not 
bias outcome ascertainment”. Trial publications commonly presented insufficient detail 
or explanation on the analysis sets used for benefit and harms outcomes. Fifty-seven 
percent of trials did not explain the composition of analysis sets for their benefit 
outcomes, and 62% of trials that presented harms analyses did not specifically define 
harms analysis populations. This common lack of discussion regarding whether, and if 
so why, patients were excluded from analysis and the potential biases which may result 
from such exclusions, indicates a low priority given to the issue of nonadherence to 
treatment protocol in the analysis of published trials.  
6.4.6. “ITT” analysis to handle nonadherence to treatment protocol 
Eighteen trials in this review carried out what were referred to as “ITT” analyses but the 
ITT analysis set excluded participants if they did not adhere to the treatment protocol in 
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some manner. This mislabelling of ITT analyses has been noted in previous reviews of 
ITT analyses in recent trial publications (174-177).  
It is potentially interesting to compare the results of these four surveys of trial 
publications with those from our review, in order to investigate whether the reporting 
of trials and the use of ITT analysis has improved over time. Indeed, such comparison 
(summarised in Table 19) suggests that the use of the phrase “ITT” to describe analyses 
of RCTs is becoming more common (48% in 1999 (176), 71% in 2007 (174) and 83% in 
2008), at least in these four leading medical journals, but that the correct definition of 
ITT analysis is being followed less commonly: 13% of “ITT” trials published in 1999 
excluded participants who did not receive the randomised treatment (176) compared to 
22% of such trials in our review (p=0.086, Pearson’s 2 statistic = 2.95).  
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Table 19   Reviews of ITT analyses in RCTs 
 Hollis (1999) Kruse (2002)1 Gravel (2007) Herman (2009) Dodd 
Journals 
BMJ, JAMA, Lancet, NEJM Multiple English 10  
(including BMJ, JAMA, Lancet, 
NEJM) 
8 
(surgical) 
BMJ, JAMA, Lancet, NEJM 
Publication year 1997 1999 2002 2005-Aug 2008 2008 
Number of trial publications  
[number in BMJ, JAMA, Lancet, 
NEJM] 
249  
 
[249] 
100 (random selection) 403  
 
[283] 
274 100 (random selection) 
 
[100] 
ITT reported: number (% of trials)  
 
[number (% of trials) reporting ITT 
in BMJ, JAMA, Lancet, NEJM] 
119 (48%) 
 
 
[119 (48%)] 
100  
(by definition of search) 
 
249 (62%) 
(ITT for primary analysis)  
(including 23 (9%) “modified ITT”) 
[201 (71%)] 
96 (35%) 83 (83%)  
 
(plus additional 6 “modified ITT”)  
[83 (83%)] 
Assessment of appropriateness of 
ITT analysis:  
number (% of trials reporting ITT)  
     
 
Analysis as 
randomised (solely 
with respect to 
deviation from 
treatment protocol) 
104 (87%) 
 
 
 
Analysis as 
randomised 
 
 
 
42 
 
 
 
Analysis as 
randomised  
(without 
consideration of 
eligibility) 
 
97 (39%) 
 
 
 
Analysis as 
randomised  
No missing data  
Imputed missing data 
 
45 (47%) 
17 (18%) 
28 (29%) 
Analysis as 
randomised (solely 
with respect to 
deviation from 
treatment protocol)  
65 
(78%) 
Explicitly stated 34 (29%)      
 
Explicitly stated 
21 
(25%) 
Appeared to 65 (55%)      
 
Appeared to 
40 
(48%) 
Stated no deviations 5 (4%)       Stated no deviations 4 (5%) 
 
Excluded participants 
from analysis due to  
 
15 (13%) 
 
Excluded participants 
from analysis 
 
58 
 
 
Excluded participants 
from analysis  
 
152 (61%) 
 
Excluded participants 
from analysis 
 
51 (53%) 
 
 
Excluded participants 
from analysis due to  
 
18 
(22%) 
 
deviation from   Missing follow up 
data 
17 Missing follow up 
data 
95 (39%) Missing follow up 
data 
44 (46%) deviation from  
 
 
treatment protocol  Treatment non-
receipt 
15 Treatment non-
receipt 
10 (4%) Treatment non-
receipt 
6 (6%) treatment protocol3 
 
 
[specifically non- [12 
(10%)] 
Ineligible 12 “Modified ITT”2  23 (9%)    [specifically non- 
[15 
 
initiation of 
treatment] 
 Drop out 4 Disease 
exacerbation/  
4 (2%)   initiation of trt3] 
(18%)] 
   Protocol violations 4 adverse effects      
   Unclear 13 Unclear 17 (7%) Unclear 1 (1%)   
   Other 9 Other 3 (1%)     
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 Hollis (1999) Kruse (2002)1 Gravel (2007) Herman (2009) Dodd 
Missing outcome data:  
number (% of ITT trials) 
     
Stated none missing 30 (25%) 42 97 (39%) 17 (18%) 8 (10%) 
<10% missing 60 (50%) 47 100 (40%)  46 (55%) 
>=10% missing 29 (24%) 11 52 (21%)  26 (31%) 
Unclear (but >0%)     3 (4%) 
Missing data techniques:  
number of trials (% of ITT trials 
with missing outcome data) 
     
Complete case analysis only 44 (49%)  89 (59%) 44 (46%) 21 (28%) 
All available information4  29 (33%)    25 (33%) 
Imputation technique 
[of which conducted sensitivity 
analysis5] 
16 (18%) 
[1 (exact methods unstated)] 
 36 (24%) 28 (29%) 
[6] 
29 (39%)  
[7] 
LOCF 7  12 18 11 
Explicit assignment of good/poor 
outcome 
3  2 3 3 
Implicit assumption of good/poor 
outcome (included in denominator) 
4  18  8 
Group average 1   4  
Complex6   1 2 10 
Unspecified    1  
Unclear handling of missing data 
  
27 (18%) 
6 (6%) (only mentioned 
exclusion of participants who 
did not receive allocated 
treatment) 
 
Flow diagram included:  
number (% of trials) 
 41   96 (96%) 
ITT method mentioned in one 
place only: number (% of ITT trials) 
    
 
 
 
Methods section   132 (33%)  81 (98%) 
Results section   15 (3%)  2 (2%) 
Abstract    18 (4%)   
Discussion   1 (0.4%)   
Effect of CONSORT 
 Journals adhering to 
CONSORT more likely to 
display flow diagram 
Journals adhering to CONSORT 
more likely to perform ITT analysis 
  
1 % of trials reporting ITT is equal to number of trials in all cells, as 100 trials reporting an ITT analysis were selected in this review 
2 Made exclusions due to ineligibility or non-receipt of treatment 
3 Note that this figure includes two trials that explicitly stated that participants who did not initiate randomised treatment would be excluded from the ITT analysis but which did not report any such 
deviations. 
4 For example, censoring participants at end of follow up.  
5 Note that some of these trials compared a single imputation technique against complete case analysis. 
6 Includes regression and multiple imputation, maximum likelihood, Markov chain Monte Carlo imputation, repeated measures analysis of covariance 
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6.4.7. Missing data 
Missing outcome data may be linked to treatment nonadherence, and thus this review 
assessed the prevalence and statistical handling of missing primary outcome data. The 
majority (84%) of trials (excluding those with a time to event primary outcome) had 
some missing primary outcome data, but nearly half of these (46.8%) ignored these 
missing data in analysis and carried out complete case analyses only.  
Wood et al (163) also reviewed how trialists report and adjust for missing outcome data 
in RCTs published in July-December 2001 in the same four medical journals as used in 
our review. Wood highlighted the need for multiple sensitivity analyses in the presence 
of missing outcome data, in order to assess robustness of the assumptions made in the 
principal analysis, and that sensitivity analyses should make different assumptions to the 
principal analysis. For example, extreme case analyses (whereby patients in the 
respective treatment groups are assumed to have the most and least favourable 
outcomes, and vice versa) may be performed to demonstrate extreme case scenarios; if 
conclusions from such analyses are not substantially different to complete case analyses, 
it may be concluded that the conclusions are not heavily affected by loss to follow up. 
Of the 62 trials in our review that reported missing primary outcome data excluding 
those that censored participants at final follow up, 33 (53%) implemented methods to 
handle the missing data, including 9 (14.5%) that tested the assumptions of the principal 
analysis with sensitivity analyses or secondary analyses of the primary outcome. This 
compares to 32% and 21% of such trials, respectively, reported in the review by Wood 
et al, suggesting that although trialists seem to be increasingly likely to implement 
missing data methods, the practice of testing the robustness of the assumptions made in 
these analyses through sensitivity analyses is not becoming more common. 
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It is important to report the reason that outcome data are missing, in order to inform 
missing data assumptions (163); for example, only if data are missing completely at 
random will complete case analysis will be appropriate. Only one trial in this review 
explicitly stated the assumptions behind the missing data analysis, namely that the 
multiple imputation of missing data was carried out assuming the data were missing at 
random. It is also important to describe the missing data in each treatment group 
separately, as recommended in the CONSORT diagram. All studies did this, but reasons 
for discontinuation of treatment or missing outcome data were not given in 22 of the 96 
trials that provided a CONSORT diagram; 13 of these stated only that participants were 
lost to follow up. Reporting reasons for missing data allows the reader to assess whether 
the missingness is likely to be random or not, as well as informing analysis assumptions. 
In particular, rather than simply reporting “withdrawal rates”, it is important to 
differentiate withdrawal from treatment (failure to complete treatment protocol) from 
withdrawal from study (failure to complete follow up). 
6.4.8. Harms analyses 
A variety of analysis sets were used for the analysis of harms data in this cohort of trials, 
and this may be a consequence of the lack of consensus in the research literature on the 
most appropriate harms analysis population to be used in the event of departures from 
treatment protocol. The 2001 version of the CONSORT statement (160) supports the 
view of Lewis (75) that ITT is not appropriate for analysis of harms outcomes, stating 
that that “a pure ITT approach to the analysis of safety simply adds to the risk of failing 
to identify potential safety problems, and is therefore never advocated”.  Similarly, the 
ICH GCP guidelines (61) suggest that analysis of harms data should be according to 
treatment received (in other words, all participants who received at least one dose of a 
treatment should be included in that treatment group for harms analyses), and this was 
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the most common analysis set specifically defined for harms outcomes in this review. 
Furthermore, although only one quarter (18/69) of the trials that presented a harms 
analysis specified this analysis population for their harms outcomes, in fact over half 
(37/69) carried out analysis according to treatment received (including, for example, 
trials which specified an ITT analysis where no treatment switches occurred). 
However the 2004 CONSORT extension for reporting harms (49) conversely states 
that ITT is usually preferred for both benefit and harms outcomes because it reflects 
the original trial design. The CONSORT 2010 statement has removed any reference to 
the appropriateness or otherwise of ITT analysis populations for harms outcomes.  
The observed variation in the analysis populations chosen for harms outcomes in the 
presence of treatment protocol nonadherence (in this review of trials) suggests that 
explicit guidance is needed on how harms data from patients who deviate from 
treatment protocol should be analysed, for example what to do if a patient receives both 
or none of the trial treatments, or if they receive a treatment to which they were not 
randomised. 
6.4.9. Trial report discussions relating to treatment nonadherence 
Twelve reports specifically discussed the potential influence of treatment nonadherence 
on the observed treatment effect (but only seven of these trials actually carried out 
analyses that in some way handled departure from treatment protocol). Four trials 
discussed the fact that the observed results may be an underestimate of the true 
treatment effect because of non-acceptance of the intervention (two trials), crossover 
from placebo to active therapy (one trial) or discontinuation of active drug and 
commencement of rescue medication (one trial). Another trial concluded that 
decreasing compliance had not significantly influenced the results of the trial, as the 
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results of the sensitivity analysis assessing whether diminishing compliance had caused 
the treatment effect to wane over time did not differ greatly from those of the main 
analysis. Three trials reported contamination between treatment groups, and two of 
these commented that contamination from the intervention to control group may well 
have contributed to the discouraging observed treatment effects. Two of these trials 
also noted an unexpected improvement in the control arm, and they discussed the fact 
that those who had opted to take part in these behavioural intervention studies may well 
have been more motivated than the general target population, and that simply taking 
part in the trial may have improved their performance (because of increased awareness 
of the issues or increased time spent with research nurses). In addition, two cancer trials 
discussed the related problem of how to interpret ITT analysis in the face of substantial 
switching from placebo to active treatment, or from standard to new intervention, when 
patients’ disease progressed, and they commented on the fact that this crossover was 
likely to have caused a diminished treatment effect on overall survival. Such treatment 
changes, rather than being caused by nonadherence to treatment protocol, were actually 
permitted by the protocol.  
6.4.10. Limitations 
This review is limited by a sample size of 100 trial publications taken from only four 
high impact general medical journals, and thus the generalisation of our results to other 
less widely read or more subject-specific journals may be limited. However it is 
therefore arguable that, for this reason, the findings evident from this review should be 
regarded as an estimate of the upper limit of the quality of reporting and analysis of 
nonadherence to treatment protocol.  
As regards the critique of analysis methods, because trial authors were not contacted 
directly, it cannot be verified that the details reported in the trial publications were 
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complete and accurate accounts of how analysis proceeded. Additionally, it would have 
been of interest to ascertain, via discussion with authors, whether any ambiguity or 
absence of results on nonadherence analyses may simply have been due to poor (or 
restricted) reporting rather than poor practice. Furthermore, without access to the 
protocols or statistical analysis plans for the trials in this review, it was not possible to 
ascertain whether the analyses carried out to examine the effect of treatment protocol 
deviations were decided on prior to data collection or were post-hoc decisions. Two 
trials in this review admitted that the statistical method to deal with departures from 
treatment protocol were post hoc analyses. 
The main limitation of this review was the use of a single reviewer for data extraction. 
However this reviewer was able to consult the opinion of a second reviewer whenever 
there was doubt as to appropriate classifications. This was necessary, however, in less 
than 5% of the articles reviewed, as systematic data extraction from all trial reports was 
undertaken using clear definitions for classification of results. 
6.5. Recommendations  
This chapter has highlighted numerous limitations relating to the measurement, 
reporting and adjustment for treatment adherence in published trials. In particular, 
trialists rarely employ reliable methods to measure adherence and fail to provide 
justification for thresholds used to determine good or poor compliance. Reporting on 
adherence to treatment is poor, particularly relating to treatment initiation and treatment 
adherence with long term treatment protocols. Causal methodology is rarely employed 
to handle treatment deviations; instead trialists typically employ simple naïve analysis 
methods. Investigations regarding the impact of missing outcome data are often basic, 
generally without regard for the impact of assumptions made in such analyses. 
   
   
235 
 
Thus the work carried out for this chapter has led to a number of recommendations. 
Firstly, recommendations were made to the CONSORT steering group to improve the 
wording regarding the reporting of treatment receipt in the CONSORT flow diagram. 
In particular, the suggestion was made that it would be more meaningful to ask trialists 
to report the number of participants who “initiated” rather than “received” 
intervention, as “received” may be interpreted either as initiation or as receipt of the 
entire study treatment. Furthermore, the error included in the 2010 CONSORT 
elaboration document (in table 3, which states that the treatment allocation box should 
include the number of participants who “completed” treatment as allocated, rather than 
“initiated” or at least “received”) was brought to the attention of the steering 
committee, who subsequently acknowledged this error and stated that it would be 
corrected in the next revision of this document. 
Secondly, specific recommendations were developed (see Table 8) for trialists regarding 
explicit reporting (in trial reports) of information relating to adherence to treatment 
protocol, providing a clear template for authors to ensure transparency and 
unambiguous interpretation of trial results.  
Finally, in Table 20, more general recommendations are provided in order to improve 
trial conduct, reporting and analysis on issues relating to adherence to treatment 
protocol. 
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Table 20 Recommendations for trial conduct, reporting and analysis 
1. Trialists should document in the trial protocol how they plan to measure and 
report nonadherence to treatment protocol, with explanation in protocol and 
publication of why the chosen adherence measure is clinically the most 
important and relevant.  
2. The decision on whether, and how, to examine the effect of nonadherence to 
treatment protocol should be made prior to data collection, and details of the 
planned analyses should be documented in the protocol (and statistical analysis 
plan) with explanation for proposed methods. Trial publications should include 
a discussion of potential bias introduced by any such analyses, and efforts 
should be made in the statistical analysis to reduce any bias introduced by 
excluding participants from analysis.  
3. Composition of analysis sets used for benefit and harms outcomes should be 
defined explicitly, rather than merely labelled as “ITT” or “PP”. 
4. The total numbers of participants who were randomised, excluded (with 
reasons) and analysed for each outcome should be reported as recommended in 
the CONSORT statement (41). 
5. Potentially ambiguous phrases such as “protocol deviations”, “completed 
study/treatment  protocol”, “withdrawal”, “intention to treat”, “modified 
intention to treat”, and “per protocol” should be carefully defined in terms of 
the treatment protocol if used in trial reports.  
6. Trial reports should clearly distinguish between withdrawal from treatment and 
withdrawal from study: i.e. clarify whether participants withdrew from treatment 
but agreed to continuing to provide follow up data or whether participants also 
withdrew from further follow up, and if the latter, whether or not they 
consented for the data collected up to the point of withdrawal to be included in 
the analysis. 
7. Reasons for treatment changes and withdrawal from study should be recorded 
in order to inform causal analyses (adjusting for treatment deviations) and 
sensitivity analyses (assessing the impact of missing outcome data on trial 
conclusions).  
8. Reporting of treatment receipt and completeness should reflect the duration of 
trial intervention(s): 
a. Trials with intervention given at a single time point should report the 
number of participants who received allocated intervention in each 
randomised group. 
b. Trials with short term intervention should report the number of 
participants initiating and completing allocated treatment as specified in 
the protocol in each randomised group. 
c. Trials with long term intervention should report the number of 
participants initiating and persisting with allocated treatment as specified 
in the protocol, along with a measure of participant and/or treatment 
provider adherence over the treatment period, in each randomised 
group. 
9. Participant adherence should usually be assessed in at least a random subsample 
of individuals in trials involving participant-administered treatment using a 
reliable method or, if necessary, using more than one method to gauge reliability 
of the assessment.  
10. Biological or medical explanation should be provided for any thresholds used to 
define adequate adherence, and these should be specified in the trial protocol. 
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6.6. Conclusions 
The results of the review suggest that nonadherence with randomised treatment occurs 
in the vast majority of trials but is poorly considered and poorly reported in trial 
publications. Nonadherence information presented in trial reports can be ambiguous or 
scant, particularly relating to treatment initiation and completeness. Despite availability 
of appropriate adjustment methods (as summarised in the previous chapter), this review 
has demonstrated that trialists rarely consider approaches beyond simple biased 
methods such as PP or AT analysis to adjust for nonadherence, thus typically excluding 
or censoring participants who deviate from treatment protocol without discussion of 
the potential bias introduced in such analyses.  
This suggests a need to explore potential barriers that prevent routine use of 
appropriate adjustment methods, with particular emphasis on the analysis of survival 
outcomes, given that these are most commonly associated with long term treatments 
and dynamic treatment regimens which are typically subject to treatment deviations. As 
such, subsequent chapters of this thesis will demonstrate the challenges and 
complications arising in the application of two contrasting causal techniques for survival 
analysis in a selection of the expository trials described in Chapter 4. Prior to these 
practical demonstrations of analysis methods, the next chapter aims to clarify the causal 
estimation process by considering the practical steps that are necessary to carry out such 
analyses, presenting two pictograms intended as research aids to simplify the process for 
non-specialist analysts. 
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7. Causal estimation process and 
considerations 
7.1. Introduction 
The results of the review of reporting and analysis of nonadherence in published trials, 
summarised in Chapter 5, demonstrate clearly that nonadherence to randomised 
treatment is a common problem affecting virtually all trials, but that appropriate 
methods of statistical analysis to adjust for this nonadherence are rarely applied. Instead 
naïve and statistically biased methods, such as PP or AT analyses, are frequently used.  
There is therefore a pressing need to explore and address the barriers that prevent trial 
statisticians from applying appropriate methods to estimate efficacy of treatment when 
faced with treatment deviations. 
   
   
239 
 
Firstly, trialists and trial statisticians may simply be unaware, not only of the bias that 
may be introduced when methods that destroy the balance of randomisation are 
implemented, but also of alternative methods that more effectively prevent selection 
bias when accounting for departure from randomised treatment. Even when analysts 
are familiar with such methods, they are likely to face financial and time constraints at 
the point of trial analysis, as funding bodies may themselves be relatively unaware of the 
value of causal analysis methodology. Statistical analysis plans may already be 
substantial, covering analysis of numerous secondary outcomes as well as potentially 
addressing issues relating to missing data. Trial analysts and funding bodies may 
therefore question the value of spending time, resources and money on analyses beyond 
those that are usually carried out, and it may be difficult to persuade funders to cover 
additional costs that are required to ensure that compliance analyses can be carried out 
with sufficient rigour and attention. This suggests that there is a need to promote 
awareness of the usefulness of considering compliance methodology to complement the 
accepted ITT and PP analyses, both within trial and clinical communities as well as 
among funding and regulatory bodies. 
Furthermore, the culture of acceptance of ITT as the standard method of analysis, 
along with a reluctance on the part of trialists to consider alternative methods of 
analysis out of fear of potentially introducing selection bias has meant that trials have 
typically been carried out with a strong focus on pragmatic aims, thus deterring 
statisticians from investigating or promoting alternatives methods of causal analysis. 
This may be particularly true for trials carried out in general medical practice, where the 
effectiveness of treatment is generally considered of greater importance than biological 
efficacy. However, as has been discussed in previous chapters, causal methodology is 
useful for demonstrating effectiveness of treatment, for example in alternative clinical 
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settings with different patient populations. Thus trials may benefit from additional 
analyses investigating the impact of adherence issues regardless of the ultimate trial aim. 
However, when such methods are introduced, their sheer complexity, along with a lack 
of experience of how to apply such methods in practice to what may be a complex 
compliance trial scenario, may hinder their use further. As such, in accordance with the 
remit of this PhD to facilitate use of appropriate but potentially complex and unfamiliar 
causal estimation techniques by non-specialist trial statisticians, this chapter presents a 
discussion of the issues that must be considered as part of the causal estimation process, 
not simply in terms of modelling and interpretation of results, but also with 
consideration for the necessary planning (of data collection and statistical analysis 
methods) to ensure transparency and applicability of chosen statistical methods.  
A pair of pictograms are presented, intended as analysis aids, the first presenting a clear 
depiction of the necessary considerations that must be addressed prior to undertaking 
causal analysis of trial data and the second summarising the statistical issues and 
methodologies according to the particular trial traits. In subsequent chapters, these 
pictograms are put to use with demonstration of how theoretical methodologies may be 
applied, as an example for analysts who may be interested in carrying out similar 
adjustments for nonadherence. 
7.2. Causal analysis considerations  
Causal analysis estimation necessitates consideration, not only of the choice of statistical 
methodology, but also of the clinical requirements and data limitations. As such, before 
causal estimation is possible, it is necessary to consider the whole trial scenario relating 
to the causal estimands of interest.  
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The process of causal estimation necessarily involves a complicated, and potentially 
compromising, marriage between a number of factors. First, the causal research 
question of interest must be translated into appropriate causal contrasts (of treatment 
received) forming the basis for the causal modelling estimation. Secondly, it is necessary 
to decide on how to collect and convert available data on compliance (or treatment 
received) into appropriate formats to inform the causal contrasts of interest. Then it will 
be necessary to select the most appropriate method of statistical analysis, taking into 
consideration relevant compliance issues, necessary covariate adjustments and outcome 
type. Finally, the results from this analysis must be interpreted in light of the limitations 
presented by the data and methodology, with potential use of sensitivity analyses to 
investigate the robustness of conclusions to underlying assumptions.  
Each of these key elements of the causal estimation process will be explored in this 
chapter. 
7.3. Define research questions and causal contrasts of interest  
First and foremost, (as introduced in Chapter 4) it is necessary to decide on a clear 
research question of interest, which will in turn allow identification of the causal 
estimand of interest. In order to estimate any effect beyond that of treatment 
assignment, it will be necessary to consider how the treatment patterns in the trial 
setting relate to this causal estimand. This will determine which of these deviations 
would be usefully factored out of analysis because they contravene the treatment path 
of interest, and which are inherently part of the treatment path that is of interest, such 
that their occurrence is not problematic for that particular causal estimation. As such, it 
is necessary to consider how deviations from treatment assignment are likely to 
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manifest themselves, both within the trial setting and the particular (potentially 
hypothetical) setting to which the trial results are to be applied.  
The focus of this research question, and its subsequent implications on analysis, will 
vary according to the perspective of interested parties. For example, as discussed in 
Chapter 3, a motivated patient interested in the likely benefit of treatment if they 
comply with doctors’ prescription of said treatment may be interested in the causal 
effect of treatment taken as prescribed while allowing for the potential for necessary 
changes to their prescription if they experience side effects or the treatment fails to be 
efficacious. Alternatively a policy maker may be interested in applying trial results to a 
general community setting where treatment changes such as those which occurred in 
the trial are likely but perhaps to different degrees to those observed in the trial. 
Differently again, funding decisions by regulatory bodies such as NICE often require 
full cost-effectiveness analysis which typically relate to the effect of treatment taken for 
life, particularly for drugs which impact on survival; as such, they require estimation of 
causal effects which factor out all changes from originally randomised treatment that do 
not reflect typical real-life availability of treatments.   
As such, the treatment deviations to be factored out of analysis for a particular causal 
analysis will not necessarily contravene the treatment protocol. It may, for example, be 
necessary for recruitment or ethical reasons to permit trial patients to switch treatments 
on disease progression, but nevertheless the causal research question of interest may 
relate to the effect of treatment on survival in the absence of all switches. 
On the other hand, deviations may also occur that are unexpected or undesired, for 
example when patients (or clinicians) have pre-existing ideas about the efficacy of the 
randomised treatments, and thus may request (or prescribe or administer) different 
treatments to those which have been allocated by randomisation. Patients may not 
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honour the agreement made at randomisation when they consented to receiving and 
complying with either of the potential randomised treatments, and may request to have 
their treatment changed or may simply cease taking their randomised treatments, 
possibly withdrawing from follow up altogether. Or clinicians external to the trial may 
overrule and allocate what they perceive to be the best treatment for their patient. 
Although such treatment changes may also be expected to occur as part of clinical 
practice, and thus some may argue that the ITT analysis reflects a true assessment of the 
policy of assigning treatment, this will only hold if the patterns of deviation from 
treatment protocol that occur in practice are the same as those occurring in the trial. 
This may be unlikely: with the passage of time, new treatments will emerge as the “most 
promising”, and thus alternative treatments switched to in the trial may well differ from 
those that are experimented with in years following the trial. Also the conclusions and 
dissemination of results from the trial may in fact alter the pattern of compliance with 
the drug: if the results of the trial are seen as positive by the clinical community or the 
media, patients’ likelihood and willingness to persist with treatment may be increased 
and thus fewer deviations from treatment protocol may occur in practice than in the 
trial. Thus a simple ITT analysis may not answer any question of interest reflecting 
everyday clinical practice.  
If instead one is able to estimate a true causal effect of treatment from a trial, this can 
then be used to answer a patient’s enquiry as to what treatment effect they could expect 
if they were able to persevere with treatment. This causal estimate may also be used to 
estimate the treatment’s effectiveness in clinical practice assuming various levels of 
acceptability by patients and clinical staff. Thus regardless of whether deviation from 
treatment protocol is expected in the trial setting or in clinical practice, there is a strong 
   
   
244 
 
argument for estimating a true causal effect of treatment, to accompany the necessary 
primary ITT analysis (91).  
Thus, the definition of the exact efficacy question of interest should depend on the 
types of deviations from treatment protocol that are accepted as integral to the course 
of treatment or the disease, and which deviations would be usefully factored out as 
“noise”. Once the particular clinical question to be answered has been defined in terms 
of treatment deviations to be factored out of analysis, it is then necessary to consider 
how the corresponding treatment effect of interest can be estimated, taking into 
account availability of the appropriate data in order to inform the relevant statistical 
methodology. 
The causal analysis method will in some way transform data from the experimental and 
control patients’ outcome data back to what would have been observed if they had 
followed exactly that course of treatment corresponding to the research question. 
Therefore, prior to undertaking any such analysis, it is necessary to firstly identify and 
specify these (potentially counterfactually) contrasting states of treatment. 
Thus, as for PP and AT analyses, where it was necessary to define when patients were 
considered to be “on” and “off” treatment, these definitions must be considered when 
defining the causal contrasts between control and experimental conditions (relevant to 
the causal research question). These definitions of treatment receipt will vary according 
to whether the relevant measure of treatment receipt was constant or time-varying, and 
whether it was recorded using a binary (for example, all-or-nothing compliance or 
repeated binary measures over time) or quantitative measurement (such as dose, 
recorded as a single summary measure (for example, cumulative dose) or changing dose 
over time), or as a time to event variable (such as time to treatment withdrawal). It may 
also be necessary to consider wider forms of nonadherence, for example switching to 
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the alternative trial treatment; switching to, or supplementing randomised treatment 
with, non-trial treatments; premature withdrawal from all treatment or intermittent 
nonadherence.  
7.3.1. Data collection 
Thus, having identified the relevant forms of nonadherence which will impact on the 
estimation of the treatment outcome of interest, it is necessary to ensure that relevant 
data on treatment receipt have been recorded in order to appropriately inform this 
estimation. The precise collection of data should be determined by the trial 
interventions and type of nonadherence that need to be reported and adjusted for. 
Gross (178) discusses the difficulties in accurate measurement of adherence information 
(with respect to preventive intervention trials, but with relevance to other forms of 
intervention) which stem from the ambiguities and subtleties surrounding compliance 
issues. In particular, prior to collection of any compliance data is the need to explicitly 
define the meaning of compliance relevant to the study. “Nonadherence” may be 
manifested in a number of ways relating to both treatment and follow up. For example, 
with a long term intervention, participants may fail initiate any part of their allocated 
intervention or attend any follow up; engage in some but not all of the intervention; 
start but then prematurely terminate participation or attend clinical follow up but not 
follow allocated intervention.  
It may be possible to capture the most important features of treatment receipt using a 
binary factor; for example, as a simple all-or-nothing treatment receipt indicator in the 
case of a one-off treatment, or when treatment switches occur immediately following 
randomisation only. When partial compliance is of interest, treatment receipt may be 
recorded as a continuous measurement which potential changes over time; for example, 
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patients may vary their dose intake or may intermittently take prolonged drug holidays. 
Even with a one-off treatment, time to (rather than simply occurrence of) treatment 
receipt may be particularly relevant, when timing of treatment is related to prognosis as 
well as outcome (for example, in the case of surgery trials). 
Compliance information may need to be recorded for both treatment arms, though the 
relevance of both control and experimental treatment deviations will again be 
determined by the causal estimand of interest (and in particular whether treatment 
deviations should be factored out from both or just one of the treatment arms). 
Similarly it may be necessary to supplement data on how well the patient adhere to their 
original randomised prescription with information on whether the patient sought 
alternative treatments or counter indications.  
Thus, it is necessary to implement appropriate measurement techniques in order to 
capture information on the particular manifestations of nonadherence that are relevant 
to the clinical setting, in particular to the disease, treatment and patient population being 
studied, and the research questions of interest. Furthermore, the measures used to 
record compliance should be described in sufficient detail to allow assessment of the 
reliability of the measurements (76). 
7.3.2. Validity of compliance measurements 
Until relatively recently, trialists have necessarily measured patient compliance using 
techniques which provide only basic and unreliable compliance information, such as pill 
counts, treatment diaries and patient interviews. The emergence of methods such as 
internal monitoring of patients’ drug levels and MEMS technology have facilitated the 
collection of more comprehensive compliance data, but even these methods are not 
without their disadvantages, most notably cost (a single MEMS device currently costs 
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approximately £50) or invasiveness, and may be equally unreliable. For example, it is 
known that patients will improve their treatment adherence in the days leading up to a 
clinic visit, thus inflating apparent levels of compliance measured at their follow up 
appointments (known as ‘white coat compliance’) (20). Measurement of compliance and 
assessment of its impact become even more complicated when patients take multiple 
potentially interacting treatments, especially if the poor adherence to one prescribed 
treatment impacts on the efficacy or toxicity of others. 
The validity and suitability of each adherence measurement method must be assessed in 
light of the particular clinical setting being studied, as variations in the definition of 
compliance across research or medical settings may render even the most reliable or 
accurate techniques unusable in a particular trial.  
Given that none of the available methods provide entirely unbiased or accurate 
accounts of compliance, a multi-method approach combining objective and self-
reporting methods has been recommended to provide the most reliable information (5). 
For example, it may be noted that, in contrast to the indirect account of treatment 
timing rather than a direct measure of treatment ingestion provided by MEMS, 
measurement of chemical markers in the blood provides an indication of drug ingestion 
but not actual timing. Thus use of both electronic and chemical monitoring methods 
may be necessary to obtain optimal drug compliance information (15).  
Pocock (71) discusses the need to question the validity of trial compliance data rather 
than accepting its reliability at face value, in particular with respect to whether the 
compliance data are sufficiently detailed and reliable. For example, it is important to 
assess whether individual patient compliance data have been measured using reliable 
methods along with reasons for non-compliance, and that these data have been 
collected using the same process for each randomised group. Furthermore, trialists 
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should endeavour to collect outcome data on non-compliers, to avoid the bias 
introduced when non-compliance is associated with missing outcome data. Ultimately it 
is necessary to decide whether the trial demonstrates sufficient quality in design and 
conduct to warrant any further complicated compliance analyses. 
7.3.3. Reporting of compliance data 
It is important to consider not only how the compliance data will be analysed, but also 
how it will be summarised and reported, in order to usefully and accurately convey the 
compliance profile within the trial. Indeed, even when trial aims do not include 
adjustment for non-compliance, it is important for trialists to report on compliance 
levels, in order that readers (and potentially meta-analysts) can assess the similarity of 
the trial setting to their own clinical setting. Thus, in the same way that the appropriate 
measurement technique will depend on the clinical setting being studied, so too will the 
precise reporting or definition of compliance or adherence. 
When addressing the issue of how to summarise potentially complicated compliance 
data (for example, time series data available from MEMS), trialists should consider the 
consequences of potential forms of nonadherence on the course of disease. Compliance 
information recorded in the trial should be sufficiently detailed and accurate to allow 
reporting of relevant features of non-compliance which are likely to impact on the 
course of disease and associated AEs (for example, allowing estimation of the incidence 
of drug holidays when they are likely to cause disease exacerbation, drug resistance or 
rebound effects). 
In the case of medication adherence, measurement and reporting of adherence data 
should differentiate between the three phases of drug taking, namely initiation, 
implementation and persistence, thus distinguishing between primary non-compliance 
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(when patients fail to initiate randomised treatment), non-compliance with the assigned 
drug regimen during the implementation phase and non-persistence (when patients 
prematurely discontinue randomised treatment). The tool used for collecting 
nonadherence information will impact not only on the accuracy and reliability, but also 
on the level of detail, provided by any reported measure.  
Initiation rates are straightforward in their calculation and interpretation, but without 
MEMS data (potentially corroborated with chemical monitoring), unwillingness on the 
part of patients to admit failing to even start their randomised treatment may lead to 
exaggerated initiation rates. Non-persistence rates may be equally easy to calculate but 
unreliable, particularly as withdrawal from treatment is typically associated with 
complete withdrawal from the trial. Furthermore non-persistence is unlikely to be 
constant over trial follow up (for example, more patients are likely to discontinue 
treatment early on) and as such, non-persistence should be reported per unit time (for 
example, as an annual treatment withdrawal rate) (78). The choice of summary measures 
to describe adherence during the implementation stage must relate to those features of 
nonadherence that impact on patient health or treatment efficacy, but will be limited 
according to the level of detail provided by the chosen method of adherence 
measurement.  
In failing to provide any precise information on dose timings, pill counts can inform 
only on very broad patterns of treatment taking, and are commonly summarised as the 
average proportion of prescribed doses taken by patients in each randomised group 
perhaps broken down into temporal intervals (for example, annual rates). However, 
given that adherence is likely to fluctuate over the course of the treatment 
implementation period, such a single summary measure is unlikely to adequately capture 
important differences between patients’ prescribed and observed patterns of treatment 
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taking. For example, a high proportion of doses taken may mask features such as drug 
holidays or incorrect timing, which may have a greater impact on the course of disease 
or side effects. 
The recognised flaws in using pill counts to assess adherence are compounded when 
these data are used to dichotomise patients into “good” or “poor” compliers defined by 
a certain threshold of drug taking, most commonly according to whether patients 
receive at least 80% of their prescribed intervention (or between 80 and 120%, allowing 
for overdose toxicity). Such categorisations not only disregard the continuous nature of 
the relationship between compliance and response, but are often based on arbitrary 
criteria without any pharmacological justification, despite the fact that the required 
amount of treatment exposure for therapeutic benefit will vary according to the 
particular disease or condition, drug and its formulation (20).  
Availability of more detailed information on dose timings and quantities from MEMS 
allows estimation of more informative summary measures quantifying more precisely 
the fluctuations in patient adherence over time. Variations in dose quantities and 
timings may be informatively combined in a single summary measure known as 
therapeutic coverage, defined as the proportion of patients exposed to a (predefined) 
minimum clinically relevant level of drug exposure, required to provide a clinically 
beneficial therapeutic effect, for (at least) a specified percentage of time. It may be 
difficult to provide clinical justification for the chosen lower (and upper, if over-dosing 
on treatment can cause toxicity) limit of treatment exposure required to ensure validity 
of this measure. Other commonly reported summary measures from MEMS data are 
the proportion of doses taken at the correct daily dose or the correct interval, or the 
average number of drug holidays taken per patient within a certain time period (19).  
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In differentiating between temporary and permanent discontinuation of treatment, 
without use of MEMS, temporary deviations (for example, occasional missed doses or 
longer drug holidays) are more difficult to record accurately, as are temporary deviations 
(such as incorrect conditions or timings of treatment-taking). On the other hand, 
although permanent discontinuation of treatment is more obvious and concrete, it is 
typically associated with end of follow up, such that important details relating to the 
reasons for, or the patient’s clinical state at the time of discontinuation may be 
inaccurate or incomplete (179). 
The relative importance of collecting information on temporary versus permanent 
discontinuations depends not only on the impact of such deviations on the drug’s 
action and the course of disease, but also on the potential for bias resulting from each 
different form of nonadherence. Vrijens (20) argues that nonadherence to the treatment 
schedule during the treatment implementation period (in other words, temporary 
deviations to treatment schedule), rather than being associated with the treatment or 
patients’ prognosis, is more likely to be caused by patient forgetfulness or suboptimal 
organisation. Such deviations are therefore likely to occur in a random fashion rather 
than being associated with a certain treatment or particular types of patients, and as 
such are unlikely to introduce bias if unaccounted for.  
In contrast, patients who prematurely and permanently discontinue treatment are likely 
to do so for reasons related to their condition, difficulties in taking treatment or 
apparent efficacy of treatment; as such, this subgroup are likely to differ systematically 
from those who persist with treatment and their exclusion from analysis will likely 
introduce bias. Thus, although challenging, it is vital to collect information on the 
reasons for, and patient outcomes following non-persistence. 
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Reporting of adherence must also relate to the types of treatment changes expected or 
encouraged in the trial setting. For example, when treatment switches or additions are 
likely, it may be relevant to record information not only on patients’ compliance with 
their original randomised treatment but also with any alternative treatments received, as 
well as the timing of, and reasons for, such changes (68). It may also be of relevance to 
determine who or what was responsible for the decision or request to change treatment 
prescription (be that the patient, treating clinician or potentially the protocol itself) and 
whether this decision was made in a blinded fashion (179).  
7.3.4. Planning requirements 
The need for relevant compliance data collection highlights the importance of 
considering causal estimation during the planning stage of a trial, rather than simply at 
the point of statistical analysis. Given that compliance is typically a multifaceted feature 
of patient behaviour which is difficult to measure and quantify, considerations must be 
made during the planning stage of which data should be collected, and how, such that 
analysis adjusts for clinically relevant measures of treatment received. The method used 
to collect compliance data will determine the format of these data and how the data may 
be included in the model; thus it will be necessary to consider how to collect this 
information accurately (considering the potential for measurement errors) and 
unbiasedly (recognising the typical associated biases as discussed in Chapter 3). In 
particular, forethought of the likely missingness mechanisms may allow procedures to 
be employed in order to counter such biases. Furthermore, the complexities associated 
with recording compliance data mean that it may be useful to pilot any CRFs prior to 
trial recruitment, in order to ensure sufficient clarity for treatment providers, assessors 
and patients.  
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7.3.5. Statistical analysis plan 
Consideration of the statistical methods that will be applied to adjust for nonadherence 
must also take place during a trial’s design stage, not only to demonstrate transparency 
with respect to the planned analyses but also to ensure collection of all necessary 
information required to facilitate the chosen methods of analysis. This is especially 
important when considering how to adjust for nonadherence, as adherence is rarely a 
simple dichotomous measure and may fluctuate within individual over the course of the 
trial, providing opportunities for manipulation of the particular definition of 
“nonadherence” in a certain trial in order to produce the most favourable results, for 
example by excluding certain patients with particularly good or poor prognoses (35, 71). 
As such, in order to avoid accusations of bias, a specific analysis plan should accompany 
every trial protocol, providing technical details of planned statistical analyses (61). 
Ideally, this plan should include definitions of “nonadherence” and whether, and if so 
how, the efficacy analysis will be adjusted for any nonadherence. These analyses should 
be linked to the research questions of interest, which then determine the corresponding 
forms of nonadherence which need to be factored out in order to investigate these 
questions. This may be a challenging exercise, given the difficulty in predicting all forms 
of participant or clinician nonadherence that will occur in a trial and therefore in 
defining precisely how particular patients’ data will be analysed (which may explain why, 
despite the argument for upfront transparency, decisions regarding compliance analyses 
are often made post hoc) (71).  
Cox (70) argues, however, that although it is necessary to provide a general plan of 
statistical analysis, it may be unrealistic to require analysts to stick rigidly to specific 
analysis plans, and that, following analyses carried out according to the original plan, 
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there may be justifiable reasons for making amendments to specific analyses. This will 
be demonstrated in practice in the next chapters of this thesis. 
7.4. Use of compliance data in statistical methods 
Collection of compliance information must reflect, not only the clinically relevant 
aspect of adherence defined by the causal question, but also how this compliance 
information will be used in the modelling process. Thus it is necessary to consider how 
the data that can be collected in practice (with all their likely limitations) can then be 
manipulated into useable forms for the modelling exercise.  
The statistical methodology chosen to estimate particular causal estimand of interest will 
rely on availability of (compliance, covariate and outcome) data in the appropriate 
format. Collected data may therefore need to be transformed into a usable format for 
the chosen method of statistical analysis, in order to simplify modelling and its 
subsequent interpretation. For example, continuous dose data may be reduced to a 
single summary quantity, for example as the proportion of prescribed treatment 
received over the whole treatment period, or longitudinal treatment withdrawal data 
may be summarised as a time to event variable. 
Similarly it is necessary to identify which covariates will likely be related to the 
occurrence of treatment changes and outcome, and whether these are likely to be 
recorded as baseline or time-varying covariates or confounders (which, as well as 
affecting future treatment, may furthermore be affected by prior treatment). It is vital 
therefore to consider what information clinicians (or patients) actually use when 
deciding to change treatment. Once it has been determined which of these factors are 
likely to be important, again it will be necessary to consider how to collect this 
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information to provide reliable (accurate and unbiased) data, again considering the likely 
mechanisms which will lead to missing data.   
The chosen statistical methodology must of course also depend on the form of the 
outcome data of interest (typically either binary or continuous) and on the frequency 
and nature of the measurement of the outcome, which may be taken at a single time 
point or repeatedly over time, or may be recorded as a time to event variable. 
Furthermore, the missingness mechanism for each type of data included in the trial will 
impact on the modelling limitations and capabilities and its subsequent interpretation. 
Available data will then need to be incorporated into appropriate models, taking into 
consideration modelling aims (research question and corresponding causal estimand of 
interest), inherent data limitations and statistical capabilities and limitations of the 
model. In particular, one should consider the assumptions implied by the model, and 
check the robustness of the results to these assumptions using sensitivity analyses 
(varying parameters or assumptions) or alternative models. 
Therefore, prior to investing resources and time in the potentially challenging task of 
collecting compliance data, trialists should consider how these data are likely to be used 
in adjustment methods, in a manner which directly relates to the causal question of 
interest. It may be necessary to manipulate the collected raw compliance data into a 
format usable by the chosen model, such that the original compliance data recorded in 
patient CRFs can be transformed into a summary measure for inclusion in the model. 
However, the clinically relevant features of compliance must also be captured in these 
measures, for example it may be relevant to model time to treatment compliance rather 
than a simple summary measure of average compliance over the whole treatment period 
(180). 
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7.4.1. Manipulation of compliance data for modelling 
Adherence data may take the form of (or may need to be transformed into) a constant 
or time-varying quantity, summarised as a binary, ordinal, continuous or time to event 
measure. 
The form taken by the adherence data will determine the interpretation of the model. 
This may be most easily observed in the case of naïve models: for example, a time-fixed 
measure of compliance (or treatment received) may be included in a naïve model in 
place of the original randomised treatment group indicator. The simplest example of all-
or-nothing compliance (for a one-off treatment, say) can be easily summarised as a 
binary factor; the corresponding naïve PP analysis would include only those patients 
whose randomised treatment indicator (𝑍) was equal to their received treatment (𝐴), 
whereas an AT analyses would replace the randomised treatment indicator (𝑍) with the 
treatment received (𝐴) for all patients. If more complicated data are collected, for 
example, when patient dose data are summarised into the proportion of total 
randomised drug actually taken by the patient, a dose-response model may be used to 
estimate the treatment effect, allowing for cumulative dose received. When treatment is 
time-varying, an AT analysis may feature a time-varying treatment covariate, for 
example a time-dependent treatment covariate in a standard Cox model. 
7.4.2. Binary compliance  
If treatment is a one-off event (for example, in the case of a single application or 
administration of treatment, such as a vaccine), compliance is naturally summarised as a 
binary factor and the associated causal effect may simply be defined as contrast between 
receiving experimental treatment versus standard (or no) treatment, as appropriate. This 
“all-or-nothing” compliance is the most straight forward form of compliance data to 
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analyse, as it provides a natural dichotomisation of patients into compliers and non-
compliers and resulting binary contrasts to be included in the model.  
Furthermore, analysis is simplified further if non-compliance only occurs in one, rather 
than both, treatment arms. For example, if trial design is such that control patients 
receive standard care as usual and are not given the option of beginning the novel 
experimental treatment (such that contamination is not possible) but those randomised 
to experimental treatment are able to refuse initiating this treatment, the only type of 
non-compliance that may be of interest is the simplest type of binary compliance 
categorization, all-or-nothing compliance in one treatment arm only, such that 
experimental patients either start and continue with allocated treatment or do not 
receive any of their allocated treatment.  
However it is rare in practice for compliance to be a purely dichotomous feature. 
Instead, the typical multifaceted nature of treatment protocol compliance means that 
patients usually demonstrate various degrees of partial compliance, rather than full or 
no compliance. Furthermore, rather than being fixed over time, compliance may 
fluctuate according to patient’s conditional or other external factors. Thus data collected 
on compliance is often continuous in nature, and may be time-dependent.  
However, partial or time-varying compliance data are more complicated to analyse, 
requiring more identifiability assumptions. Complex compliance information requires 
definition of multiple potential outcomes and treatment contrasts, and in the case of PS 
methods, additional principal compliance categories (119). Thus, even when clinical 
scenarios are complex, compliance data may need to be categorised in order to simplify 
modelling.  
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For example, continuous or time-varying measures of compliance may need to be 
dichotomised in order to allow methods to be carried out which can accommodate only 
binary compliance categorisation. Whenever compliance data have been reduced, 
however, it is necessary to consider the sensitivity of results to the (potentially arbitrary) 
cut-off level used to define the dichotomy, as it may distort the resultant treatment 
effect by including disparate types of patients within each category (71). 
7.4.3. Time-varying treatment  
The more complex the prescribed treatment schedule, the more complicated the 
definition of regime “compliance” becomes and the more consideration is required 
regarding collection of data to inform compliance-adjusted analyses. These 
considerations must all be taken in light of the particular causal effect of interest. 
When treatment is longitudinal in nature, the associated definition of causal treatment 
effect in the case of longitudinal treatment is therefore likely to demand greater 
consideration than for all-or-nothing compliance. The causal effect may simply take the 
form of a comparison between “continuous treatment with experimental treatment 
during trial treatment period” versus “continuous treatment with standard treatment 
during trial treatment period”. The clinical scenario or research question of interest may, 
however, demand a more precisely defined causal effect estimate. For example, in a 
pragmatic trial reflecting a clinical setting where side effects or drug inefficacy may lead 
to alterations to prescribed treatment in practice, it may not be appropriate to factor out 
all changes to initial randomised treatment, as some treatment changes will necessarily 
occur in practice; for example, it may instead be of interest to estimate causal effects of 
treatment taken continuously but only until the point of toxicity or other counter-
indications (87).  
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Thus information collected on compliance in a trial setting must relate directly to the 
causal effect of interest, in order to inform the associated causal analyses.  
7.4.4. Sensitivity analysis  
Given that it is not possible to estimate causal effects without invoking untestable 
assumptions, it follows that sensitivity analyses to investigate robustness of results to 
each analysis’ particular assumptions should be a matter of course. Analyses may be 
repeated considering a wider range of assumptions, as demonstrated for example by 
Vansteelandt (116) and Dunn (181).  
Furthermore, it may be necessary to check sensitivity of results when compliance data 
have necessarily been simplified; for example, it may be important to check whether 
conclusions alter when changes are made to (potentially arbitrary) dichotomising 
definitions of continuous measures of compliance, or if multiple aspects of exposure to 
treatment (for example, frequency and dose) have been combined into a single summary 
(116). 
When undertaking causal analyses, it is also important to appreciate the particular 
nuances of the clinical setting, in order to ensure that these contrasts are clinically as 
well as statistically relevant. For example, White’s analyses of the MRC hypertension 
trial (68, 89) demonstrate the need for an understanding of the subtleties of the 
particular disease or treatment being studied before one can confidently produce and 
interpret causal findings from an analysis. Effective communication between the 
statistical analysts and the clinical experts for a particular trial is therefore of paramount 
importance to ensure such nuances are not overlooked in the analysis, and to prevent 
statistical anomalies or biased interpretation of trial results. 
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7.4.5. Summary 
Thus, despite the greater control afforded by a research setting, barriers to accurate 
collection of trial compliance data are many, often mirroring those arising in general 
practice. The methods typically used in trials have been discredited, as they are so often 
easy to falsify (pill counts), rely on unrealistic or biased recall by patients (patient 
interviews), or may be resisted by patients because of the daily reminder of their disease 
presented by the recording method (treatment diaries). Similarly health care providers 
who (in their opinion, justifiably) deviate from randomised treatment regimens when 
prescribing or administering patients’ treatment may prefer not to disclose such 
treatment protocol deviations. An added dimension of complexity arises if therapeutic 
action of medication is provided only under certain conditions, for example when 
swallowed whole or chewed, with or without food. Assessing whether patients 
consistently followed such instructions when taking long term treatment is particularly 
difficult to ascertain. 
The compliance measure actually used for analysis will depend on a number of factors. 
First, the clinical setting and research question will determine the measure of 
compliance that would be most clinically relevant. However, the complexity and detail 
of available data will depend on the compliance measurement method used to measure 
compliance during the course of the trial (for example, pill counts, treatment diaries or 
MEMS). Finally, the chosen statistical model may impose restrictions on the compliance 
measurement that can be included in the model (for example, the method may be 
restricted to handling a time-invariant (for example, single binary or continuous 
measure) rather than a time-varying measure of compliance). 
In order that suitable chosen methods of analysis can be implemented in practice, it is 
therefore necessary for researchers to consider certain issues at the design stage of the 
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trial. Appropriate planning is required to ensure the necessary data are collected, not 
only regarding treatment receipt and outcome, but also on all potential confounding 
factors that may need to be accounted for. Furthermore, statistical analysis plans should 
be developed a priori to ensure that trialists are not accused of altering analysis 
techniques once outcome data have been collected and observed in order to obtain 
optimal results. 
7.5. Pictogram 
Two pictograms are presented intended as a research aid to simplify the causal 
estimation process, first by guiding researchers through the necessary considerations for 
each step of the causal analysis process and then by summarising which statistical 
method would be most appropriate depending on the trial scenario.  
The first pictogram (Figure 2) can be used to clarify how relatively complex trial 
compliance scenarios can be converted into answerable research questions and 
estimable causal effects, while also highlighting the need to consider the limitations and 
assumptions underlying the chosen analysis. For example, trialists may feel 
overwhelmed when faced with the likelihood of numerous forms of deviation from 
randomised treatment which typically occur with prescription of long term medication 
in trials and in clinical practice (for example, treatment switches, additions, withdrawals 
(permanent and/or intermittent) and incorrect treatment administration) potentially in 
both treatment arms and involving trial and non-trial treatments. In such cases, rather 
than attempting to collect (potentially unreliable) data on all sources of nonadherence to 
randomised treatment, it will be simpler to identify which features of nonadherence will 
impact on the outcome, and then focus on how to obtain accurate data on these 
features alone, which can meaningfully be used to inform relevant analysis techniques. 
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Once data collection and manipulation issues have been considered, it is necessary for 
the researcher to then determine the most appropriate statistical methodology to apply.  
Thus, the second pictogram (Figure 3) is also intended as an aid to the researcher, who 
must consider the requirements and implications of each option available. The statistical 
literature review summarised in Chapter 5 demonstrated that the available methods of 
adjustment varied in their underlying assumptions and data requirements, not only 
regarding the outcome but also the compliance and covariate information. To a non-
specialist statistician or trialists, the choice may be somewhat confusing. As such, the 
pictogram provides a reminder of the statistical issues and appropriate methods to use 
when faced with a certain trial scenario.  
As such, this pictogram aims to guide analysts in their thought processes regarding the 
underlying statistical complications of their particular trial, relating not only to the 
confounders which will may need to be allowed for in the chosen statistical method, but 
also regarding the choice of method, depending on the available data, assumptions and 
outcome type. 
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Figure 2 Causal estimation process 
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For example, the pictogram reminds the user that standard statistical methods can be 
used to adjust for confounding in the absence of any time-varying confounders, 
assuming all baseline confounders are known, measured and can be accounted for. 
However, in the absence of information on all confounders or if time-varying 
confounders are likely to affect both treatment received and outcome, alternative 
methods should be considered. 
Alternatively, if a particularly appropriate method of analysis requires compliance or 
covariate data to take a certain format, the chosen method of analysis may determine 
the format necessary for the data being used in the model. 
Furthermore the pictogram reminds the user that the interpretation of these methods 
varied depending on the underlying assumptions and causal estimation framework. 
Observational-based IPW methods assume that all confounders have been measured 
and adjusted for in the calculation of weights. The two forms of randomisation-based 
methodologies differ in their interpretation, which in turn relate to their relevance in 
answering a particular causal research question: PS (intervention-based) methods 
estimate treatment effects amongst the (latent) subgroup who would comply with 
whichever of the two treatments being contrasted they were assigned, whereas (efficacy-
based) structural models estimate causal treatment effects for the entire population, thus 
assuming that all patients would be able to (or could be persuaded to) comply with their 
randomised assignment.  
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Figure 3 Statistical methods and considerations for causal analysis 
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7.6. Causal diagrams 
A further aid to researchers when undertaking causal analyses may be to create a causal 
diagram relating to the causal scenario being considered. Causal diagrams help to 
qualitatively convey the nature of relationships between variables and the underlying 
implicit assumptions being made when making causal inferences regarding these 
relationships. In demanding explicit expression (and underlying assumptions) of 
relationships between causes, effects, confounders and selection variables, causal 
diagrams may help to identify potential forms of bias due to confounding and selection, 
as well as guiding plans on data collection (for example, regarding which variables will 
need to be included in analysis) and methods of analysis (182).  
All statistical methods depend on underlying (often unverifiable) assumptions, and 
causal inferences from such models require even more assumptions than those required 
for associational inferences. Causal diagrams help to convey these additional 
assumptions in a manner that cannot be portrayed using standard statistical notation, 
thus highlighting whether these assumptions are reasonable, and the extent to which 
any variations in these assumptions may affect conclusions. Furthermore, causal graphs 
are useful in helping investigator to think about what causal relationships may be 
missing from the graph and whether the proposed analysis methods will appropriately 
adjust for these underlying relationships (182). 
Thus, although causal diagrams are usually associated with more traditional methods 
(SEMs), they can be useful in guiding analysts, regardless of the exact method employed 
for causal estimation, by clarifying the likely causal links in their particular trial scenario 
as well as highlighting the underlying assumptions and relationships which must be 
appreciated when undertaking their analysis.  
   
   
267 
 
7.7. Conclusion  
In order to address potential barriers for the obvious lack of wider appreciation by the 
trial community of the importance of adjusting for departure from randomised 
treatment in a manner that will not introduce selection or confounding bias, this chapter 
has presented recommendations and guidelines to trial analysts in order to simplify and 
facilitate wider use of available causal estimation techniques. In the subsequent chapters 
of this thesis, this aim will be further realised through the presentation of practical 
demonstrations of adjusting for treatment deviations, thereby illustrating not only some 
typical challenges arising during the causal estimation process but also how potential 
solutions to these problems may be developed. 
 
  
   
   
268 
 
 
 
8. Demonstration of novel 
applications of the RPSFTM 
The review of statistical methods in Chapter 5 introduced a number of methods to 
adjust for treatment deviation in trials, but it became apparent from the review of 
published trials summarised in Chapter 6 that these methods are rarely employed, 
potentially because of their complexity or simply a general lack of awareness that such 
methods exist. Thus in Chapter 7, the range of available methods were presented 
pictorially with the aim of guiding researchers on the most appropriate methodology to 
use, along with a pictogram highlighting the pertinent practical issues relating to model 
requirements and interpretation. In this and the remaining chapters of this thesis, these 
recommendations are demonstrated in practice; in particular, the use of these 
pictograms are put into practice, demonstrating how a relatively complicated trial 
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scenario can be simplified into a feasible research question setting to facilitate analysis, 
as well as helping to highlight the limitations and assumptions associated with the 
application of the chosen analysis techniques.  
Thus, in this and the following chapters, the aim of this thesis is achieved with novel 
application of two methodologies appropriate for survival outcomes in contrasting trial 
settings, demonstrating necessary considerations and practical solutions to the 
challenges arising when applying these methods, and providing an example to future 
researchers on implications and interpretation of important causal methods. The general 
format of these chapters is designed, not simply to aid the reader in understanding the 
analysis process required for the purposes of these particular trials, but also as to 
demonstrate to other researchers the level of thought and detail required prior to, and 
during, application of these methodologies. 
8.1. Introduction 
The review of statistical methods for adjusting for nonadherence to randomised 
treatment, summarised in Chapter 5, revealed the most appropriate methods to adjust 
for departure from randomised treatment when analysing survival outcomes, namely the 
RPSFTM and the IPCW modelling techniques. In this chapter, the first of these 
methods will be applied to three trials introduced in Chapter 4: the honey trial, SANAD 
arm A and SANAD arm B. These trials present issues and scenarios of increasing 
complexity with respect to adjustment for nonadherence. In particular, the SANAD 
trial provides numerous analysis issues and challenges, due to the nature of the trial 
design and treatment changes that occurred. These challenges are likely to be common 
in other chronic disease areas, where treatment changes occur for a number of reasons 
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and interest lies in achieving remission of symptoms. As such, this trial provides a useful 
illustration for discussion of the analysis issues and methods.   
8.1.1. Model considerations 
This chapter will demonstrate the RPSFTM and compare the results and conclusions 
with those of standard methods (using ITT and PP analysis populations).  
As with any causal estimation, it is necessary to match the causal research question with 
the model treatment parameters; furthermore, given that the RPSFTM only reliably 
adjusts for one causal contrast (between experimental and control treatments), it is 
necessary to determine which single form of treatment deviation should be accounted 
for. As introduced in Chapter 5, a simple version of the RPSFTM can be presented as 
follows 
𝑈0𝑖(𝛽) = 𝑇0𝑖 + 𝑒
𝛽𝑇1𝑖 
which demonstrates the first key property of the RPSFTM, namely that it assumes that 
there are only two exposures within the clinical trial. For example, 𝑇0𝑖 may be defined as 
time spent on control intervention and 𝑇1𝑖 as time spent on experimental intervention, 
such that 𝑒𝛽  reflects the expansion (or contraction) in survival time attributable to 
treatment (130).  
In practical terms, this means it is possible to adjust for only one form of treatment 
change, that which is most easily accommodated being direct switches between 
randomised treatments, such that each patient’s follow up time is comprised solely of 
time spent on either control or experimental treatment (rather than alternative non-trial 
treatments or withdrawal from treatment altogether). This in turn implies that follow up 
is necessarily censored at the point of any other form of treatment change.  
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Therefore, as will be demonstrated in this chapter, it is necessary to define “on” and 
“off” treatment times ( 𝑇0𝑖 and 𝑇1𝑖 ) relating to the particular research question of 
interest. 
Furthermore, as discussed in Chapter 5, given the need to recensor individuals to 
remove the dependence (on the 𝑈0  scale) between censoring time and treatment 
received, it is necessary to define each individual’s maximum censoring time.  
These model requirements will be addressed in each application of the RPSFTM 
demonstrated in turn for each of the trials using the “strbee” code in Stata (134). Stata 
software is particularly user-friendly, making it ideal for this demonstration of the 
RPSFTM for non-specialist statisticians.  
8.2. Honey trial 
Departure from randomised treatment in the honey trial occurred in the form of 
withdrawal from randomised treatment, switches to the alternative treatment (honey or 
conventional treatment) or to a different course of treatment altogether (surgery, 
radiotherapy or antibiotics) or loss to follow up.  
Although it is ethically necessary to allow patients to receive alternative or more 
powerful treatment if they experience side effects or wound deterioration, the aim of 
this trial was to ascertain the biological efficacy of honey treatment when compared to 
the best standard care. As such, it was of interest to estimate the causal effect of honey 
treatment compared with conventional dressings in the absence of any treatment changes.  
However, given that the RPSFTM can only handle one treatment contrast, which here 
is taken to be the comparison between conventional and honey dressings, any time 
   
   
272 
 
spent receiving alternative treatment is necessarily discounted. Thus, in the model 
below,  
𝑈0𝑖(𝛽) = 𝑇0𝑖 + 𝑒
𝛽𝑇1𝑖 
𝑇0𝑖  is time spent with conventional wound dressing, 𝑇1𝑖  is time spent with honey 
applied to wound and any time spent in receipt of other forms of treatment is ignored. 
Follow up continued until a potential maximum of 24 weeks from randomisation 
(which thus defines the maximum censoring time).  
The RPSFTM is compared here for the primary outcome (time to healing) and 
secondary outcome (time to 50% reduction in wound size) against the results obtained 
using three other analysis sets, namely an intention-to-treat (ITT) analysis set, a per 
protocol (PP) analysis set and an as treated (AT) analysis set.  
In the ITT analysis, patients were analysed in the group to which they were originally 
randomised, and thus treatment switches were ignored. However, given that the trial 
comparison was intended for wounds healing by secondary intention (rather than due to 
direct invention on the wound), when patients were given more extreme forms of 
treatment (radiotherapy, surgery or antibiotics) or were lost to follow up, their follow up 
was censored (98). This censoring is potentially highly informative, given that the need 
for more radical treatment indicates a poor wound prognosis, and loss to follow up 
often occurred for reasons related to the satisfaction or motivation of the patient, which 
again are not likely to be independent of their prognosis. Death introduced a competing 
risk but for the sake of simplicity, this was ignored here and censored in the usual 
manner.  
The PP analysis set only included patients who received the treatment to which they 
had been randomised, and censoring was introduced at the point of any deviation from 
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this treatment (thus excluding patients altogether when they switched to the alternative 
trial treatment at the start of the trial). 
The AT analysis used a time-invariant binary measure of treatment received by 
categorising patients according to the treatment received from the start of the treatment 
period, and again censored follow up at the point of any deviation from the starting 
treatment. Thus AT analysis differed from the PP analysis set by including patients who 
switched treatment at randomisation in the group to which they switched (thus ignoring 
randomisation completely). 
These variations of analysis were compared with the results from a RPSFTM which 
adjusted for treatment switches to the alternative trial treatment, but in which censoring 
was again necessary when patients received more extreme (non-trial) interventions or 
were lost to follow up. Thus the four analyses differed only in their handling of patients 
who switched to the alternative trial treatment; all other deviations from treatment 
protocol were necessarily censored.  
8.2.1. Analysis 
The strbee program in Stata requires that the user creates additional variables 
capturing information on whether (and if so, when) the patient switched between 
treatment arms. These variables are treatment arm specific (for example 
honey_switch_t, honey_switch, conv_switch_t, conv_switch) and equal to 
zero if patients did not experience treatment switches. For example, a patient who 
switched from honey to conventional treatment 20 days following randomisation would 
be assigned values equal to (20, 1, 0, 0) for these four variables respectively, whereas a 
patient randomised to receive honey who did not switch would be assigned a value of 0 
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for each of these variables. The strbee program can analyse only binary treatment 
comparisons and requires that treatments are defined as 0 (control) or 1 (experimental). 
Prior to using the strbee program, it is necessary to specify the event time 
(t_healing) and indicator  (h_status) variables using stset: 
stset t_healing, failure(h_status) 
The user then must indicate the switch timing and indicator variables (in that order) for 
the control and experimental arms separately within the brackets preceeded by xo0() 
and xo1() respectively. For example, the code with randomised treatment indicator 
rand_trt would simply be  
strbee rand_trt, xo0(conv_switch_t conv_switch) xo1(honey_switch_t 
honey_switch)  
Options include hr (to display results in terms of HR rather than AF), kmgraph to 
display KM curves and trace for a list of recensoring times. 
8.2.2. Sensitivity analysis  
The censoring of patients at the point of deviation from treatment protocol for reasons 
related to severe wound deterioration (when more radical clinical intervention was given 
in the form of antibiotics, radiotherapy or surgery, or when the patient was unable to 
attend clinic because the wound was so debilitating) is likely to be especially biased, 
given that the state of their wounds is not likely to be typical of all wounds in their 
randomised group at this time point; the prognosis for the healing of these wounds at 
the point of censoring is very poor. Thus a sensitivity analysis was carried out in the 
ITT, AT and RPSFTM analyses, reflecting the likelihood that such wounds would likely 
not have healed in the follow up time even if treatment and follow up had continued as 
per the protocol. Thus, when clinical intervention occurred due to concern over the 
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poor progress in healing process (for example, when a patient began taking antibiotics 
or was referred for radiotherapy or surgery) or when the patient was unable to attend 
clinic because the wound was so debilitating, instead of censoring follow up at these 
points of treatment change or loss to follow up, follow up was censored at the longest 
possible follow up (24 weeks) for the sensitivity analyses (in other words, assuming that 
the outcome event did not occur during this follow up period). 
The results from these analyses, and the corresponding sensitivity analyses, are given in 
Table 22 to Table 25 below.  
8.2.3. Results 
105 patients were randomised to receive medical grade honey or conventional treatment 
for treatment of wounds. The number of treatment changes that occurred in each 
treatment group are presented in Table 21. There were only four (11.5%) switches from 
honey to conventional treatment (two immediately following randomisation) and six 
(11.3%) from conventional to honey treatment (all immediately following 
randomisation). Ten (19%) other patients from each treatment arm experienced another 
form of deviation from treatment (or follow up) protocol; these patients’ follow up time 
was extended to the maximum (24 weeks) for the sensitivity analysis to reflect their 
poor prognosis at the time of treatment change or loss to follow up.  
The results in Table 22 and Table 23 demonstrate that the RPSFTM did not have a 
large impact on trial conclusions, not surprisingly given that only a small proportion of 
treatment deviations were accounted for (four out of 14 (28.6%) in the honey arm and 
six out of 16 (37.5%) in the conventional arm). In fact, the impact of censoring at the 
maximum censoring time rather than at the point of receiving extreme treatment (in the 
sensitivity analysis) was generally similar to that of the adjustment for between-arm 
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treatment switches using the RPSFTM; both the RPSFTM and sensitivity analysis 
tended to increase the acceleration factor (AF = 𝑒𝛽), implying that these adjustments 
both increased the effect of honey on healing compared with standard dressings.  
The AF is interpreted in terms of the rate at which time to healing is “used up” when 
honey is applied in comparison to standard conventional dressing. Thus the AF (95% 
CI) from the ITT equivalent of the SFTM (with no adjustment for treatment changes) 
suggest that healing is achieved sooner with honey, on average 1.27 times faster than 
with conventional dressing, though this relative effect may extend between 0.80 and 
2.33 times; in other words, the result is not statistically significant. When the sensitivity 
analysis is applied (when censoring for alternative (extreme) treatment changes occurs at 
the maximum follow up time (24 weeks) but again without adjustment for any such 
treatment switches), healing time is “used up” even faster with honey (AF 1.31) and the 
upper confidence limit increases.  
This difference in AF attributable to the sensitivity analysis (i.e. between the ITT 
version of the SFTM with and without the sensitivity analysis applied) is exactly the 
same as that observed when the RPSFTM correction is applied. Application of the 
sensitivity analysis in the RPSFTM adjustment further increases the AF (to 1.4 and 1.38 
with and without recensoring respectively). 
Recensoring in the main RPSFTM analyses did therefore not drastically influence 
results, as very few observed events were recensored (only two patients, both from the 
honey arm, had their event times censored). However, in the sensitivity analyses for 
both time to healing and 50% reduction, recensoring survival times reduced the 
estimated AF (1.38) compared to no recensoring (1.4); this is expected, given that 
follow up time was greatly extended for these patients (to the maximum of 24 weeks), 
increasing the probability that recensoring would alter this survival time. 
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Similar results are observed in Table 23 for the secondary outcome, time to 50% 
reduction in wound size. 
As described in Chapter 5, the AF obtained from RPSFTM can be converted to HRs if 
one assumes a constant hazard ratio (i.e. according to a Weibull distribution). Thus, the 
corrected HRs obtained from the conversion of the RPSFTM AF are given in Table 24 
and Table 25 below, to allow comparison with the results from the other (ITT, PP and 
AT) analysis sets. It can be seen that the effect of RPSFTM (and corresponding 
sensitivity analyses) is intermediary between the ITT and PP/AT analyses. This is 
intuitive, given that the RPSFTM in fact censors for many of the treatment deviations in 
a manner identical to that of the PP analysis, with only one third of the treatment 
switches being accounted for in the model. This demonstrates the main limitation of the 
RPSFTM in this context – an inability to handle more than one type of treatment 
change.  
The results in Table 24 and Table 25 also demonstrate the effect of analysing according 
to treatment received, as the HRs from the PP and AT analyses are more extreme in 
favour of honey, even approaching statistical significance (0.085 for time to healing 
from AT analysis and 0.068 for time to 50% reduction in wound size from PP analysis). 
The bias in favour of honey is expected, given that the majority of switches between 
treatments occurred when clinicians transferred young fit patients to receive honey 
despite randomisation to control. Thus, by censoring their follow up in conventional 
arm (in PP analysis) or attributing their healing to honey (in AT analysis), the effect of 
honey was enhanced as demonstrated by the increase in HR. 
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Table 21 Compliance information  
All values are number (% of randomised treatment group). 
 Randomised treatment 
Conventional 
treatment (n=53) 
Honey 
treatment  
(n=52) 
Withdrawal from trial   
Death 2 (3.8) 1 (1.9) 
Lost to follow up 0 1 (1.9) 
Wanted honey 1 (1.9) 0 
Did not want to attend clinic 1 (1.9) 1 (1.9) 
Dissatisfied with progress 0 1 (1.9) 
   
Clinical intervention during the course of the trial 
due to severity of wound1 
  
Antibiotics 1 (1.9) 1 (1.9) 
Radiotherapy 0 1 (1.9) 
Too ill to attend clinic4 0 1 (1.9) 
Surgery 3 (5.7)  1 (1.9) 
   
Switched to other treatment during the course of 
treatment  
  
Pain 0 1 (1.9) 
Deterioration of ulcer 0 1 (1.9) 
   
Switched to other treatment immediately following 
randomisation 
  
Patient choice 1 (1.9) 1 (1.9) 
Clinician choice 5 (9.4) 1 (1.9) 
   
Withdrawal from trial immediately following 
randomisation 
  
Surgery 0 1 (1.9) 
Radiotherapy 0 1 (1.9) 
Disappointed with allocation 1 (1.9) 0 
Transferred to other hospital 1 (1.9) 0 
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Table 22 RPSFTM for time to healing 
 𝒆𝜷 (95% CI) 
  
No RPSFTM adjustment (equivalent to ITT) 1.27 (0.80, 2.33) 
  
Sensitivity analysis1 1.31 (0.80, 2.57) 
  
RPSFTM adjustment  
No recensoring 1.31 (0.75, 2.52) 
Recensoring2 1.31 (0.75, 3.29) 
  
Sensitivity analysis1  
No recensoring 1.40 (0.75, 3.07) 
Recensoring3 1.38 (0.75, 3.44) 
 
1 Sensitivity analysis censors patients with changes to alternative treatment at the maximum 
follow up time (24 weeks) rather than at the observed time of treatment change. 
2 Number of patients (events) recensored: conventional: 0 (0), honey: 9 (2) 
3 Number of patients (events) recensored: conventional: 1 (0), honey: 12 (2) 
 
 
Table 23 RPSFTM for time to 50% reduction in wound size 
 𝒆𝜷 (95% CI) 
  
No RPSFTM adjustment (equivalent to ITT) 1.33 (0.75, 2.27) 
  
Sensitivity analysis1 1.33 (0.68, 2.67) 
  
RPSFTM adjustment  
No recensoring 1.38 (0.67, 2.81) 
Recensoring2 1.38 (0.69, 2.81) 
  
Sensitivity analysis1  
No recensoring 1.42 (0.59, 3.50) 
Recensoring3 1.38 (0.62, 3.23) 
1 Sensitivity analysis censors patients with changes to alternative treatment at the maximum 
follow up time (24 weeks) rather than at the observed time of treatment change. 
2 Number of patients (events) recensored: conventional: 0 (0), honey: 9 (2) 
3 Number of patients (events) recensored: conventional: 1 (0), honey: 12 (2) 
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Table 24 Comparison of analyses for time to healing 
 Median time (IQR) [range] HR (95% CI) p-value 
 Conventional (n=51) Honey (n=50)   
     
ITT 140 (91, - ) [59, - ]  100 (51, 142) [42, - ]  1.30 (0.77, 2.19) 0.316 
Sensitivity analysis 140 (91, - ) [59, - ] 100 (54, 162) [42, - ] 1.32 (0.79, 2.23)  0.289 
     
RPSFTM  
No recensoring 
Recensoring 
 
140 (98, - ) [59, - ]  
140 (98, - ) [59, - ]  
 
100 (54, 142) [42, - ] 
100 (54, 142) [42, - ]  
 
1.37 (0.74, 2.56)  
1.27 (0.80, 2.03)  
 
0.316 
0.316 
     
Sensitivity analysis 
No recensoring 
Recensoring 
 
147 (98, - ) [59, - ] 
145 (98, - ) [59, - ] 
 
114 (54, 162) [42, - ] 
114 (54, 162) [42, - ] 
 
1.42 (0.74, 2.73)  
1.45 (0.73, 2.86)  
 
0.289 
0.289 
     
PP 140 (84,-) [49, - ]  91 (51, 142) [42, 163]  1.48 (0.86, 2.55)  0.161 
     
AT 140 (84,-) [59, - ]  100 (54, 132) [42, 163]  1.60 (0.94, 2.72)  0.085 
Sensitivity analysis 154 (84, - ) [59, - ] 105 (55, 133) [42, - ] 1.54 (0.91, 2.62)  0.111 
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Table 25 Comparison of analyses for time to 50% reduction in wound size 
 Median time (IQR) [range] HR (95% CI) p-value 
 Conventional (n=51) Honey (n=50)   
     
ITT 46 (23, 61) [16, 159] 32 (20, 48) [16, 101] 1.29 (0.82, 2.03)  0.266 
Sensitivity analysis 46 (28, 68) [16, - ] 32 (20, 48) ([16, 120] 1.24 (0.79, 1.96)  0.355 
     
RPSFTM  
Not re-censored 
Re-censored 
 
46 (23, 68) [18, 159] 
46 (23, 68) [18, 159] 
 
32 (20, 48) [16, 101] 
32 (20, 48) [16, 101] 
 
1.36 (0.80, 2.33)  
1.31 (0.84, 2.06)  
 
0.260 
0.237 
Sensitivity analysis 
Not re-censored 
Re-censored 
 
46 (28, 70) [20, - ] 
46 (28, 69.1) [19, - ] 
 
32 (20, 48) [16, 120] 
32 (20, 48) [16, 120] 
 
1.30 (0.75, 2.24)  
1.25 (0.78, 1.99)  
 
0.350 
0.350 
     
PP 46 (23, 68) [18, 165] 29 (20, 48) [15, 95] 1.54 (0.97, 2.43)  0.068 
     
AT 47 (28, 70) [20, - ] 29 (20, 48) [15, 105] 1.40 (0.88, 2.22)  0.157 
Sensitivity analysis 46 (20, 61) [18, 159] 29 (20, 48) [15, 95] 1.45 (0.91, 2.32)  0.119 
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8.2.4. Conclusion 
The application of the RPSFTM to these honey trial data suggest that adjusting for 
switches tends to increase the treatment effect in favour of honey to an intermediate 
degree to that observed from PP or AT analyses. However this analysis was limited due 
to very small numbers of direct switches between treatment arms, and the need to 
censor follow up at the point of any other change in treatment. Furthermore, as well as 
being unable to adjust for switches to non-trial treatments, the RPSFTM was subject to 
bias due to an inability to appropriately handle competing risk events such as death. As 
will be discussed in the next chapter, it is potentially possible to adjust for such 
competing events using the RPSFTM in conjunction with IPW methods. However, 
prior to considering this alternative method, the RPSFTM will now be demonstrated in 
the larger, more complex scenario present in the SANAD trial. 
8.3.  SANAD  
Despite the overtly pragmatic nature of the SANAD trial, involving inevitable treatment 
changes when patients experienced UAEs or ISC, there was interest in the efficacy of 
treatments in the absence of such treatment changes. Prior to considering RPSFTM 
specifications, however, it is necessary to discuss a number of complications in this trial 
which make any causal analysis somewhat challenging. 
8.3.1. Data issues 
First the treatment receipt data available in SANAD relate only to the drugs and doses 
prescribed by clinicians rather than actual adherence of patients to these prescriptions. 
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The only compliance data compromises a single general question on an annual quality 
of life questionnaire asking patients to estimate how often they miss doses. The 
distribution of answers is given in Figure 4 (where NR refers to non-response); 
although less than 5% of patients who returned the questionnaire each year reported 
missing medication more than once a week, at least one third of patients did not return 
questionnaire each year.  
 
Figure 4 Adherence to medication from annual questionnaire 
 
Thus, the data used in the analysis reflect prescribed drugs and doses, rather than actual 
treatment taken. Changes to randomised treatment prescribed by clinicians could take a 
variety of forms (including changes to prescribed dose, switching to other trial (or non-
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trial) treatments and the addition of other trial (or non-trial) treatments) for reasons 
usually related to ISC or UAEs. Often patients experienced multiple treatment changes 
(up to three changes were recorded in the dataset).  
Given the complicated treatment changes that occurred during patient follow up in 
SANAD, and the need to prepare data for a number of different types of analysis, as 
well as for comprehensive descriptions of the treatment changes that occurred, it was 
necessary to think carefully about how to code the data, in order to prevent time 
wasting with unnecessary data management prior to each analysis. However, these 
complications presented a challenge for data coding. First, it was necessary to consider 
carefully how best to code the treatment changes, to ensure a useful record of the time, 
type and reason for each treatment change in order to facilitate various potential 
subsequent analyses addressing different causal questions. Although the SANAD case 
report forms (CRFs) endeavoured to reliably capture information on treatment changes, 
inconsistencies in the interpretation of treatment information questions on the CRFs by 
different clinicians meant that the data on treatment changes needed to be extracted by 
hand from the dataset. This exercise demonstrated the need to appreciate the 
importance of careful consideration of data collection issues which must be undertaken 
during the trial planning stage, in order to ensure that the data required for any 
proposed statistical methods of adjustment are ultimately available and readily 
accessible. 
It was necessary to classify changes to prescription, for each patient at each follow up 
visit, as either treatment switches (from randomised drug to alternative trial/non-trial 
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drug), additions or withdrawals. Furthermore, it was recorded when patients were still 
taking previous monotherapy at the time of randomisation.  
Treatment changes in epilepsy rarely occur quickly; instead a withdrawal (from current 
treatment) and loading (increasing dose of new treatment) phase is required to prevent 
reactions to sudden treatment changes. Though SANAD CRFs recorded dates of (start 
and end of) treatment withdrawals and additions, it was necessary to decide on how to 
distinguish treatment switches (which necessarily involve an overlap period) from 
treatment additions. The overlap between starting a new AED and withdrawing from the 
randomised AED varied widely between patients (as demonstrated in Table 26, which 
summarises the withdrawal process and treatment overlap periods among SANAD A 
patients who switched between CBZ and LTG). Reasons for this depended on the 
patient’s clinical condition; for example, the prescribing clinician may have wanted the 
patient to get established on their new drug before starting to withdraw from 
randomised drug. 
Table 26 Withdrawal process details 
 CBZ (n=20/21) LTG (n=6/8) 
Duration between starting/completing randomised 
AED 
19.5 (0, 154) 15 (0, 21) 
Duration between starting withdrawal from 
randomised AED and starting new AED 
0 (-28, 42) 1 0 (0, 7) 
Overlap between starting new AED and finishing 
randomised AED 
19.5 (-42, 155) 2 13.5 (-1, 21)3 
All values are median (range) number of days. 
1 Negative value means that patient started new drug before starting withdrawal from randomised drug: 3 patients 
with -28, -14 and -1 
2 Negative value means that patient finished taking randomised drug before starting new drug: 3 patients with -42, -7 
and -2 
3 Negative value means that patient finished taking randomised drug before starting new drug: 1 patient with -1 
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The wide variety of treatment changes meant that it was necessary to code each 
treatment change according to the type (switch, addition, addition before switch (when 
a new treatment was added prior to the initiation of withdrawal of the randomised 
drug), withdrawal of randomised drug and subsequent reintroduction of randomised 
drug), timing (since randomisation), order (in the sequence of treatment changes 
experienced by that patient) and drug(s) involved in each treatment change.  
The decision was made that, in the case of treatment switches or additions, the date of 
switch (or addition) was taken to be that on which the new treatment was added, 
regardless of how long the withdrawal period (in the case of treatment switches) or 
loading phase lasted. 
The data available from GP records were not always complete, and some patients had 
extensive gaps between recorded visits. Prescribed dose data were missing on a number 
of patients, and it was unlikely that these data were missing completely at random: 
indeed, these patients were more likely to withdraw due to UAE and typically had 
shorter time to withdrawal than those with regular dose data. 
Furthermore, following scrutiny of the data set and consultation with neurology experts, 
it became obvious that GPs often followed irregular prescribing patterns reflecting the 
uncertainty of the efficacy and safety of AEDs; for example, a new drug may have been 
recorded once only without an accompanying dose, demonstrating an underlying doubt 
on the part of the patient or clinician regarding whether the drug was suitable for the 
patient; given the lack of precise adherence information, it was not possible to 
determine in these cases whether the patient even started taking these additional drugs.  
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Thus, before carrying out the RPSFTM, it was necessary to decide how these vagaries 
would be handled. First, as in the case of White’s analysis (89), it was decided that a lack 
of follow up or treatment data indicated no change in seizure or prescription. Given the 
evidence suggesting informative missingness, it would have been interesting to carry out 
a sensitivity analysis to investigate such effects. However, for this analysis, those with 
sparse follow up or treatment data (for example, 7 patients had their first treatment 
information recorded more than 365 days since randomisation, ranging from 428 to 919 
days since randomisation) were assumed not to have experienced unrecorded treatment 
change or seizures between visits. 
After consulting expert opinion, it was decided that a treatment switch (as opposed to 
addition) required less than one month (30 days) between the dates of the start of the 
withdrawal phase and the first prescription of alternative treatment. When short term 
drugs were prescribed (for example, in preparation for surgery, as surgery may induce 
seizures) it was decided not, for the pragmatic purposes of the trial, to consider these as 
treatment switches or additions. 
8.3.2. Complications of the SANAD trial 
The SANAD trial presented numerous other complications beyond that of the 
treatment data. First, both arm A and arm B involved multiple randomisation, with 
patients randomised to one of five treatment groups (in arm A) and three treatment 
groups (in arm B).  
The solution to the problem of these multiple randomised groups was provided by 
considering the causal research question of greatest clinical interest, namely the 
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comparison between CBZ versus LTG. For patients with focal epilepsy (recruited in the 
main to arm A of SANAD), CBZ was the standard treatment most familiar to clinicians 
at the time of the trial, while LTG was the new drug of greatest interest to clinicians. 
Thus the CBZ arm of the trial presented a sensible baseline comparator for a two-way 
comparison with LTG for patients in arm A of SANAD. This decision was supported 
not only by clinical interest but also because the most common switches were between 
the CBZ and LTG arms; for example, more than half  (31 (and 20) respectively) of the 
60 (36) patients who changed treatment prior to achieving 12 month remission in the 
CBZ (LTG) treatment groups had switched to the alternative LTG (CBZ) treatment. As 
such, this treatment switching scenario appeared to lend itself quite well to the 
RPSTFM in practical as well as clinical respects. 
Another complication in SANAD relates to the primary efficacy outcome, time to 12 
month remission (T12mR). As will be discussed in section 8.4, although very important 
from a practical perspective, analysis of T12mR is a complicated non-standard summary 
of repeat events data which introduces problems when applying RPSFTM for two main 
reasons. First, analysis of time to 12 month remission using the RPSTFM is complicated 
by the fact that the event cannot happen prior to 12 months. The assumption of a 
constant acceleration factor is thus violated, given the necessary truncation of its effect 
prior to 12 months (without which the model will incorrectly predict remission times of 
less than 12 months). Secondly, a significant proportion of patients (in the region of 
30%) are expected to achieve immediate 12 month remission (I12mR), such that there 
will be a peak of events at this time point. The RPSTFM is not able to recognise either 
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of these characteristics of the data (peak at 12 months and no events prior to this time) 
and is likely to incorrectly predict event times prior to 12 months.  
Thus it was decided, as an initial investigation, the RPSFTM would be used to adjust the 
simpler secondary outcome, time to first seizure (TFS), for treatment switches occurring 
between those randomised to CBZ and LTG in arm A of SANAD, and would be 
compared against ITT and PP analyses. 
Similarly to the RPSFTM analysis of the honey trial, the difficulty presented by the 
numerous types of treatment changes (withdrawal from randomised treatment, still 
taking other treatment at randomisation, switching to other (trial or non-trial) 
treatments or addition of other treatments) was addressed, although somewhat 
inadequately, by simply censoring those with any treatment changes other than switches 
to the alternative treatment arm (CBZ/LTG) at the point of the ‘illegal’ treatment 
change (including those who were still taking a drug at randomisation).  
Finally, it was decided (as per the original analysis (99)) that those patients who were 
later found not to have epilepsy would be excluded from the analysis, the justification 
being that diagnostic methods have improved markedly since the SANAD began 
recruiting, and that receipt of AEDs by non-epileptics can be especially harmful. 
Thus, all analysis sets excluded those patients found not to be epileptic, the PP analysis 
set censored patients at the point of any treatment change that occurred prior to first 
seizure, and the RPSFTM analyses censored at the point of any treatment changes that 
occurred prior to first seizure except switches between CBZ and LTG. (These 
treatment changes are referred to here as “illegalities”, and include switches to other 
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trial/non-trial treatments, starting additional treatment (including starting LTG (or 
CBZ) without withdrawing from randomised CBZ (or LTG) treatment) or still taking 
an additional drug at randomisation). In order for a patient to be eligible for the analysis 
of the outcome TFS, any illegality must have occurred after the time of first seizure (or 
the end of follow up for first seizure, whichever occurred first). In order for a switch to 
be eligible for the analysis of the outcome TFS, the switch must have occurred prior to 
first seizure (or the end of follow up for first seizure, whichever occurred first). In other 
words, in order for a patient to be included in the RPSFTM analysis as a treatment switch, 
the following had to be true: time of legal switch to alternative (CBZ/LTG) < time of 
first seizure < time of any illegality. “Switch” therefore refers to switch from 
randomised treatment CBZ to LTG or from randomised treatment LTG to CBZ. 
8.3.3. Model  
As set out in section 8.1.1, it is necessary to define the “on” and “off” treatment times 
(𝑇0𝑖 and 𝑇1𝑖 ) relating to the particular research question of interest, as well as the 
maximum censoring time. Thus for this comparison, the model  
𝑈0𝑖(𝛽) = 𝑇0𝑖 + 𝑒
𝛽𝑇1𝑖 
relates the underlying remission time 𝑈0𝑖 (if patient had remained on CBZ throughout)  
to 𝑇0𝑖 (the time spent on CBZ) and 𝑇1𝑖 (the time spent on LTG). The maximum follow 
up time (necessary for recensoring) was calculated for each patient as the difference 
between their date of randomisation and known final date of follow up.  
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8.3.4. Results 
Table 27 sets out how data and treatment changes were handled in each (ITT, PP and 
RPSFTM) analysis, with a summary of the number and timing of eligible and ineligible 
treatment switches for the RPSFTM analysis given in Table 28. The “eligible” switches 
between CBZ and LTG arms made up a small proportion of total treatment changes; of 
those treatment changes occurring prior to TFS, only 19 (43% of 44 treatment changes 
among patients randomised to CBZ) and 9 (26% of 35 treatment changes among LTG 
patients) were direct switches between treatment arms. 
Table 27 Definition of ITT, PP and RPSFTM analysis sets 
 Number of patients ITT PP RPSFTM 
 CBZ LTG  
Originally 
randomised 
378 378 
No dose data 24 20 Excluded Excluded Excluded 
Not epileptic1 10 8 Excluded Excluded Excluded 
    
Potential for 
inclusion in analysis  
346 352  
Treatment changes2   
Switch to alternative 
CBZ/LTG3 
19 9 Ignored Censored5 Switch6  
Switch to other AED 14 6 Censored5 Censored5 Censored5 
Start additional AED 0 3 Censored5 Censored5 Censored5 
Still on AED at 
randomisation4 
11 17 Censored5 Censored5 Censored5 
1 Note that dose data are missing for two patients from each group who were found not to be epileptic 
2 Only relates to changes occurring prior to first seizure; those occurring after first seizure are ignored 
3 Switch from randomised CBZ to LTG, or from randomised LTG to CBZ, prior to any other treatment 
changes 
4 Those still on an AED at randomisation were censored at time 0.1 days. 
5 Those with any changes in treatment that occurred prior to first seizure (switches, additions or those 
already taking an AED at time of randomisation) were censored at the time of the first occurring 
treatment change 
6 Switches from randomised CBZ to LTG or vice versa were accounted for in this analysis. 
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Table 28 Summary of the number and timing of eligible and ineligible switches  
 CBZ arm (n=346) LTG arm (n=352) 
 Number 
(%) 
Time from 
randomisation to switch   
Number 
(%) 
Time from randomisation 
to switch   
 Median 
(IQR) 
Range Median 
(IQR) 
Range 
Eligible switch1  19 (5.5) 84  
(25, 112) 
(1, 213) 8 (2.3) 56  
(21.5, 110.5) 
(14, 794) 
Ineligible 
switch2 
40 
(11.6) 
180  
(49.5, 370)  
(3, 1498) 48 
(13.6) 
283.5 
(87, 479) 
(4, 2043) 
1 Switch occurred prior to first seizure and any illegality occurred after first seizure. 
2 Switch occurred after first seizure, or switch and illegality occurred prior to first seizure. 
 
Table 28 demonstrates that similar proportion of each treatment group experienced a 
switch to the alternative group (CBZ/LTG) (CBZ arm: 59 (17%); LTG arm: 56 (16%)) 
but many more of these switches in the CBZ group were eligible (19/59, 34%) 
compared to the LTG group (8/56, 14%). This was primarily because, in the LTG 
group, switches tended to occur due to ISC (and therefore after the first seizure) because 
clinicians were less familiar with this novel drug and therefore less adept at prescribing 
the correct dose to prevent seizures. In contrast, clinicians were more familiar with CBZ 
and therefore more likely to prescribe higher initial doses to ensure good seizure 
control, potentially at the expense of tolerability, thus increasing the likelihood of 
switches due to UAEs before the first seizure.  
The results (for the relative effect of LTG vs CBZ) are given in Table 29. Comparison 
of the treatment effects obtained using these different analysis sets demonstrates that 
PP, ITT and RPSFTM analyses increasingly suggest that TFS is earlier with LTG than 
with CBZ (acceleration factors 1.87, 1.92 and 2.00 and hazard ratios of 1.20, 1.21 and 
1.22 respectively), as was concluded in the original HTA report. Thus adjustment for 
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direct switches between treatments using the RPSFTM implies a slightly greater 
advantage of LTG over CBZ than that demonstrated by ITT or PP analyses. 
Table 29 ITT, PP and RPSFTM analyses for SANAD A  
 𝒆𝜷 (95% CI) HR (95% CI)  
LTG:CBZ 
p-value 
    
ITT 1.92 (1.03, 3.41) 1.21 (1.01, 1.44) 0.034 
    
RPSFTM  
No recensoring 
Recensoring1 
 
2.00 (1.03, 3.94) 
2.00 (1.02, 3.70) 
 
1.23 (1.02, 1.48) 
1.22 (1.01, 1.46) 
 
0.034 
0.037 
    
PP 1.87 (1.001, 3.33) 1.20 (1.005, 1.44) 0.042 
1 Number of patients (events) recensored: CBZ: 27 (2), LTG: 82 (16) 
 
The considerable difference between AF and HR suggest that, if approximating the data 
using a Weibull distribution, the shape parameter would not be equal to 1 (in other 
words, the TFS data do not follow an exponential distribution). This would occur, for 
example, if the hazard rate was initially steep and then flattened out, perhaps due to an 
initial peak in the number of events due to early seizures in a subset of patients for 
whom treatment was inefficacious, followed by a more stable period of seizures among 
remaining trial participants. 
8.3.5. Limitations of time to first seizure CBZ/LTG RPSTFM 
There are a number of limitations of this analysis. Firstly, this analysis compares only 
two of the five treatment arms. Although more treatment contrasts could in theory be 
included in the RPSTFM, estimation is likely to be unreliable due to model instability 
(94).  
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Because only those treatment changes occurring up to the time of first seizure are 
considered in this analysis, analysis of TFS by definition considers only those changes 
due to UAE and thus does not relate to problems related to seizure control. Analysis of 
TFS is further disadvantaged because it is likely to be influenced by initial dose: 
standard AEDs are more familiar to the prescribing clinicians, and hence are likely to be 
introduced at higher doses than those drugs which are newer and less familiar. Given 
that seizure control is directly correlated with dose, this familiarity and subsequent 
higher dosing with the standard drugs is expected to bias the treatment comparison of 
TFS in their favour.  
In addition, as the RPSTFM can only reliably adjust for one type of treatment change, if 
patients experience changes other than pure treatment switches between the 
comparator drugs (for example, those who add on another AED or those who 
withdraw from their randomised drug without switching to the alternative AED of 
interest), their follow up is necessarily artificially censored at this point. This censoring 
is likely to introduce bias, as those who undergo treatment changes may well have a 
particularly poor prognosis (for example, in the case of adding further AEDs) or good 
prognosis (if, say, they have decided to stop taking randomised treatment because they 
have not experienced seizures for some time) at the point of their treatment change. 
Thus, the most notable limitation of this analysis is that the majority of treatment 
changes are necessarily discounted in the RPSFTM, because of the need to censor any 
patients experiencing (prior to their first seizure) any treatment changes other than 
direct switches between CBZ and LTG. Of the potential 59 switches that occurred 
from randomised drug CBZ to LTG, and 56 that occurred from randomised drug LTG 
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to CBZ, only 19 and 8 respectively were included in the RPSFTM analysis, either 
because of some ineligibility that occurred prior to the first seizure (for example, when 
the patient started an additional drug or switched to a different drug) or because the 
switch (between CBZ and LTG) occurred after the first seizure. Indeed, it is of interest 
to note that these direct switches (after the first seizure) occurred more often in the 
randomised LTG group, given that patients tended to switch from LTG to CBZ due to 
ISC (i.e. after first seizure) whereas patients were more likely to switch from CBZ to 
LTG because of UAEs (i.e. potentially before first seizure). The omission of these 
treatment changes from analysis not only reduces the power of the RPSFTM analysis, 
but is also likely to introduce selection bias, given that censoring at the time of such 
treatment changes is likely to be informative (related to the patients’ prognosis). 
Thus, these RPSFTM results do not relate to patients who experienced treatment 
changes other than switches between CBZ and LTG, and the choice of outcome (TFS) 
means that only switches primarily due to UAE (rather than ISC) were accounted for. It 
is therefore of interest to therefore consider a more relevant outcome reflecting long 
term remission of seizures, as demonstrated in the next analysis. 
8.4. SANAD B 
The third version of the RPSFTM relates to adjustment for treatment changes when 
analysing the primary outcome of the SANAD trial, time to 12 month remission 
(T12mR). T12mR is of greater interest to patients and clinicians alike than TFS, not 
only because of its significance for regaining the right to a driver’s licence but also 
because it is less dependent on initial dose (as it requires a sustained effect of treatment 
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on preventing seizures). However, as will become evident, it is a complicated summary 
of repeated events data that introduces complications for analysis. 
Given that the primary explanatory effect of interest for SANAD investigators was the 
causal effect of treatment in patients with generalised, rather than focal, epilepsy, this 
final evaluation of causal effects using the RPSFTM is applied among those randomised 
to arm B, rather than arm A, of the SANAD trial. At the time of recruitment, clinicians 
recorded whether patients had generalised or focal epilepsy (or if unclear at the time, the 
patient was recorded as having “unclassified” epilepsy). In the case of focal epilepsy, the 
drug of choice is CBZ, and such patients should have been recruited into arm A of 
SANAD (where the standard comparator treatment was CBZ). VPS is the drug of 
choice for generalised epilepsy, and such patients were intended to be recruited into arm 
B (where the standard treatment was VPS). However this did not always occur: some 
clinicians entered patients into arm B despite there being focal elements to their 
epilepsy, where VPS is definitely not a recommended treatment. Given that this 
inclusion of patients with focal type epilepsy is likely to blur the true difference between 
the treatments, it was decided that these patients should be excluded from the 
explanatory analysis. Although it may have been more statistically valid to avoid 
excluding patients and instead include an interaction term for the type of epilepsy in the 
causal model, this would have added to the complexity of the model; furthermore, this 
exclusion affected only 39 (9%) of those randomised to arm B. 
The choice of treatment comparison was once again guided by clinical factors. The 
standard treatment for patients with generalised epilepsy at the time of SANAD was 
VPS, and, as for arm A, the newest most promising alternative drug was LTG; as such, 
   
   
 
297 
 
 
treatment switches most commonly occurred between these treatment arms, and it was 
considered of greatest clinical interest to compare efficacy of LTG versus VPS.  
Thus in this analysis, only those arm B patients with generalised (or unclassified) 
epilepsy were evaluated to determine the causal effect of LTG versus VPS on the 
primary outcome T12mR. Although treatment switches occurred relatively commonly 
between these two treatment arms, other treatment changes also occurred. Thus it was 
necessary (as for the previous two RPSFTM applications) to consider how to handle 
these other treatment changes in the analysis, particularly in relation to the causal 
contrast from the model as defined by the research question. A reminder of the 
RPSFTM  
𝑈0𝑖(𝛽) = 𝑇0𝑖 + 𝑒
𝛽𝑇1𝑖 
highlights the need to determine the “on” and “off” treatment states, which relate 
directly to this research question (and thus, in turn, to the handling of changes other 
than direct switches between treatments).  
8.4.1. Clinical question of interest 
In the arm A analysis presented earlier in this chapter, the inputted times (𝑇0𝑖 and 𝑇1𝑖) 
related only to time spent on CBZ or LTG monotherapy (respectively); thus censoring 
was introduced at the point of any changes to treatment prescription excluding direct 
switches between these treatments, in an attempt to estimate a purely explanatory 
relative treatment effect (by adjusting for “true” switches between randomised 
treatments).  
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However, in reality, the main research question of interest for SANAD clinicians is not 
purely explanatory, but rather exists on the explanatory/pragmatic continuum: although 
interest lies in the biological effects of certain treatments, it is acknowledged that AED 
treatment is given in a pragmatic setting, where patients may experiment with doses or 
new drugs before finally settling on a treatment of choice, or where patients may begin 
randomised treatment while still taking a previous monotherapy, or where switches 
between treatments may involve an extensive overlapping period to allow for necessary 
loading or withdrawal phases.  
Thus, a more realistic analysis would adjust for situations where patients end up on the 
alternative treatment, perhaps first having tried other treatments or combinations, rather 
than automatically censoring such patients at the point at which they try other 
treatments. This pragmatic take on the causal analysis allows for the fact that patients 
may have been offered treatments and may have tried them for a short period before 
deciding whether to take them as long term treatment, and assumes that these short 
dalliances with other treatments do not overly influence the effect on sustained freedom 
from seizures. 
Thus, one may make a comparison between two pragmatic treatment regimes, namely 
“VPS plus any treatment changes that occur (except those involving LTG)” versus 
“LTG plus any treatment changes that occur (except those involving VPS)”. In such an 
analysis, no artificial censoring would be necessary, as any treatment changes not 
involving the alternative treatment of interest are considered to be part of the pragmatic 
treatment regimens being compared.  
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In the case of the SANAD trial, the question of interest for clinicians may well lie 
somewhere in between these “true” and “pragmatic” treatment switch scenarios. 
Discussion with neurology consultants suggests that interest lies primarily in adjusting 
for switches which result in the patient “ending up on” the alternative treatment; thus 
they are willing to accept the pragmatic situation that patients may well try other 
treatments or combinations of treatment prior to ending up on the alternative treatment 
of interest. However, if a patient then ceases to take this alternative monotherapy (for 
example, if they subsequently add on alternative treatments or withdraw from all 
treatment), it is more clinically appropriate to censor the patient’s follow up at this point 
of treatment change. Thus all such treatment changes are ignored prior to the occurrence 
of a direct switch (between the randomised treatments of interest), but following a direct 
switch, any such treatment changes are considered to blur the comparison and thus 
would need to be censored.  
8.4.2. Causal contrasts 
The chosen definition of switch (either true, pragmatic or clinically relevant) translates 
directly to the causal research question and causal contrast, defined by 𝑇0𝑖 and 𝑇1𝑖, in 
the RPSFTM.  
First consider the pragmatic question “what are the relative effects of LTG (with any 
treatment changes that ensue with this treatment policy, excluding adding or switching 
to VPS) and VPS (with any treatment changes that ensue with this treatment policy, 
excluding adding or switching to LTG)?”  
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For such a pragmatic analysis, 𝑇0𝑖 would be calculated as the total time spent on VPS 
(including time following any other additions or switches to subsequent treatments, but 
excluding addition with, or switching to, LTG); similarly 𝑇1𝑖 would be calculated as the 
total time spent on LTG (including any other additions or switches to subsequent 
treatments, but excluding addition with, or switching to, VPS). Thus, in evaluating the 
effect of “ending up on” the alternative treatment, this analysis considers any other 
changes to treatment as a pragmatic continuation of randomised (or switched) 
treatment, thus removing the need to censor follow up at the point of these alternative 
treatment changes.  
Note, however, that this pragmatic assessment of treatment switches is somewhat 
inconsistent, as the addition of VPS to (randomised) LTG would be recorded as 𝑇0𝑖 and 
thus is considered the opposite (in terms of treatment contrasts) to when LTG is added 
to (randomised) VPS (recorded as 𝑇1𝑖), despite these scenarios being identical in terms 
of treatment received.  
In practical terms, this approach meant that any changes to randomised drug (VPS or 
LTG) such as withdrawal, addition and switches of AEDs were ignored, except those 
which involve the alternative drug of interest (LTG or VPS): any addition or switch to 
alternative (LTG or VPS) was considered to be a “switch”. Subsequent changes 
following such a “switch” were also ignored, as they too were considered to be part of 
the pragmatic treatment on the alternative treatment (as shown in Figure 5, where 
different coloured lines indicate different treatments).  
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In contrast, the explanatory approach to this analysis adjusted only for “true” switches 
(direct switches between LTG and VPS) which occurred prior to any other treatment 
changes (as demonstrated by Figure 6 below), thus answering the research question 
“what are the relative treatment effects of LTG versus VPS?” Thus in this scenario (as 
for arm A comparison), follow up is censored at the point of any treatment changes 
(including additions of the alternative drug (LTG or VPS)) other than direct switch to 
alternative (LTG or VPS). 
Finally, of greatest clinical interest would be adjustment for those pragmatic switches in 
which the patient ends up on alternative treatment but any subsequent deviation from that 
treatment would then be censored, thus assessing the research question of interest 
“what is the effect of LTG versus VPS, when any treatment changes prior to the 
treatment switch are considered to be part of the treatment experience on each 
randomised drug?” (shown in Figure 7). 
This analysis, although clinically sensible, is neither consistent nor statistically valid 
(even beyond that of the “pragmatic” analysis mentioned above), as a certain treatment 
change would be handled differently depending on whether it occurred before or after 
the treatment switch of interest. Thus this example demonstrates how careful discussion 
between statistician and clinician is necessary to reach a decision on how to analyse the 
data in a manner which is both statistically and clinically appropriate. 
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Figure 5 Pragmatic scenario 
 
Figure 6 Explanatory scenario 
 
Figure 7 Clinically relevant scenario 
8.4.3. Methods 
Thus, given that the intermediary (though most clinically relevant) scenario was not 
statistically valid, the two remaining versions of the analysis of time to 12 month 
remission were carried out, allowing for switching between LTG and VPS; the first 
adjusted for “true” switches, thus censoring at the time of any other treatment changes, 
while the second “pragmatic” switches analysis considered other treatment changes to 
be part of the pragmatic treatment regimens being compared and thus no artificial 
censoring was introduced. Each patient’s maximum censoring was calculated as the 
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difference between their date of randomisation and the known universal final date of 
trial follow up.  
Individuals’ treatment times 𝑇0𝑖  and 𝑇1𝑖  were calculated according to the adjustment 
scenario: when considering the effect of “true” switches, 𝑇0𝑖 (𝑇1𝑖) were calculated as the 
times patients spent receiving VPS (LTG) prior to censoring due to any “illegalities”. 
For the “pragmatic” switches adjustment, 𝑇0𝑖 (𝑇1𝑖) were calculated as the times patients 
spent receiving VPS (LTG) including any time spent receiving additional treatments to,  
or switches from, these drugs (except switches to or additions of the alternative LTG 
(VPS) drug). 
8.4.4. Results 
The frequency of these switches in the VPS and LTG randomised arms is described in 
Table 30, with further detail given in Table 31 and Table 32 regarding the relationship 
between these pragmatic and true switches, and differences between the (censored) 
remission times between the true and pragmatic switches in each treatment arm (due to 
the differential censoring patterns implicit in the definitions of these two types of 
switch). It can be seen that only 60% of the 59 (and 53% of the 34) “pragmatic” 
switches that occurred in the LTG (VPS) arm were eligible to be analysed as “true” 
switches; furthermore 2 (5) of these were censored earlier for the “true” switch analysis 
than for the “pragmatic” switch analysis, because of another treatment change that 
occurred following the “true” switch. Thus these tables describe the effect of artificial 
censoring (due to disallowed events referred to as “illegalities”) necessary for the “true” 
switch comparison.  
   
   
 
304 
 
 
Table 30 True and pragmatic switches between VPS and LTG  
Values indicate number (% of treatment group).  
 LTG (n=218) VPS (n=217) Total (n=435) 
Pragmatic switch  59 (27.1) 34 (15.7) 93 (21.4) 
True switch  36 (16.5) 18 (8.3) 54 (12.4) 
 
Table 33 (Table 34) provides detail on the timing and reason for true (pragmatic) 
treatment changes, broken down according to whether or not patients achieved 
remission. These tables demonstrate that true switches were twice as common (and 
pragmatic switches were nearly twice as common) in LTG compared with VPS patients; 
true (and pragmatic) switches tended to occur earlier in the VPS arm, and these true 
switches were most likely to be triggered by ISC in the LTG arm. 
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Table 31 Summary of switches for LTG arm 
LTG arm (n=218) Total Remission time1 
 Remission time 
(true) = remission 
time (pragmatic)2 
 
Remission/follow up time (true) < remission time (pragmatic) 
i.e. censored early because of other treatment change (not switch) 
 
 Total Remission  
time (true) < 
(pragmatic) switch 
time3 
i.e. treatment change 
occurred prior to 
pragmatic switch 
Remission time (true) = 
(pragmatic) switch time4 
i.e. censoring at 
pragmatic switch time 
(as pragmatic “switch” 
involved adding 
alternative AED) 
Remission time 
(true) > (true and 
pragmatic) switch 
time5 i.e. treatment 
change occurred 
after pragmatic 
switch  
No pragmatic switch 
 
159 132 27 0 0 0 
Withdrew  18    
Added AED 3    
Switched AED 6    
Pragmatic switch 
 
59  34 25 9 14 2 
No true switch 23 0 23 9 14 0 
  Withdrew  4   
  Added AED 5 Added 
AED 
14 (14 VPS)  
True switch  36 34 2 0 0 2 
   Switched AED 2 
1 Note that “remission time” refers to length of follow up for remission (i.e. minimum of time to remission or censoring) 
2 No censoring event occurs before remission time 
3 Censoring event occurs prior to pragmatic switch 
4 Pragmatic switch is censoring event (i.e. involves addition of, rather than switch to, VPS) 
5 Censoring event occurs after (true and pragmatic) switch 
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Table 32 Summary of switches for VPS arm 
VPS arm (n=217) Total Remission time1 
Remission time 
(true) = 
remission time 
(pragmatic)2 
 
Remission time (true) < remission time (pragmatic) 
i.e. censored early because of treatment change after switch  
 
Total Remission 
time (true) < 
(pragmatic) switch 
time3 
Remission time (true) 
= (pragmatic) switch 
time4 
Remission time (true) 
> (true and 
pragmatic) switch 
time5 
No pragmatic switch 183 154 29 0 0 0 
Withdrew  18    
Added AED 6    
(VPS, CNZ, ETH, LVT, 2 
TPM) 
   
Switched AED 5    
(3 VPS, VPS/TPM, ETH)     
Pragmatic switch 34 13 21 8 8 5 
       
No true switch 16 0 16 8 8 0 
  Withdrew  7   
  Switched VPS 1 Added 
VPS 
8 (8 VPS)  
 (LVT)   
True switch  18 13 5 0 0 5 
   Switched AED 2 
      Added AED 2 
     Reintroduced 
randomised AED 
1 
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Table 33 Summary of (time to) remission or censoring according to true switch status 
 LTG  VPS 
 Number (% within 
treatment or 
treatment/switch 
group) 
Time to event 
(median, range) 
Reason for (first) 
treatment change 
Number (% 
within 
switch 
group) 
Time to event 
(median, range) 
Reason for (first) 
treatment change 
       
True switch  36 (16.5) 174.5 (1, 1245)  18 (8.3) 136 (14, 734)  
         
Remission 27 (75.0)  ISC 16 10 (55.6)  ISC 2 
  UAE 7   UAE 5 
  ISC/UAE 4   ISC/UAE 2 
      Pregnancy 1 
Time to switch   182 (20, 790)   135.5 (14, 570)  
Time from switch to remission    373 (244, 1066)   326.5 (162, 1704)  
Time to remission   617 (365, 1819)   475 (365, 1934)  
       
Censoring 9 (25.0)  ISC 5 8 (44.4)  ISC 3 
   UAE 3   UAE 1 
   Other 1   ISC/UAE 2 
       Pregnancy 1 
       No seizures  1 
Time to switch   32 (1, 1245)   158.5 (56, 734)  
       
Time from switch to censoring   449 (55, 1900)   294 (3, 508)  
Time from switch to censoring due to 
other treatment change* 
 
(n=2) 
 
55, 145 
  
(n=5) 
 
335 (40, 508) 
 
       
Time to censoring   1387 (76, 1932)   442 (168, 1063)  
Time to censoring due to other 
treatment change* 
 
(n=2) 
 
76, 150 
  
(n=5) 
 
429 (168, 610) 
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 LTG  VPS 
 Number (% within 
treatment or 
treatment/switch 
group) 
Time to event 
(median, range) 
Reason for (first) 
treatment change 
Number (% 
within 
switch 
group) 
Time to event 
(median, range) 
Reason for (first) 
treatment change 
No switch  182 (83.5)   199 (91.7)   
       
Remission 101 (55.5) 379 (365, 2192)  132 (66.3) 365 (365, 1718)  
       
Censoring 81 (44.5)   67 (33.7)   
Time to censoring   344 (5, 1735)   225 (1, 1840)  
       
Time to censoring due to other  (n=50) 188 (5, 1280) ISC 27 (n=45) 147 (1, 1036) ISC 15 
treatment change*   UAE 13   UAE 17 
   ISC/UAE 3   ISC/UAE 5 
   Pregnancy  1   Pregnancy 6 
   No seizures 4   Patient 
decision  
1 
   Non-
compliance 
1   Non-
compliance  
1 
   Unknown 1     
* i.e. includes only patients whose censoring time was brought forward because of other treatment change. 
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Table 34 Summary of (time to) remission or censoring according to pragmatic switch status 
 LTG  VPS 
 Number (% within 
treatment or 
treatment/switch 
group) 
Time to event 
(median, range) 
Reason for 
(first) 
treatment 
change 
Number (% 
within switch 
group) 
Time to event 
(median, range) 
Reason for 
(first) 
treatment 
change 
       
Pragmatic switch  60 (27.1) 229 (1, 1523)  34 (15.7) 164.5 (14, 1036)  
       
Remission 40 (67.8)   22 (64.7)   
Time to switch  218 (5, 958)   142 (14, 570)  
Time from switch to remission  418.5 (169, 1070)   394 (162, 1704)  
Time from randomisation to remission  686.5 (365, 1819)   724 (365, 1934)  
       
Censoring 19 (32.2)   12 (35.3)   
Time to switch  252 (1, 1523)   225 (39, 1036)  
Time from switch to censoring   960 (151, 1900)   545.5 (3, 1700)  
Time from randomisation to censoring   1539 (678, 2010)   1087.5 (328, 1802)  
       
No switch  159 (72.9)   183 (84.3)   
       
Remission 117 (73.6) 380 (365, 2192)  147 (80.3) 365 (365, 1753)  
Censoring 42 (26.4) 739 (71, 1899)  36 (19.7) 644 (13, 1932)  
       
* i.e. includes only patients whose censoring time was brought forward because of other treatment change. 
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Table 35 demonstrates the degree to which artificial censoring in PP analysis and the 
“true” switches RPSFTM curtail analysis times, as the median (and IQR) of survival 
times drop considerably in the PP analysis (due to censoring at the time of each 
patient’s initial treatment change) and to a lesser degree, as expected, in the “true” 
switches RPSFTM (given that all treatment changes except the “true” switches are 
censored). 
Table 35 Summary of T12mR 
 Treatment 
LTG (n=218) VPS (n=217) 
 No. 
switches 
Median (IQR) No. 
switches 
Median (IQR) 
PP - 488 (365,960) - 370 (365,677) 
ITT - 570 (365, 1162) - 438 (365, 906) 
RPSFTM (true switches) 36 540 (365, 912) 18 371 (365, 733) 
RPSFTM (pragmatic switches) 59 570 (365, 1162) 34 438 (365, 906) 
 
 
Table 36 ITT, PP and RPSFTM analyses for SANAD B VPS vs LTG  
 𝒆𝜷 (95% CI) HR (95% CI)  p-value 
 (LTG:VPS)  
    
ITT 0.88 (0.74, 0.9993) 0.76 (0.63, 0.93) 0.008 
    
RPSFTM  
True switches  
Pragmatic switches  
 
0.85 (0.69, 0.9994) 
0.81 (0.58, 0.9993) 
 
0.70 (0.54, 0.91) 
0.63 (0.44, 0.89) 
 
0.007* 
0.008 
    
PP 0.90 (0.78, 0.9995) 0.74 (0.59, 0.93) 0.009 
* P-value differs from ITT due to censoring at the time of other treatment changes in the “true” switch analysis. 
 
It is interesting to note (in Table 36), first that the AF (𝑒𝛽) and HR differ within the 
same analyses, indicating again that the shape parameter is unlikely to be close to 1; this 
is because the hazard is initially steep (with approximately 30% of patients achieving 
I12mR) and then flattens off. Also, it is noted that the AF for the PP analysis is closer 
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to 1 than the AF for the ITT analysis, whereas the HR for the ITT analysis is closer to 1 
than that for the PP analysis. This apparent anomaly would arise if the baseline hazard 
functions have different shapes in the PP and ITT analyses, thus providing an 
explanation of why the relationship between HR and AF differ between analyses.  
Adjustment for pragmatic (and true) switches in this trial causes the estimated AF (and 
HR) to fall further away from one compared to ITT and PP analyses. The AF is 
interpreted in terms of rate of “using up” survival time; hence these results suggest that 
T12mR is “used up” increasingly slowly (with LTG compared to VPS) from PP to ITT 
to true switch adjustment and finally to pragmatic switch adjustment. In other words, as 
more switches are accounted for, the benefit of VPS becomes increasingly apparent.  
Thus, in summary, although it is important to consider clinical opinion when deciding 
on how to approach causal estimation, the clinically relevant causal scenario in this trial 
did not provide a valid basis on which to perform statistical assessment, thus requiring a 
compromise in approach. Although the “pragmatic” switch scenario requires less 
artificial censoring (and hence is less biased than the PP or “true” switch equivalent), it 
addresses a less clear cut clinical question, distinguishing only between randomised 
(VPS and LTG) treatments, rather than accounting for any the impact of any other trial 
(or non-trial) treatments. The “true” switch scenario is more precise but results in a 
large amount of censoring (due to other treatment changes occurring before legitimate 
treatment switches or end of event follow up).  
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8.5. Discussion 
8.5.1. Honey trial 
When interpreting results from the RPSFTM, it is necessary to consider the suitability 
of the assumptions underlying use of the acceleration factor in the RPSFTM; first, it is 
assumed that the effect of treatment is immediate and there is no carryover effect from 
previous treatment received. This is likely to be true in the honey trial; although it may 
be possible that treatment effects extend for a short while beyond the time of treatment, 
and that treatments take some time before becoming clinically effective, the extent of 
delayed or extended treatment effects is not likely to be substantial in this context. The 
model also assumes that the causal effect is attributable directly to the actual treatment 
received, rather than to any effect caused by switching treatments. However, in this 
clinical area, it is not likely that the act of switching treatments will cause a biological 
reaction beyond the actual effect of treatment. The constant treatment effect implied by 
a single acceleration factor may however be contravened in this setting; although 
switches do not occur solely at a fixed clinically defined point (such as disease 
progression), they are most likely to occur when prognosis with randomised treatment 
appears poor. As such, the effect of treatment received at randomisation may differ 
from that of treatment received at the point of switch (when wounds are likely to have 
deteriorated). 
Thus, in theory, the ability to assess the impact of time-dependent treatment changes on 
the time to the event of interest without needing to make any assumptions about the 
relationship between a patient’s baseline prognosis and their actual treatment would 
suggest that the RPSFTM would be especially useful in the honey trial, as the treatment 
switches in this trial were often informative and related to prognosis. Patients who 
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discontinued treatment because they were disappointed not to have received honey 
were unlikely to have been experiencing healing success with their conventional 
treatment. Conversely patients randomised to conventional treatment who were 
switched to receive honey by external clinicians were often younger, fitter patients who 
were expected to do well with honey, and thus these switches were related to prognosis 
also.  
However, the restriction of the RPSFTM to a single causal contrast (comparing 
conventional and honey dressings only) meant that, in the same way as for the other 
analysis sets, all treatment changes other than direct switches between randomised 
treatment arms needed to be censored in the RPSFTM analysis, even though such 
censoring is likely to be informative and may therefore introduce selection bias. For 
example, censoring patient follow up when wound deterioration necessitated more 
extreme treatment options (such as surgery, radiotherapy or antibiotics) introduces bias, 
as these wounds are not typical of all the wounds in the trial at the point of censoring.  
The need for such censoring would be removed if the time spent on alternative 
treatments (to conventional or honey dressings) could be incorporated into the causal 
contrasts (𝑇0𝑖  and 𝑇1𝑖 ), but this would then change the interpretation of the causal 
research question being addressed by the RPSFTM. For example, if the time 𝑇0𝑖 instead 
included all the time spent on all alternative treatments (including the more extreme 
options such as surgery), this (at least in theory) would remove the need to censor 
follow up at these alternative treatment changes; however the interpretation of the 
causal estimand would change, as the RPSFTM would instead compare honey to all 
other (minor and major extremes of) treatment, ranging from conventional wound 
dressings to surgery, which is not likely to be a clinically sensible contrast.  
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Furthermore, given that the trial staff were often unable for practical reasons to 
continue following up patients who experienced treatment changes other than simple 
switches to the alternative trial treatment, corresponding healing times were typically 
unavailable following such switches; as such, the lack of follow up data due to practical 
reasons meant that it would not have been possible to account for the causal effect of 
such deviations from treatment protocol even if this alternative causal question (or 
indeed a more complex RPSFTM model involving more than one causal contrast) was 
practicable. 
The extent of this bias is demonstrated by the use of a sensitivity analysis censoring 
patients at the longest possible follow up time when they received extreme forms of 
treatment due to severity of their condition, reflecting the fact that they would 
otherwise have been unlikely to experience healing during the trial follow up. This 
sensitivity analysis had a similar impact on the treatment effect estimates as the 
RPSFTM adjustment, demonstrating the impact of this informative censoring is similar 
to that introduced by switches between randomised treatments.  
8.5.2. SANAD 
Similar considerations are necessary for the evaluation of the use of RPSFTM in 
SANAD as for the honey trial, in particular concerning the underlying assumptions 
regarding the effect of treatment as specified by the model. For example, the simple 
RPSFTM implies that the impact of treatment is immediate and constant, without any 
carryover effect or inherent effect attributable to (the act of) switching.  
The validity of these assumptions again depends on the clinical scenario. Thus, in 
SANAD B, it may be more appropriate to introduce lagged coefficients to allow for the 
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likely reduced effect of treatment during the titration phase, or a coefficient that 
decreases with time from the start of the withdrawal phase (as discussed for the MRC 
trial by White (89). It may be necessary to allow for the overlapping phases of treatment 
withdrawal (from randomised drug) and loading (of alternative drug) when patients are 
receiving two treatments (even though they are technically experiencing a treatment 
switch). Also the very act of switching treatment, regardless of the actual treatments 
involved, could potentially be a trigger for seizures, such that the switch is having a 
causal effect independently of treatment. To investigate whether this was the case, it 
would be necessary to test the significance of an indicator variable for treatment 
switches in the causal model. Furthermore, it is important to consider the impact of 
recensoring, in particular whether recensoring is likely to influence overall estimated 
treatment effects (if, for example, there is a treatment-time interaction, such that 
recensoring of late events causes a distortion in the estimated overall treatment effect). 
However the greatest concern regarding the use of the RPSFTM in the context of 
SANAD B relates to the complexities introduced by the T12mR outcome. In particular, 
as introduced briefly earlier, the RPSFTM fails to recognise two key features of T12mR. 
 
Figure 8 SANAD outcomes 
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First, by definition, 12 month remission cannot occur before 12 months, representing a 
discontinuity when modelling the effect of treatment. Secondly, a substantial proportion 
of patients are expected achieve I12mR, resulting in a large peak of events occurring at 
12 months (for example, in SANAD B, 28.4% (41%) of LTG (VPS) patients achieved 
I12mR). In order to accurately represent these data, the estimated AF from the 
RPSFTM would therefore need to be able to predict a very high event rate at 12 months 
with truncation of this treatment effect immediately prior to 12 months, which is not 
possible given the assumption of constant treatment effect. 
One solution to this would be to simply bring the event time forward by 12 months and 
instead analyse the time to the start of 12 months remission, equivalent to 𝑡 − 12. This 
simple transformation of event times would mean that the event could then occur at 
any time from randomisation onwards. However, this may introduce problems from a 
philosophical point of view, as one is technically analysing an outcome that occurs in 
the future: at the start of a period of 12 months remission, one does not actually know 
that, during this period, the patient will be seizure free. 
The RPSTFM would be used to adjust for the effect of treatment switches on time to 
start of achieving delayed 12 month remission (in other words, time to start of achieving 
12 month remission, conditional on not having achieved it by 12 months), estimated in 
only those patients who did not achieve I12mR. However, this model would also be 
complicated by the shift along the time axis (𝑡 − 12), given that the first 12 months of 
follow up not only regarding outcome but also treatment would no longer be considered 
in the model; in other words, the clock would start at 12 months for the time-
dependent treatment covariate as well as outcome.  
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It would not be appropriate to simply disregard the treatment received during the first 
12 months following randomisation, as this period importantly reflects the short- to 
medium-term tolerability of AEDs, during which treatment changes are common: for 
example, in the LTG arm, 45/59 (76.3%) of treatment switches (to VPS) occurred 
within the first 365 days, of which 40 occurred in patients with remission (or censoring 
time) beyond 1 year, whereas in the VPS arm, 25/34 (73.5%) of treatment switches (to 
LTG) occurred within the first 365 days, of which 18 occurred in patients with 
remission/censoring time beyond 1 year. 
It may at first seem possible to address this problem by including a summary measure 
of compliance until first seizure (or until 12 months, if the patient achieved I12mR) as a 
time-fixed rather than time-varying covariate (for example, by including a baseline 
variable “proportion of first 12 months spent on randomised treatment”) and then use 
a time-varying binary treatment covariate from 12 months onwards. However, this 
would introduce bias, given that this post-randomisation summary compliance variable 
is very likely to be related to prognosis. Instead, a time-varying summary measure of 
treatment receipt (such as the proportion of the previous 12 months that the patient 
was on randomised treatment) could be included in the RPSFTM as a time-varying 
indicator of treatment, thus capturing treatment information from the time of 
randomization. However, this introduces practical problems, as the RPSFTM software 
(in Stata) currently can only utilise binary treatment factors (although there are plans to 
extend the program to accommodate other forms of treatment variable in the near 
future).  
Furthermore, bringing forward the analysis time by 12 months would introduce another 
complication, namely that those with an I12mR (as well as those patients who were 
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censored with less than 12 months of follow up) would be excluded from the analysis 
(as their 𝑡 − 12   analysis time would be less than or equal to 0). Given that 
approximately 30% of newly diagnosed epilepsy patients achieve I12mR, this would 
result in a considerable loss of information and the model results would provide no 
information on this important class of patients. Although it would be possible to add on 
a small fraction of time (say 0.5 days) to these “0” event times to ensure that these 
patients are included in the analysis, this would reintroduce the problem concerning the 
peak in the number of events at this time, which cannot be accurately represented by 
the RPSFTM.  
An alternative solution would be to consider a mixture modelling approach, excluding 
those patients with I12mR from the RPSTFM and instead including them (along with 
all of the other patients) in an appropriate (causal) version of logistic regression to 
assess the effect of treatment on achieving I12mR.  
However, causal analysis of the simplified binary outcome I12mR is not 
straightforward, as compliance remains time-dependent despite the simplification to a 
binary outcome; therefore it is not appropriate, for example, to use the method of 
Sommer and Zeger (91), which instead assumes all-or-nothing compliance. Instead the 
method must in some way account for different treatments received within the first 12 
months of follow up (if immediate remission was achieved) or until the time of the first 
seizure (if a seizure occurred within 12 months of randomisation); treatment 
information following the first seizure (or 12 months, whichever occurs first) is 
irrelevant as it has no causal impact on achieving (immediate 12 month) remission.   
There is, however, no obviously appropriate method to assess binary outcome (I12mR) 
with a time-dependent treatment covariate that reflects treatment receipt only up to 
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time of time seizure. For example, the general structural mean model (GSMM) 
proposed by Vansteelandt (146) accommodates time-dependent compliance with binary 
outcomes, but this method assumes no switches from the control to experimental arm, 
which is invalid in this setting. Thus, although it would have been interesting to 
consider mixture modelling, given that the treatment switch variable is time dependent, 
it is likely to be overly complicated to implement such a method for these data.  
8.5.3. Conclusion 
The exploration of the RPSFTM in this chapter has highlighted its limitations when 
applied to complex trial scenarios, most notably the problems associated with multi-way 
randomisation and numerous forms of treatment deviation, given that the model is 
likely to become unstable with inclusion of more than one treatment covariate. 
Furthermore, the assumptions relating to the estimated AF do not match the 
characteristics of the remission outcome. Given that these complicating features are 
likely to be typical of trials in clinical areas subject to deviations from long term 
treatment of chronic disease, it would be useful to consider alternative methods of 
analysis for adjusting for such deviations when analysing survival outcomes. 
In particular, for the SANAD trial, the main problems with the application of RPSFTM 
related to the irregular distribution of event times at 12 months (the discontinuity of 
events before 12 months coupled with a peak of events at 12 months) and bias 
introduced by censoring of treatment changes other than direct switches between 
randomised treatments. As such, in light of these limitations in applying RPSFTM in 
these two trials, the next chapter will consider the use of an alternative approach to 
causal estimation for this complicated trial scenario, based on observational 
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methodology of inverse probability weighting rather than the counterfactual framework 
employed by the RPSFTM.  
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9. Novel application of IPCW 
methodology  
9.1. Introduction 
As seen in the previous chapter, the RPSFTM suffers from a number of major 
limitations when applied to analysis of T12mR in the complex SANAD trial scenario. In 
this chapter, an alternative method suitable for survival outcomes, but based on 
observational techniques rather than randomisation, will be considered, namely the 
IPCW method.  
The IPCW has the advantage over the RPSFTM in being more able to handle a variety 
of types of treatment changes, rather than simply dealing with a single type of treatment 
change. We will see how this added scope means that the IPCW is able to differentiate 
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between different reasons for treatment change, and more readily answer clinical 
questions of interest. 
The IPCW overcomes problems of a standard time-dependent treatment Cox model by 
adjusting for TVCs externally to the outcome model through their impact on treatment 
probability weights. In this chapter we will consider the fundamental issues of IPCW, 
the assumption of NUC in the presence of numerous potential confounders, of which 
some are complicated TVCs changing on a daily basis for some patients.   
9.2. Methods 
The IPCW method recognises the fact that any change from randomised treatment will 
likely lead to distorted event times which do not accurately reflect the experience of 
patients without such treatment changes. Thus, in the context of a randomised 
controlled trial with a survival outcome, the IPCW can be used to adjust for changes 
from randomised treatment by artificially censoring patients at the point of the first of 
any (relevant) treatment change. The potential bias introduced by this censoring is 
removed if one is able to make the assumption of NUCs, in other words, all variables 
which predict both the occurrence of treatment change and of the outcome event of 
interest, in this case 12 month remission, have been accurately recorded and are 
available for analysis. The time to treatment change is typically modelled separately for 
each treatment arm, as the effect of each confounder may differ according to treatment. 
The probability of remaining uncensored (i.e. not experiencing a treatment change) at 
each time point and for each patient is estimated from this treatment-specific model, 
dependent on their values of the variables included in the model. The inverse of these 
probabilities are then used to weight the analysis of the time to outcome event, which 
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must also be adjusted for all the baseline covariates. The reasoning behind this 
methodology is that, if one is able to determine all factors that jointly predict treatment 
change and outcome, weighting up the analysis of time to outcome (by the probability 
of remaining uncensored), while censoring at the point of any treatment change, assigns 
appropriate weight to individuals who remain uncensored to account for loss of those 
previously censored who share their same characteristics. Given the assumption that all 
predictors of the outcome have been included in the model, this weighting provides a 
pseudo-population that mimics the same likelihood of occurrence of outcome events 
that would have been observed if none of the patients’ follow up had been censored 
due to treatment changes.  
The IPCW analysis procedure therefore involves three main stages, to be described 
here, before considering their practical application in the SANAD arm B comparison of 
LTG versus VPS comparison on T12mR. 
9.2.1. Step 1: Fitting the weight determining (WD) model 
First, it is necessary to identify the important baseline and time-varying covariates that 
predict both switching and outcome. If the pool of potential confounders is large, it 
may be necessary to use some form of variable selection process, to avoid the 
possibility of overfitting the model (leading to model instability due to a low event per 
variable (EPV) ratio) and including variables that are correlated with each other. 
With time-varying covariates, it may be helpful to set up panel data, for example (as in 
SANAD) if the covariates are updated on a daily basis for some patients (for example, 
for those with multiple daily seizures) and it would be too complicated to adjust for 
covariates changing on a daily basis. These panel data are created by partitioning each 
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patient’s follow up data into intervals of fixed length, with TVCs which are valid at the 
start of each interval (e.g. seizure counts for month 𝑛 equal the total up to the end of 
month 𝑛 − 1). 
The probability of remaining uncensored (in other words, not experiencing treatment 
change) at each follow up time point, given these covariates, is then estimated for each 
patient using the weight determining (WD) model, either a Cox model for time to 
(first) treatment change or pooled logistic regression (PLR) for the discretised interval 
data with treatment change as the dependent variable.  
It may be more practical to use a discrete time model (based on logistic regression) 
rather than a model assuming continuous event follow up (survival model) to estimate 
the probability of remaining uncensored, not only when the TVCs are necessarily 
discretised into intervals (and therefore naturally lend themselves to discrete time 
analysis) but also because weight determination analysis with TVCs result in weights 
that vary within individual over time. Unless the statistical software can allow for 
within-individual time-varying weights in Cox regression, normal standard errors (SEs) 
from the Cox model (ignoring the patient identifier in the analysis) will be inaccurate 
and it will be necessary to implement bootstrapping (BS) for valid confidence interval 
(CI) estimation.  
Pooled logistic regression  
Therefore, as an alternative to the Cox model (using BS CIs), it may be helpful to 
instead consider applying the variety of logistic regression known as pooled logistic 
regression (PLR), in which follow up time is split into uniform short time intervals such 
that LR can be performed independently in each interval (183). If follow up time is 
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discretised into sufficiently short time periods such that the probability of event within 
each interval remains low (less than 10%), logistic regression (LR) approximates Cox 
model well, so that the estimated HR within each interval can be estimated from the 
odds ratio (OR) obtained from LR (184). Each observation interval (of equal length) is 
in essence a mini follow up study in which the current risk factor measurements are 
used to predict the probability (𝑝) of event of interest in the interval among patients at 
risk of the event at the start of the interval; thus the probability of not experiencing the 
event (1 − 𝑝) can be calculated for each interval. The cumulative probability of not 
experiencing the event by each time point (mimicking the estimated survival 
probabilities at each follow up time obtained from the Cox model) are obtained by 
simply multiplying the (1 − 𝑝) estimated for the current and all previous intervals, 
leading to the term pooled logistic regression (PLR). 
Therefore, if PLR is used, the cumulative probability of remaining on assigned 
treatment is calculated by multiplying a patient’s predicted probability of remaining 
uncensored in the current time interval by all their previous time intervals’ estimated 
probabilities of remaining uncensored. These probabilities are then used to determine, 
for each patient 𝑖 at each time point 𝑘, their probability of remaining under randomised 
treatment (in other words, their probability of not experiencing a treatment change and 
therefore remaining uncensored).  
Note that, regardless of choice of WD model, it is advisable to calculate the 
probabilities of censoring separately for each randomised treatment group, as the 
influence of covariates on the probability of treatment changes are likely to differ 
according to treatment. As such, separate WD models should be created for each of the 
randomised treatment groups separately.  
   
   
 
326 
 
Bootstrapped CIs 
The incorporation of weights has been shown to reduce SEs (185) (186). Thus bias 
results when standard methods as used for CI estimation as they regard the weights as 
fixed, whereas non-standard methods (such as bootstrapping) can explicitly allow for 
the estimation of the weights, reflecting more accurately the associated reduction in 
variability. Thus, it may be advantageous to use bootstrapping for CI estimation 
regardless of the choice (between Cox or PLR) of WD model, in order to appropriately 
account for the reduction in SE estimates as a result of the weight estimation process. 
Splines necessary for PLR  
When using PLR in place of a Cox model, one needs to consider how best to model the 
underlying baseline event rate. In order to mimic the underlying hazard function of Cox 
regression, while avoiding the need for a separate intercept term for each interval in 
PLR, spline variables can be used to allow the underlying risk of the event to vary from 
interval to interval (187). (Although penalised splines are another popular choice that 
would have been suitable in this context, these were not considered here, as they require 
specialised software and are thus less generally applicable for wider use by non-experts.)  
The simplest example of a spline function is a linear spline function, such that each 
section between each pair of knots consists of a linear function. For example, with three 
knots at positions a, b and c, the linear spline function would be defined as 
𝑓(𝑋) = 𝛽0 + 𝛽1𝑋 + 𝛽2(𝑋 − 𝑎)+ + 𝛽3(𝑋 − 𝑏)+ + 𝛽4(𝑋 − 𝑐)+ 
where (𝑢)+ = {
𝑢, 𝑢 > 0,
0, 𝑢 ≤ 0.
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In practice, linear splines are overly simple and are not smooth; instead, cubic 
polynomials are more suited to modelling curving distributions. In order to ensure that 
such splines are smooth at the joining positions (i.e. at each knot), the first and second 
derivatives of these functions are forced to agree at each knot position. Furthermore, in 
order to overcome the potential problem of irregular behaviour of such splines in the 
tails of the distribution (i.e. preceding the first knot and following the last knot) due to 
sparse data, restricted cubic splines which constrain the function to be linear in these tails, 
are recommended, with the additional advantage of requiring estimation of only (𝑘 − 1) 
parameters (instead of the usual 𝑘 + 3  parameters required for unrestricted cubic 
splines) (187). A restricted cubic spline with 𝑘 knots 𝑡1, 𝑡2, . . , 𝑡𝑘 is defined by 𝑓(𝑋) =
𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + ⋯ + 𝛽𝑘𝑋𝑘−1, where 𝑋1 = 𝑋 and for 𝑗 = 1,2 … , 𝑘 − 1, 
𝑋𝑗+1 = (𝑋 − 𝑡𝑗)+
3
− (𝑋 − 𝑡𝑘−1)+
3
(𝑡𝑘 − 𝑡𝑗)
(𝑡𝑘 − 𝑡𝑘−1)
+ (𝑋 − 𝑡𝑘−2)+
3
(𝑡𝑘−1 − 𝑡𝑗)
(𝑡𝑘−1 − 𝑡𝑘−2)
 
In order words, for restricted cubic splines, variables are created equal to the positive 
part of (𝑥 − 𝑘1)
3 , (𝑥 − 𝑘2)
3 , (𝑥 − 𝑘3)
3  but with restrictions imposed to ensure 
linearity in the tails (i.e. for 𝑥 < 𝑘1 and 𝑥 > 𝑘3). 
Placing knots at fixed percentiles of each covariate is recommended, thus ensuring 
sufficient data points within each interval and preventing undue influence from outliers 
on the choice of knot location. For example, for 𝑘 = 3, knots may be placed at the 10th, 
50th and 90th percentiles; for 𝑘 = 4, knots may be placed at the 5th, 35th, 65th and 95th 
percentiles; and for 𝑘 = 5, knots may be placed at the 5th, 27.5th, 50th, 72.5th and 95th 
percentiles. Durrleman (188) demonstrated that results are generally insensitive to the 
location of knots unless they are placed in particularly non-uniform locations (for 
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example at 25th, 75th, 90th, 95th and 99th percentiles). However, if the hazard is likely to 
change shape or be particularly changeable at a certain time, one or more knots may 
need to be placed near these change points (187). 
The number of knots can impact on the EPV ratio, as a spline with 𝑘 knots will require 
(𝑘 − 1) parameters, in addition to the coefficient for the linear time variable (which 
necessarily accompanies the spline variable) (thus adding 𝑘 knots in all). When choosing 
the number of knots to be used when fitting a spline, one should aim for balance 
between allowing sufficient flexibility without overfitting the model to the data, which 
leads to loss of precision (189). Stone suggests that between three and five knots will 
usually be adequate, depending on number of events (in the case of logistic or Cox 
regression).  
The number of knots to use for the time spline variables must therefore be considered 
in light of the number of other variables included in the WD model and relative to the 
number of treatment change events, in order to avoid overfitting the model. If data are 
available on numerous potential confounders, some of which may be correlated, it may 
be necessary to impose some form of selection procedure in order to cut down the 
number of variables in the model. 
These spline variables are created in Stata using the command spbase: 
centile m if treat_num==0, centile(5(45)95) 
spbase m if treat_num==0, gen(m_spline_LTG) knots(1, 9, 34) 
 
centile m if treat_num==1, centile(5(45)95) 
spbase m if treat_num==1, gen(m_spline_VPS) knots(1, 9, 30) 
 
* combine splines into one variable 
forvalues i = 1(1)3 { 
 gen m_spline_`i' = m_spline_LTG`i' if treat_num == 0 
 replace m_spline_`i' = m_spline_VPS`i' if treat_num == 1 
} 
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forvalues i = 1(1)3 { 
 rename m_spline_LTG`i' original_m_spline_LTG`i' 
 rename m_spline_VPS`i' original_m_spline_VPS`i' 
} 
 
Selection of variables 
Some advocate not using any selection procedure to determine which covariates to 
include as confounders in the models of time to treatment change and time to event, 
but instead to include all covariates that are considered to be clinically important (151). 
The justification for this approach is to ensure that no important confounders are 
excluded on the basis of the chosen selection procedure, especially if the selection of 
variables depends on their statistical significance in predicting these events, as there may 
be insufficient power in the dataset to demonstrate such significance.  
However there is a danger that including too many covariates which are not correlated 
with outcome may introduce more uncertainty into the analysis results (specifically very 
variable weights), rather than the intended opposite of reducing variability. Thus, 
although it may therefore be tempting simply to adjust for all known baseline and time-
varying covariates, the inclusion of variables that do not predict both outcome and 
remission will lead to spurious results. Furthermore, there is a danger of overfitting the 
model if too many variables are included, leading to model instability (manifested by 
very large coefficients and SEs) due to low EPV ratios (190).  
Therefore, in aiming for the most parsimonious model that still explains treatment 
changes, it may be deemed necessary to use a variable selection process to determine 
which of the many measured covariates should be adjusted for in this model. The 
selection of variables for inclusion in a model is usually determined by p-values of 
potential variables in the model. There are, however, a number of reasons why this 
would not be an appropriate selection method for this model. 
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Although both time-varying covariates and baseline variables need to be included in the 
WD model, the WO model only includes baseline variables that predict remission, in 
order to increase power. Confounding due to TVCs has been eliminated via weights, 
simulating a balanced RCT, and explicitly adjusting for the TVCs in the model would 
introduce bias. As such, there are no p-values generated for the TVCs in the WO 
model. 
Furthermore, as discussed above, the SEs (and hence the p-values) from the weighted 
PLR model of time to remission and from the Cox model (in particular) are invalid; 
thus bootstrapped SEs must be constructed. If the selection procedure relied on p-
values, it would be necessary to bootstrap the entire selection procedure, adding to the 
complexity of the selection procedure beyond what would be feasible.  
Therefore it is advisable to use an alternative method, which assesses the change in 
treatment effect HR from WO Cox model (or odds ratio (OR) if using PLR) when each 
potentially confounding variable is included (if using forward selection) or excluded (if 
using backward selection) from the IPCW model, using a relatively small threshold 
(suggested maximum of 10%) to determine whether each variable should be included. 
For example, when using backward selection, if exclusion of the variable (from the WD 
model) causes the treatment effect HR (in the WO model) to change by more than 10% 
(also known as the CHEST (CHange in ESTimate) criterion), the variable would be 
retained (191).  
Practical considerations for this selection process include the choice of threshold for 
inclusion of covariates, choice of whether to use forward or backward selection 
procedures and the inherent reliability of the selection procedure, in terms of EPV 
ratios. 
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9.2.2. Step 3: Creating stabilised weights  
The WD model is then used to provide time-dependent stabilised weights, which are 
created for each patient 𝑖 at each time point 𝑘  during which they remain under 
randomised treatment, derived from the inverse of their estimated probabilities (of 
remaining uncensored). As described in Chapter 5, two separate WD models are in fact 
required in order to generate these stabilised weights: the first WD model adjusts for 
baseline characteristics only, whereas the second WD model adjusts for both 
baseline and time-dependent covariates. Stabilised weights for each time interval are 
calculated as the ratio of the cumulative probability of remaining uncensored (due to 
treatment change) from randomisation until (the end of) that interval given only 
baseline covariates (in other words, using estimated probabilities from the first WD 
model) divided by the corresponding probability given both baseline and time-
dependent covariates (using estimated probabilities from the second WD model).  
For example, the numerator of the censoring weights 𝑊𝑘  at time point 𝑘  (where 
subscript 𝑖 denoting individual is dropped for simplicity) could be estimated, using a 
PLR model applied separately for each treatment arm (𝑍) to determine the likelihood of 
remaining uncensored at time 𝑘  dependent on baseline covariates 𝑋0 :  Pr [𝐶𝑘 =
0|𝐶?̅?−1 = 0, 𝑋0 = 𝑥0, 𝑍 = 𝑧]. Similarly, the denominator of the censoring weights 𝑊𝑘 
would be estimated, again separately for each treatment arm, using a PLR model to 
determine the likelihood of remaining uncensored at time 𝑘 dependent on baseline and 
time-varying covariates valid at the start of time period 𝑘 (i.e. ?̅?𝑘−1): Pr [𝐶𝑘 = 0|𝐶?̅?−1 =
0, ?̅?𝑘−1 = ?̅?𝑘−1, 𝑍 = 𝑧].   
These estimated probabilities are then used to produce the following stabilised weights  
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𝑊𝑘 =
Pr [𝐶𝑘 = 0|𝐶?̅?−1 = 0, 𝑋0 = 𝑥0, 𝑍 = 𝑧]
Pr [𝐶𝑘 = 0|𝐶?̅?−1 = 0, ?̅?𝑘 = ?̅?𝑘, 𝑍 = 𝑧]
 
Therefore each individual only contributes observations for the time points during 
which they remain under their assigned treatment protocol (after which 𝐶𝑘 = 1). 
Once these weights have been created, it is necessary to check their distribution to 
identify any extreme weights, which may occur for a number of reasons. Firstly, if the 
majority of patients in a given subgroup (defined by the cross-classification of the 
baseline and time-varying covariates included in the WD model) change treatment, the 
remaining patients will be assigned very large weights to account for the huge loss of 
information from all other patients in this subgroup. Extreme weights will also result if 
an incorrect functional form for covariates is specified in the WD model, as predictions 
of probabilities are then based on an incorrect relationship between each covariate and 
the outcome.  
9.2.3. Step 3: Fitting the weighted outcome (WO) model  
Once any problems regarding weights have been addressed, the stabilised weights are 
applied to the WO model of time to outcome event, regressed on randomised treatment 
group and baseline covariates only and artificially censoring patients when they deviate 
from their assigned treatment.  Thus this weighted outcome (WO) model (Cox 
model or PLR) is fit to the randomised group data, applying the time-dependent 
patient- and interval-specific stabilised weights to the outcome data, with patients who 
change treatment being assigned a weight equal to 0 (i.e. inducing censoring) in all 
intervals after treatment change.  
   
   
 
333 
 
As for the WD model, when the probability of the outcome event in each time interval 
is relatively small, the cumulative probability of remaining uncensored (obtained by 
multiplying each person’s estimated probabilities for each successive month of follow 
up) estimated using PLR will be approximately equal to the probability obtained using a 
Cox model (183). 
The randomised treatment indicator and baseline covariates included in the WD model 
are included as covariates in the WO model, but the time-dependent covariates are not 
included, given that their influence has been removed via the weighting process; indeed 
adjusting for TVCs in the WO model would introduce bias as would any standard 
analysis regressing on TVCs. Note that, if the analysis plan specified that no baseline 
variables were to be adjusted for in analysis, the first “baseline only” WD model 
(providing the numerator of the stabilised weights) would include no covariates; in 
other words, for such an unadjusted WO model, it would be necessary to simply apply 
the unstabilised weights = 
1
Pr [𝐶𝑘+1=0|?̅?𝑘=0,?̅?𝑘=?̅?𝑘,𝑍=𝑧]
 . 
9.3. Application of IPCW to SANAD B 
SANAD is an example of a trial with dynamic treatment regimens, in which, following 
random assignment of initial treatment, a patient’s prescribed treatment over the course 
of the trial may vary depending on the patient’s evolving prognosis (118). When 
defining the causal research question for such a trial, it may not be clinically sensible to 
ignore the underlying reasons for these changes, for example, as for a simple 
comparison of “always treated” versus “no treatment” contrasts, which adjusts for all 
observed treatment changes. Instead a more precise causal contrast may be more 
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appropriate, given that some treatment changes are inevitable and therefore it may not 
be relevant to factor them out of causal estimation.  
The ability to account for all treatment changes in the IPCW model (rather than simply 
treatment switches, as in the RPSFTM) provides added scope to extend investigation to 
consider the underlying reasons for treatment changes, and thus more adequately address 
the clinical question of interest.  
Thus, it was necessary to consider how the treatment effect estimated by the IPCW 
model is directly linked to causal question of interest through the adjustment of relevant 
competing forms of treatment change. 
9.3.1. Reasons for treatment changes  
When considering the reasons for treatment change in SANAD, in contrast to the 
RPSTFM, which was only able to adjust for treatment switches between randomised 
treatments, the IPCW is able to adjust for all varieties of treatment changes, of which 
there are many. Adjustment for all types of treatment changes answers a slightly 
different research question from that which was answered by the RPSTFM, by 
providing an estimate of the relative treatment effect between treatments that would 
occur in the absence of any departure from randomised AED. 
Furthermore, in contrast to treatment changes which occur prior to the TFS (which are 
primarily due to unacceptable adverse events (UAEs) associated with randomised drug), 
treatment changes prior to a period of 12 month remission may occur for a number of 
competing reasons, most commonly UAEs or ISC. These events are inversely related 
via dose: as dose increases, seizure control is likely to improve but adverse effects may 
well increase. Withdrawal due to UAE was largely limited to early post-randomisation 
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period, and withdrawal due to ISC was generally later because upward titration of dose 
took place before clinicians decided to withdraw patients due to ISC. 
Although there is interest in the causal efficacy of treatment generally (obtained by  
adjusting for all treatment changes), clinicians are primarily interested in adjusting for 
switches that occurred due to ISC rather than because of UAEs. The argument follows 
that it may be possible to reduce the incidence of treatment changes due to ISC by 
persevering with the treatment and applying more appropriate dosing (incrementally 
increasing dose until seizure control is achieved) whereas the issue of UAEs is less easily 
solved without appropriately ameliorating drugs. Thus, given that it is unlikely that 
genetic testing will develop sufficiently to allow identification of patients who will be 
able to tolerate such AEs, adjustment for this cause alone isn’t a relevant clinical 
question. Instead the causal treatment effect estimate of primary interest to clinicians is 
that which adjusts for switches occurring due to ISC alone (private discussion with 
Marson, Smith 2012).  
Competing risks approach 
Given the medical interest in the competing reasons for treatment change, it may seem 
natural to consider adjustment for multiple causes of treatment change using a standard 
competing risks approach (as demonstrated by (151)), whereby each patient’s follow up 
is censored at the time of the first treatment change, with separate weights being 
calculated for each of the (first occurring) different competing reasons for treatment 
change. These weights can then be applied in separate analyses (to adjust for each type 
of treatment change independently of the others) or combined into overall weights by 
simple multiplication (under the assumption that the covariates in the model remove 
any association between these weights) (151).  
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Indeed, in the analysis of time to treatment withdrawal, it is relevant to consider 
competing reasons for treatment change, as the effect of ISC and UAE may compete, 
cancelling out the effect of a certain treatment on outcome (192). However when 
considering adjustment for treatment change, the question of whether to adjust for 
treatment changes occurring for different reasons instead directly relates to the 
relevance of these treatment changes to the causal research question. Thus, rather than 
applying standard competing risks methodology to the context of IPCW modelling 
(151), it was deemed more appropriate to approach this investigation into the effect of 
different reasons for treatment change using a sequence of IPCW analyses, determined 
according to the relative clinical importance of each reason.  
This alternative approach was possible primarily due to the luxury provided by this data 
set, such that follow up generally continues beyond the point of each treatment change; 
therefore, it was not automatically necessary to censor patient follow up at the point of 
the first treatment change. As such, if a particular form of treatment change was not 
relevant to the causal research question being investigated, the treatment change could 
simply be ignored without introducing any informative censoring; for example, if 
considering what the causal effect of treatment would be in the absence of treatment 
changes due to ISC alone, none of the other treatment changes would be adjusted for in 
the weighting or outcome model. 
Sequential analyses according to reasons for treatment changes 
Thus, an alternative, more appropriate approach to adjusting for different reasons for 
treatment changes in this context was to consider a sequence of analyses, adding 
different reasons for treatment changes sequentially according to clinical importance. 
Therefore, as adjustment for reasons related to ISC was of primary interest in SANAD, 
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this was the first reason for treatment change included in the hierarchy. Then, assuming 
that it would be easier to persuade a patient to remain on treatment when they are 
considering changing treatment for reasons of personal choice (for example, due to 
non-compliance or potential to become pregnant), this was the second reason added to 
the hierarchy, with the final analysis including all treatment changes (in other words, 
including UAEs also, which is considered the least easily or ethically altered treatment 
change).  
Analysis mimicking ITT was also possible, in other words, one that adjusts for no 
treatment changes at all and thus requires no weight estimation. Furthermore, the 
possibility of carrying out an additional analysis, similar to an ITT analysis but which 
allows for the possibility of informative censoring due to LTFU, was considered. The 
probability of such censoring can be modelled in a similar way to the probability of 
treatment change, using the appropriate baseline and time-varying covariates in a PLR 
or Cox model; the inverse probability of censoring weights can be multiplied by the 
inverse probability of treatment change weights in order to obtain an overall weight to be 
used in the model of time to 12 month remission. (The validity of simply multiplying 
these weights to obtain an overall weight holds if one is able to assume that inclusion of 
the baseline and time-varying covariates in the model removes the dependence between 
these two events, censoring and treatment change.) This analysis would provide an 
estimate of the expected treatment effect if no informative censoring had occurred. 
In the context of SANAD, however, although it would have been interesting to 
investigate the effect of censoring (of time to remission) that occurred as a result of 
LTFU, non-epilepsy-related death or withdrawal of consent (collectively referred to as 
LTFU), such an analysis was not possible, as there were very few patients who were 
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censored prior to remission or treatment change. Thus it was not feasible to reliably 
model separate weights for the probability of treatment change versus censoring. 
However, as there were very few censoring events, any associated bias due to this 
censoring is unlikely to unduly influence the overall results. Instead, therefore, given 
that the ITT analysis assumes that censoring is non-informative, this assumption was 
applied to all censored observations throughout the hierarchy of analyses (even when 
patients were LTFU, withdrew consent or died for reasons not related to epilepsy), 
implying that such weights (to reduce bias due to early censoring) were not necessary.  
Thus the sequential structure to the investigation of the effect of covariates on 
treatment change and remission took the following format, with interpretation of the 
corresponding causal research question given in Table 37. 
Table 37 Sequence of IPCW analyses, relating to reason for treatment changes 
 Artificial censoring Interpretation 
ITT (no treatment 
changes) 
No artificial censoring Observed treatment effect demonstrating 
effectiveness of treatment assignment  
ISC alone Artificial censoring at the 
time of treatment changes 
occurring due to ISC  
Treatment effect estimate that would have 
been observed if it had been possible to 
prevent treatment changes occurring due to 
ISC (of primary interest to clinicians) 
ISC/personal 
choice 
Artificial censoring at the 
time of treatment changes 
occurring due to ISC or 
personal choice  
Treatment effect estimate that would have 
been observed if it had been possible to 
prevent treatment changes occurring due to 
ISC or for reasons of personal choice 
All (ISC/personal 
choice/UAEs) 
Artificial censoring at the 
time of (the first of) any 
treatment change 
Treatment effect estimate that would have 
been observed if it had been possible to 
prevent all treatment changes occurring 
   
In practice, this artificial censoring affects analysis only if the (relevant) treatment 
change occurred prior to the remission time. If the treatment change occurred before 
the patient achieved remission (or before their follow up for remission was censored), 
their remission time 𝑇𝑖 would be brought forward to the time of their (first) treatment 
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change 𝐹𝑖 and the corresponding remission indicator 𝑅𝑖 (denoting whether or not the 
patient had experienced remission (𝑅𝑖 = 1) or had simply been censored (𝑅𝑖 = 0)) 
would be changed to indicate censoring (𝑅𝑖 = 0). If the treatment change occurred 
post-remission, however, the remission time remains unchanged. Furthermore, 
outcome analysis is affected only if the reason for the patient’s first treatment change 
corresponds with the causal question; for example, when adjusting only for treatment 
changes due to ISC or personal choice, a patient’s remission time would not be 
artificially censored if their first treatment change occurred because of UAE.  
9.3.2. Causal diagram 
In applying this method to the SANAD B (VPS versus LTG) data, there were a number 
of factors requiring careful consideration. Prior to making decisions regarding analysis, 
it was helpful to sketch a causal diagram, such as the one in Figure 9, to clarify the 
causal scenario and summarise the interplay between (initial and updated) treatments, 
prognosis (in terms of baseline and time-varying factors related to the patients’ 
condition) and remission. In this simplified diagram, 𝑍 denotes randomisation, 𝐴0 initial 
prescribed (i.e. randomised) AED, 𝐴1 first change in treatment determined by patient’s 
state at time 1 (denoted by time-varying prognostic factors 𝑋1 such as UAE or seizure 
occurrence), 𝑈  underlying baseline prognosis and 𝑌  refers to outcome (time to 
remission). 
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Figure 9 Simplified causal diagram for SANAD T12mR 
A causal diagram is particularly helpful when applying IPCW methodology to complex 
scenarios such as SANAD. First, the diagram may help when deciding which causal 
effect is of interest, for example, perhaps that corresponding to the effect of initial 
treatment (only up to the point of a certain clinical event, such as UAEs) (∆1) or to the 
whole treatment experience (∆). Furthermore, the diagrams prompt one to identify all 
baseline and time-varying factors that are likely to confound the relationship between 
treatment received and outcome, such as dose, seizure control and AE occurrence. 
Indeed this was one of the main challenges when applying the IPCW methodology in 
SANAD, as data were collected on a large number of such potential confounders.  
Thus one of the main complication of this modelling exercise was in determining which 
of the numerous (time-dependent and baseline) variables should be included in the WD 
models. In SANAD there were a number of important baseline characteristics that 
conceivably influence the occurrence of both treatment changes and remission, 
including eight categorical variables (gender, febrile seizure history, first degree relative 
with epilepsy, treatment history, neurological insult, EEG result at randomisation, 
seizure type and epilepsy type) and three continuous variables (age, time interval 
between first ever seizure and randomisation, and total number of tonic clonic seizures 
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prior to randomisation). Additionally the three time-varying covariates (TVCs) 
(prescribed dose of randomised drug, and the number of AEs and seizures since 
randomisation) were all conceivably influential on the occurrence of changes from 
randomised treatment and on time to remission. 
Prior to deciding which of these covariates should be included in the WD and WO 
models, by way of a selection procedure, it was necessary to decide how to model the 
TVCs in a manner that was clinically meaningful and statistically viable; this was extra 
challenging in SANAD given the highly skewed nature of these variables due to extreme 
values of these covariates experienced by a minority of patients. 
9.3.3. Time varying covariates 
The first obvious TVC was (cumulative) seizure count (since randomisation), as seizure 
occurrence impacts on the likelihood of treatment change as well as remission. 
Although seizure count is in fact structurally related to the remission outcome, its 
adjustment in this setting is nevertheless valid (and indeed essential), given that (as a 
TVC) it is included only in the treatment change (WD), rather than the remission (WO), 
model. 
Data on seizures were collected in line with the pragmatic nature of trial; given that it 
would have been too difficult to collect date of each individual seizure, patient CRFs 
simply collected dates of first and last seizures and total seizure count since last visit. 
This imprecise record of seizure times, coupled with the potential for multiple daily 
seizures for some patients (such that their value of this TVC changed on a daily basis) 
suggested that instead of using individual estimated seizure times to calculate daily 
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updated records of cumulative seizure counts, a sensible compromise would instead be 
to use interval data.  
In order to calculate such interval data, the date of individual seizures were first 
estimated based on the assumption of regular intervals between seizures (by subtracting 
date of first seizure from date of last seizure, and dividing by the total number of 
seizures to get an estimate of the interval between each seizure, and then working out 
approximate dates of seizures based on this interval). These estimated seizure dates 
were then used to create cumulative interval-based counts of seizures, leading to a step 
function that changed on an interval (for example, monthly or weekly) basis. 
The second obvious confounder, being related to both remission and treatment 
changes, was the occurrence of AEs. Unlike seizure dates, the date of onset of each type 
of AE was recorded precisely in patient CRFs, along with information on whether the 
patient was hospitalised and the length of their stay in hospital. In order to account for 
the severity of the AE, the occurrence of any AE which resulted in hospitalisation was 
weighted by the number of nights spent in hospital. Hence the cumulative AE variable 
increased by a value of one on the date that each AE occurs, except when the AE 
required hospitalisation, in which case the variable increased by a value equal to the 
number of nights spent in hospital.  
The third potential confounder was dose of randomised treatment, which was recorded 
at each clinic visit (and was assumed to be unchanged and adhered to between visits). 
When these TVCs were discretised into interval values, the value assigned to each 
interval was that which was valid at the start of each interval, such that this value was 
then assumed to stay constant for that entire time period (to ensure that the values were 
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not affected by any event occurring within that interval). For example, the cumulative 
AE (or seizure) counts for time interval 𝑛 equaled the total up to the end of interval 
𝑛 − 1. Similarly, the interval value for dose at a particular interval was the last recorded 
dose from within the previous interval.  
Width of time interval 
Prior to modelling using these TVCs, it was therefore necessary to decide on the 
optimal length of time interval, in order to strike the balance between greater accuracy 
(which increases as interval length decreases) and computational intensity (which 
increases with interval length). Taking into account the frequency and duration of 
follow up information in this analysis, it appeared sensible to use fortnightly intervals; 
however, in order to check whether this choice of interval length was overly influential 
on the results, repeat analyses using weekly and monthly intervals for these time-varying 
cumulative counts were also planned.  
9.3.4. Covariate issues relating to stability of model  
The next feature of the model that required investigation related to the impact of 
covariate profiles on the stability of the model, firstly with regard to the highly skewed 
distribution of all of the continuous baseline and time-varying covariates. It was 
necessary to consider how reduce the influence of these outlying values in the 
regression modelling. Royston (193) advocates truncating continuous variables at their 
1% and 99% centiles, in order to prevent unstable modelling due to overly influential 
extreme values; thus this truncation was applied to these variables. 
The next issue regarding covariate distributions related to the small number of patients 
in some categories of the baseline categorical variables; for example, an uneven split of 
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patients among treatment history and seizure types meant that some categories 
contained very patients or events, which would lead to unstable modelling. As such, 
clinical guidance was sought on how to collapse categories within these variables to 
increase statistical stability whilst preserving clinical relevance. For example, the two 
“previously treated” categories of the treatment history variable (current monotherapy 
(M) and relapse following previous remission and withdrawal from therapy (R), in 
which there was no variation in the occurrence of events for certain treatment/history 
combinations (as shown in Table 38) such that these patients were in effect excluded 
from PLR analysis) were combined so that patients were instead simply classified as 
either previously treated or untreated.  
Additionally, given its high correlation with the binary variable epilepsy type (generalised 
or unclassified), it was decided that the seizure type variable (with five different 
categories, some of which contained very few patients) would not be considered for 
potential inclusion in the model. In reducing the number of potential (categories of) 
variables available for inclusion in the model, these considerations also helped to 
address the problem of low EPV ratios. 
 
Table 38 Number of patients with treatment withdrawal out of total number of 
months of follow up (out of total number of patients) 
Treatment change due 
to 
Treatment 
group  
Monotherapy Relapse after 
remission  
Untreated 
ISC LTG 5/268 (5/13) 1/184 (1/6) 44/2941 (44/178) 
VPS 4/190 (4/14) 0/110 (0/7) 22/2881 (22/175) 
ISC/choice LTG 5/168 (5/13) 2/167 (2/6) 46/2926 (46/178) 
VPS 4/190 (4/14) 0/110 (0/7) 25/2885 (25/175) 
All treatment changes  LTG 6/242 (6/13) 3/90 (3/5) 56/2502 (56/166) 
VPS 4/178 (4/13) 2/79 (2/7) 50/2355 (50/169) 
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9.3.5. Low power 
As already mentioned, there were too few patients who experienced LTFU (prior to 
their first treatment change or remission outcome) to allow independent investigation 
into the effect of LTFU on remission. However, as each analysis proceeded in the series 
of treatment change scenarios, it similarly became apparent that there were low 
numbers of treatment changes in each treatment group on which to base the treatment-
specific WD models for the “restricted” treatment change scenarios. Thus, as can be 
seen in Table 39, treatment changes were especially low in the VPS arm, in particular 
those occurring due to ISC alone (26) or ISC/choice (29). Thus the corresponding 
analyses had little power to determine which confounders were influential on the 
treatment effect (HRs or ORs from Cox or PLR WO models, respectively) for these 
scenarios. 
Table 39 Number of events 
 Withdrawal  Remission  
 VPS LTG VPS LTG 
None (ITT) - - 154 143 
ISC only 26 50 141 110 
ISC/choice  29 53 139 108 
All (ISC/choice/UAEs) 56 64 114 90 
 
To put this into context, allowing for (𝑘 − 1) dummy variables required for a 
categorical variable with 𝑘 categories, there were 20 variables being considered for each 
FS and BE selection process: three time-varying covariates (dose, cumulative seizure 
count, cumulative AE count), three baseline continuous variables (age, time between 
first ever seizure and randomisation, total number of tonic clonic seizures ever before 
randomisation), four binary variables (sex, neurological insult, febrile seizures, first 
degree relative with epilepsy) and three categorical variables with more than two 
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categories (treatment history: untreated, taking (non-trial) monotherapy at 
randomisation, relapsed after previously achieving remission following treatment; EEG 
result: epileptic abnormality, nonspecific abnormality, normal, not done; seizure type: 
generalised tonic-clonic seizures only, absence seizures, myoclonic or absence seizures 
with tonic-clonic seizures, tonic-clonic seizures uncertain if focal or generalised, focal 
seizures with or without tonic-clonic seizures, and other unclassified).  
Thus, given the rule of thumb that a stable model requires at least 10 events per variable 
considered in a model selection process (180), the validity of using a FS or BE selection 
processes was called into question, especially in the restricted withdrawal scenarios (ISC 
or ISC/choice) in the VPS arm.  
There were a number of options to prevent model overfitting and instability: either 
reducing the number of variables considered for selection; carrying out only FS (as the 
full models (including all variables) in BE would exhibit extreme overfitting); or only 
fitting models for the “all treatment changes” scenario. The last of these would be the 
least favourable option, as clinicians are primarily interested in the “ISC” scenario. It 
was decided, therefore, to cut down the initial pool of potential variables before FS or 
BE were carried out, by applying a cut-off of at least 1% change in HR; in other words, 
when the inclusion of the variable in the WD model caused the treatment effect 
estimated in the WO model to vary by more than 1% compared to the estimated 
treatment effect when the variable was excluded (and therefore the WD contained only 
the time spline variables). The likelihood of overfitting would also be checked by 
explicit reference to the EPV ratio for each model, relating to the maximum model size 
for each (considering in particular the full initial model for BE).  
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This consideration of EPV ratio relates directly to the next issue that required 
consideration for this modelling exercise. 
9.3.6. Knots for spline variables  
The next major consideration for analysis regarded the number and positioning of the 
knots required for spline variables in the PLR analyses. These spline variables are 
intended to mimic the underlying probability of treatment change (in the WD model) or 
remission (in the WO model) over time.  
In order to determine the optimal number and position of knots for the spline variables, 
a comparison of PLR results using 3, 4 and 5 knots were made against those obtained 
from a Cox model. As this analysis progressed, there were a number of key 
observations that are worthy of note relating to the choice of number of knots and their 
positioning. 
Initially it was decided that the splines would be generated using the number (and 
position) of spline knot positions as recommended by Stone (189); hence, for 𝑘 = 3, 
knots were be placed at the 10th, 50th and 90th percentiles of the observed follow up time 
intervals (weeks, fortnights or months); for 𝑘 = 4, knots were placed at the 5th, 35th, 65th 
and 95th percentiles; and for 𝑘 = 5, knots were placed at the 5th, 27.5th, 50th, 72.5th and 
95th percentiles.  
First, it is important for users to appreciate that different spline variables must be 
created for the WD and WO models, according to the (chosen) percentiles of the 
follow up times for the treatment change and outcome events respectively. The spline 
variables for the WD model should be treatment-specific, based on the centiles of 
observed treatment change times in each treatment group separately, whereas the WO 
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spline variables are positioned according to centiles of the observed outcome times for 
the overall trial.  
If, instead, the same spline variables are used (for the WD and WO models), the PLR 
model becomes unreliable and unstable. This instability results because the use of the 
treatment-specific splines (generated for the WD models) in the WO (remission) 
models in turn means that separate baseline odds are estimated for each treatment 
group in the WO models, implying a complex underlying time-treatment interaction (as 
opposed to the overall baseline hazard estimated by the Cox model). For example, in 
Table 45 of Appendix A, it can be seen that, if the (treatment-specific) splines generated 
for the WD model are applied to the WO, the PLR results become highly sensitive to 
the number of knots, demonstrating highly variable treatment estimates across time 
intervals and treatment change scenarios compared to the corresponding Cox model 
estimates. Given that this occurs even under the ITT scenario and without weights (in 
other words, when no TVCs were adjusted for), this model instability is obviously due 
to mis-modelling of the main time effect; otherwise, with correct specification of the 
time effect, the PLR model (including no baseline or TVCs) would have more closely 
mirrored the Cox model.  
Thus it was necessary to create separate spline variables for the WD and WO models, 
the former being treatment-specific and the latter overall for the whole trial. When 
considering the positioning of knots for the WO model, in the particular case of 
SANAD, it was important to recognise that the remission outcome could not (by 
definition) occur prior to 12 months. However, at 12 months, there is then a peak in the 
number of events occurring, due to a high proportion (approximately 30%) of patients 
achieving I12mR. Thus a major non-linearity (a spike) of the underlying hazard occurs 
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at this time point, presenting a challenge for the spline variable to adequately fit the 
data.  
Investigation into the empirical distribution of the probability of treatment change and 
remission over time demonstrated the obvious nonlinearity in remission at 12 months 
(for example, see plots in Figure 10 of these empirical probabilities when all treatment 
changes are accounted for).  
  
Figure 10 Empirical remission and treatment change probabilities, adjusting for 
all treatment changes 
It was therefore necessary to consider how best to construct the (WO) spline variable 
around the 12 month point in order to ensure the model fit the data well at this point, 
for example by fixing one or more knots around 12 months and dropping observation 
times less than 12 months when calculating percentiles. Note that in the case of the 
latter, the effect of TVCs and baseline covariates on the probability of withdrawal prior 
to 12 months would still be modelled in the WD (treatment change) models, but their 
(cumulative) effect up to 12 months would only be included as weights in the WO 
(remission) model from 12 months onwards. 
An investigation into model fit (assessed by stability of treatment effect and baseline 
hazard (odds) fit between Cox (and pooled) LR models) was therefore undertaken to 
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assess the effect of the number and position (particularly in relation to the 12 month 
time point) of splines on the simple (covariate- and weight-free) remission model, using 
overall spline variables for each of the following four scenarios:  
1) All follow up times were modelled, with centiles (for knot positions) 
calculated from all follow up times. 
2) All follow up times were modelled, with centiles (for knot positions) 
calculated for all follow up times and 1 (for 3 knots scenario) or 2 (for 4-5 
knots scenario) knots fixed at (or clustered around) 12 months. 
3) All follow up times were modelled, with centiles (for knot positions) 
calculated only for follow up times ≥ 12 months and spline variables for 
time < 12 months were forced to be 0. 
4) Only follow up time ≥12 months were modelled, with centiles (for knot 
positions) calculated only for follow up times ≥ 12 months. 
Remission models were assessed using pseudo log likelihood (pll) and AIC measures 
(where a lower AIC demonstrates better model fit) and by comparing treatment effects  
across scenarios, as well as baseline hazards and odds plots from Cox and PLR models 
respectively (see Table 46 to Table 48 in Appendix B). Assessment of the effect of 
number of knots on these unweighted remission models demonstrated a problem of 
non-convergence most particularly for scenarios 1-3. As would be expected, given that 
there is no chance of the event occurring prior to 12 months, the relative stability of 
results from scenario 4 suggested that it would be sensible to exclude follow up prior to 
12 months (for centile estimation as well as outcome modelling).  
Indeed, the baseline hazards and odds plots from the comparison between the Cox and 
pooled LR models (with 3 to 5 knots) demonstrate an (expected) high hazard at 12 
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months followed by a rapid decline and subsequent little variation over time. As such, it 
was decided that this pattern would be best fit by dropping any time at which there 
are no events occurring (which automatically included times less than 12 months) and 
fixing one or more knots around 12 months. Given that the outcome is rare, it would 
also be advantageous to fix knot positions at centiles of the distribution of observed 
event times, rather than all observation times. Note that dropping times at which there 
are no events occurring does not affect modelling (as event probability at such times are 
perfectly predicted by the model, given that there is no variation in outcome at this 
point, and are therefore automatically dropped at this point); the only effect would be to 
reduce the range of data used to construct the splines, leading to greater stability in the 
model. 
Applying these restrictions reduced the problems of non-convergence, but there was 
still evidence of overfitting in those scenarios with fewer observations (with longer time 
intervals) and fewer events (more restrictive treatment change scenarios). However the 
results were not definitive regarding the most appropriate choice for the number of 
knots to use for each scenario; although non-convergence was an issue as the number 
of knots increased in scenarios with fewer observations or events, the AIC (and 
loglikelihood) measures tended to favour models with more knots. As such, it was 
decided that the variable selection procedure would be carried out using both 3 and 5 
knots for each scenario in the proposed analysis plan, with due attention being paid to 
the stability of the estimated coefficients and their SEs, as well as to the EPV ratio (as 
an indicator of the reliability of the model).  
Given that a maximum threshold of 10% is recommended when applying a selection 
procedure according to the CHEST criterion (191), a threshold of 5% was chosen for 
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the main selection procedure, with sensitivity analyses using 2 and 10% to assess 
whether the conclusions of the analysis varies according to threshold. Furthermore, it 
was decided that both forward selection (FS) and backward elimination (BE) would be 
employed, in order to provide insight into the impact of the selection procedure on the 
choice of covariates, with consideration for the stability of each model assessed using 
the maximum EPV ratios for each selection process (for example, the EPV 
corresponding to the full initial model when undertaking BE).  
9.3.7. Analysis plan 
Given the uncertainty surrounding these modelling issues, an analysis plan was 
developed to facilitate an organised and structured approach in order to investigate the 
relative impact of each of the variable factors on the model results. For each of the 
treatment change analyses (namely adjusting for no treatment changes (ITT); treatment 
changes due to ISC alone; treatment changes due to ISC or personal choice; and finally 
all treatment changes) there were four factors to consider: model type (Cox regression 
(with bootstrapping) or PLR (with and without bootstrapping)), time intervals for 
discretised TVCs (weekly, fortnightly or monthly), selection procedure (FS or BE) and 
variable selection threshold (2%, 5% or 10%). Thus the IPCW modelling procedure was 
applied using a factorial design, allowing the impact of each of the following model 
features on estimated treatment effects to be assessed, described in Table 40.  
The analysis plan therefore consisted of a comparison of three versions of the IPCW 
model for the SANAD comparison: Cox regression (with bootstrapping), PLR (with 
bootstrapping) and PLR (without bootstrapping). Comparison of PLR with and without 
bootstrapping would assess the validity of the SEs produced by the model in 
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comparison to bootstrapped SEs. Comparison of PLR and Cox regression (both with 
bootstrapping) would assess how similar the models are, both in terms of the variables 
that are selected for inclusion in the model and in the estimated treatment effect 
estimates (bearing in mind, however, that the models will not be directly comparable as 
the logistic regression model estimates ORs, and the Cox model estimates HRs). In 
particular it was of interest to determine whether the use of smaller time intervals (for 
example, weekly or fortnightly intervals compared with monthly intervals) would lead to 
more similar results between the logistic and Cox regression, as would be expected 
(given that event rates decrease with decreasing time intervals, and therefore the 
estimated ORs should more closely match the corresponding HR estimates). 
Table 40 Analysis plan 
 Levels of analysis  
  
Reason for treatment 
change 
ITT (no treatment changes) 
ISC alone 
 ISC/personal choice 
 All (ISC/personal choice/UAEs) 
  
Model Cox regression (with bootstrapping)  
 PLR (with bootstrapping) 
 PLR (without bootstrapping) 
  
Time interval Weekly 
 Fortnightly 
 Monthly 
  
Selection procedure Forward selection (FS) 
 Backward elimination (BE) 
  
Selection threshold 2% 
5% 
 10% 
  
Bootstrapping was carried out using by drawing (200 repeat) samples at the patient level 
(in other words, selecting the entire record for that patient) rather than at an individual 
   
   
 
354 
 
record level (in other words, restricted to a particular time interval for that patient) to 
ensure correct allowance for clustering. 
In linking with the causal question of interest, the estimation sample for the IPCW 
modelling excluded patients with focal epilepsy (as for the RPSFTM) as these patients 
were not intended to receive VPS or LTG treatment; the estimation population thus 
consisted only of those with generalised or unclassified epilepsy.  
Research questions  
This analysis plan sought to provide answers to the following pertinent questions:  
1. Which baseline and time-varying covariates are identified as confounders 
between treatment changes and remission? 
2. Regression models 
a. How does bootstrapping compare with normal CI estimation? 
b. Are the same variables selected using Cox and PLR (with three and five 
knots)? 
c. Do treatment effect estimates differ greatly between regression 
models? 
3. Time intervals (for logistic regression) 
a. How does the time interval affect selection of variables and subsequent 
treatment effects? 
b. Are treatment effects from Cox and PLR models more similar with 
smaller (weekly) intervals? 
4. Reasons for treatment change 
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a. What are the general differences in the selection of variables and 
subsequent treatment effects when different treatment changes are 
adjusted for?  
b. What is the overall treatment effect adjusting for specified treatment 
changes? 
9.3.8. Data preparation 
In order to carry out this modelling, the data needed to be prepared appropriately, 
which was not a trivial exercise. In particular, determination of the cumulative seizure 
counts, whether at monthly, fortnightly or weekly intervals, required careful 
programming in Stata. 
Seizure counts 
First, it was necessary to create a total seizure count for each patient across multiple 
visits 
bysort trialid: gen cum_total_seizures = sum(totsez_num) 
It was then necessary to generate individual seizure dates (which were assumed to lie 
equally between the first and last date of seizure recorded for each visit) 
forvalues i = 1(1)1000 { 
 gen date_sez_raw_`i' = . 
 gen date_sez_`i' = .        
 } 
 
in order to convert these into monthly (or fortnightly or weekly) interval counts. For 
example, monthly counts were calculated using the following code: 
forvalues i = 1(1)30 { 
  gen cum_sez_m`i' = . 
  } 
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forvalues i = 1(1)30 { 
 local j 1 
  while `j' <=1000 { 
   bysort trial: replace cum_sez_m`i' = `j' if 
((date_sez_`j' -  rand) > 30*(`i'-1)) & ((date_sez_`j' -  rand) <= 
30*(`i')) & _n==1  
   local j = `j'+1 
  } 
} 
 
forvalues i = 1(1)30 { 
 forvalues j = 1(1)1000 { 
  bysort trial: replace cum_sez_m`i' = `j' + 
cum_total_seizures[_n-1] if ((date_sez_`j' -  rand) > 30*(`i'-1)) & 
((date_sez_`j' -  rand) <= 30*`i') & _n > 1   
 } 
} 
replace cum_sez_m1 = 0 if cum_sez_m1 == . 
 
forvalues i = 2(1)30 { 
 local j = `i'-1   
 sort trial visit 
 bysort trial: replace cum_sez_m`i' = cum_sez_m`j' if 
cum_sez_m`i' == . 
 local i = `i'+1 
} 
 
 
Adverse event counts 
AE counts were weighted according to the number of nights spent in hospital 
gen AE_num = 1 if hosp =="N" 
replace AE_num = nights if hosp=="Y" 
 
gen date_AE = datons 
gen month_AE_fraction = (date_AE - rand)/30 
gen month_AE_fornextmonth = ceil(month_AE_fraction) 
 
* cumulative AE at the end of one month counts towards next month 
gen month_AE = month_AE_fornextmonth + 1 
note month_AE: total AEs up to start of previous month (ie 
corrected) 
 
sort trialno month_AE date_AE 
* keep only one entry per month 
bysort trialno month_AE: keep if _n==_N 
 
Dose data 
Dose data were recorded whenever a patients’ prescription (treatment or dose) changed, 
and these data needed to be converted into monthly (or fortnightly or weekly) values.  
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forvalues i = 1(1)63 { 
 gen dose_prelim_m`i' = . 
} 
* dose is carried forward from anytime in the previous month 
forvalues i = 1(1)63 { 
 replace dose_prelim_m`i' = dose if ((date_pres_fup -  rand) > 
30*(`i'-1)) & ((date_pres_fup -  rand) <= 30*`i') 
} 
 
* if more than one entry for a given month, use the last entry 
forvalues i = 1(1)63 { 
 replace dose_prelim_m`i' = . if dose_prelim_m`i'[_n+1]~=. & 
trial==trial[_n+1] 
} 
* create single line per patient 
forvalues i = 1(1)63 { 
 bysort trial: egen dose_m`i' = total(dose_prelim_m`i'), 
missing 
} 
bysort trial: keep if _n==1 
drop dose_prelim* 
forvalues i = 2(1)63 { 
 local j = `i'-1   
 replace dose_m`i' = dose_m`j' if dose_m`i' == . 
} 
forvalues i = 1(1)63 { 
 count if dose_m`i' == . 
} 
 
local i = 23  
while `i' <= 23 & `i'>0 { 
 local j = `i'+1   
 replace dose_m`i' = dose_m`j' if dose_m`i' == . 
 local i = `i' - 1 
 } 
 
reshape long dose_m, i(trialno) j(m) 
 
 
Merging time-varying covariates 
It was then necessary to merge the three time-varying covariates appropriately according 
to time interval. 
gen month_AE_sez = m if include_AE==1 
replace month_AE_sez = m if include_sez==1 
sort trial month_AE_sez 
 
* check only one entry per month for AE/sez 
sort trial m 
assert m > m[_n-1] if trial==trial[_n-1] & m~=. & m[_n-1]~=. 
 
sort trial m 
assert m > m[_n-1] if trial==trial[_n-1] & m ~=. & m[_n-1]~=. 
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sort trial month_AE_sez include_sez 
gen cum_AE_month_withsezdata = cum_AEnum  
bysort trial: replace cum_AE_month_withsezdata = 0 if 
cum_AE_month_withsezdata==. & _n==1  
 
* if no cumulative AE total for sez month, copy from previous 
cumulative AE total 
bysort trial: replace cum_AE_month_withsezdata = 
cum_AE_month_withsezdata[_n-1] if month_AE_sez < month_AE_sez[_n+1] 
& include_sez==1 & cum_AE_month_withsezdata==. & _n>1 
* if cumulative AE total for sez month (ie more than one entry for 
that month - one relating to AEs, one relating to seizures), copy 
from following cumulative AE total (from that month) 
bysort trial: replace cum_AE_month_withsezdata = 
cum_AE_month_withsezdata[_n+1] if month_AE_sez == month_AE_sez[_n+1] 
& include_sez==1 & cum_AE_month_withsezdata==. & _n>1 
 
sort trial month_AE_sez include_AE 
gen cum_sez_month_withAEdata = cum_sez_m 
bysort trial: replace cum_sez_month_withAEdata = 0 if 
cum_sez_month_withAEdata==. & _n==1  
bysort trial: replace cum_sez_month_withAEdata = 
cum_sez_month_withAEdata[_n-1] if month_AE_sez < month_AE_sez[_n+1] 
& include_AE==1 & cum_sez_month_withAEdata==. & _n>1  
bysort trial: replace cum_sez_month_withAEdata = 
cum_sez_month_withAEdata[_n+1] if month_AE_sez == month_AE_sez[_n+1] 
& include_AE==1 & cum_sez_month_withAEdata==. & _n>1 
 
* fill down cum_AEnum values now that we have full months up to 62 
months 
sort trial m 
by trial: replace cum_AEnum = 0 if _n==1 
by trial: replace cum_AEnum = cum_AEnum[_n-1] if cum_AEnum==. & _n>1 
 
It was also necessary to create time-varying treatment change and remission (indicator 
and time) variables corresponding to each analysis in the sequence of analyses 
investigating reasons for treatment change.  
* create reason for dropout or withdrawal 
gen w_reason = 0 if wclass=="C"|wclass=="D"|wclass=="L"|wclass=="RE" 
* note that there is one patient who was censored because of "RE" at 
< 365 days (trialno B1092009 withtime 255, wcens 0 but remtime 365, 
rcens 1) 
* ? consider sensitivity analysis treating this patient as having 
event (withdrawal of treatment) at 225 days 
replace w_reason = 1 if 
wclass=="ISC"|wclass=="DISC"|wclass=="ISCUAE" 
replace w_reason = 2 if wclass=="PAE"|wclass=="PRE"|wclass=="UAE" 
replace w_reason = 3 if 
wclass=="NC"|wclass=="O"|wclass=="P"|wclass=="PD"|wclass=="U" 
replace w_reason = 4 if wclass=="NA" 
label variable w_reason "Reason for withdrawal from drug or study" 
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label define w_reason 0 "Ltfu, death or consent withdrawn" 1 "ISC" 2 
"UAE" 3 "Personal reasons" 4 "NA" 
label values w_reason w_reason 
 
* Changing for any reason: w_reason = 1/2/3; or censoring: w_reason 
= 0; hence wr0123 
 
gen rem_with_wr0123_min_date = min(withdate, remdate, 
totsez_censdate)  
label variable rem_with_wr0123_min_date "Minimum of trt withdrawal 
(for any reason, including end of fup and lftu (both have wcens==0)) 
or remission dates" 
 
For example, time of treatment change was brought forward to the time of remission 
and censored, if the time of treatment change was greater than the remission time; 
alternatively it was necessary to bring the remission time forward to the time of 
treatment change and to censor (if the time of treatment change was less than the 
remission time).  
gen min_cens_withdate = min(totsez_censdate, withdate) 
gen rcens_wcens_wr0123 = rcens 
replace rcens_wcens_wr0123 = 0 if rem_with_wr0123_min_date < remdate 
label variable rcens_wcens_wr0123 "Remission indicator censored at 
first treatment change (for any reason)" 
 
* create rem_with_min_month/biweek/bimonth: so that any event during 
the present month/biweek/bimonth counts towards the end of the 
previous month/biweek/bimonth 
* note that the (n-1)th values of tvcs are aligned with nth values 
of outcome (see bottom of p413 in Fewell) as we have brought the (n-
1)th values forward to the nth:  
* need cumulative sum up to m`i' to count towards next m (`i' + 1) 
* sort trial m 
* bysort trial: gen cum_sez_m = final_cum_sez_m[_n-1] if _n>1 
* bysort trial: replace cum_sez_m = 0 if _n==1  
gen rem_with_wr0123_min_month = floor((rem_with_wr0123_min_date - 
rand_date)/30) 
* gen rem_with_wr0123_min_biweek = floor((rem_with_wr0123_min_date - 
rand_date)/14) 
* gen rem_with_wr0123_min_week = ceil((rem_with_wr0123_min_date - 
rand_date)/7) 
 
These times and indicators variables varied according to the particular reason for 
treatment change; for example, changes occurring due to ISC would be adjusted in this 
manner for all analyses except the ITT analysis, whereas changes due to UAEs were 
only adjusted for in the final overall adjustment for all treatment changes.  
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Once these analysis-specific variables were created, they were converted into time-
varying event indicator variables in order to allow them to be linked with the TVCs.  
The ITT version of the models (for both survival and PLR) required no WD model, as 
there were by definition no treatment changes to account for, and thus there were no 
weights applied to the WO (remission) model; as such, TVCs were not required for ITT 
analysis (as they enter only through their influence in the WD model). 
9.3.9. Selection process 
The forward and backward selection processes required manual programming in Stata, 
which increased in complexity as the number of variables were added to (or included in) 
the model (in FS and BE respectively). For example, the simplest stage in analysis 
(determining the “significance” of individual baseline variables in initial models for the 
ITT outcome, in other words adjusting for no treatment changes and thus requiring no 
weights) was programmed as follows: 
* trt only model:  
* fit logistic model for remission outcome 
xi: logistic rcens_ITT_AE_sez_m_tv treat_num m m_spline_*, 
cluster(trial) 
gen hr_trt_ITT = exp(_b[treat_num]) 
 
* baseline only models: 
foreach var in age_t fi_t t_t { 
 * fit logistic model for remission outcome 
 xi: logistic rcens_ITT_AE_sez_m_tv treat_num `var' m 
m_spline_*, cluster(trial) 
 gen hr_trt_ITT_`var' = exp(_b[treat_num]) 
 * determine ratio of HR with and without variables  
 gen r_hr_trt_ITT_`var' = hr_trt_ITT_`var'/hr_trt_ITT  
 } 
foreach var in sex ni feb rels hist type eeg stype { 
 * fit logistic model for remission outcome 
 * NOTE: no need for weights as no time-dependent variables 
included in model 
 xi: logistic rcens_ITT_AE_sez_m_tv treat_num i.`var' m 
m_spline_*, cluster(trial) 
 gen hr_trt_ITT_`var' = exp(_b[treat_num]) 
 * determine ratio of HR with and without variables  
 gen r_hr_trt_ITT_`var' = hr_trt_ITT_`var'/hr_trt_ITT 
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} 
foreach var in age_t fi_t t_t sex ni feb rels hist type eeg stype { 
 di "`var'" " " r_hr_trt_ITT_`var' 
} 
 
foreach var in age_t fi_t t_t sex ni feb rels hist type eeg stype { 
 gen hr_diff_trt_ITT_`var' = abs(1-r_hr_trt_ITT_`var')  
 di "`var'" " " hr_diff_trt_ITT_`var' 
} 
 
Much more complex programming was required when it was necessary to include 
weights, as in the excerpt below using FS to determine “significant” variables when 
adjusting for all treatment changes: 
* baseline only models: 
foreach var in age_t fi_t t_t { 
 * NOTE: calculating weights for future use only 
 * fit logistic model for wcens outcome, separate for each 
treatment (as causes of withdrawal differ between treatments) to 
determine weights for logistic model for remission outcome 
 xi: logistic wcens_rcens_wr0123_AE_sez_m_tv `var' m 
original_m_spline4_VPS* if treat_num==0 
 predict p_wr0123_VPS_trt_`var' if e(sample)  
 gen p_nwr0123_VPS_trt_`var' = 1 - p_wr0123_VPS_trt_`var' 
 sort trial m 
 by trial: replace p_nwr0123_VPS_trt_`var' = 
p_nwr0123_VPS_trt_`var'*p_nwr0123_VPS_trt_`var'[_n-1] if _n>1 
 * p_nwr0123_ are weights (probability of remaining uncensored 
at each time point) 
 xi: logistic wcens_rcens_wr0123_AE_sez_m_tv `var' m 
original_m_spline4_LTG* if treat_num==1 
 predict p_wr0123_LTG_trt_`var' if e(sample)  
 gen p_nwr0123_LTG_trt_`var' = 1 - p_wr0123_LTG_trt_`var' 
 sort trial m 
 by trial: replace p_nwr0123_LTG_trt_`var' = 
p_nwr0123_LTG_trt_`var'*p_nwr0123_LTG_trt_`var'[_n-1] if _n>1  
 * create weight variable including both treatment arms 
 gen p_nwr0123_trt_`var' = p_nwr0123_VPS_trt_`var' if treat_num 
== 0 
 replace p_nwr0123_trt_`var' = p_nwr0123_LTG_trt_`var' if 
treat_num == 1 
 gen ip_nwr0123_trt_`var' = 1/p_nwr0123_trt_`var' 
 * fit logistic model for remission outcome 
 * NOTE: no need for weights as no time-dependent variables 
included in model 
 xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num `var' m 
m_spline4_*, cluster(trial) 
 gen hr_trt_wr0123_`var' = exp(_b[treat_num]) 
 * determine ratio of HR with and without variables  
 gen r_hr_trt_wr0123_`var' = hr_trt_wr0123_`var'/hr_trt_wr0123
  } 
 
foreach var in sex ni feb rels hist hist2 type eeg stype { 
 * NOTE: calculating weights for future use only 
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 * fit logistic model for wcens outcome, separate for each 
treatment (as causes of withdrawal differ between treatments) to 
determine weights for logistic model for remission outcome 
 xi: logistic wcens_rcens_wr0123_AE_sez_m_tv i.`var' m 
original_m_spline4_VPS* if treat_num==0 
 predict p_wr0123_VPS_trt_`var' if e(sample)  
 gen p_nwr0123_VPS_trt_`var' = 1 - p_wr0123_VPS_trt_`var' 
 sort trial m 
 by trial: replace p_nwr0123_VPS_trt_`var' = 
p_nwr0123_VPS_trt_`var'*p_nwr0123_VPS_trt_`var'[_n-1] if _n>1 
 * p_nwr0123_ are weights (probability of remaining uncensored 
at each time point) 
 xi: logistic wcens_rcens_wr0123_AE_sez_m_tv i.`var' m 
original_m_spline4_LTG* if treat_num==1 
 predict p_wr0123_LTG_trt_`var' if e(sample)  
 gen p_nwr0123_LTG_trt_`var' = 1 - p_wr0123_LTG_trt_`var' 
 sort trial m 
 by trial: replace p_nwr0123_LTG_trt_`var' = 
p_nwr0123_LTG_trt_`var'*p_nwr0123_LTG_trt_`var'[_n-1] if _n>1  
 * create weight variable including both treatment arms 
 gen p_nwr0123_trt_`var' = p_nwr0123_VPS_trt_`var' if treat_num 
== 0 
 replace p_nwr0123_trt_`var' = p_nwr0123_LTG_trt_`var' if 
treat_num == 1 
 gen ip_nwr0123_trt_`var' = 1/p_nwr0123_trt_`var' 
 * fit logistic model for remission outcome 
 * NOTE: no need for weights as no time-dependent variables 
included in model 
 xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num i.`var' 
m m_spline4_*, cluster(trial) 
 gen hr_trt_wr0123_`var' = exp(_b[treat_num]) 
 * determine ratio of HR with and without variables  
 gen r_hr_trt_wr0123_`var' = hr_trt_wr0123_`var'/hr_trt_wr0123 
} 
foreach var in age_t fi_t t_t sex ni feb rels hist hist2 type eeg 
stype { 
 di "`var'" " " r_hr_trt_wr0123_`var' 
} 
 
* tvcs: AE/seizure variables 
* need to stabilise weights: rename p_nwr0123_ p_nwr0123_denom; 
refit without tvcs: rename p_nwr0123_ p_nwr0123_num; gen 
stab_wgt_AE/sez = p_nwr0123_num/p_nwr0123_denom 
 
* fit logistic model for wcens outcome, separate for each treatment 
(as causes of withdrawal differ between treatments) to determine 
weights for logistic model for remission outcome 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv cum_sez_t m 
original_m_spline4_VPS* if treat_num==0 
predict p_wr0123_VPS_trt_sez if e(sample)  
gen p_nwr0123_VPS_trt_sez = 1 - p_wr0123_VPS_trt_sez 
sort trial m 
by trial: replace p_nwr0123_VPS_trt_sez = 
p_nwr0123_VPS_trt_sez*p_nwr0123_VPS_trt_sez[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) but need to be stabilised 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv cum_sez_t m 
original_m_spline4_LTG* if treat_num==1 
predict p_wr0123_LTG_trt_sez if e(sample)  
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gen p_nwr0123_LTG_trt_sez = 1 - p_wr0123_LTG_trt_sez 
sort trial m 
by trial: replace p_nwr0123_LTG_trt_sez = 
p_nwr0123_LTG_trt_sez*p_nwr0123_LTG_trt_sez[_n-1] if _n>1  
* create weight variable including both treatment arms 
gen p_nwr0123_trt_sez = p_nwr0123_VPS_trt_sez if treat_num == 0 
replace p_nwr0123_trt_sez = p_nwr0123_LTG_trt_sez if treat_num == 1 
* create stabilised weight: use for numerator the weights from a 
model without same baseline vars but no tvcs 
gen ip_nwr0123_trt_sez_stab = p_nwr0123_trt/p_nwr0123_trt_sez 
* fit weighted logistic model for remission outcome 
logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num cum_sez_t m 
m_spline4_* [pw=ip_nwr0123_trt_sez_stab], cluster(trial) 
gen hr_trt_wr0123_sez = exp(_b[treat_num]) 
* determine ratio of HR with and without variables  
gen r_hr_trt_wr0123_sez = hr_trt_wr0123_sez/hr_trt_wr0123  
di r_hr_trt_wr0123_sez 
 
* tvcs: AE/seizure variables 
* need to stabilise weights: rename p_nwr0123_ p_nwr0123_denom; 
refit without tvcs: rename p_nwr0123_ p_nwr0123_num; gen 
stab_wgt_AE/sez = p_nwr0123_num/p_nwr0123_denom 
 
* fit logistic model for wcens outcome, separate for each treatment 
(as causes of withdrawal differ between treatments) to determine 
weights for logistic model for remission outcome 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv cum_AE_t m 
original_m_spline4_VPS* if treat_num==0 
predict p_wr0123_VPS_trt_AE if e(sample)  
gen p_nwr0123_VPS_trt_AE = 1 - p_wr0123_VPS_trt_AE 
sort trial m 
by trial: replace p_nwr0123_VPS_trt_AE = 
p_nwr0123_VPS_trt_AE*p_nwr0123_VPS_trt_AE[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) but need to be stabilised 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv cum_AE_t m 
original_m_spline4_LTG* if treat_num==1 
predict p_wr0123_LTG_trt_AE if e(sample)  
gen p_nwr0123_LTG_trt_AE = 1 - p_wr0123_LTG_trt_AE 
sort trial m 
by trial: replace p_nwr0123_LTG_trt_AE = 
p_nwr0123_LTG_trt_AE*p_nwr0123_LTG_trt_AE[_n-1] if _n>1  
* create weight variable including both treatment arms 
gen p_nwr0123_trt_AE = p_nwr0123_VPS_trt_AE if treat_num == 0 
replace p_nwr0123_trt_AE = p_nwr0123_LTG_trt_AE if treat_num == 1 
* create stabilised weight: use for numerator the weights from a 
model without same baseline vars but no tvcs 
gen ip_nwr0123_trt_AE_stab = p_nwr0123_trt/p_nwr0123_trt_AE 
* fit weighted logistic model for remission outcome 
xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num cum_AE_t m 
m_spline4_* [pw=ip_nwr0123_trt_AE_stab], cluster(trial) 
gen hr_trt_wr0123_AE = exp(_b[treat_num]) 
* determine ratio of HR with and without variables  
gen r_hr_trt_wr0123_AE = hr_trt_wr0123_AE/hr_trt_wr0123  
di r_hr_trt_wr0123_AE 
 
* fit logistic model for wcens outcome, separate for each treatment 
(as causes of withdrawal differ between treatments) to determine 
weights for logistic model for remission outcome 
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xi: logistic wcens_rcens_wr0123_AE_sez_m_tv dose_m m 
original_m_spline4_VPS* if treat_num==0 
predict p_wr0123_VPS_trt_dose if e(sample)  
gen p_nwr0123_VPS_trt_dose = 1 - p_wr0123_VPS_trt_dose 
sort trial m 
by trial: replace p_nwr0123_VPS_trt_dose = 
p_nwr0123_VPS_trt_dose*p_nwr0123_VPS_trt_dose[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) but need to be stabilised 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv dose_m m 
original_m_spline4_LTG* if treat_num==1 
predict p_wr0123_LTG_trt_dose if e(sample)  
gen p_nwr0123_LTG_trt_dose = 1 - p_wr0123_LTG_trt_dose 
sort trial m 
by trial: replace p_nwr0123_LTG_trt_dose = 
p_nwr0123_LTG_trt_dose*p_nwr0123_LTG_trt_dose[_n-1] if _n>1  
* create weight variable including both treatment arms 
gen p_nwr0123_trt_dose = p_nwr0123_VPS_trt_dose if treat_num == 0 
replace p_nwr0123_trt_dose = p_nwr0123_LTG_trt_dose if treat_num == 
1 
* create stabilised weight: use for numerator the weights from a 
model without same baseline vars but no tvcs 
gen ip_nwr0123_trt_dose_stab = p_nwr0123_trt/p_nwr0123_trt_dose 
* fit weighted logistic model for remission outcome 
xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num m m_spline4_* 
[pw=ip_nwr0123_trt_dose_stab], cluster(trial) 
gen hr_trt_wr0123_dose = exp(_b[treat_num]) 
* determine ratio of HR with and without variables  
gen r_hr_trt_wr0123_dose = hr_trt_wr0123_dose/hr_trt_wr0123  
di r_hr_trt_wr0123_dose 
 
foreach var in age_t fi_t t_t sex ni feb rels hist hist2 type eeg 
stype AE sez dose { 
 gen hr_diff_trt_wr0123_`var' = abs(1-r_hr_trt_wr0123_`var')  
 di "`var'" " " hr_diff_trt_wr0123_`var' 
} 
 
These commands demonstrate the need for careful labelling in order to facilitate easy 
iterative programming. This is especially true in the case of BE, as demonstrated in the 
excerpt below. This extract considers only the effect of baseline variable age, adjusting 
for all treatment changes: 
* only baseline variables included (for stabilised weights) 
* predict probability of treatment failure 
(wcens_rcens_wr0123_AE_sez_m_tv) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv age_t fi_t t_t i.sex 
i.ni i.feb i.rels i.hist i.eeg i.stype m original_m_spline_LTG* if 
treat_num==0 
predict p_wr0123_L_bl if e(sample) 
gen p_nwr0123_L_bl = 1 - p_wr0123_L_bl 
sort trial m 
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by trial: replace p_nwr0123_L_bl = p_nwr0123_L_bl*p_nwr0123_L_bl[_n-
1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv age_t fi_t t_t i.sex 
i.ni i.feb i.rels i.hist i.eeg i.stype m original_m_spline_VPS* if 
treat_num==1 
predict p_wr0123_V_bl if e(sample) 
gen p_nwr0123_V_bl = 1 - p_wr0123_V_bl 
sort trial m 
by trial: replace p_nwr0123_V_bl = p_nwr0123_V_bl*p_nwr0123_V_bl[_n-
1] if _n>1 
* create weight variable including both treatment arms 
gen p_nwr0123_bl = p_nwr0123_L_bl if treat_num == 0 
replace p_nwr0123_bl = p_nwr0123_V_bl if treat_num == 1 
 
* all variables included 
* predict probability of treatment failure 
(wcens_rcens_wr0123_AE_sez_m_tv) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv age_t fi_t t_t i.sex 
i.ni i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
original_m_spline_LTG* if treat_num==0 
predict p_wr0123_L_all if e(sample) 
gen p_nwr0123_L_all = 1 - p_wr0123_L_all 
sort trial m 
by trial: replace p_nwr0123_L_all = 
p_nwr0123_L_all*p_nwr0123_L_all[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv age_t fi_t t_t i.sex 
i.ni i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
original_m_spline_VPS* if treat_num==1 
predict p_wr0123_V_all if e(sample) 
gen p_nwr0123_V_all = 1 - p_wr0123_V_all 
sort trial m 
by trial: replace p_nwr0123_V_all = 
p_nwr0123_V_all*p_nwr0123_V_all[_n-1] if _n>1 
* create weight variable including both treatment arms 
gen p_nwr0123_all = p_nwr0123_L_all if treat_num == 0 
replace p_nwr0123_all = p_nwr0123_V_all if treat_num == 1 
* create stabilised weight: use for numerator the weights from a 
model without same baseline vars but no tvcs 
gen p_nwr0123_all_stab = p_nwr0123_bl/p_nwr0123_all 
* fit weighted logistic model for remission outcome 
xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num age_t fi_t t_t 
i.sex i.ni i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
m_spline_* [pw=p_nwr0123_all_stab], cluster(trial) 
gen hr_wr0123_all = exp(_b[treat_num]) 
 
* remove each variable in turn 
 
* remove age_t 
* only baseline variables included (for stabilised weights) 
excluding age_t 
* predict probability of treatment failure 
(wcens_rcens_wr0123_AE_sez_m_tv) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv fi_t t_t i.sex i.ni 
i.feb i.rels i.hist i.eeg i.stype m original_m_spline_LTG* if 
treat_num==0 
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predict p_wr0123_L_bl_eag if e(sample) 
gen p_nwr0123_L_bl_eag = 1 - p_wr0123_L_bl_eag 
sort trial m 
by trial: replace p_nwr0123_L_bl_eag = 
p_nwr0123_L_bl_eag*p_nwr0123_L_bl_eag[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv fi_t t_t i.sex i.ni 
i.feb i.rels i.hist i.eeg i.stype m original_m_spline_VPS* if 
treat_num==1 
predict p_wr0123_V_bl_eag if e(sample) 
gen p_nwr0123_V_bl_eag = 1 - p_wr0123_V_bl_eag 
sort trial m 
by trial: replace p_nwr0123_V_bl_eag = 
p_nwr0123_V_bl_eag*p_nwr0123_V_bl_eag[_n-1] if _n>1 
* create weight variable including both treatment arms 
gen p_nwr0123_bl_eag = p_nwr0123_L_bl_eag if treat_num == 0 
replace p_nwr0123_bl_eag = p_nwr0123_V_bl_eag if treat_num == 1 
 
* predict probability of treatment failure 
(wcens_rcens_wr0123_AE_sez_m_tv) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv fi_t t_t i.sex i.ni 
i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
original_m_spline_LTG* if treat_num==0 
predict p_wr0123_L_all_eag if e(sample) 
gen p_nwr0123_L_all_eag = 1 - p_wr0123_L_all_eag 
sort trial m 
by trial: replace p_nwr0123_L_all_eag = 
p_nwr0123_L_all_eag*p_nwr0123_L_all_eag[_n-1] if _n>1 
* p_nwr0123_ are weights (probability of remaining uncensored at 
each time point) 
xi: logistic wcens_rcens_wr0123_AE_sez_m_tv fi_t t_t i.sex i.ni 
i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
original_m_spline_VPS* if treat_num==1 
predict p_wr0123_V_all_eag if e(sample) 
gen p_nwr0123_V_all_eag = 1 - p_wr0123_V_all_eag 
sort trial m 
by trial: replace p_nwr0123_V_all_eag = 
p_nwr0123_V_all_eag*p_nwr0123_V_all_eag[_n-1] if _n>1 
* create weight variable including both treatment arms 
gen p_nwr0123_all_eag = p_nwr0123_L_all_eag if treat_num == 0 
replace p_nwr0123_all_eag = p_nwr0123_V_all_eag if treat_num == 1 
* create stabilised weight: use for numerator the weights from a 
model without same baseline vars but no tvcs 
gen ip_nwr0123_all_eag_stab = p_nwr0123_bl_eag/p_nwr0123_all_eag 
* fit weighted logistic model for remission outcome 
xi: logistic rcens_wcens_wr0123_AE_sez_m_tv treat_num fi_t t_t i.sex 
i.ni i.feb i.rels i.hist i.eeg i.stype cum_sez_t cum_AE_t m 
m_spline_* [pw=ip_nwr0123_all_eag_stab], cluster(trial) 
gen hr_wr0123_all_eag = exp(_b[treat_num]) 
* determine ratio of HR with and without variables 
gen r_hr_wr0123_all_eag = hr_wr0123_all_eag/hr_wr0123_all 
di r_hr_wr0123_all_eag 
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9.4. Key considerations as part of IPCW modelling process 
There were a number of further modelling complications which arose during the 
somewhat evolutionary process of carrying out this sequential investigation. Thus this 
analysis demonstrates how an initial causal analysis plan may need to change when 
practical problems or limitations arise while undertaking such analyses due to features 
of the data or modelling techniques. The first issue related to missing TVC data.  
9.4.1. Missing seizure dates 
Forty-two patients (at 58 visits) had missing values for their total number of seizures 
experienced between current and previous visit, despite recoded valid dates of first and 
most recent seizures entered for the corresponding visit. This missing data field suggests 
that the clinician was not able to estimate the number of seizures experienced by the 
patient since the previous visit but that seizures did occur between the given dates. 
Given the potential importance of cumulative seizure count as a TVC, it was necessary 
to decide how to address this missing data problem.  
There were a number of options available, the simplest being to simply exclude these 
patients from the analysis, or to assume that in fact no seizures had occurred. 
Alternatively, it may seem more plausible to assume that two seizures had in fact 
occurred (one each on the first and last dates of seizures given) or just one seizure (if 
the first and last dates of seizures were the same). More sophisticated imputation 
methods could have been employed, for example by estimating the missing total 
number of seizures based on the patient’s seizure rates for previous (and potentially 
future) visits, perhaps using only those visits at which the patient was taking the 
randomised drug. This approach could be extended further using multiple imputation 
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regression techniques to more accurately predict missing seizures rates based on factors 
such as dose, treatment and patient characteristics, potentially considering the relative 
importance of within- compared to between-patient variability, the distribution of 
seizure counts over time and the potential for carryover treatment effects affecting 
seizure rates even after the patient stopped taking their randomised treatment. 
Each of these imputation approaches were deemed either to be unrealistically simplistic 
or overly complicated in this setting, relying on assumptions that could not be easily or 
accurately verified. As such, it was decided that the approach used in the original 
analysis (194) would be employed here, namely that patients with missing seizure counts 
would simply be censored at the date of the first seizure recorded for this interval, as 
this was the last point at which the cumulative seizure count was known. The only 
exception to this was when the dates of first and last seizure were equal, and the 
patient’s seizure history suggested that the patient typically experienced very few 
seizures; in this case, it was assumed that the patient experienced only one seizure on 
that date (so that a count of one was assumed for the missing total number of seizures). 
This censoring (and simple imputation) resulted in eight patients’ remission (or 
censoring) time being brought forward, changing the event status of three (and one) 
patients who had achieved remission (or a treatment change) but were instead censored. 
It is acknowledged that this censoring could introduce bias if the unknown seizure 
counts were correlated with the frequency of seizures. However, given that seizure 
intervals varied considerably among those patients with missing seizure counts, this bias 
was not overtly obvious.  
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9.4.2. Extreme weights 
The other major problem that was encountered during this modelling exercise was that 
of extreme weights. In order to address this issue, it was necessary to understand the 
underlying reasons; on inspection of the data, it became obvious that this problem was 
related to two features of the data.  
As mentioned in section 9.2.2, a potential cause for extreme weights is when an 
incorrect functional form for covariates is specified in the PLR model, thus implying an 
incorrect relationship between each covariate and the outcome. In particular, if the 
model wrongly assumes linearity (in other words, the untransformed covariates are 
included in the model), patients with extreme values of TVCs will be disproportionately 
influential. Thus, alternative models with log or inverse links (that asymptote rather than 
increase linearly as the TVC increases) were explored. 
Martingale residuals are useful in determining the most appropriate functional form of 
covariates to be included in the model. As such, in order to decide on the best model fit 
between linear, log and inverse fit of continuous variables, a locally weighted smoothing 
(lowess) curve of the martingale residuals from the (constant only) Cox model was 
plotted against each transformation of each TVC in turn, namely untransformed values 
( 𝑋 ), logged values ( log(1 + 𝑋) ) and inverse values ( 1/(1 + 𝑋) ). An appropriate 
transformation would exhibit an approximately linear lowess smooth; thus, on visual 
inspection of these smoothing curves, it became apparent that the logarithmic 
transformation was appropriate for the TVC seizure count and three baseline 
continuous variables (interval between first ever seizure and randomisation, total 
number of tonic clonic seizures prior to randomisation and age). 
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Although this transformation helped to reduce the problem somewhat, extreme weights 
occurred, though to a lesser extent, particularly as more covariates were added to the 
model. This disproportionate influence of certain individuals had a large effect on 
estimated treatment effects and hence the selection process as a whole. For example, 
censoring one patient’s follow up 15 months early made a large difference to the 
treatment effect (and range of weights), which changed from 0.05 (0.6, 2888.7) to 0.35 
(0.6, 27.0).  
Secondly, as expected, these extreme weights tended to occur in patients with large 
values of TVCs (particularly seizure counts and dose) late on in follow up, whose data 
were overly influential because there remained few other similar patients on which to 
base weight estimation. For example, one patient’s prolonged follow up data was 
leading to extreme weights because of their high treatment dose received late on in 
follow up, when few patient-months of follow up remained in their treatment group. 
Thus, the available options to counter the extreme weights that continued to dominate 
the analysis were either to truncate continuous variables at the 95th (instead of just the 
99th) centile; to censor patient’s follow up when their weights exceeded a predefined cut-
off level; or to categorise continuous variables in order to reduce the influence of 
outlying values. The last option is not ideal, as it would lead to a great loss of 
information. Thus, firstly the effect of truncation at the 95th centile was investigated.  
Extreme weights still occurred in a small number of cases despite truncation at the 95th 
(rather than 99th) centile of continuous variables. Thus, although it is acknowledged that 
censoring patient’s follow up when their weights become problematically high is likely 
to introduce a certain amount of bias, it is also recognised that simply ignoring the 
problem of extreme weights is likely to lead to a grossly incorrect model, given the 
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influence that extreme weights have on the resultant treatment effects. Thus it was 
decided that an individual’s follow up would be censored when their weight exceeded 
30; this cut-off level was approximately equal to one tenth of each treatment group size, 
a level at which it seemed reasonable to restrict a single individual’s contribution. 
Although such censoring may introduce bias, it is worth noting that this censoring 
affected only approximately 0.01% of patient-time intervals in each analysis. 
9.4.3. Revised plan  
Thus, following these model considerations and investigations, the FS and BE selection 
procedures were carried out according to a slightly revised analysis plan. Cox regression 
was compared to PLR (using three and five knots); all continuous variables were 
analysed following logarithmic transformation and truncation at the 95% centile, and 
certain categorical variables were collapsed to remove the problem of small event 
numbers within combinations of factors. Patients’ follow up was censored if they had 
missing seizure count data or if their weight exceeded 30 for a given time interval 
(month, fortnight or week). Variables were included in the initial pool of baseline and 
time-varying covariates only if their inclusion in the treatment-only WD model altered 
the WO treatment effect by at least 1%. 
9.5. Summary of initial results 
In order to determine which of the baseline and TVCs should be adjusted for in this 
IPCW analysis (thus addressing the first research question listed in 9.3.7), the Cox and 
PLR IPCW models were completed for the sequence of treatment change scenarios 
(none (ITT), ISC alone, ISC/personal choice and all changes) for each of time intervals 
(weekly, fortnightly and monthly) used for the creation of time-updated covariates 
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(seizures, AEs and dose). Both forward and backward selection (based on an initial pool 
of explanatory variables which alter the treatment hazard (or odds) ratio by at least 1%) 
were used to determine final models which included variables affecting the HR (or OR) 
by at least 2%, 5% or 10%. The corresponding bootstrapped CIs were also calculated, 
as the usual SEs for the Cox regression could not be calculated accurately due to time-
varying weights within individual. These results have been summarised in forest plots of 
treatment effects and BS CIs (Figure 11 to Figure 14) as well as tables (Table 49 to 
Table 54) to allow easy comparison across treatment change scenarios and model types 
(see Appendix B). 
Generally, the results show that baseline covariates were not usually selected into the 
WD model, but time-varying covariates are often selected, most commonly seizures but 
also dose and occasionally AE counts.  
The forward and backward selection procedures were not always consistent in their 
selection of different variables; this is not surprising, however, given that the selection 
criterion was defined in terms of the change in treatment effect relative to that from the 
previous model, which differed when using FS (which, for example, starts with an initial 
treatment-only model) compared to BE (which begins with the full model containing all 
potential variables). 
The PLR bootstrap confidence intervals (CIs) were generally wider than the usual CIs, 
due to the added uncertainty associated with bootstrapping. Indeed, initially, the 
bootstrap procedure for the PLR models resulted in very high sample failure rates due 
to lack of convergence (using both three and five knots), especially for the month spline 
variable. Investigation into the problems relating to knot positions and extreme weights 
(discussed above) helped to address this problem to a certain extent; however, this 
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model instability continued to affect the PLR five knot models in particular, leading to a 
continued problem of non-convergence of some bootstrap samples, extreme estimated 
covariate coefficients (typically >107) and artifactual peaks in the underlying baseline 
odds plots towards the end of follow up, suggesting instability of splines beyond the 
95th centile. Further evidence of overfitting was provided by the coefficients for the 
spline variables (which were often very close to zero) and low EPV ratios (especially for 
the VPS treatment change model) as more variables were added to the models, 
suggesting that it may be more appropriate to use fewer knots for the PLR spline 
variables.  
One potential consequence of this overfitting was that the number of variables selected 
into each PLR model was consistently smaller than for the corresponding Cox model, 
perhaps due to lack of power. These problems suggest that it may have been more 
appropriate to fit the model with fewer knots, potentially even with no knots (which 
equates to an underlying linear function of time).  
In general, more covariates were selected into the model as more treatment changes 
were adjusted for (from none (ITT) to ISC alone to ISC/choice to all treatment 
changes), because of the increased power in the treatment change model as more events 
are available for model estimation. The number of covariates selected into the model 
also tended to increase as the frequency of follow up information increased (in other 
words, as the length of time intervals decreased, from month to fortnight to week), 
again because the amount of information available (from time-varying covariates) is 
increased. 
As more variables were selected into the model, the treatment effect also tended to 
move away from one (towards zero, in other words further in favour of the control arm 
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VPS). However, given the fact that the number of variables selected into the model 
increased as more treatment changes were adjusted for, this variable selection process 
did not clearly reveal whether the reduction of the treatment effect (away from one) was 
due to the increased number of (and type of) treatment changes being considered or 
because of the increased number of variables being adjusted for. 
9.6. Conclusions  
As such, although this investigation into the selection of variables across the whole 
range of model features (model type (including the effect of bootstrapping on CIs), time 
interval, variable selection threshold and procedure, and the treatment changes 
accounted for) provides guidance on which (of the many) baseline and TVCs should be 
adjusted for in order to adequately satisfy the assumption of NUC, there are a number 
of questions of interest which remain to be answered, most notably whether the 
treatment effect is affected most by model type, reasons for treatment change or time 
interval. 
Thus, in order to allow direct comparisons to be made between each scenario and thus 
an assessment of the independent effect of each of these sources of variation on the 
resultant treatment effect, it became apparent that it would be necessary to fit a 
standard set of models which adjust for the same covariates for each of the model 
type/treatment change/time interval combinations.  
To this end, it was necessary to choose a standard set of covariates in order to 
investigate the influence of other factors (choice of model type and time interval, 
selection threshold and procedure, and the validity of normal or bootstrapped CIs for 
the PLR). Given that baseline covariates were not often selected into the ITT version of 
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each model, it seemed sensible to consider including a variety of combinations of only 
TVCs in the IPCW models. The results of this variable selection procedure across 
different modelling scenarios demonstrated that, on the whole, seizure count was 
selected most often into the IPCW models, followed by dose and then AEs. Thus it 
seemed appropriate that the following sequence of models should be considered: 
adjusting for time alone; adjusting for time and seizures; adjusting for time, seizures and 
dose; and finally adjusting for time, seizures, dose and AEs.  
Furthermore, given the evidence of overfitting with three and five knots for the PLR 
spline variables (with spline coefficients close to zero and frequent non-convergence of 
bootstrapped CIs), it was decided that a series of PLR models with only a linear time 
variable (in other words, without any splines) should be compared to those with three 
and five knots, in order to assess any subsequent effect on treatment effect estimates 
and evidence of overfitting. 
This proposed analysis using a standard set of covariates, the choice of which has been 
informed by the general trends of variable selection observed in this chapter’s 
investigational analysis, will be described in the next chapter. Furthermore, the use of a 
standard set of IPCW models will allow direct comparison with the corresponding 
RPSFTM analysis to determine the effect on inferences drawn using these contrasting 
methods.  
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10.      Comparison of IPCW and 
RPSFTM 
 
In Chapter 9, IPCW models were fit using forward and backward selection procedures 
with a range of selection thresholds in order to determine which of the numerous 
available covariates would most usefully be adjusted for in the IPCW analysis of the 
VPS vs LTG comparison of SANAD arm B. The results of this investigation suggested 
that the three TVCs (dose and cumulative seizure and AE counts) were all (to varying 
degrees) important confounders of the relationship between treatment received and 
remission, while the baseline covariates were less important.  
Thus, in this chapter, the IPCW and RPSFTM will be compared in the context of the 
SANAD arm B, using this standard set of TVCs determined by investigations described 
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in Chapter 9. The  use of a standard set of covariates allows the impact of various 
statistical factors on IPCW modelling to be investigated, including the choice of 
regression model (PLR or Cox), time interval for determining time-varying covariates 
(month, fortnight or week) and competing reasons for treatment changes. PLR 
modelling required further consideration of the method of confidence interval (CI) 
estimation (normal versus bootstrapped CIs) and number of knots for the spline time 
variable.  
10.1. Final standardised analysis  
For this standardised analysis, the IPCW analyses were conducted using Cox and PLR 
models, adjusting for an increasing number of TVCs (none; seizures alone; seizures and 
dose; seizures, dose and AEs) for each set of treatment changes (none (mimicking ITT); 
ISC only; ISC or choice; all treatment changes) and each time interval (month; fortnight; 
week). Normal and bootstrapped CIs were compared for the PLR models, fitted using 
zero, three and five knots for the time spline variable in order to evaluate the likelihood 
of overfitting in these models. This comparison allows a clear assessment to be made of 
the relative importance and influence of each of these factors on the treatment effect. 
Furthermore, the RPSFTM introduced in Chapter 8 was adapted in order to allow 
direct comparison with these IPCW models, thus only adjusting for those switches that 
relate to each particular treatment change scenario; therefore a series of RPSFTMs 
(adjusting only for “true” switches, as defined in Chapter 8) were fit according to the 
hierarchical structure of the causal research questions defined for the IPCW models. 
Note that it is possible to adjust the RPSFTM for any baseline factors that may be 
imbalanced between groups; however, given that no such covariates were identified as 
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particularly important in the IPCW selection procedure, this was not necessary. In 
contrast, it is inappropriate to adjust the RPSFTM for the TVCs that were selected for 
inclusion in the RPSFTM, as such adjustment would introduce selection bias. 
10.1.1. Causal questions of interest 
When faced with modelling decisions, it is important to keep focused on the clinical 
questions of interest, which in this case related to the treatment effect of LTG 
compared to VPS allowing for various reasons for treatment change. In addition to 
facilitating the comparison between the RPSFTM and IPCW in this trial, the use of a 
standard set of covariates in the IPCW models helps to answer the following 
(unanswered) questions from Chapter 9 regarding the impact of model type, reasons for 
treatment change or time interval on IPCW treatment effects: 
1. Do IPCW treatment effect estimates differ between Cox and PLR (and according 
to number of knots in PLR)? 
2. Do IPCW treatment effects change as more TVCs are adjusted for in the weight 
estimation model? 
3. How does the choice of time interval impact on IPCW treatment effects? In 
particular, does the use of smaller intervals (weekly intervals) for IPCW analysis 
make Cox and PLR models more similar?  
4. What are the general differences in IPCW treatment effects when different 
treatment changes are considered? 
5. How do IPCW and RPSFTM treatment effects compare for each of these 
treatment change scenarios? 
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Treatment change scenarios 
Table 41 demonstrates the practical differences between each of the modelling 
scenarios, in particular according to which treatment changes are adjusted for (which 
relates to the causal question of interest) and which TVCs are included in the WD 
model (which relates to the NUC assumption). When no treatment changes are 
accounted for, the results across all sets of TVC models are identical, given that no 
weights are generated. Artificial censoring is introduced at the time of a patient’s first 
treatment change (𝐹𝑖) if the reason for this change corresponds to the treatment change 
scenario under consideration; therefore, for each treatment change scenario, models 
vary only according to the number of TVCs that are used to generate time-varying 
weights in the WD models (in other words, according to the underlying NUC 
assumption).   
Bootstrap CIs compared with normal CIs 
Furthermore, these standardised analyses allow comparisons to be made between 
normal and bootstrapped CIs, as outlined in Table 42. As described in Chapter 5, 
normal SEs estimated from the Cox model are invalid, given that no allowance can be 
made for patient identity when applying their time-varying weights. Although such 
within-patient time-varying weights do not present a problem for PLR models, the 
actual process of estimating weights is known to artificially reduce the estimated SEs, 
suggesting the need for bootstrapped CI estimation for PLR models also. 
However, in scenarios requiring no artificial censoring (and hence no weights), namely 
those ITT scenarios where no treatment changes are adjusted for or for the treatment 
only models which do not adjust for any TVCs, the standardised analyses described in 
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this chapter allow direct assessment of the effect of bootstrapping compared to normal 
CI estimation methods. Without the complication of within-patient time-varying 
weights, the normal CIs for these Cox models are valid, thus providing an opportunity 
to directly compare the usual and bootstrapped CIs, such that any general observed 
differences between CIs can be attributed to the impact of bootstrapping (in order to 
verify the (generally accepted) validity of bootstrapping in this context).  
Furthermore, comparison between normal and bootstrapped CIs from PLR models 
which do require weight estimation will provide evidence of whether the process of 
estimating weights impacts on CI estimation. Although it is recognised that any such 
differences between these two CIs will reflect the impact of bootstrapping as well as 
weight estimation, the general effect of bootstrapping (alone) on PLR models is evident 
from the comparison between CIs for models that do not require weights (namely the 
ITT (or treatment only) models). Therefore, the difference in general trends seen 
between these two forms of CIs in models with and without weights give an indication of 
the effect of weight estimation on CI estimation over and above that of bootstrapping.  
These models were also assessed for evidence of overfitting, by considering EPV ratios 
for each model, as well as any non-convergence of bootstrapped samples or extreme 
model coefficients (as displayed in Table 42).  
EPV ratios 
As discussed in Chapter 9, a restricted cubic spline variable with 𝑘 knots introduces 
(𝑘 − 1) extra terms into the model; however given that a linear term is also required to 
accompany the spline variable, the total number of estimated coefficients required to 
model the underlying time effect for a restricted spline variable with 𝑘 knots is equal to 
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𝑘. A PLR model that includes no spline variables simply assumes a linear effect of 
treatment (and is indeed equivalent to a restricted cubic spline with one knot, given that 
such a spline restricts the tails (in other words, the whole spline) to be linear) and thus 
requires estimation of a single coefficient (for the linear term). The EPV ratios are 
interpreted in light of the recommendation that at least ten events (treatment change or 
remission, as appropriate) are required per variable included in the model, in order to 
ensure model stability (180). 
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Table 41 Artificial censoring and weighting, according to treatment changes (determined by causal question) and TVCs in WD 
model 
 TVCs adjusted for in analysis (relating to underlying NUC) 
  
 Treatment only Treatment + seizures Treatment, seizures + dose Treatment, seizures, dose + 
AEs 
     
Treatment change 
scenario 
    
None (ITT) 
 
No artificial censoring, therefore no weights required 
 
ISC 
 
Artificial censoring at 𝑭𝒊 (if first treatment change is due to ISC) 
 
No weights  
(as no TVCs are accounted 
for) 
Weights allowing for seizure 
count 
Weights allowing for seizure 
count and dose 
Weights allowing for seizure 
count, dose, AEs 
  
ISC/choice 
 
Artificial censoring at 𝑭𝒊 (if first treatment change is due to ISC or personal choice) 
 
No weights  
(as no TVCs are accounted 
for) 
Weights allowing for seizure 
count 
Weights allowing for seizure 
count and dose 
Weights allowing for seizure 
count, dose, AEs 
  
All 
 
Artificial censoring at 𝑭𝒊  
 
No weights  
(as no TVCs are accounted 
for) 
Weights allowing for seizure 
count 
Weights allowing for seizure 
count and dose 
Weights allowing for seizure 
count, dose, AEs 
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Table 42 Assessment of BS results, according to treatment changes and TVCs in WD model 
 Treatment alone Treatment + seizures Treatment, seizures + dose Treatment, seizures, dose 
+ AEs 
ITT 
 
 
No treatment changes (and hence no weights used) in ITT analysis: 
normal CI is valid; thus assess validity of BS by comparison with normal CI* 
ISC 
 
 
No TVCs and hence no 
weights: therefore 
normal CI is valid; 
assess validity of BS by 
comparison with 
normal CI* 
 
TVCs and treatment changes are both present; hence weights due to treatment changes are 
necessary:  
1) Cox:  
a. Normal CI is invalid (with no account made for multiple (time interval) 
observations for each patient) 
2) PLR (3 or 5 knots):  
a. Normal CI may be affected by weight estimation process: compare normal/BS CI 
to assess effect of weighting on SE (taking into account validity of BS from *) 
b. Overfitting of PLR models (especially with 5 knots) may lead to extreme 
coefficients and non-convergence of BS samples  
i. Typically very small coefficients (~0, i.e. OR~1) for spline variables, 
demonstrating little variation over time, but occasionally very large (>107) 
coefficients for 5th spline (leading to non-convergence of the 
bootstrapping model) indicating instability of model when fitting peak at 
the end of the range of time intervals.  
ii. Thus investigate PLR models with no spline variables (i.e. linear time 
effect only) 
ISC/choice 
 
All 
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10.2. Results 
In order to interpret this relatively complex analysis, it is helpful to focus, in turn, on 
each of the main research questions of interest listed in 10.1.1, while bearing in mind 
that the main purpose of the modelling exercise is ultimately to determine the treatment 
effect according to different reasons for treatment change. 
1. Do IPCW treatment effect estimates differ between Cox and PLR (and 
according to number of knots in PLR)? 
First, the results of the PLR and Cox models need to be assessed in terms of the effect 
of time interval, spline knots (for PLR models) and bootstrapping on model estimation 
and stability. 
The results in Table 58 to Table 59 (in Appendix C) demonstrate that spline variables 
(with 3 or 5 knots) cause low EPV, especially for withdrawal models. These low EPV 
ratios lead to overfitting of the treatment change models, evident by extreme 
coefficients for the tails of the spline distribution and non-convergence of the 
bootstrapped samples (indicated by subscripts in Table 60 to Table 63 (in Appendix C) 
as the number of bootstrapped samples (out of a total of 200) for which the model 
failed to converge). This is a particular problem for models where the number of 
observations on which to base the PLR is low (in other words, when using the month 
interval). This problem worsened as the number of events (treatment changes) on 
which to base this estimation fell (in other words, with more restricted treatment change 
scenarios) and as more variables were added to the treatment change model (either in 
the form of TVCs or due to the increasing number of knots in the spline variables). 
Thus non-convergence is a particular problem for the PLR models with five spline 
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knots assessing restricted treatment change scenarios with a monthly time interval, 
where more than half of the bootstrapped samples fail to reach convergence. 
However, despite this evidence of overfitting with increasing number of spline knots, 
the variation in terms of the treatment effect (OR) according to the number of spline 
knots is minimal. Interestingly, the difference between PLR treatment effects with 
different numbers of spline knots is greater for scenarios without adjustment for any 
treatment changes (ITT); otherwise the variation between OR estimates (between 
models with zero, three and five knots) tends to be at most 0.02.  
In contrast, the difference between treatment effects is far greater between model types 
(in other words between PLR and Cox models), as the Cox model seems to be more 
susceptible to changes in experimental factors (such as time interval and choice of 
TVCs).  
CI estimation 
The independent effects on CI estimation of weight estimation, bootstrapping and 
failing to account for patient identity (when Cox estimation involves within-patient 
time-varying weights) need to be investigated by considering three separate 
comparisons, summarised in Table 42.  
First, the comparison between usual and BS CIs for the models not involving any 
weight estimation (in other words, when no treatment changes or TVCs are adjusted 
for) will give an indication of the effect of bootstrapping on CI estimation. The PLR 
models without weights demonstrate the expected result that BS CIs tend to be wider 
than normal CIs (though not usually by more than 0.1) with the usual CI contained 
entirely within the BS CI (in other words, the upper (lower) limit from BS estimation 
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tends to be higher (lower) than the corresponding usual CI limit), but this is not true in 
all cases. In contrast the BS CIs from the corresponding Cox models (without weight 
estimation) tend to be narrower than the normal CIs. 
The effect of failing to account for patient identity in weighted Cox estimation is 
evident from the comparison between the normal and BS CIs for Cox models which 
adjust for TVCs (and which hence involve weights). Standard CIs are much narrower 
than BS CIs in these cases, because they fail to account for correlation between within-
patient time-varying weights. However, given the above result (that BS CIs tend in fact 
to be narrower than the corresponding (valid) normal CIs), this observation demonstrates 
just how misleading these invalid CIs are. 
Finally, the effect of weight estimation can be observed by comparing normal and BS 
CIs obtained for those PLR models involving weight estimation. The difference 
between these CIs comprises the effect of both weight estimation and bootstrapping; 
however given the finding above (that PLR BS CIs tend to be wider than their 
corresponding standard CIs but not usually by more than 0.1), the independent effect of 
weight estimation can be inferred by comparing this finding with the observation that 
normal CIs from weighted PLR models were consistently narrower (and tended to be 
contained within) the corresponding BS CIs, with a width difference in the region of at 
least 0.3.  
Thus, this informal analysis of the general trends across scenarios supports the theory 
that weight estimation does in fact lead to smaller SEs, and that standard Cox CIs 
estimated without regard for correlation for each patient’s time-varying weights are 
grossly inaccurate. In settings where normal CIs for PLR treatment effects can be 
validly estimated (not involving weight estimation), BS CIs tend to be marginally wider 
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than the corresponding normal CIs; surprisingly, however, BS CIs from corresponding 
Cox models in these analyses tend to be narrower than the normal CIs. 
The Cox models seem to be more affected than PLR by the need for a reliable pool of 
patients on which to base weight estimation; in the ISC treatment change scenarios, the 
Cox model CIs are particularly wide, reflecting the uncertainty with which the weights 
are estimated. 
For both the PLR and Cox models, as more treatment changes and TVCs are 
accounted for, the treatment effects move away from the null towards zero (in favour 
of VPS); this is especially true for Cox models; for example in Table 67, the HR fell 
from 0.77 (adjusting for no treatment changes) to 0.16 (adjusting for all treatment 
changes) for the monthly interval version of the Cox model. 
This meant that, without adjustment for any treatment changes (ITT), Cox treatment 
effect estimates were higher (closer to one) than the corresponding estimates from PLR 
regression. However, as Cox estimates were affected more markedly than PLR by 
changing model factors, once treatment changes were adjusted for, Cox treatment effect 
estimates fell and were lower (closer to zero) than their corresponding PLR estimates. 
2. Do IPCW treatment effects change as more TVCs are adjusted for in the 
weight estimation model? 
As more TVCs are added to the model, the treatment effects tend to move further 
towards zero; although this is true for both the PLR and Cox models, it is especially 
obvious in the Cox model. Furthermore, as the number of TVCs increases, the resulting 
treatment effect CIs widen, reflecting the uncertainty with which the weights are 
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estimated within each pool of participants with each covariate combination at each 
time. 
3. How does the choice of time interval impact on IPCW treatment effects? In 
particular, does the use of smaller intervals (weekly intervals) for IPCW analysis 
make Cox and PLR models more similar?  
Generally, it can be seen in Table 64 to Table 67 (in Appendix C) that varying time 
interval width does not greatly impact on treatment effects estimated by PLR, though 
BS CIs do vary between time intervals (though showing no systematic or obvious 
pattern, thus potentially simply due to Monte Carlo error, which would be overcome 
with a higher number of repeat samples). In contrast, treatment effects tend to fluctuate 
more markedly across time intervals when using Cox regression, with the HR tending to 
decrease (in favour of VPS) as the time interval lengthens (from week to fortnight to 
month). Furthermore, as would be expected, the difference between Cox and PLR 
treatment effect estimates generally (but not always) increases with time interval.  
4. What are the general differences in IPCW treatment effects when different 
treatment changes are considered? 
As more reasons for treatment change are adjusted for, treatment effects tend to drop 
further away from one, in favour of VPS. This effect is again observed much more 
markedly for Cox rather than PLR models.  
When weight estimation is based on few treatment changes (for example, when only 
adjusting for changes due to ISC), treatment effect CIs tend to be wide, especially for 
the Cox model. As more treatment changes are adjusted for, the CIs become narrower 
   
   
 
389 
 
due to increased stability of model weights because of the larger pool of patients on 
which the weights have been modelled.    
Generally, although susceptible to overfitting (due to spline variables and TVCs added 
to weight estimation models), PLR models appeared more stable than corresponding 
Cox models. Cox models seemed to be more susceptible to changes to modelling 
factors (BS CI estimation, time interval and TVC adjustment) and displayed greater 
fluctuations in treatment effect than PLR models. This apparent greater stability of 
PLR, even when subject to severe overfitting, suggests an advantage of PLR modelling 
in this context, which counter the inevitable complications in modelling relating to the 
fitting of spline variables.  
5. How do IPCW and RPSFTM treatment effects compare for each of these 
treatment change scenarios? 
In order to allow direct comparison between the IPCW and RPSFTM analyses, it is 
now of interest to approach the RPSFTM analysis using the same specific research 
questions as carried out for the IPCW; as such, the same hierarchical series of analyses 
allowing for different reasons for treatment changes were carried out using the 
RPSFTM, the results of which are shown in Table 68. Given that no baseline covariates 
were included in the IPCW models (and it would be inappropriate to include any TVCs 
in the RPSFTM), no extra covariates are added to the RPSFTM here. However, it 
should be noted that these results differ slightly from those in Chapter 8, as this analysis 
relates only to those patients who were included in the IPCW analysis, namely those 
with available data on dose, seizure and AE counts. 
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As with the IPCW, the main disadvantage of focusing on more specific reasons for 
treatment changes is the resulting reduction in power due to the reduced number of 
treatment change events on which to base the analysis. This issue is all the more 
problematic in the RPSFTM setting, as it compounds the existing limitation that all 
treatment changes other than direct switches between trial treatments are necessarily 
censored in the analysis. Therefore, even when adjusting for all treatment switches (due 
to ISC, choice or UAEs), these direct switches between trial treatments make up only 
one sixth (one third) of all treatment changes occurring prior to remission time in the 
VPS (LTG) group; the remaining five sixths (two thirds) of treatment changes are 
necessarily censored. Thus when analysis is restricted to adjust for treatment switches 
due to ISC alone, this proportion (of treatment changes that are appropriately 
accounted for in the analysis) drops to less than one tenth (one quarter) of the VPS 
(LTG) arm.   
Bearing in mind these limitations, it is however interesting to note that adjustment for 
treatment switches due to ISC alone causes the HR to move closer towards one, 
suggesting a smaller advantage of VPS compared to the result reflecting no adjustment 
for any treatment switches. (Note that this scenario does not entirely reflect the original 
ITT analysis, given that censoring is applied at the time of all treatment changes (other 
than just direct switches between LTG and VPS) as for the other sequential analyses.) 
This implies that if, rather than switching from VPS to LTG and vice versa, patients 
were treated with more appropriate dosing to tackle poor seizure control, the longer 
term beneficial effect of LTG in terms of providing seizure control, and ultimately 
remission, would be enhanced, although VPS would continue to be the treatment of 
choice.  
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However, it is equally important to note the relatively dramatic fall in HR (from 0.877 
to 0.772) when treatment switches occurring for reasons of personal choice (as well as 
ISC) are adjusted for. This change in treatment effect is especially surprising, given that 
the ISC/choice analysis adjustment differs from the ISC analysis adjustment only with 
respect to data from two VPS patients who switched out of choice, suggesting that the 
RPSFTM is relatively sensitive to small changes in the data. However, this trend 
continues as more treatment switches are adjusted for; the HR falls further (to 0.756) 
when treatment switches due to UAEs are also accounted for. 
In comparison to the IPCW analyses, adjustment for treatment switches using RPSFTM 
has a less dramatic effect on treatment effect estimates. This is expected, given that 
these treatment switches between LTG and VPS make up only one sixth (one third) of 
the treatment changes accounted for in the IPCW methods.  
Overall, this investigation into more specific, clinically relevant causal research questions 
demonstrated that (across all model variations), as more treatment changes were 
accounted for, the advantage of VPS over LTG increased; in other words, without 
deviation from randomised assignment, the observed (ITT) treatment effect would have 
indicated a further advantage of VPS over LTG.  
10.3. Conclusions 
There were a number of reasons why the IPCW was likely to perform better than the 
RPSFTM in this trial: first, in contrast to the RPSFTM, the IPCW is easily able to 
handle multiple randomisation arms (although for the sake of comparison, the same 
two-way comparison will be presented here as in the previous chapter). Furthermore, 
unlike for most other models, the initial 12 month period being devoid of events will 
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not violate the assumptions of the underlying Cox model used in IPCW, as this model 
makes use only of the ranking of events, rather than actual event times. 
The explicit allowance for time-varying confounders (under the NUC assumption) is a 
particular advantage of the IPCW, given that this form of confounding is especially 
relevant in the SANAD trial, where variables such as prescribed dose, and cumulative 
seizure and AE counts are likely to influence the probability not only of remission but 
also of treatment changes. For example, a high dose of treatment increases the chance 
of seizure control while simultaneously increasing the probability of adverse drug 
reactions, which in turn may trigger treatment changes. Indeed, it may be particularly 
important to consider adjustment for treatment doses in this trial, given the pragmatic 
trial design (where prescribed dose was completely at the discretion of clinician, and 
even the initial dose of randomised drug was not standardised) and lack of blinding. 
The greatest advantage of the IPCW analysis over the RPSFTM, however, is its ability 
to deal with any form of treatment change, without the need to bias analysis by 
exclusion or censoring of patients. This is because an IPCW analysis handles all types of 
(relevant) treatment change identically: namely by artificially introducing censoring of 
patients at the point of treatment change while appropriately accounting for this 
censoring using weighting, under the NUC assumption. Thus, in adjusting for all forms 
of treatment changes, the application of the IPCW method to the SANAD data 
addresses a slightly different research question from that to which the RPSTFM related, 
by providing an estimate of the relative treatment effect between treatments that would 
occur in the absence of any departure from randomised AED. 
Indeed, a direct comparison between IPCW and RPSFTM methods was not possible, as 
RPSFTM can only reliably account for a specific type of treatment change (in this case, 
direct switches between trial treatments); in order to allow a direct comparison between 
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these methodologies, adjustment in the IPCW analysis would have need to have been 
restricted to treatment switches alone. However, a further reduction in the number of 
treatment changes (on which weight estimation is based) to treatment switches alone 
would compound the existing problem of model instability due to low EPV ratios in the 
IPCW analysis. Unsurprisingly, therefore, the effect of RPSFTM on treatment effect 
reduction was less pronounced than with IPCW methods, as the majority of treatment 
changes were necessarily ignored (and in fact introduced censoring) in the RPSFTM. 
10.4. IPCW 
This chapter has demonstrated how a complex trial scenario can be translated into 
relevant causal contrasts to enable estimation using different approaches to survival 
analysis. However, there were a number of complications in the IPCW leading to 
necessary compromises and simplifications in the modelling exercise. It is now 
necessary to consider the conclusions in light of the inevitable limitations of this 
simplification process. 
10.4.1. Limitations 
There were a number of limitations relating to the application of IPCW methods in this 
context. Firstly, although the PLR version of the WD model seemed in general to be 
the most reliable and appropriate method to apply in this context, this model was 
complicated by the issue of how many knots to include in the spline variables. In this 
analysis, the same number of knots was used for the spline variables in both the 
remission and treatment change models. However, given the less complex pattern of 
probability of treatment change (compared to remission, which is complicated by the 
zero probability of event occurring prior to 12 months coupled with the peak of events 
at 12 months) and fewer treatment change events (compared to remission), it may have 
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been more appropriate to use a smaller number of knots (perhaps two or three) in the 
treatment change model, while using more knots in the remission model (clustered 
around the 12 month point to more accurately reproduce the evident non-linearity). 
Additionally, PLR modelling was developed originally for a large study (with over 5000 
subjects) (183), which provided many more treatment changes on which to base the 
WD model than in SANAD; thus, given the potential bias which increases as the 
number of (treatment change) events decreases when modelling is implemented without 
conditioning (187), it would have been interesting to investigate use of conditional (rather 
than pooled) logistic regression in this context.  
Furthermore, PLR is known to approximate well to the Cox model only when the 
probability of event within each discretised time interval is small (for example, <10%) 
(183). This was generally the case for all time intervals in the SANAD study apart from 
one major exception: given the large number of remission events occurring at 12 
months (with approximately 30% of patients achieving I12mR), this approximation is 
unlikely to hold at this time point. The magnitude of the bias introduced by this peak in 
event rates at the very start of the follow up period is unknown; thus it may have been 
useful to consider a simulation study (with known true HR and varying degree of peaks 
in event rates) in order to investigate the impact of this peak of event rates on PLR 
estimates.  
However, despite complications in PLR modelling due to necessary considerations 
regarding time interval, CI estimation and spline variables (and evidence of severe 
overfitting in some cases), PLR models were more stable than corresponding Cox 
models, which were highly susceptible to fluctuations in treatment effect with changes 
to modelling factors. For example, the effect of time interval (week, fortnight or month) 
was observed in the Cox model when all other factors were held constant, suggesting 
   
   
395 
 
that the differences in TVC values (held fixed at the start of each interval) between the 
different time interval analyses impacted on treatment effect estimation.  
The differences between the Cox and PLR models may have arisen because of the 
different way in which these models estimate the baseline hazard (or risk of event): PLR 
modelling explicitly introduces extra parameters (by way of spline variables) in the 
model to describe the hazard, while Cox models condition the baseline hazard out of 
the model likelihood.  
A further limitation of the application of the IPCW method in SANAD was the fact 
that the reason for treatment change was provided only for the first observed treatment 
change (as the first deviation from randomised treatment related to the primary 
outcome, time to treatment withdrawal). Although drug and dose data were available 
regarding each patient’s first three treatment changes, the reasons for these subsequent 
treatment changes were not collected. As such, when considering analyses adjusting 
only for certain reasons for treatment change, treatment changes occurring for other 
reasons were ignored without introducing artificial censoring; however, ignoring these 
changes (due to other reasons) invoked the implicit assumption that no further 
treatment changes relating to the reason of interest occurred subsequently in that 
patient. This demonstrates that, when considering the design of studies, trialists should 
consider carefully how data collection relating to treatment changes beyond the initial 
changes may impact on analysis limitations. 
Another drawback of the IPCW was the reliance on patient-reported information for 
the TVCs relating to seizure and AE counts. Chronic disease, because of their long term 
nature, cannot be as closely assessed as acute conditions; as such, follow up information 
in trials of diseases such as epilepsy often rely on patient self-reports for information on 
covariates such as adherence, adverse events or clinical events such as seizures. As 
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previously discussed, it is well known that patients may over-exaggerate their adherence 
in order to avoid disapproval from their health care provider; however there is also 
evidence to suggest that patients may under-report the occurrence of symptoms of their 
disease, particularly if their occurrence will lead to unwanted measures being taken.  
In the case of epilepsy, patients may not want to disclose the occurrence of seizures, 
especially if they have been seizure free for some time and are aiming to achieve a 
period of remission in order to regain their driver’s license. Previous (unpublished) 
analysis suggests a difference in the proportion of males and females achieving 
remission in SANAD, despite there being no clinical reason for the apparent 
disadvantage in females with respect to this outcome. It is hypothesized that males may 
have a greater incentive to regain their license (for example, when their job relies on 
their ability to drive) and thus may under-report their seizures. As such, given the 
importance of accurate data on all relevant TVCs in order to meet the NUC 
assumption, the potential for biased under-reporting of seizures may limit the value of 
the IPCW analysis in this setting. 
10.4.2. Assumptions 
Having discussed the practical application of the IPCW and RPSFTM methods in detail, 
it is useful to provide a reminder of the more general key factors for consideration when 
deciding whether to apply each of these methods. Given that these methods differ in 
terms of their assumptions and data requirements, their relative appropriateness 
depends on the circumstances to which they are applied; thus, it is necessary to consider 
the plausibility of their assumptions with each application. However, given that these 
assumptions are on the whole untestable, it is more realistic to consider whether these 
assumptions are generally reasonable rather than necessarily wholly satisfied in the given 
context (142). 
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IPCW is based on the fundamental assumption that groups are appropriately rebalanced 
after reweighting each (uncensored) individual’s contribution to analysis (195). However 
this in factor relies on two separate assumptions, not only that all factors used to match 
those who did and did not crossover (but who otherwise had identical prognosis) are 
known and measured, and therefore able to be accounted for when calculating weights 
(NUC assumption), but also that the trial setting provides a pool of exchangeable 
patients for each combination of prognostic factor, such that for each patient who 
change treatment, there are sufficient patients with equal prognosis and similar 
likelihood of changing treatment who did not switch treatments (positivity). If too few 
patients of each prognostic profile level either did or did not change treatment at a 
particular time point, the weight generation model will be unstable and extreme weights 
will result for the corresponding patients. These patients would then receive undue 
influence in the model, which will increase the chance of spurious model results (often 
manifested as extreme coefficients or large SEs). 
Rather than sample size per se, therefore, it is the number of events on which to base 
weight estimation that is important (along with NUC) in order to ensure that the 
exchangeability assumption is met. Indeed the IPCW method has been shown to be 
prone to high levels of bias in relatively large sample sizes (500) when a high proportion 
(>90%) of control patients switch to experimental treatment, even when the NUC 
assumption holds (142). Therefore, as expected, in smaller sample sizes where very few 
events have been observed, the IPCW method is likely to perform poorly (196).  
However, the NUC assumption represents a key limitation of the IPCW method 
(which, unlike the positivity assumption, cannot be overcome by increasing sample size) 
and may be particularly problematic in an RCT context. Typically RCT datasets are 
much smaller than observational datasets and when fewer data are available, the IPCW 
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method may become less stable and CIs may become wide. In addition, key predictors 
of treatment switching are not always collected in RCTs (such as patient switching 
preferences) and often data collection on key indicators is stopped at some point (for 
example, upon treatment discontinuation or disease progression) which hampers the 
applicability of the IPCW method (142).  
With time-varying confounders, the exchangeability assumption (dependent on the 
NUC and positivity assumptions) is particularly unlikely to be true throughout follow 
up, especially as number of remaining patients receiving treatment as randomised falls. 
Furthermore, as observed in this analysis, large values of time-dependent confounders 
strongly associated with treatment change may lead to extreme weights (even after 
stabilising) and subsequent invalid causal estimands. 
The NUC assumption as part of the IPW method introduces further conundrums. 
Although the probability of treatment change is assumed to depend on known 
confounders alone, in order to allow valid IPW estimation, it is necessary that not all 
patients with these confounding features actually do change treatment. Thus it must be 
considered why these patients did not experience a treatment change; it may simply be a 
random occurrence, or it may be that these patients differ systematically from those 
who did change treatment, indicating that an additional selection effect has been missed 
(and the NUC assumption is therefore invalid) (111). 
Thus Robins (111) stipulates that the IPTW method should be accompanied by 
sensitivity analyses to assess the degree to which violations of the NUC assumption may 
change analysis conclusions. Robins demonstrates how such sensitivity analyses may be 
carried out, first by defining a measure that quantifies the degree of confounding due to 
unmeasured factors and then assessing whether conclusions alter materially when this 
measure is allowed to vary over a range of non-zero values. 
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10.4.3. Further investigations 
As demonstrated in this chapter, even in a large trial like SANAD with common 
treatment changes and excellent follow up (without the usual problems when deviation 
from treatment protocol leads to deviation from follow up protocol), there remained 
uncertainty regarding the most appropriate method to use, with obvious major 
limitations and assumption violations with each method. In particular, the limited 
number of events relating to the most important clinical question (of adjusting for 
treatment changes due to ISC alone) meant there was very little scope for further 
extensions to the model in this context.  This is unfortunate, given that there were a 
number of issues that warranted further investigation in this trial.  
Firstly, given that loss to follow up is often related to prognosis, it would have been 
interesting to assess the impact of (potentially informative) loss to follow up (when 
patients’ outcome data are censored prior to the administrative censoring date of the 
trial or to achieving remission) on conclusions, for example using IPCW methods to 
calculate weights relating to the probability of loss to follow up (rather than treatment 
change). However, there were insufficient numbers of patients who experienced 
censoring prior to remission or treatment change to allow valid estimation of such 
weights.  
Furthermore, it would have been useful to investigate the impact of assumptions 
regarding those 42 patients with missing seizure data for at least one of their clinic visits, 
comparing simple and multiple imputation techniques (with estimation of missing 
values  based on predictive patient characteristics) as described in Chapter 9. 
The IPCW model could have been extended to compare all three randomised arms in 
arm B of the SANAD trial. However, this three-way comparison was not attempted, 
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not only because of the additional complexity that would be introduced by such an 
analysis, but also because the clinical question of interest related particularly to the two-
way comparison between VPS and LTG alone. 
A further data quality issue affecting the IPCW model was the assumption that long 
periods without follow up data indicated no change in outcome or treatment 
prescription. Given that the occurrence of any missed clinic visits may well be related to 
a patient’s condition, it would have been interesting to carry out a sensitivity analysis 
where patients’ data were censored if the interval since their previous follow up 
information exceeded a certain (clinically informed) time period (for example, six or 
twelve months), with adjustment for potential bias introduced by such censoring 
accounted for using IPW (adjusting for all confounding factors predicting loss to follow 
up and outcome). If the overall conclusions of the IPCW were affected greatly by 
varying the time before follow up was censored, this would demonstrate the sensitivity 
of the analysis to the assumption that all follow up data were accurately accounted for. 
A further consideration regarding data accuracy is that of measurement error. For 
example, it is known that patients with extreme numbers of seizures (some with 
multiple seizures per day) were only able to provide approximations of the number of 
seizures experienced between clinic visits. The impact of this inevitable measurement 
error is likely to be inflated due to the increased influence of extreme values of TVCs in 
determining time-varying weights. Although this issue would be addressed to a certain 
degree through the use of truncation of seizure counts (at the 95th centile), it would have 
been useful to assess the sensitivity of conclusions drawn when extreme seizure counts 
were varied systematically (for example, increased or decreased by a certain amount). 
It would also be interesting to investigate further the impact of extreme weights on 
analysis, as were observed in this application, potentially using simulation studies. 
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Indeed, the practical and statistical problems associated with weight estimation that 
were encountered during this analysis are not unusual, and research into improving 
methods for weight estimation is a continuing area of debate (197). 
Adherence to treatment prescription 
However, perhaps of greatest interest and impact would be the consideration of 
adherence to treatment prescription. Given that there were no detailed compliance 
information collected as part of the SANAD trial, it was not possible to assess the effect 
of treatment adherence, rather than simply treatment prescription on remission. Given 
that AEDs can lead to unpleasant side effects, it is likely that a substantial proportion of 
patients do not always adhere to their daily dose. It is quite plausible that the effect of 
nonadherence to treatment prescription on outcome could be of a similar magnitude to 
that of changes in treatment prescription; however, without any adherence data, it was 
not possible to investigate this in the causal analyses presented in these chapters. 
In order to explore the likely impact of adherence on causal estimation, it would be 
useful to carry out a simulation study, assessing the effect on outcome of various levels 
of compliance and various degrees of association between a patient’s compliance and 
their prognosis. The parameters used to simulate these compliance data would be 
informed by the small amount of compliance information collected in the annual quality 
of life questionnaire in SANAD. In estimating the impact of (ignoring) adherence 
information on clinical interpretation of results, this simulation study would differ from 
that previously suggested, which instead would assess the statistical validity of applying 
this methodology in this setting. 
An additional simulation study assessing impact would also be useful to investigate 
adjustment for particular reasons for treatment change. In particular, although clinicians 
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were primarily interested in the question of treatment effect adjusted for treatment 
changes caused by ISC, there was inadequate power in the SANAD data to estimate this 
treatment effect with any confidence. The reason for this is that patients are likely to 
experience treatment changes due to other events before making changes due to ISC. If 
seizures persist, rather than giving up and changing treatment immediately, clinicians 
often initially increase the dose of randomised drug to see if seizure control can be 
achieved through more appropriate dosing (198). However given that increasing dose 
increases the likelihood of adverse reactions, patients may then be censored for reasons 
related to UAEs prior to switching treatment (because of ISC) or achieving remission. 
Alternatively, treatment changes for other indications may well occur (prior to remission 
or treatment changes due to ISC), such as the patient requesting to change treatment 
(for example, because they believe themselves to be in a state of remission (even though 
they have not yet achieved 12 months of remission from seizures) or because of a desire 
to become pregnant, which is contraindicated with some AEDs). In providing more 
power than the original SANAD data, a simulation study based on observed treatment 
change profiles in SANAD would allow valid and independent estimation of specific 
weights for each cause of treatment change (ISC, personal choice or UAEs); thus it 
would be possible to use IPCW methods to obtain individual’s weights (and hence 
adjust) for each (relevant) cause of treatment change.  
Furthermore, it would then be possible to use results from such analyses to adjust for 
multiple reasons for treatment change, with patients’ overall weights obtained simply by 
multiplication of their individual (relevant) reason-specific weights. The resulting 
treatment effects, adjusted for each combination of reason for treatment change, could 
then be compared to those obtained using the sequential approach demonstrated in this 
chapter; if broadly similar, this would validate and support the use of the hierarchical 
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approach in model scenarios with low power (given that weight estimation for 
individual reasons for treatment change is compromised when there are insufficient 
treatment changes for each individual reason within each treatment group). 
10.4.4. Alternative methods 
In censoring follow up at the point of each patient’s first treatment change, IPCW 
methods may present an advantage, if follow up data post-change are considered 
misleading or unhelpful, and hence may be more powerful than ITT. If, instead, the 
follow up data after first treatment change are believed to contain potentially useful 
information, it may be advantageous to fit a MSM, which uses information from all 
periods of treatment, in other words, after as well as before the change from randomised 
treatment.  
For example, IPTW weighting could have been applied to the SANAD data, where 
these weights are estimated from the inverse probability of observed (rather than simply 
randomised) treatment. Rather than artificially censoring at the time of treatment 
change, an IPTW model regresses the outcome on a suitable summary of treatment 
history (such as a time-varying binary treatment indicator) throughout follow up, 
adjusting for each individual’s estimated probability of receiving their observed 
treatment. The difference between IPTW (MSM) and IPCW methods may best be 
understood by considering their interpretation in the absence of any relevant TVCs: is 
such a case, an IPTW model would reduce to a simple (unweighted, baseline covariate-
adjusted) AT analysis (with a time-varying treatment indicator); in contrast, without 
TVCs, the IPCW method reduces to an (unweighted, baseline covariate-adjusted) PP 
analysis (censored at the point of first relevant treatment change). 
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Such a method would also have been feasible for the honey trial, in which factors likely 
to confound the relationship between treatment and outcome included a patient’s age 
and their (time-varying) wound size. Clinicians were inclined to treat younger, fitter 
patients with honey as they believed it to be a promising treatment for such patients; 
this is evident when comparing the median (IQR) age of the five patients who were 
switched from conventional to honey treatment by their clinician [44 (38, 53) years] to 
that of the remaining patients [72 (56.5, 79) years]. Conversely, treatment of large 
wounds with a poor prognosis was likely to be switched to more extreme modalities, 
such as surgery. Thus, in theory, it would have been feasible to fit an IPTW model to 
this trial data, by first using a Cox or PLR model to predict each patient’s probability of 
receiving their actual observed treatment for each time interval, dependent on their age 
at randomisation and (time-varying) wound size. The inverse of these predicted 
probabilities could then be used to weight analysis of time to healing (or time to 50% 
reduction in wound size) regressed on treatment received, thus providing a treatment 
effect estimate free from selection bias. Furthermore, it would have been interesting to 
account for LTFU (for example, when patients moved wards or hospitals) using 
separate IPCW (where censoring is due to LTFU rather than artificial censoring at the 
time of treatment changes). However, the validity of this model would rest on the 
questionable assumption that these two prognostic factors wholly account for the 
association between treatment changes and prognosis. Unfortunately there were 
insufficient numbers of treatment changes to allow the IPCW method to be performed 
with any confidence. 
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10.5. RPSFTM  
10.5.1. Limitations 
As discussed in Chapter 8, there were a number of severe limitations when the 
RPSFTM was applied to analysis of time to 12 month remission in the SANAD B trial; 
in particular, the model is unable to accurately represent the peak in remission events at 
12 months or the lack of events prior to 12 months, resulting in model predictions of 
remission event times prior to 12 months.  
Furthermore, in handling only one form of treatment change (direct switches between 
randomised treatments), patients’ follow up was necessarily censored at the time of all 
other treatment changes (thus introducing bias in a similar manner to that of PP 
analyses). The application to the RPSFTM of the hierarchical structure (adjusting for 
certain reasons for treatment change) in this chapter presents a further challenge, due to 
the reduction in power as fewer numbers of relevant treatment switches are adjusted for 
in the restricted treatment change scenarios. 
10.5.2. Further investigations 
As such, given the severity of these fundamental limitations of the RPSFTM in this 
context relating to violations of basic necessary assumptions and limited power, a 
discussion of potential refinements or extensions to the model may seem somewhat 
redundant. However, for the sake of completeness, these will be presented here, 
particularly as a number of these model variations would, in theory at least, provide 
partial solutions to some of these major flaws. 
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10.5.3. Assumptions  
The first of these potential solutions relate to the likely violation of the common 
treatment effect in SANAD, given that the treatment effect may vary according to 
whether treatment is received on diagnosis (which was the time of randomisation for 
the majority (87%) of recruited patients in these treatment groups) or following 
treatment failure of the alternative (randomised) treatment. Although in theory it would 
be possible to extend the RPSFTM to include more than one treatment effect (perhaps 
with a different treatment covariate for treatment received prior to and after treatment 
failure (of randomised drug), thus differentiating between treatment received from 
randomisation or following treatment switch), the resulting complexity of the model 
would mean that, in practice, the additional parameter would be not be estimable with 
any degree of certainty. 
The RPSFTM assumes the treatment effect is multiplicative, immediate and constant 
(which may not be true, as a patient’s response to treatment may change as patient 
progresses through disease); therefore the acceleration factor is interpreted as an 
average effect over time, across patients and disease stages (195). 
Thus it is important to consider whether the assumptions underlying the modelled 
treatment effect are likely to reflect the true treatment effect. For example, if the 
common treatment effect assumption does not hold (such that the treatment effect 
differs according to when treatment is initiated), the RPSFTM will produced biased 
results (as demonstrated by Morden (137)). 
Given that treatment switches are likely to be associated with prognosis, it is not 
possible to confirm the validity of the common treatment effect assumption using 
observed data alone; instead it is important to seek expert clinical guidance in order to 
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back up claims regarding the plausibility of this assumption. In particular, it is useful to 
ascertain the likely variation in effectiveness of treatment as disease progresses (142). 
For example, the plausibility of the common treatment effect may be questionable if 
treatment switches only occur when clinically indicated, such as on disease progression, 
at which time the capacity for a patient to benefit may be different compared to pre-
progression because of their advanced disease. 
Although it would be of interest in many clinical scenarios, therefore, to estimate 
multiple treatment effects, the RPSFTM is limited in that it becomes increasingly 
unstable when trying to estimate more than one such parameter. As such, alternative 
methods are required to address this issue. 
10.5.4. Alternative methods 
One such method, an alternative two-stage version of the RPSFTM, was proposed and 
demonstrated by Robins (95) and Yamaguchi (199) respectively, in an attempt to 
overcome the problem of violations of the common treatment effect assumption. These 
methods are appropriate when there is a definitive secondary baseline (for example, date 
of disease progression) at which point alone switching may occur, such that 
randomisation is assumed to be adhered to until this point. These methods effectively 
recognise that the clinical trial is randomised up until the point of disease progression, 
for example, but beyond that point, essentially becomes an observational study.  
This two-stage approach first uses a counterfactual SNM (which, as described in 
Chapter 5, is similar to the RPSFTM but relies on the assumption of NUC rather than 
randomisation for g-estimation) to obtain estimates of the treatment effect specific to 
control patients in order to allow estimation of their counterfactual event times (in 
other words, as if they had not switched to receive experimental treatment); these 
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“shrunk” survival times then form a counterfactual dataset unaffected by switching, 
thus providing an inferred “uncontaminated” control arm against which the treatment 
effect specific to experimental group patients can be estimated. However, given that the 
SNM is essentially an observational version of the RPSFTM and attempts to account 
for time-dependent confounding using the NUC assumption, this method has similar 
limitations to the IPCW (135). In particular, when very high switching proportions are 
combined with small sample sizes, these two-stage methods are likely to be prone to 
error and bias. 
Latimer (142) proposes that these methods can be simplified to remove dependence on 
g-estimation, if it is plausible to assume no time-dependent confounding between time 
of disease progression and time of treatment switch, such that only those factors 
collected at the point of treatment switch which determine treatment switch are adjusted 
for, rather than requiring data on all time-dependent confounders (as required by the 
more general two-stage approaches).  
Such two-stage methods remove the need to rely on the potentially implausible 
common treatment effect assumption, but they do depend on identifiability of a suitable 
secondary baseline (at which point (alone) switches occur and at which all patients are 
assumed to be at a similar stage of disease) and on the NUC assumption to hold at this 
secondary baseline time point. When switching occurs soon after the secondary 
baseline, the scope for such time-dependent confounding is limited, but this is not the 
case if switching happens substantially after the secondary baseline, in which case the 
potential for such bias becomes substantial (142). 
In summary, this simplified two-stage model removes the dependence on the common 
treatment effect assumption, and does not require data to be collected on confounders 
at time points other than at the time of the treatment switch. However, such a method 
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may be prone to time-dependent confounding if switches occur beyond this time point. 
Furthermore, it may not be generalisable to all disease areas, given its reliance on the 
ability to identify a secondary baseline at which point all switches occur. 
These methods may be particularly relevant for cancer clinical trials, where the decision 
when and whether to initiate second-line treatment on disease progression is often left 
largely at the discretion of the treating clinician, though the protocol may provide brief 
or broad guidance on this. Factors which influence this decision include the patient’s 
clinical condition, abnormal laboratory markers or adverse drug reactions; as such, the 
effect of second line therapies may be viewed as arising from observational studies 
(136). The argument against the common treatment effect in this clinical setting stems 
from the fact that a constant AF essentially consider first-line and second-line patients 
equally, whereas in clinical practice they are considered to be different patient 
populations.  
However, in disease areas such as epilepsy with less clearly defined points of treatment 
change (as a clinician’s decision to alter treatment prescription varies on an individual 
patient basis, depending on their own tolerability and priorities), such a secondary 
baseline is less obvious, therefore rendering such methods less useful. 
A further potential refinement to the RPSFTM in this setting relates to the typical 
lengthy withdrawal periods when patients switch AEDs; in theory it would therefore be 
relevant to consider allowing for lagged effects of treatment, whereby the treatment 
effect is extended by a certain time period beyond the recorded date when withdrawal 
began, either up to the recorded date when the drug was taken for a final time, or by 
assuming a general withdrawal period (informed by clinical opinion) for all patients 
coming off each treatment.  
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As discussed in Chapter 8, mixture modelling may be applied in order to get around the 
problem of necessary truncation of AF prior to 12 months (as 12 month remission 
cannot, by definition, occur before this time) and the peak of events at 12 months. 
Mixture modelling involves fitting separate models for immediate and delayed 
remission, where the immediate remission model needs to reflect treatment over 12 
months but is complicated by the fact that a basic time-varying treatment covariate is 
appropriate only until the time at which first seizure occurs.  
An alternative approach to adjustment for treatment changes would be to consider 
adjustment for changes to prescribed treatment using joint modelling of survival 
outcome and longitudinal dose data (under an NUC identifying assumption), as 
demonstrated by Williamson et al (198) for the CBZ versus LTG comparison among 
arm A SANAD patients. Given that dose titration differed between these treatment 
arms (as clinicians were more familiar with the standard CBZ drug and hence tended to 
prescribe higher doses more quickly, whereas they were more cautious with newer 
LTG), there was a concern that UAEs would be more likely in patients randomised to 
the more well-known standard drugs. Hence analysis was carried out, adjusting for 
standardised dose levels between treatment groups (calculated by dividing patients’ 
doses by their treatment-group-specific median initial doses) in joint modelling of dose 
and survival. This analysis demonstrated that the observed benefit of LTG in terms of 
preventing AEs was maintained even allowing for the difference in titration rates 
between arms, and that the two arms remained similar in terms of seizure control once 
doses had been accounted for. 
Although useful in adjusting for differential rate titration between groups, this joint 
modelling analysis did not, however, account for treatment changes or switches 
between arms: supplementation with additional drugs was ignored, and once 
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randomised treatment was withdrawn (in other words, the dose of randomised 
treatment dropped to zero), analysis was censored. Given that such censoring is likely to 
introduce bias, it would be desirable to extend the joint model to allow for between-
group switches using RPSFTM methods. However, given the complexity of both the 
joint modelling and RPSFTM models, extensions to allow for between-arm switches as 
well as dose titration would be overly complicated and beyond the scope of this PhD. 
Alternatively, it would be possible to combine the methodology of the RPSTFM (to 
model the effect of direct switches between randomised treatments of interest) with that 
of the IPCW (to remove the bias caused by the necessary censoring of events that occur 
prior to or after the “true” switches of interest and also to potentially allow for 
competing events). However, any benefit gained by reduction in bias when undertaking 
such an analysis would be unlikely to outweigh the problems caused by the additional 
model complexity or underlying flaws associated with the use of the RPSFTM in this 
context. 
Thus, in applying the hierarchical structure regarding reasons for treatment change to 
the analysis of T12mR in this chapter, it is apparent that the severe limitations of the 
RPSFTM, discussed in Chapter 8, are compounded further. In adjusting only for those 
switches occurring for particular reasons, the usefulness of this model is reduced, while 
the bias is increased (because of additional necessary censoring when patients 
experience treatment switches for other reasons). 
10.6. Conclusions 
This comparatory analysis has demonstrated a number of key conclusions regarding the 
use of IPCW and RPSFTM methods in a context such as SANAD.  
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In particular, as regards IPCW modelling, analysts must consider whether the 
underlying assumption of NUC is convincing, and whether accurate data are available 
on all relevant confounders between treatment changes and outcome (for example, 
information used by clinicians when deciding to change a patient’s treatment 
prescription or when recommending a treatment switch, as this clinical information will 
often also relate to outcome). Furthermore, it is necessary to determine whether there is 
a sufficiently large pool of those who did (and did not) change treatment at each 
particular time point within each category (defined by cross-classification of all 
confounders in the model) to allow reliable weight estimation; in practical terms, this 
requires assessment of the proportion changing treatment in relation to the sample size 
at each time point for each combination of patient factors; analysts must also be vigilant 
regarding evidence of extreme weights or coefficients. 
Technically speaking, when applying IPCW methods, it is not necessary to continue 
outcome follow up beyond the time of the first relevant treatment change. However, 
given that it may be of interest to apply sensitivity analyses (for example, adjusting for 
other forms of treatment change) or to compare IPCW methods with those obtained 
using the RPSFTM, it is wise to collect survival information on patients beyond the 
time of treatment changes until the outcome (or censoring) event occurs.  
In contrast to the IPCW, which accommodates all types of treatment changes (indeed, 
treatment changes are not differentiated in the analysis; they are all treated identically, by 
artificial censoring at the point of the first treatment change), the RPSTFM cannot 
easily handle more than one type of treatment change. Although the RPSFTM could in 
theory be extended to adjust for multiple forms of treatment change, in practice such 
complexity leads to model instability (94). Generally, the RPSFTM will be most 
appropriate when the treatment deviations mostly take the form of switches between 
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trial treatments and when it is plausible to assume that the effect of treatment is 
constant (regardless of when treatment is received).  
Thus, the main considerations when applying RPSFTM relate to the assumption of a 
common treatment effect and limitations regarding adjustment for only a single form of 
treatment deviation. Thus, analysts may need to consider whether the treatment effect 
may continue after discontinuing treatment (in which case it may be appropriate to 
introduce a lagged treatment effect; for example, this may have been particularly 
important in SANAD given the long withdrawal phases following the date when 
treatment was officially stopped) or whether the impact of treatment may differ 
according to the clinical state of the patient (in which case the common treatment effect 
assumption is violated). Although these assumptions are untestable with empirical data, 
it is possible to evaluate the performance of the RPSFTM by examining the model 
results; for example, analysts should consider the extent of recensoring (and its potential 
impact on treatment effects, if a treatment-time interaction is clinically plausible) and 
judge the success of G-estimation (by assessing the similarity of the distribution of the 
adjusted counterfactual (“untreated” or “control” state, as appropriate) event times 
between randomised groups). 
10.7. Summary 
As demonstrated in this chapter, even in a large trial like SANAD with common 
treatment changes and excellent follow up (without the usual problems when deviation 
from treatment protocol leads to deviation from follow up protocol), there remained 
uncertainty regarding the most appropriate method to use, with obvious major 
limitations with each available method. In particular, the limited number of events 
relating to the most important clinical question (of adjusting for treatment changes due 
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to ISC alone) meant there was very little scope for further extensions to the model in 
this context.   
In the next chapter, general guidelines will be presented for trialists facing similar 
decisions on how best to adjust for treatment changes in order to estimate causal effects 
in a randomised trial with survival outcomes, taking into account the modelling 
requirements and practical limitations of the alternative methods. 
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11.       Discussion 
The aim of this thesis has been to explore, explain, demonstrate and compare the use of 
causal methodologies in the analysis of RCTs, in order to make the available (but 
somewhat technical) statistical methods more readily accessible and comprehensible by 
non-specialist analysts. 
The thesis began with an overview of the impact of treatment nonadherence in general 
practice as well as in trials, highlighting that nonadherence to medical advice has been 
recognised as a widespread problem since the 1970s but its impact on clinical trial 
analyses is less well appreciated. Increased understanding of the reasons for deviation 
from prescribed treatment and recognition of the expertise patients often have 
regarding their own disease state have led to a move away from the traditional 
paternalistic, authoritative relationship of a doctor with their patients, towards a more 
shared decision-making model of concordance. However this notion of concordance 
does not easily translate into the world of RCTs, because of the need for inferences to 
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be made based on a known treatment structure, required for even the most pragmatic 
of trial protocols.  
Any deviation from assigned treatment renders ITT analysis (the only analysis that 
properly mirrors the randomisation process) defective in estimation of any effect except 
effectiveness of treatment as implemented in the trial. Examples of real life trials 
featuring different patterns of nonadherence and various research questions of interest 
demonstrated the need for methods beyond ITT to answer such questions.  
Thus an overview of statistical methods was presented, intended as an aid to researchers 
who are new to the field of causal inference, thus presented with an emphasis on 
practical considerations necessary to ensure appropriate implementation of techniques 
and a particular focus on interpretation of methods, rather than technical detail. This 
background research and consideration of the wider issues (for example, when it is 
appropriate to use different methods, and how to approach such analyses with 
necessary consideration of both the clinical and statistical issues) has been usefully 
summarised in a number of guidance tools, complemented by demonstration of 
analyses, intended to provide guidance for trialists and statisticians on how to approach 
causal analysis.  
In particular, this statistical literature review demonstrated the bias inherent in naïve 
methods which fail to respect randomisation, and presented various statistical methods 
to more appropriately estimate causal effects, with a particular focus on survival 
methods, as these are often relevant in settings typically associated with nonadherence 
(featuring long term treatment and follow up). 
A review of published trials then demonstrated that, despite the fact that deviation from 
allocated treatment occurs in the vast majority of trials, issues relating to bias caused by 
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deviation from treatment are rarely considered or addressed appropriately by trial 
analysts, suggesting the need for wider appreciation of the availability of other causal 
methods. 
Following a description of the necessary practical and statistical considerations required 
for such causal analyses, two methods to account for treatment deviation were 
presented and applied in the analysis of survival outcomes, in trials of contrasting 
complexity. In particular, the SANAD trial provided numerous analysis issues and 
challenges, due to the complexities of the trial design and nature of treatment changes 
that occurred. These challenges are likely to be common in other chronic disease areas, 
where treatment changes may occur for a number of competing reasons and interest lies 
in achieving remission of symptoms. As such, this novel application of complex 
methods in this complicated trial scenario provided a useful example for discussion of 
the analysis issues and methods, striking a balance between simplifications of 
compliance scenarios and associated assumptions in order to make the methods 
sufficiently easy to apply, and yet without compromising on the necessary detail on 
nature of and reasons for non-compliance which importantly inform analysis.   
This application of methods has provided a transparent discussion of issues, potential 
biases and limitations, as well as how to interpret results obtained from causal methods 
for analysis of survival outcomes. In particular, these analyses demonstrated a number 
of issues which are likely to be common among trials with long term treatments and 
deviation from protocol, for example, when difficulties arise when trying to account for 
numerous forms of treatment deviation (in RPSFTM) or problems relating to extreme 
weights (in IPCW modelling). These issues were addressed using various approaches, 
for example, truncation and transformation of skewed covariates in order to reduce the 
impact of the resulting extreme weights in IPCW modelling. Other complications in 
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IPCW modelling included the need to apply variable selection processes independently 
of (invalid) p-values, the use of bootstrapping to address the problem of deflated SEs 
resulting from weight estimation, data preparation and modelling complexities 
associated with time-varying covariates, issues of low power when investigating 
competing reasons for treatment change, and the need to consider knot positions for 
underlying time spline variables necessary for PLR modelling. 
The analyses demonstrated in these final chapters have demonstrated how the two 
pictograms presented in Chapter 7 can be used, first to clarify the compliance scenario 
such that a relatively complicated compliance situation, such as that in the SANAD trial, 
can be simplified into a feasible scenario for analysis, and secondly to guide the analyst 
when choosing which appropriate method of analysis to employ. Sketching a cDAG 
may also help to clarify the causal scenario, for example in helping researchers to 
determine whether factors are likely to be time-dependent confounders affected by 
prior treatment (and thus appropriate for adjustment using IPCW methods) or simply 
time-dependent covariates.  
A final reference tool for researchers is now provided, presenting general guidelines for 
trialists when faced with the decision of whether to use RPSFTM or IPCW 
methodology to adjust for treatment deviations when analysing survival outcomes. 
11.1. Choice of survival analysis methods 
When planning to carry out adjustment for treatment changes in trials with survival 
outcomes, analysts need to consider which of the available methods would be most 
appropriate, while recognising that no one method will be appropriate for all 
circumstances; instead the performance of each method will depend on the particular 
trial setting to which they are applied. Table 43 and Table 44 provide a reminder for 
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trialists of the modelling assumptions and practical limitations of the alternative 
methods. 
Table 43 RPSFTM considerations 
Model feature Consideration required 
Common treatment 
effect 
Consider whether treatment effect is likely to be constant regardless of 
when treatment commenced. 
  
Secondary baseline  If treatment switches tend to occur at a common “secondary baseline” 
(for example, on progression), at which point treatment effect is likely 
to differ from treatment started at randomisation (for example, on 
diagnosis) thus violating common treatment effect, consider instead 
using two-stage RPSFTM. 
  
Various forms of 
treatment change 
Consider how to address treatment changes (other than those 
directly accounted for by definition of “on” and “off” treatment in 
model) in relation to causal research question of interest: substantial 
numbers of treatment changes (which are not relevant to the causal 
scenario in question) will undermine validity of analysis, due to 
necessary censoring at the time of such changes.  
  
Impact of 
recensoring 
Assess effect of recensoring by checking the number of event times 
(and events) that were recensored, considering the potential impact on 
treatment effect estimation (if a treatment-time interaction is possible). 
  
Test model 
performance 
Assess success of G-estimation by comparing the counterfactual 
distributions (the control state event times estimated by applying the 
optimal AF to the RPSFTM) for the treatment and control arms; these 
should be similar under the randomisation assumption. 
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Table 44 IPCW modelling considerations 
Model feature Consideration required 
Selection of TVCs Consider how best to determine which TVCs are important in 
predicting treatment change and outcome: consult clinical opinion; 
may be necessary to apply selection procedure (if numerous TVCs) 
Functional form of 
covariates  
Check optimal functional form using lowess curve of martingale 
residuals (from Cox model) 
Extreme covariate 
values 
Truncate at the 99th centile to avoid extreme weights (which in 
turn distort treatment effect estimate) due to influential outlying 
values of important predictors of treatment change/outcome  
Time intervals (for 
discretised TVCs) 
Strike the balance between greater accuracy (increases as interval 
length decreases) and computational intensity (increases with 
interval length) 
Model type:  
Cox or PLR 
PLR is useful if using lagged variables or if TVCs change frequently 
(and therefore are too complicated to be analysed without 
discretising) 
 Cox modelling avoids the need to consider splines to mirror 
underlying risk function in PLR model 
Splines                   
(for PLR only) 
Create and use treatment-specific spline variables for WD model, 
but use overall splines for the WO model 
 Consider shape of underlying risk, in order to identify times where 
risk changes, in order to inform positioning of knots 
CI estimation Estimate CIs using bootstrapping to overcome correlation due to 
within-patient time-varying weights (in Cox model) and the reduction 
in SEs due to the weight estimation procedure 
EPV ratio  Consider ratio of number of variables in model to number of 
treatment change events, in particular when considering the number 
of knots to use for spline variables (spline with 𝒌 knots requires 𝒌 
variables) 
Model assumptions  Consider plausibility of NUC assumption (whether all confounding 
variables have been accounted for) by seeking clinical expert opinion  
 Examine model weights for evidence of violation of positivity 
assumption: extreme weights may indicate unreliable pool of patients 
who do (or do not) change treatment at a particular time (within a 
given subgroup of patients defined by cross-classification of model 
covariates) 
 
   
   
421 
 
Given their differing assumptions and data requirements, neither IPCW nor RPSFTM 
methods will be directly applicable in every trial setting. It may be useful to apply both 
(or alternative variations of these) methods, as a means of assessing the sensitivity of 
results to the associated assumptions (200, 201). Furthermore, although it is good 
practice to decide on an analysis plan before undertaking analysis, the application 
presented in the previous chapters demonstrate that the analysis plan may need to be 
altered as analysis proceeds. However, in order to avoid accusation of selective 
reporting, it is important to be transparent and report fully on all modifications of 
analyses that take place. Thus, if several methods have been applied, it is important to 
provide a discussion of the limitations and potential biases associated with each method 
when presenting results, as an aid for interpretation. 
11.2. Economic evaluation 
These two causal methods for survival outcomes are important, not only from a patient 
or clinician perspective, but also for economic evaluations of drugs by regulatory 
authorities. This is a particular problem in cancer trials, given that patients are often 
permitted (or indeed encouraged) to switch treatments on disease progression or relapse 
(142), leading to distortion of OS results. Furthermore, licensing bodies such as the 
United States Food and Drug Administration and the European Medicines Agency may 
accept PFS as a primary endpoint for drug approval, reducing the incentives to maintain 
trial randomisation beyond disease progression. However, although showing an OS 
advantage may not be essential for obtaining marketing authorisation, a lifetime horizon 
is generally advocated in economic evaluations, especially for interventions that impact 
upon survival (as recommended, for example, in the NICE Guide to the Methods of 
Technology Appraisal). Thus interest is growing in how to address the issue of 
treatment switches in order to provide unbiased and clear treatment OS comparisons 
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which are not available from ITT, PP or AT analyses. Causal effect modelling 
techniques are receiving attention as a potential solution to the problem, and there have 
been a number of submissions made to NICE and the Scottish Medicines Consortium 
which have applied IPCW or RPSFTM when considering cost-effectiveness of a 
number of cancer drugs (202-204).  
However these applications tend to be post hoc, secondary analyses devised to cope 
with problems arising with the interpretation and use of ITT estimates. In order to 
increase their credence, more thought needs to be given to the use of such methods at 
the protocol development stage, considering the degree to which treatment changes are 
likely to occur, what information is likely to be used in making the decision to change 
treatment and which methods of statistical analysis are likely to be the most appropriate. 
Lack of available compliance data provide further barriers to reliable assessment of non-
compliance in CE assessments. As such, despite the significant impact of non-
compliance on clinical and economic factors, the impact of non-compliance on drug 
therapeutics is rarely considered. Reporting of the extent and nature of clinically 
relevant compliance measures by trialists would facilitate assessment of non-compliance 
in CE assessments, an area of potential further research. 
11.3. Future work 
In addition to the proposed extensions to RPSFTM and IPCW modelling discussed in 
Chapter 10, it would be interesting to use qualitative research methods to explore 
factors relating to the reasons for non-compliance, either on the part of the patient or 
treatment provider. Greater understanding of the reasons why patients do not adhere 
could usefully inform compliance analyses, in a manner analogous to using data on 
reasons for missing outcome data to inform sensitivity analyses. Furthermore, 
   
   
423 
 
knowledge regarding typical barriers to adherence could be used to improve likelihood 
of participant adherence by introducing relevant adherence-enhancing measures in 
treatment protocols.   
Following on from the review of adherence information reported in published 
randomised, it would also be interesting to examine the nature and quality of such data 
typically obtained from routine clinical records, as these records may provide a useful 
source of adherence information to inform analysis of observational studies. 
11.4. Statistical analysis plan 
In order to ensure availability of necessary data and protect against selective reporting, 
trialists need to consider at the design stage the statistical analysis methods that will be 
employed to adjust for non-compliance. First, it is necessary to consider the trial aims 
and likely directions of bias introduced by any anticipated adherence problems, in order 
to determine whether analysis by ITT is likely to be appropriate or sufficient (135). 
Regardless of trial aims, however, reporting information on the uptake and acceptance 
of treatment is important for the interpretation of the success of the trial treatments, 
even when analysis does not aim to adjust for nonadherence to treatment protocol. 
Even when clinicians are not interested in an explanatory analysis per se (but instead are 
interested in the effectiveness of the policy of starting with a certain treatment, for 
example), it is nevertheless important for clinicians to be aware of what changes did 
occur; otherwise, without an understanding of what the trial treatment policy entailed or 
how it panned out, it is not possible to fully appreciate or interpret the effectiveness of 
the trial treatment policy. Even when a trial does not involve many treatment changes, 
this fact should be communicated so that those interpreting the results are aware that 
the ITT result is likely to closely mirror the explanatory effect of treatment. Thus, 
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regardless of whether a trial is designed and analysed to demonstrate effectiveness or 
efficacy of treatment, or any measure in between, it is important to provide a clear 
description of the degree and nature of treatment changes. 
To this end, it may be helpful to create a monitoring plan which specifies how all 
relevant compliance data will be collected, recorded and reported during the course of 
the trial. Data should be collected in order to ensure clinically relevant summaries of 
compliance can be created (3). Reporting missing data is as important as disclosure of 
treatment deviations, given that the two are often related and interlinked (121). In 
particular, trial reports should distinguish withdrawal due to LTFU from active 
decisions to exclude patients from analysis (for example, due to withdrawal or deviation 
from treatment protocol) (41). 
Furthermore, without the collection of required data, any necessary statistical methods 
will never be realized; thus it is important to plan which variables should be collected, 
relevant to the chosen statistical methods (for example, which baseline and post-
randomisation time-varying covariates will predict treatment change, to facilitate IPCW 
estimation), with details given on how these compliance and covariate measures will be 
measured in practice. The choice of statistical methods should be discussed and justified 
in a detailed statistical analysis plan, given that each method has its own different 
advantages and disadvantages and relies on different assumptions, considering the use 
of sensitivity analyses to assess departures from identifying assumptions.  
Likewise, investigators must interpret the results of analyses presented in trial reports in 
light of (lack of) information regarding (or adjustment for) treatment adherence 
changes, critically appraising the trial design, conduct and analysis (50). 
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11.5. Power and sample size 
Analysts should also consider the effect of nonadherence or treatment changes on the 
power of trial analyses. Non-compliance in a trial typically reduces the power of ITT 
analyses because the treatment experiences of randomised groups are in fact more 
similar than intended. Although it may seem natural to aim to recover this lost power, it 
is often impossible to do so using the methods discussed above without making 
additional unverifiable assumptions regarding the comparability of those who do and do 
not comply, such as those underlying PP and AT analyses (69).  
For this reason, potential loss of power caused by compliance should also be considered 
when planning the sample size of a trial which aims to demonstrate treatment efficacy. 
Given that it will rarely be possible to regain the associated lost power, the initial sample 
size of a trial should incorporate an inflation factor based on realistic projections of 
relevant forms of treatment non-compliance (53).  
Snapinn (179) demonstrates how informative non-compliance impacts on sample size 
and power, discussing different methods developed to allow for likely non-compliance 
rates when planning trial sample sizes. Snapinn describes how the majority of the 
sample size methods available assume only treatment switches to the alternative 
treatment and all assume that such discontinuation is independent of outcome (i.e. 
uninformative). Snapinn argues that this (latter) assumption can lead to greatly 
underestimated sample sizes, because it is not the rate of non-compliance per se, but 
rather the proportion of endpoints occurring in non-compliant patients, that impacts on 
power; Snapinn goes on to demonstrate an alternative method of determining sample 
size which allows for informative dropout (205). 
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White (69) considers whether it is possible to regain the lost power in an ITT analysis 
caused by departures from randomised treatment without making assumptions about 
selection effects (which are implied, for example, when using PP or AT analyses in an 
attempt to regain power), and discusses two possible ways to achieve this: firstly by 
using a modelling approach to impute missing compliance-types using the observed 
outcomes (206, 207) rather than simple ITT analyses; White notes, however, that the 
gain in power stems from distributional assumptions, and as such these methods may 
be highly sensitive to departures from the distributional assumptions. Secondly, 
covariates that predict compliance may be used to regain power (for example, in CACE 
analyses or structural mean models) (144). 
In survival analysis, a related idea of weighted analysis, where earlier event times are 
assigned more weight, may provide extra power; however, in practice, this gain in power 
is unlikely to be substantial. Lagakos (208) investigated this issue when a constant HR 
among compliers yields a non-constant ITT HR (because of early termination of 
treatment among non-compliers); although the inefficiency of the ordinary log rank test 
can be improved in these situations (with weights dependent on the amount and pattern 
of early termination), the efficiency gains were small in many of the scenarios 
investigated.  
11.6. Trial designs to address deviation from randomised treatment    
Dunn (58) points out that nonadherence is not always due to a lack of cooperation on 
the part of the patient or a flaw in the design or methodology of a trial; indeed, 
nonadherence issues may be inherent to the disease and treatment process, and if 
foreseen, may be incorporated into the design of a trial during the planning stage, for 
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example in the case of encouragement or Zelen’s RCD trials, both of which incorporate 
the possibility of all-or-nothing compliance by patients in the experimental arm. 
In Zelen’s randomised consent design (209), introduced to improve trial recruitment, 
the usual order of consent followed by randomisation is reversed, so that eligible 
patients are first randomised into one of the treatment arms, and then their consent is 
sought regarding their willingness to receive this randomised treatment.  
Similarly, encouragement designs may be employed if the consent process is likely to 
lead to adherence problems, either because patients may not accept idea of 
randomisation in the given setting or if informing patients about treatment may then 
affect adherence of patients who end up in control arm. For example, if it is considered 
unethical to withhold treatment from one treatment arm, it may be possible to instead 
randomise incentives for treatment, such that one group receives no incentive different to 
usual (introducing no ethical problem) while the other group receives a treatment 
incentive (for example, in (127)).  
Other simple design features may be incorporated to aid adherence analyses; for 
example, compliance measurements may be taken during a baseline placebo run in 
phase to obtain information on baseline predictors of compliance (noting that such a 
placebo run in phase will be useful in determining which of these variables should be 
recorded because, although the magnitude of relationship between such variables and 
placebo/treatment compliance may differ, the actual variables which correlate with 
placebo and treatment compliance are likely to be the same (144)), or it may be possible 
to seek out patient preferences before they are randomised, in order to obtain 
information on preference effects for better prediction of underlying compliance (210).  
   
   
428 
 
Likewise, if a trial is likely to involve numerous forms of treatment changes (for 
example, if a variety of treatment options are available on disease progression) or if 
extreme degrees of nonadherence are expected (for example, when randomisation is 
unlikely to be acceptable to most patients), it may be helpful to pre-empt the problem 
by trying to design the trial such that specific sequences of treatment are assigned from 
randomisation, or repeat randomisations take place as and when patients require 
different treatment lines. However, such designs may themselves be subject to 
nonadherence (when clinicians prescribe alternatives to the randomised treatment 
sequences) and may be overly complex or lengthy. 
SMART designs 
Sequential multiple assignment randomised trials (SMART) for the estimation of 
dynamic treatment regimens, in order to better estimate the optimal treatment package 
(sequence of treatments) for individuals rather than for diagnosis, are of particular 
importance in chronic conditions where individual patient’s response may change over 
time, thus seeking out personalised medicine tailored to suit patients (for example, 
according to their genetic profile or at a more macro level of characteristics, such as side 
effect profiles) (211). Using functions with covariates, treatment and response history as 
arguments, with outputs of which actions should be taken (in other words, the decision 
rule on how to choose treatments rather than an “optimal” actual treatment) these 
designs assume, in a similar manner to IPCW and SMMs, that one has access to all 
known covariates which predict outcome and treatment changes (for example, patient 
and clinician preferences). 
SMART designs are particularly appropriate for diseases where sequential phases of 
treatment are common, for example chronic conditions like asthma, epilepsy and cancer 
(requiring different first- and second-line treatments following diagnosis and 
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progression, respectively) and behavioural or psychological interventions. For example, 
the efficacy of warfarin (in treating thrombosis) is highly dependent on individual 
patient factors (diet, genetic variants and interactions with other medication), with 
serious side effects if inappropriate dosing; as such dose needs to be monitored 
regularly. Use of SMART designs in such settings is complicated, however, by the need 
to take account of repeated continuous dose data.  
Depending on the particular trial characteristics, SMART designs may therefore result in 
better retention of patients (given the availability of multiple treatment options for 
patients while in the trial) and greater generalisability to clinical care (as the adaptive 
design and treatment flexibility allows for wider recruitment than in general) but 
typically involve long term follow up and large sample sizes, with associated high costs. 
Furthermore this relatively new and unfamiliar trial design is often met with reticence 
from funders and statisticians; thus it will be important for this growing area of research 
into study design to continue to be explained and explored more fully, in order to 
maximise its potential use in addressing adherence issues. 
11.7. Software  
Finally, it is important for analysts to consider whether software is available for their 
chosen analysis methods or whether specialist help and programming will be required. 
Certain methods (such as RPSFTM “strbee” code in Stata for survival outcomes 
adjusting for switching between trial treatments) are available as statistical programs that 
are user-friendly and easy to implement without specialist statistical knowledge or 
programming.  IPCW methods are also becoming increasingly incorporated into 
statistical programs (for example, IPCW methods have been included in the latest 
update of Stata); however, there may be extra coding requirements required for 
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implementation of these methods depending on the complexity presented by the trial 
data (as in the case of these applications in SANAD).  
11.8. Conclusion 
This thesis has demonstrated how an ITT effect estimate in the presence of treatment 
deviations will be biased as an estimate of treatment efficacy or effectiveness in a setting 
different from that in the trial. There is therefore often a need for other causal analysis 
methods to supplement or replace ITT analysis, depending on the research question, 
pattern of treatment deviations, trial design and particular outcome of interest. 
Despite the importance and increasing pertinence of causal analysis estimation in RCTs, 
however, whenever causal methodology is employed, analysts must remember that such 
analyses are not intended to replace or overrule analysis according to ITT; instead causal 
methodology seeks to complement analysis by randomisation, by providing greater 
insight and additional evidence regarding treatment efficacy. As encapsulated by Efron 
(39), “None of this spells the end of intent-to-treat analysis. It is and will remain a 
steadfast beacon in the foggy vistas of biomedical experimentation, but old friends need 
not feel abandoned when exciting new possibilities are explored”. 
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Appendix A: Effect of knots on treatment effect from PLR and Cox models 
Table 45 Effect of number of knots on treatment effect from PLR and Cox models 
Time 
interval 
Treatment 
changes 
Number of 
observations 
(patients) 
Number of withdrawals 
(remissions) 
Cox PH regression  
treatment effect  
(log likelihood) 
for treatment only model 
PLR treatment effect (log pseudolikelihood) 
for treatment + time only model 
LTG VPS Total 3 knots 4 knots 5 knots 
Monthly  ITT 8315  - - - 0.774  0.246 0.824 0.155 
  (395) (143) (154) (297) (-1587.9) (-1135.2) (-1152.4) (-1110.7) 
 ISC 6544  50 26 76 0.773 1.018 0.602 1.947 
  (392) (110) (141) (251) (-1318.8) (-882.4) (-915.4) (-863.0) 
 ISC/choice 6494  53 29 82 0.774 1.019 0.592 1.933 
  (392) (108) (139) (247) (-1295.1) (-869.3) (-901.6) (-850.3) 
 All 5405  64 56 120 0.736 0.889 3.897 0.005 
  (373) (90) (114) (204) (-1039.9) (-699.5) (-681.8) (-637.5) 
Biweekly  ITT 17985  - - - 0.770 0.839 1.031 0.316 
  (395) (143) (154) (297) (-1582.7) (-1349.9) (-1351.5) (-1327.6) 
 ISC 14196  52 26 78 0.769 1.017 1.274 0.923 
  (395) (110) (141) (251) (-1313.4) (-1071.4) (-1080.4) (-1068.5) 
 ISC/choice 14087  55 29 84 0.770 1.018 1.264 0.917 
  (395) (108) (139) (247) (-1289.7) (-1055.1) (-1063.8) (-1052.3) 
 All 11766  74 59 133 0.731 0.298 0.772 0.058 
  (387) (90) (114) (204) (-1035.4) (-851.8) (-865.1) (-845.1) 
Weekly  ITT 36256  - - - 0.762  0.701 1.034 0.156 
  (396) (144) (155) (299) (-1582.2) (-1628.8) (-1583.2) (-1543.8) 
 ISC 28606  52 26 78 0.767 1.021 1.176 0.086 
  (396) (111) (141) (252) (-1311.0) (-1259.1) (-1270.6) (-1223.1) 
 ISC/choice 28389  55 29 84 0.768 0.431 1.135 0.203 
  (396) (109) (139) (248) (-1287.4) (-1237.0) (-1251.5) (-1218.4) 
 All 23721  77 60 137 0.728 0.153 0.003 0.587 
  (392) (91) (114) (205) (-1033.0) (-1003.2) (-1004.3) (-993.2) 
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Table 46 Effect of knots on unweighted remission model (monthly intervals) 
Treatment 
changes 
Number of 
observations 
(patients) 
[range] 
Number of 
treatment 
changes 
(remission) 
Cox PH 
treatment 
 effect (ll) 
 
Pooled logistic regression 1. 3 knots 2. 4 knots 3. 5 knots 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
1. ITT 
8315  
(395) 
[1,63] 
- 
(297) 
0.774 
(-1587.9) 
All follow up (knots at 
usual centiles) 3, 11, 36 NC 2,8,16,45 NC 2,6,11,20,45 NC 
All follow up (knots 
clustered at ~1yr) 3, 12, 36 NC 2,11,13,45 NC 2,6,11,13,45 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
13, 22, 45 
0.702 (-1115.8) 
12,18,28,51 
0.713 (-892.0) 
12,16,22,32,51 
0.715 (-879.6) 
Only >=1yr included 
0.717 (-873.6) 0.713 (-892.0) 0.715 (-879.6) 
2. ISC 
4011  
(379) 
[1,62] 
76 
(251) 
0.772  
(-1318.8) 
All follow up (knots at 
usual centiles) 2, 9, 28 NC 1,7,12,37 NC 1,5,9,15,37 0.699 (-742.0) 
All follow up (knots 
clustered at ~1yr) 2, 12, 28 NC 1,7,12,37 NC 1,5,11,13,37 0.694 (-682.4) 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
12, 20, 40 
0.694 (-968.0) 
12,16,24,48 
0.697 (-652.0) 
12,15,20,27,48 
0.693 (-644.7) 
Only >=1yr included 
0.693 (-669.8) 0.697 (-652.0) 0.693 (-644.7) 
3.ISC or 
choice 
6494  
(392) 
[1,62] 
82 
(247) 
0.774 
(-1295.1) 
All follow up (knots at 
usual centiles) 2, 9, 28 NC 1,6,12,37 NC 1,5,9,15,37 0.705 (-731.8) 
All follow up (knots 
clustered at ~1yr) 2, 12, 28 NC 1,11,13,37 0.699 (-672.7) 1,5,11,13,37 0.699 (-672.7) 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
12, 20, 40 0.694 (-953.3) 12,16,24,48 0.700 (-642.4) 
12,15,20,27,48 
0.695 (-634.6) 
Only >=1yr included 
12, 20, 40 0.699 (-660.1) 12,16,24,48 0.700 (-642.4) 0.695 (-634.6) 
4. All 
5405  
(373) 
[1,62] 
120 
(204) 
0.736  
(-1039.9) 
All follow up (knots at 
usual centiles) 2, 9, 24 NC 1,6,11,31 NC 1,5,9,13,31 NC 
All follow up (knots 
clustered at ~1yr) 2, 12, 24 NC 1,11,13,31 0.651 (-525.7) 1,5,11,13,31 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
12, 18, 34 
0.632 (-757.8) 
12,15,22,42 
NC 
12,14,18,25,42 
NC 
Only >=1yr included 
0.650 (-516.1) NC NC 
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 Table 47 Effect of knots on unweighted remission model (fortnightly intervals) 
Treatment 
changes 
Number of 
observations 
(patients) 
[range] 
Number of 
treatment 
changes 
(remission) 
Cox PH 
treatment  
effect (ll) 
 
Pooled logistic regression 3 knots 4 knots 5 knots 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
1. ITT 
17985 
(395) 
[1,130] 
- 
(297) 
0.770  
(-1582.7) 
All follow up (knots at 
usual centiles) 5, 23, 76 NC 3,16,34,95 0.709 (-1239.7) 3,13,23,42,95 NC 
All follow up (knots 
clustered at ~1yr) 5, 26, 76 NC 3,25,27,95 0.699 (-1134.4) 3,13,25,27,95 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
28, 49, 97 
0.705 (-1346.9) 
27,40,61,109 
0.713 (-1026.4) 
27,36,49,69,109 
0.714 (-1012.7) 
Only >=1yr included 
0.712 (-1045.0) 0.713 (-1026.4) 0.714 (-1012.7) 
2. ISC 
14196 
(395) 
[1,130] 
78 
(251) 
0.769 
(-1313.4) 
All follow up (knots at 
usual centiles) 4, 20, 60 NC 2,14,26,78 NC 2,11,20,32,78 0.706 (-934.9) 
All follow up (knots 
clustered at ~1yr) 4, 26, 60 NC 2,25,27,78 NC 2,11,25,27,78 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
28, 44, 86 
0.706 (-1053.1) 
26,36,54,103 
0.699 (-796.4) 
26,33,44,60,103 
0.694 (-781.4) 
Only >=1yr included 
0.697 (-772.9) 0.699 (-796.4) 0.694 (-781.4) 
3.ISC or 
choice 
14087 
(395) 
[1,130] 
84 
(247) 
0.770 
(-1289.7) 
All follow up (knots at 
usual centiles) 4, 19, 60 NC 2,13,26,78 NC 2,11,19,32,78 0.712 (-921.1) 
All follow up (knots 
clustered at ~1yr) 4, 26, 60 NC 2,25,27,78 NC 2,11,25,27,78 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
28, 44, 87 
0.711 (-1037.9) 
26,36,54,103 
0.702 (-784.4) 
26,33,44,60,103 
0.695 (-768.6) 
Only >=1yr included 
0.698 (-760.4) 0.702 (-784.4) 0.695 (-768.6) 
4. All 
11766 
(387) 
[1,130] 
133 
(204) 
0.731  
(-1035.4) 
All follow up (knots at 
usual centiles) 4, 18, 51 NC 2,12,24,65 NC 2,10,18,28,65 NC 
All follow up (knots 
clustered at ~1yr) 4, 26, 51 NC 2,25,27,65 NC 2,10,25,27,65 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
27, 41, 75 
0.662 (-816.7) 
26,35,49,91 
NC 
26,32,41,54,91 
NC 
Only >=1yr included 
0.646 (-597.1) NC NC 
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Table 48 Effect of knots on unweighted remission model (weekly intervals) 
Treatment 
changes 
Number of 
observations 
(patients) 
[range] 
Number of 
treatment 
changes 
(remission) 
Cox PH 
treatment  
effect (ll) 
 
Pooled logistic regression 3 knots 4 knots 5 knots 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
Knot values Treatment effect 
(pll) 
1. ITT 
36122 
(396) 
[1,263] 
- 
(297) 
0.768 
(-1580.6) 
All follow up (knots at 
usual centiles) 10, 47, 152 NC 5,33,68,191 NC 5,26,47,85,191 NC 
All follow up (knots 
clustered at ~1yr) 10, 52, 152 NC 5,51,53,191 NC 5,26,51,53,191 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
58, 98, 196 
0.707 (-1559.7) 
54,81,123,219.65 
0.708 (-1192.7) 
54,73,98,139, 
219.65 
0.711 (-1170.2) 
Only >=1yr included 
0.708 (-1223.6) 0.708 (-1192.7) 0.711 (-1170.2) 
2. ISC 
28535 
(396) 
[1,263] 
78 
(251) 
0.767  
(-1311.0) 
All follow up (knots at 
usual centiles) 8, 39, 119 NC 4,27,51,155 NC 4,21,39,63,155 NC 
All follow up (knots 
clustered at ~1yr) 8, 52, 119 NC 4,51,53,155 NC 4,21,51,53,155 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
56, 88, 174 
0.710 (-1229.9) 
53,74,109,207 
0.696 (-879.6) 
53,68,88,122,207 
0.702 (-854.5) 
Only >=1yr included 
0.698 (-910.7) 0.696 (-879.6) 0.702 (-854.5) 
3.ISC or 
choice 
28318 
(396) 
[1,263] 
84 
(247) 
0.768  
(-1287.4) 
All follow up (knots at 
usual centiles) 8, 39, 120 NC 4,26,51,156 NC 4,21,39,63,156 NC 
All follow up (knots 
clustered at ~1yr) 8, 52, 120 NC 4,51,53,156 NC 4,21,51,53,156 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
56, 88, 175 
0.715 (-1211.7) 
53,74,109,208 
0.696 (-864.2) 
53,68,88,122,208 
0.703 (-839.9) 
Only >=1yr included 
0.699 (-895.9) 0.696 (-864.2) 0.703 (-839.9) 
4. All 
23671 
(392) 
[1,263] 
137 
(204) 
0.728  
(-1033.0) 
All follow up (knots at 
usual centiles) 7, 35, 102 NC 4,24,48,131 NC 4,19,35,55,131 NC 
All follow up (knots 
clustered at ~1yr) 7, 52, 102 NC 4,51,53,131 0.657 (-763.0) 4,19,51,53,131 NC 
All follow up (knots from 
time > 1 year; splines 0 < 
1 year) 
56, 83, 151.3 
0.666 (-969.5) 
53,70,99,183 
0.645 (-675.4) 
53,65,83,110,183 
0.652 (-661.3) 
Only >=1yr included 
0.647 (-706.4) 0.645 (-675.4) 0.652 (-661.3) 
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Appendix B: IPCW modelling results 
The treatment effect (CI) in the cell nearest to the left is valid for empty cells.  
[] denotes the usual normal 95% CI for comparison with the bootstrapped CI for PLR.  
Subscripts following CIs denote the number of bootstrap samples for which the model did not 
converge. 
Key for tables demonstrating variables selected into model: 
  Addition (or removal) of variable alters treatment effect by less than 1%, and variable is 
therefore not included in pool of potential variables for selection into model  
.  Variable is included in initial pool of potential variables for selection into model (i.e. 
addition of variable alters treatment effect by more than 1%) but fails to be included in the 2%, 
5% or 10% models (as its addition (or removal) of variable alters treatment effect by less than 
2%) 
 Addition (or removal) of variable alters treatment effect between 2 and 5% 
  Addition (or removal) of variable alters treatment effect between 5 and 10% 
        Addition (or removal) of variable alters treatment effect by more than 10% 
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Table 49 Treatment effect (95% BS CI) [standard CI] with monthly intervals 
 Treatment  
alone 
Variable selection threshold  
 10% 5% 2% 
No treatment changes     
PLR – 3 knots 0.71 [0.55, 0.92]    
FS  0.71 (0.57, 0.95) 
[0.55, 0.92] 
  
BE  0.71 (0.57, 0.95) 
[0.55, 0.92] 
  
PLR – 5 knots 0.72 (0.55, 0.93)    
FS  0.72 (0.57, 0.95) 
[0.55, 0.93] 
  
BE  0.72 (0.57, 0.95) 
[0.55, 0.93] 
  
Survival analysis  0.77 (0.62, 0.97)    
FS  0.77 (0.64, 0.94)   
BE  0.77 (0.64, 0.94)   
     
ISC changes only     
PLR – 3 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.52, 0.996) 
[0.52, 0.94] 
 0.68 (0.41, 1.09)1 
[0.51, 0.91] 
BE  0.70 (0.52, 0.996) 
[0.52, 0.94] 
 0.68 (0.50, 0.97) 
[0.51, 0.92] 
PLR – 5 knots 0.70 (0.52, 0.93)    
FS  0.70 (0.51, 0.99) 
[0.52, 0.93] 
 0.68 (0.39, 1.11)127 
[0.50, 0.91] 
BE  0.70 (0.51, 0.99) 
[0.52, 0.93] 
 
  
Survival analysis  0.77 (0.60, 0.99)    
FS  0.65 (0.29, 0.98) 0.71 (0.47, 1.62) 0.68 (0.43, 1.26) 
BE  0.77 (0.62, 0.99) 0.74 (0.53, 1.00) 0.68 (0.43, 1.26) 
     
ISC/choice changes only     
PLR – 3 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.52, 0.99) 
[0.52, 0.94] 
 0.68 (0.45, 1.42) 
[0.51, 0.92] 
BE  0.70 (0.52, 0.99) 
[0.52, 0.94] 
  
PLR – 5 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.51, 0.996) 
[0.52, 0.94] 
 0.68 (0.37, 1.11)104 
[0.50, 0.93] 
BE  0.70 (0.51, 0.996) 
[0.52, 0.94] 
  
Survival analysis  0.77 (0.60, 0.97)    
FS  0.63 (0.22, 0.92) 0.69 (0.42, 1.40) 0.63 (0.39, 1.34) 
BE  0.63 (0.24, 0.92)  0.63 (0.37, 1.17) 
     
All treatment changes     
PLR – 3 knots 0.65 (0.47, 0.90)    
FS  0.65 (0.48, 0.90) 
[0.47, 0.90] 
0.60 (0.41, 1.34)4 
[0.43, 0.85] 
0.63 (0.45, 0.75)4 
[0.44, 0.89] 
BE  0.65 (0.48, 0.90) 
[0.47, 0.90] 
0.58 (0.42, 1.02) 
[0.42, 1.02] 
0.62 (0.45, 1.10)4 
[0.44, 0.88] 
PLR – 5 knots 0.64 (0.46, 0.90)    
FS  0.64 (0.48, 0.90) 
[0.46, 0.90] 
0.60 (0.39, 1.36)23 
[0.43, 0.84] 
0.60 (0.38, 1.33)25 
[0.43, 0.86] 
BE  0.64 (0.48, 0.90) 
[0.46, 0.90] 
0.58 (0.41, 1.03)23 
[0.40, 0.82] 
0.62 (0.45, 1.13)22 
[0.44, 0.88] 
Survival analysis  0.74 (0.56, 0.97)    
FS  0.51 (0.31, 0.84) 0.55 (0.33, 0.92)  
BE  0.58 (0.34, 0.92) 0.58 (0.34, 0.99) 0.60 (0.34, 1.05) 
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Table 50 Variable selection (using 2%, 5% and 10% thresholds) with monthly 
intervals 
 Variables considered for selection (bold indicates time-varying covariates) 
 
A
ge
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H
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E
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T
yp
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u
re
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A
E
s 
D
o
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No treatment changes              
PLR – 3 knots              
FS   ·  ·  · · ·  - - - 
BE   ·  ·  · · ·  - - - 
PLR – 5 knots              
FS   ·  ·  · · ·  - - - 
BE   ·  ·  · · ·  - - - 
Survival analysis              
FS        ·   - - - 
BE        ·   - - - 
              
ISC changes only              
PLR – 3 knots              
FS ·   ·   · ·  ·   · 
BE    ·   · ·  · ·  · 
PLR – 5 knots              
FS ·      · ·  ·   · 
BE ·      · ·  · ·  · 
Survival analysis               
FS ·             
BE ·             
              
ISC/choice changes only              
PLR – 3 knots              
FS ·   ·   · ·      
BE ·   ·   · ·  · ·  · 
PLR – 5 knots              
FS ·   ·   · ·      
BE ·   ·   · ·  · ·  · 
Survival analysis               
FS              
BE       ·   ·    
              
All treatment changes              
PLR – 3 knots              
FS ·             
BE    ·     ·  · ·  
PLR – 5 knots              
FS ·   ·     ·     
BE    ·     ·  · ·  
Survival analysis               
FS      ·      ·  
BE              
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Table 51 Treatment effect (95% BS CI) [standard CI] with fortnightly intervals 
 Treatment alone Variable selection threshold 
 10% 5% 2% 
No treatment changes     
PLR – 3 knots 0.71 (0.55, 0.91)    
FS 
 
 0.71 (0.56, 0.94) 
[0.55, 0.91] 
  
BE  0.71 (0.56, 0.94) 
[0.55, 0.91] 
 0.73 (0.59, 0.97) 
[0.56, 0.95] 
PLR – 5 knots 0.72 (0.56, 0.93)    
FS  0.72 (0.57, 0.94) 
[0.56, 0.93] 
  
BE  0.72 (0.57, 0.94) 
[0.56, 0.93] 
  
Survival analysis  0.77 (0.61, 0.97)    
FS  0.77 (0.63, 0.96)   
BE  0.77 (0.63, 0.96)   
     
ISC changes only     
PLR – 3 knots 0.70 (0.53, 0.93)    
FS  0.70 (0.55, 1.04) 
[0.53, 0.93] 
 0.70 (0.41, 1.22) 
[0.52, 0.94] 
BE  0.70 (0.55, 1.04) 
[0.53, 0.93] 
  
PLR – 5 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.54, 0.998) 
[0.52, 0.94] 
  
BE  0.70 (0.54, 0.998) 
[0.52, 0.94] 
 0.71 (0.41, 1.26) 
[0.53, 0.96] 
Survival analysis  0.77 (0.60, 0.99)    
FS  0.59 (0.28, 0.87)  0.58 (0.28, 0.84) 
BE  0.59 (0.28, 0.87)   
     
ISC/choice changes only     
PLR – 3 knots 0.70 (0.53, 0.94)    
FS  0.70 (0.57, 1.07) 
[0.53, 0.94] 
 0.70 (0.41, 1.18) 
[0.52, 0.94] 
BE  0.70 (0.57, 1.07) 
[0.53, 0.94] 
  
PLR – 5 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.55, 0.99) 
[0.52, 0.94] 
 0.71 (0.39, 1.24) 
[0.52, 0.96] 
BE  0.70 (0.55, 0.99) 
[0.52, 0.94] 
  
Survival analysis  0.77 (0.60, 0.99)    
FS  0.52 (0.32, 0.75) 0.57 (0.30, 0.81) 0.54 (0.30, 0.76) 
BE  0.52 (0.32, 0.75) 0.57 (0.30, 0.81) 0.54 (0.30, 0.76) 
     
All treatment changes     
PLR – 3 knots 0.65 (0.47, 0.89)    
FS  0.65 (0.48, 0.91) 
[0.47, 0.89] 
0.61 (0.44, 1.07)1 
[0.44, 0.84] 
0.66 (0.41, 1.11) 
[0.48, 0.92] 
BE  0.65 (0.48, 0.91) 
[0.47, 0.89] 
 0.67 (0.45, 1.20)1 
[0.49, 0.93] 
PLR – 5 knots 0.65 (0.47, 0.90)    
FS  0.65 (0.47, 0.88) 
[0.47, 0.90] 
0.57 (0.32, 1.24) 
[0.40, 0.82] 
0.62 (0.37, 1.05) 
[0.44, 0.87] 
BE  0.65 (0.47, 0.88) 
[0.47, 0.90] 
 0.64 (0.46, 1.10) 
[0.46, 0.90] 
Survival analysis  0.73 (0.55, 0.97)    
FS  0.56 (0.33, 0.97) 0.57 (0.31, 1.01) 0.59 (0.35, 1.04) 
BE  0.58 (0.30, 0.83) 0.55 (0.26, 0.81) 0.58 (0.32, 0.87) 
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Table 52 Variable selection (using 2%, 5% and 10% thresholds) with fortnightly 
intervals 
 Variables considered for selection (bold indicates time-varying covariates) 
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No treatment changes              
PLR – 3 knots              
FS   ·  ·  · · ·  - - - 
BE   ·        - - - 
PLR – 5 knots              
FS   ·  ·  · · ·  - - - 
BE   ·  ·  · · ·  - - - 
Survival analysis              
FS        ·   - - - 
BE        ·   - - - 
              
ISC changes only              
PLR – 3 knots              
FS ·      · ·  ·   · 
BE ·   ·   · ·  · ·  · 
PLR – 5 knots              
FS ·      · ·  · ·  · 
BE       ·   ·   · 
Survival analysis               
FS              
BE ·      ·       
              
ISC/choice changes only              
PLR – 3 knots              
FS    ·   ·   ·    
BE ·   ·   · ·  · ·  · 
PLR – 5 knots              
FS    ·   ·   ·    
BE ·   ·   · ·  · ·  · 
Survival analysis               
FS ·             
BE ·             
              
All treatment changes              
PLR – 3 knots              
FS ·            · 
BE ·   ·  · ·  ·  · · · 
PLR – 5 knots              
FS    ·  ·       · 
BE    ·     ·  · ·  
Survival analysis               
FS    ·          
BE       ·    ·   
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Table 53 Treatment effect (95% BS CI) [standard CI] with weekly intervals 
 Treatment alone Variable selection threshold 
 10% 5% 2% 
No treatment changes     
PLR – 3 knots 0.70 (0.55, 0.91)    
FS  0.70 (0.55, 0.91) 
[0.55, 0.91] 
  
BE  0.70 (0.55, 0.91) 
[0.55, 0.91] 
  
PLR – 5 knots 0.72 (0.56, 0.93)    
FS  0.72 (0.54, 0.93) 
[0.56, 0.93] 
  
BE  0.72 (0.54, 0.93) 
[0.56, 0.93] 
  
Survival analysis  0.76 (0.61, 0.96)    
FS  0.76 (0.60, 0.93)   
BE  0.76 (0.60, 0.93)   
     
ISC changes only     
PLR – 3 knots 0.70 (0.53, 0.93)    
FS  0.70 (0.55, 0.97) 
[0.53, 0.93] 
 0.71 (0.45, 1.15) 
[0.53, 0.96] 
BE  0.70 (0.55, 0.97) 
[0.53, 0.93] 
 0.67 (0.49, 0.98) 
[0.50, 0.90] 
PLR – 5 knots 0.70 (0.53, 0.94)    
FS  0.70 (0.54, 0.96) 
[0.53, 0.94] 
 0.67 (0.42, 1.30) 
[0.50, 0.91] 
BE  0.70 (0.54, 0.96) 
[0.53, 0.94] 
 0.67 (0.47, 1.02) 
[0.50, 0.90] 
Survival analysis  0.77 (0.60, 0.99)    
FS  0.60 (0.31, 1.12)  0.56 (0.32, 0.90) 
BE  0.53 (0.30, 0.85) 0.58 (0.33, 1.07) 0.56 (0.32, 0.90) 
     
ISC/choice changes only     
PLR – 3 knots 0.70 (0.53, 0.94)    
FS  0.70 (0.54, 0.96) 
[0.53, 0.94] 
 0.70 (0.45, 1.14) 
[0.52, 0.94] 
BE  0.70 (0.54, 0.96) 
[0.53, 0.94] 
 0.70 (0.44, 1.15) 
[0.52, 0.94] 
PLR – 5 knots 0.70 (0.52, 0.94)    
FS  0.70 (0.53, 0.94) 
[0.52, 0.94] 
 0.68 (0.44, 1.29) 
[0.51, 0.92] 
BE  0.70 (0.53, 0.94) 
[0.52, 0.94] 
 0.68 (0.44, 0.97) 
[0.51, 0.92] 
Survival analysis  0.77 (0.60, 0.99)    
FS  0.59 (0.33, 1.02) 0.59 (0.32, 1.03) 0.56 (0.36, 0.90) 
BE  0.53 (0.29, 0.89)  0.56 (0.27, 0.91) 
     
All treatment changes     
PLR – 3 knots 0.65 (0.47, 0.89)    
FS  0.65 (0.47, 0.87) 
[0.47, 0.89] 
0.56 (0.36, 1.23) 
[0.39, 0.80] 
0.61 (0.40, 1.01) 
[0.43, 0.86] 
BE  0.65 (0.47, 0.87) 
[0.47, 0.89] 
0.59 (0.38, 0.99) 
[0.43, 0.82] 
0.61 (0.40, 1.01) 
[0.43, 0.86] 
PLR – 5 knots 0.65 (0.47, 0.90)    
FS  0.65 (0.47, 0.88) 
[0.47, 0.90] 
0.55 (0.37, 1.14) 
[0.38, 0.80] 
0.57 (0.40, 1.15) 
[0.41, 0.81] 
BE  0.65 (0.47, 0.88) 
[0.47, 0.90] 
0.58 (0.34, 1.57) 
[0.41, 0.81] 
0.62 (0.36, 1.31) 
[0.44, 0.87] 
Survival analysis  0.73 (0.55, 0.96)    
FS  0.54 (0.27, 0.93) 0.50 (0.25, 0.85) 0.60 (0.35, 1.05) 
BE  0.55 (0.29, 0.82)  0.60 (0.35, 1.05) 
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Table 54 Variable selection (using 2%, 5% and 10% thresholds) with weekly 
intervals 
 Variables considered for selection (bold indicates time-varying covariates) 
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No treatment changes              
PLR – 3 knots              
FS   · · ·  · · ·  - - - 
BE   · · ·  · · ·  - - - 
PLR – 5 knots              
FS   ·  ·  · · ·  - - - 
BE   ·  ·  · · ·  - - - 
Survival analysis              
FS        ·   - - - 
BE        ·   - - - 
              
ISC changes only              
PLR – 3 knots              
FS ·         ·    
BE ·   ·    · · · ·   
PLR – 5 knots              
FS       ·   ·    
BE ·      ·   · ·   
Survival analysis               
FS              
BE              
              
ISC/choice changes only              
PLR – 3 knots              
FS ·      ·   ·    
BE ·      ·   ·    
PLR – 5 knots              
FS    ·      ·    
BE ·   ·   · ·  · · ·  
Survival analysis               
FS              
BE          ·    
              
All treatment changes              
PLR – 3 knots              
FS ·      ·      · 
BE ·      ·      · 
PLR – 5 knots              
FS ·   ·  · ·      · 
BE ·      ·  ·  ·   
Survival analysis               
FS      ·        
BE      ·        
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Table 55  Withdrawal (VPS): Number of variables in model (EPV, including spline variables (3 with 3 knots (2 spline variables + 
linear time variable), 5 with 5 knots (4 spline variables + linear time variable)) 
Treatment  
changes 
 
Time interval / Variable selection threshold 
Month Fortnight Week 
10% 5% 2% Full model  10% 5% 2% Full model  10% 5% 2% Full model  
ITT (none)             
PLR3             
FS             
BE             
PLR5             
FS             
BE             
Survival             
FS             
BE             
ISC only             
PLR3             
FS 0 (8.7) 0 (8.7) 1 (6.5)  0 (8.7) 0 (8.7) 2 (5.2)  0 (8.7) 0 (8.7) 8 (2.4)  
BE 0 (8.7) 0 (8.7) 1 (6.5) 7 (2.6) 0 (8.7) 0 (8.7) 0 (8.7) 7 (2.6) 0 (8.7) 0 (8.7) 3 (4.3) 10 (2.0) 
PLR5             
FS 0 (5.2) 0 (5.2) 1 (4.3)  0 (5.2) 0 (5.2) 0 (5.2)   0 (5.2) 0 (5.2) 5 (2.6)   
BE 0 (5.2) 0 (5.2) 0 (5.2) 6 (2.4) 0 (5.2) 0 (5.2) 3 (3.3) 6 (2.4) 0 (5.2) 0 (5.2) 3 (3.3) 7 (2.2) 
Survival             
FS 2 (13) 3 (8.7) 4 (6.5)   3 (8.7) 3 (8.7) 5 (5.2)   4 (6.5) 4 (6.5) 6 (4.3)   
BE 0 (NA) 1 (26) 4 (6.5) 5 (5.2) 3 (8.7) 3 (8.7) 3 (8.7) 5 (5.2) 2 (13) 3 (8.7) 6 (4.3) 6 (4.3) 
ISC/choice             
PLR3             
FS 0 (9.7) 0 (9.7) 3 (4.8)   0 (9.7) 0 (9.7) 4 (4.1)  0 (9.7) 0 (9.7) 7 (2.9)  
BE 0 (9.7) 0 (9.7) 0 (9.7) 7 (2.9) 0 (9.7) 0 (9.7) 0 (9.7) 7 (2.9) 0 (9.7) 0 (9.7) 7 (2.9) 10 (2.2) 
PLR5             
FS 0 (5.8) 0 (5.8) 3 (3.6)   0 (5.8) 0 (5.8) 4 (3.2)  0 (5.8) 0 (5.8) 6 (2.6)  
BE 0 (5.8) 0 (5.8) 0 (5.8) 7 (2.4) 0 (5.8) 0 (5.8) 0 (5.8) 7 (2.4) 0 (5.8) 0 (5.8) 1 (4.8) 8 (2.2) 
Survival             
FS 1 (29) 3 (9.7) 5 (5.8)   2 (14.5) 3 (9.7) 4 (7.3)  3 (9.7) 5 (5.8) 6 (4.8)  
BE 1 (29) 1 (29) 3 (9.7) 5 (5.8) 2 (14.5) 3 (9.7) 4 (7.3) 5 (5.8) 2 (14.5) 2 (14.5) 5 (5.8) 6 (4.8) 
All              
PLR3             
FS 0 (18.7) 1 (14) 8 (5.1)    0 (18.7) 1 (14) 7 (5.6)  0 (18.7) 2 (11.2) 6 (6.2)  
BE 0 (18.7) 2 (11.2) 4 (8) 9 (4.7) 0 (18.7) 0 (18.7) 6 (6.2) 9 (4.7) 0 (18.7) 1 (14) 6 (6.2) 9 (4.7) 
PLR5             
FS 0 (11.2) 1 (9.3) 5 (5.6)   0 (11.2) 2 (8) 6 (5.1)   0 (11.2) 2 (8) 4 (6.2)  
BE 0 (11.2) 2 (8) 4 (6.2) 9 (4) 0 (11.2) 0 (11.2) 4 (6.2) 9 (4) 0 (11.2) 2 (8) 4 (6.2) 9 (4) 
Survival             
FS 2 (28) 2 (28) 7 (8)   4 (14) 6 (9.3) 8 (7)   4 (14) 5 (11.2) 8 (7)  
BE 1 (56) 5 (11.2) 9 (6.2) 9 (6.2) 2 (28) 3 (19.7) 7 (8) 9 (6.2) 1 (56) 1 (56) 8 (7) 9 (6.2) 
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Table 56 Withdrawal (LTG): Number of variables in model (EPV, including spline variables (3 with 3 knots (2 spline variables + 
linear time variable), 5 with 5 knots (4 spline variables + linear time variable)) 
Treatment  
changes 
 
Time interval / Variable selection threshold 
Month Fortnight Week 
10% 5% 2% Full model  10% 5% 2% Full model  10% 5% 2% Full model  
ITT (none)             
PLR3             
FS             
BE             
PLR5             
FS             
BE             
Survival             
FS             
BE             
ISC only             
PLR3             
FS 0 (16.7) 0 (16.7) 1 (12.5)   0 (16.7) 0 (16.7) 2 (10)   0 (16.7) 0 (16.7) 8 (4.5)   
BE 0 (16.7) 0 (16.7) 1 (12.5) 7 (5) 0 (16.7) 0 (16.7) 0 (16.7) 7 (5) 0 (16.7) 0 (16.7) 3 (8.3) 10 (3.8) 
PLR5                         
FS 0 (10) 0 (10) 1 (8.3)   0 (10) 0 (10) 0 (10)  0 (10) 0 (10) 5 (5)   
BE 0 (10) 0 (10) 0 (10) 6 (4.5) 0 (10) 0 (10) 3 (6.3) 6 (4.5) 0 (10) 0 (10) 3 (6.3) 7 (4.2) 
Survival                         
FS 2 (25) 3 (16.7) 4 (12.5)   3 (16.7) 3 (16.7) 5 (10)   4 (12.5) 4 (12.5) 6 (8.3)   
BE 0 (NA) 1 (50) 4 (12.5) 5 (10) 3 (16.7) 3 (16.7) 3 (16.7) 5 (10) 2 (25) 3 (16.7) 6 (8.3) 6 (8.3) 
ISC/choice                         
PLR3                         
FS 0 (17.7) 0 (17.7) 3 (8.8)   0 (17.7) 0 (17.7) 4 (7.6)   0 (17.7) 0 (17.7) 7 (5.3)   
BE 0 (17.7) 0 (17.7) 0 (17.7) 7 (5.3) 0 (17.7) 0 (17.7) 0 (17.7) 7 (5.3) 0 (17.7) 0 (17.7) 7 (5.3) 10 (4.1) 
PLR5                          
FS 0 (10.6) 0 (10.6) 3 (6.6)  0 (10.6) 0 (10.6) 4 (5.9)   0 (10.6) 0 (10.6) 6 (4.8)   
BE 0 (10.6) 0 (10.6) 0 (10.6) 7 (4.4) 0 (10.6) 0 (10.6) 0 (10.6) 7 (4.4) 0 (10.6) 0 (10.6) 1 (8.8) 8 (4.1) 
Survival                          
FS 1 (53) 3 (17.7) 5 (10.6)   2 (26.5) 3 (17.7) 4 (13.3)  3 (17.7) 5 (10.6) 6 (8.8)  
BE 1 (53) 1 (53) 3 (17.7) 5 (10.6) 2 (26.5) 3 (17.7) 4 (13.3) 5 (10.6) 2 (26.5) 2 (26.5) 5 (10.6) 6 (8.8) 
All                          
PLR3                         
FS 0 (21.3) 1 (16) 8 (5.8)   0 (21.3) 1 (16) 7 (6.4)   0 (21.3) 2 (12.8) 6 (7.1)   
BE 0 (21.3) 2 (12.8) 4 (9.1) 9 (5.3) 0 (21.3) 0 (21.3) 6 (7.1) 9 (5.3) 0 (21.3) 1 (16) 6 (7.1) 9 (5.3) 
PLR5                          
FS 0 (12.8) 1 (10.7) 5 (6.4)   0 (12.8) 2 (9.1) 6 (5.8)   0 (12.8) 2 (9.1) 4 (7.1)   
BE 0 (12.8) 2 (9.1) 4 (7.1) 9 (4.6) 0 (12.8) 0 (12.8) 4 (7.1) 9 (4.6) 0 (12.8) 2 (9.1) 4 (7.1) 9 (4.6) 
Survival                         
FS 2 (32) 2 (32) 7 (9.1)  4 (16) 6 (10.7) 8 (8)  4 (16) 5 (12.8) 8 (8)   
BE 1 (64) 5 (12.8) 9 (7.1) 9 (7.1) 2 (32) 3 (21.3) 7 (9.1) 9 (7.1) 1 (64) 1 (64) 8 (8) 9 (7.1) 
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Table 57 Remission: Number of variables in model (EPV, including spline variables (3 with 3 knots (2 spline variables + linear 
time variable), 5 with 5 knots (4 spline variables + linear time variable)) 
Treatment  
changes 
 
Time interval / Variable selection threshold 
Month Fortnight Week 
10% 5% 2% Full model  10% 5% 2% Full model  10% 5% 2% Full model  
ITT (none)             
PLR3             
FS 1 (74.3) 1 (74.3) 1 (74.3)   1 (74.3) 1 (74.3) 1 (74.3)  1 (74.3) 1 (74.3) 1 (74.3)   
BE 1 (74.3) 1 (74.3) 2 (59.4) 6 (33) 1 (74.3) 1 (74.3) 6 (33) 7 (29.7) 1 (74.3) 1 (74.3) 1 (74.3) 8 (27) 
PLR5                         
FS 1 (49.5) 1 (49.5) 1 (49.5)  1 (49.5) 1 (49.5) 1 (49.5)  1 (49.5) 1 (49.5) 1 (49.5)  
BE 1 (49.5) 1 (49.5) 1 (49.5) 7 (24.8) 1 (49.5) 1 (49.5) 1 (49.5) 7 (24.8) 1 (49.5) 1 (49.5) 1 (49.5) 7 (24.8) 
Survival                          
FS 1 (297) 1 (297) 1 (297)   1 (297) 1 (297) 1 (297)  1 (297) 1 (297) 1 (297)   
BE 1 (297) 1 (297) 1 (297) 2 (148.5) 1 (297) 1 (297) 1 (297) 2 (148.5) 1 (297) 1 (297) 1 (297) 2 (148.5) 
ISC only             
PLR3             
FS 1 (62.8) 1 (62.8) 1 (62.8)   1 (62.8) 1 (62.8) 2 (50.2)  1 (62.8) 1 (62.8) 6 (27.9)   
BE 1 (62.8) 1 (62.8) 2 (50.2) 6 (27.9) 1 (62.8) 1 (62.8) 1 (62.8) 6 (27.9) 1 (62.8) 1 (62.8) 2 (50.2) 8 (22.8) 
PLR5                         
FS 1 (41.8) 1 (41.8) 1 (41.8)  1 (41.8) 1 (41.8) 1 (41.8)  1 (41.8) 1 (41.8) 3 (31.4)  
BE 1 (41.8) 1 (41.8) 1 (41.8) 5 (25.1) 1 (41.8) 1 (41.8) 3 (31.4) 5 (25.1) 1 (41.8) 1 (41.8) 2 (35.9) 5 (25.1) 
Survival                         
FS 2 (125.5) 2 (125.5) 3 (83.7)   2 (125.5) 2 (125.5) 4 (62.8)  2 (125.5) 2 (125.5) 4 (62.8)  
BE 1 (251) 1 (251) 3 (83.7) 4 (62.8) 2 (125.5) 2 (125.5) 2 (125.5) 4 (62.8) 1 (251) 1 (251) 4 (62.8) 4 (62.8) 
ISC/choice             
PLR3             
FS 1 (61.8) 1 (61.8) 2 (49.4)   1 (61.8) 1 (61.8) 3 (41.2)   1 (61.8) 1 (61.8) 5 (30.9)   
BE 1 (61.8) 1 (61.8) 2 (49.4) 6 (27.4) 1 (61.8) 1 (61.8) 1 (61.8) 6 (27.4) 1 (61.8) 1 (61.8) 5 (30.9) 8 (22.5) 
PLR5                           
FS 1 (41.2) 1 (41.2) 2 (35.3)  1 (41.8) 1 (41.8) 3 (30.9)  1 (41.2) 1 (41.2) 4 (27.4)   
BE 1 (41.2) 1 (41.2) 1 (41.2) 6 (22.5) 1 (41.8) 1 (41.8) 1 (41.2) 6 (22.5) 1 (41.2) 1 (41.2) 1 (41.2) 6 (22.5) 
Survival                         
FS 1 (247) 2 (123.5) 4 (61.8)  1 (247) 2 (123.5) 3 (82.3)  2 (123.5) 3 (82.3) 4 (61.8)   
BE 1 (247) 1 (247) 2 (123.5) 4 (61.8) 1 (247) 2 (123.5) 3 (82.3) 4 (61.8) 1 (247) 1 (247) 3 (82.3) 4 (61.8) 
All              
PLR3             
FS 1 (51) 1 (51) 6 (22.7)  1 (51) 1 (51) 6 (22.7)   1 (51) 1 (51) 5 (25.5)   
BE 1 (51) 1 (51) 6 (22.7) 7 (20.4) 1 (51) 1 (51) 6 (22.7) 7 (20.4) 1 (51) 1 (51) 5 (25.5) 7 (20.4) 
PLR5                         
FS 1 (34) 1 (34) 3 (25.5)   1 (34) 1 (34) 5 (20.4)   1 (34) 1 (34) 3 (25.5)  
BE 1 (34) 2 (29.1) 4 (22.7) 7 (17) 1 (34) 1 (34) 4 (22.7) 7 (17) 1 (34) 1 (34) 3 (25.5) 7 (17) 
Survival                         
FS 1 (204) 6 (34) 6 (34)   3 (68) 4 (51) 6 (34)  3 (68) 3 (68) 6 (34)   
BE 1 (204) 4 (51) 7 (29.1) 7 (29.1) 1 (204) 2 (102) 6 (34) 7 (29.1) 1 (204) 1 (204) 6 (34) 7 (29.1) 
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Figure 11 Treatment effects (95% BS CIs) from PLR and Cox models without 
adjustment for treatment changes (ITT) 
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Figure 12 Treatment effects (95% BS CIs) from PLR and Cox models, with 
adjustment for treatment changes due to ISC alone 
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Figure 13 Treatment effects (95% BS CIs) from PLR and Cox models, with 
adjustment for treatment changes due to ISC or personal choice 
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Figure 14 Treatment effects (95% BS CIs) from PLR and Cox models, with 
adjustment for all treatment changes 
 
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
adjusted for
changes
Treatment
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Month
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Biweek
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
Week
intervals
Time
Survival
Survival
Survival
Survival
Survival
Survival
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
Survival
Survival
Survival
Survival
Survival
Survival
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
Survival
Survival
Survival
Survival
Survival
Survival
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (3 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
PLR (5 knots)
type
Model
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
FS
FS
FS
BE
BE
BE
BE
or
FS
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
2
5
10
Threshold
8
28
28
6.2
11.2
56
7
56
14
28
7.4
9.8
14.8
8.4
19.7
29.5
8.4
59
9.8
7.5
12
15
7.5
60
60
10
30
10
60
(w_vps)
EPV
9.1
32
32
7.1
12.8
64
8
64
16
32
9.3
12.3
18.5
10.6
24.7
37
10.6
74
12.3
9.6
15.4
19.3
9.6
77
77
12.8
38.5
12.8
77
(w_ltg)
EPV
34
34
204
29.1
51
204
34
204
204
34
204
204
34
51
68
34
102
204
34
204
204
34
204
204
34
68
68
34
204
204
40.8
204
204
40.8
204
204
(rem)
EPV
6.2
6.2
6.2
4.3
4.3
4.3
3.7
3.7
3.7
6.6
6.6
6.6
4.5
4.5
4.5
3.9
3.9
3.9
6.7
6.7
6.7
4.6
4.6
4.6
4
4
4
w_vps)
(Full BE
EPV
7.1
7.1
7.1
4.9
4.9
4.9
4.3
4.3
4.3
8.2
8.2
8.2
5.7
5.7
5.7
4.9
4.9
4.9
8.6
8.6
8.6
5.9
5.9
5.9
5.1
5.1
5.1
w_ltg)
(Full BE
EPV
29.1
29.1
29.1
18.5
18.5
18.5
15.7
15.7
15.7
29.1
29.1
29.1
18.5
18.5
18.5
15.7
15.7
15.7
29.1
29.1
29.1
18.5
18.5
18.5
15.7
15.7
15.7
rem)
(Full BE
EPV
  
10 .2 .4 .6 .8 1.2 1.4 1.6 1.8
   
   
461 
 
Appendix C: Comparison of IPCW and RPSFTM 
Table 58 EPV ratios of WD model, according to treatment change scenarios and TVCs 
WD 
models 
 PLR (0 knots) PLR (3 knots) PLR (5 knots) Cox 
  VPS LTG VPS LTG VPS LTG VPS LTG 
Seizure only model         
 Number of variables  2 2 4 4 6 6 1 1 
 Treatment changes: EPV 
ratio 
        
 None (ITT) - - - - - - - - 
 ISC only 13 25 6.5 12.5 4.3 8.3 26 50 
 ISC/choice  14.5 26.5 7.3 13.3 4.8 8.8 29 53 
 All 28 32 14 16 9.3 10.7 56 64 
          
Seizures and dose model         
 Number of variables  3 3 5 5 7 7 2 2 
 Treatment changes: EPV 
ratio         
 None (ITT) - - - - - - - - 
 ISC only 8.7 16.7 5.2 10 3.7 7.1 13 25 
 ISC/choice  9.7 17.7 5.8 10.6 4.1 7.6 14.5 26.5 
 All 18.7 21.3 11.2 12.8 8 9.1 28 32 
          
Seizures, dose and AEs model         
 Number of variables  4 4 6 6 8 8 3 3 
 Treatment changes: EPV 
ratio         
 None (ITT) - - - - - - - - 
 ISC only 6.5 12.5 4.3 8.3 3.3 6.3 8.7 16.7 
 ISC/choice  7.3 13.3 4.8 8.8 3.6 6.6 9.7 17.7 
 All 14 16 9.3 10.7 7 8 18.7 21.3 
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Table 59 EPV ratios of WO model, according to treatment change scenarios 
WO 
models 
 PLR (0 knots) PLR (3 knots) PLR (5 knots) Cox 
  VPS LTG VPS LTG VPS LTG VPS LTG 
         
 Number of variables  2 2 4 4 6 6 1 1 
 Treatment changes: EPV 
ratio 
        
 None (ITT) 148.5 74.3 49.5 297 148.5 74.3 49.5 297 
 ISC only 125.5 62.8 41.8 251 125.5 62.8 41.8 251 
 ISC/choice  123.5 61.8 41.2 247 123.5 61.8 41.2 247 
 All 102 51 34 204 102 51 34 204 
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Table 60 Treatment only models 
Treatment only 
models: 
Month Fortnight Week 
Treatment effect 95% CI 95% CI (BS) Treatment effect 95% CI 95% CI (BS) Treatment 
effect 
95% CI 95% CI (BS) 
       
No adjustment for treatment changes (ITT)       
PLR (0) 0.679 (0.516, 0.894) (0.527, 0.906) 0.673  (0.512, 0.887) (0.524, 0.901) 0.673 (0.512, 0.885) (0.516, 0.916) 
PLR (3) 0.714  (0.551, 0.924) (0.565, 0.945) 0.707  (0.548, 0.912) (0.561, 0.943) 0.704 (0.545, 0.908) (0.547, 0.909) 
PLR (5) 0.717  (0.553, 0.931) (0.567, 0.950) 0.719  (0.556, 0.929) (0.569, 0.944) 0.721 (0.559, 0.930) (0.544, 0.928) 
Cox 0.774  (0.616, 0.973) (0.637, 0.944) 0.770 (0.613, 0.968) (0.632, 0.956) 0.768 (0.611, 0.966) (0.616, 0.940) 
       
Adjusted for treatment changes due to ISC only       
PLR (0) 0.699 (0.513, 0.953) (0.522, 0.989) 0.668 (0.491, 0.909) (0.403, 1.111) 0.699 (0.513, 0.952) (0.532, 0.985) 
PLR (3) 0.699 (0.521, 0.936) (0.522, 0.996) 0.701 (0.527, 0.934) (0.546, 1.035) 0.702 (0.527, 0.934) (0.549, 0.968) 
PLR (5) 0.695 (0.517, 0.934) (0.514, 0.994) 0.700 (0.523, 0.936) (0.536, 0.998) 0.701 (0.525, 0.935) (0.535, 0.960) 
Cox 0.773 (0.602, 0.992) (0.621, 0.993) 0.769 (0.598, 0.987) (0.642, 1.000) 0.767 (0.597, 0.986) (0.618, 0.962) 
       
Adjusted for treatment changes due to ISC/choice only       
PLR (0) 0.703 (0.515, 0.961) (0.514, 1.007) 0.673 (0.493, 0.919) (0.397, 1.206) 0.703 (0.515, 0.961) (0.537, 0.961) 
PLR (3)  0.702 (0.522, 0.942)  (0.518, 0.990) 0.704 (0.527, 0.939) (0.568, 1.070) 0.704 (0.527, 0.939) (0.539, 0.957) 
PLR (5) 0.696 (0.516, 0.938) (0.510, 0.996) 0.701 (0.523, 0.940) (0.548, 0.992) 0.701 (0.524, 0.938) (0.532, 0.939) 
Cox 0.774 (0.601, 0.990) (0.623, 0.990) 0.770 (0.598, 0.991) (0.638, 0.996) 0.768 (0.597, 0.989) (0.624, 0.956) 
       
Adjusted for all treatment changes (ISC/choice and UAEs)       
PLR (0) 0.644 (0.457, 0.909) (0.456, 0.886) 0.602 (0.427, 0.849) (0.412, 1.232) 0.641 (0.455, 0.905) (0.449, 0.881) 
PLR (3)  0.646 (0.465, 0.899) (0.477, 0.899) 0.647 (0.469, 0.891) (0.480, 0.911) 0.646 (0.470, 0.890) (0.471, 0.867) 
PLR (5) 0.644 (0.462, 0.899) (0.476, 0.904) 0.649 (0.468, 0.900) (0.474, 0.881) 0.648 (0.469, 0.897) (0.471, 0.876) 
Cox 0.736 (0.577, 0.973) (0.590, 0.929) 0.731 (0.553, 0.965) (0.581, 0.887) 0.728 (0.551, 0.962) (0.552, 0.905) 
 
Note that none of these models contain time-varying covariates and therefore no weighting is applied. 
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Table 61 Treatment and seizure models 
Treatment + seizures 
models: 
Month Fortnight Week 
Treatment effect 95% CI 95% CI (BS) Treatment effect 95% CI 95% CI (BS) Treatment effect 95% CI 95% CI (BS) 
       
No adjustment for treatment changes (ITT)*        
PLR (0) 0.679 (0.516, 0.894) (0.527, 0.906) 0.673  (0.512, 0.887) (0.524, 0.901) 0.673 (0.512, 0.885) (0.516, 0.916) 
PLR (3) 0.714  (0.551, 0.924) (0.565, 0.945) 0.707  (0.548, 0.912) (0.561, 0.943) 0.704 (0.545, 0.908) (0.547, 0.909) 
PLR (5) 0.717  (0.553, 0.931) (0.567, 0.950) 0.719  (0.556, 0.929) (0.569, 0.944) 0.721 (0.559, 0.930) (0.544, 0.928) 
Cox 0.774  (0.616, 0.973) (0.637, 0.944) 0.770 (0.613, 0.968) (0.632, 0.956) 0.768 (0.611, 0.966) (0.616, 0.940) 
       
Adjusted for treatment changes due to ISC only       
PLR (0) 0.662  (0.486, 0.902) (0.453, 1.256) 0.668 (0.491, 0.909) (0.403, 1.111) 0.665 (0.490, 0.904) (0.384, 1.349) 
PLR (3) 0.678  (0.505, 0.909) (0.411, 1.089) 0.681 (0.511, 0.908) (0.406, 1.250) 0.676 (0.507, 0.900) (0.413, 1.170 
PLR (5) 0.676  (0.501, 0.911) (0.386, 1.112)127 0.687 (0.511, 0.923) (0.387, 1.256) 0.689 (0.514, 0.925) (0.376, 1.122)1 
Cox 0.610  (0.458, 0.814) (0.187, 0.916) 0.609 (0.456, 0.814) (0.139, 0.907) 0.658 (0.502, 0.862) (0.392, 1.146) 
       
Adjusted for treatment changes due to ISC/choice only       
PLR (0) 0.669 (0.490, 0.914) (0.477, 1.386) 0.673 (0.493, 0.919) (0.397, 1.206) 0.673 (0.494, 0.916) (0.364, 1.076) 
PLR (3)  0.684 (0.509, 0.919) (0.399, 1.155) 0.686 (0.514, 0.916) (0.419, 1.485) 0.680  (0.510, 0.907) (0.376, 1.209) 
PLR (5) 0.681  (0.504, 0.920) (0.372, 1.111)104 0.691  (0.513, 0.930) (0.378, 1.248) 0.692 (0.515, 0.931) (0.376, 1.219) 
Cox 0.628  (0.474, 0.831) (0.222, 0.917) 0.627 (0.473, 0.831) (0.265, 0.907) 0.663 (0.507, 0.868) (0.396, 1.083) 
       
Adjusted for all treatment changes (ISC/choice and UAEs)       
PLR (0) 0.605 (0.428, 0.854) (0.417, 1.141) 0.602 (0.427, 0.849) (0.412, 1.232) 0.592 (0.420, 0.832) (0.367, 1.107) 
PLR (3)  0.604 (0.431, 0.847) (0.406, 1.343) 0.609 (0.440, 0.843) (0.437, 1.072) 0.591 (0.427, 0.820) (0.379, 0.989)1 
PLR (5) 0.599  (0.426, 0.844) (0.385, 1.362)23 0.605  (0.433, 0.846) (0.402, 1.089) 0.596 (0.426, 0.834) (0.371, 1.066) 
Cox 0.581  (0.441, 0.767) (0.340, 0.921) 0.529 (0.395, 0.710) (0.161, 0.892) 0.552 (0.416, 0.732) (0.286, 0.819) 
 
* Note that none of these models contain time-varying covariates and therefore no weighting is applied; therefore these models correspond with those presented in Table 60. 
 
CIs in italics indicate invalid normal Cox regression CIs, while subscripts indicate the number of bootstrapped samples (out of a total of 200) which failed to converge due to overfitting. 
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Table 62 Treatment, seizure count and dose models 
Treatment + seizures 
+ dose models: 
Month Fortnight Week 
Treatment effect 95% CI 95% CI (BS) Treatment effect 95% CI 95% CI (BS) Treatment 
effect 
95% CI 95% CI (BS) 
       
No adjustment for treatment changes (ITT)*        
PLR (0) 0.679 (0.516, 0.894) (0.527, 0.906) 0.673  (0.512, 0.887) (0.524, 0.901) 0.673 (0.512, 0.885) (0.516, 0.916) 
PLR (3) 0.714  (0.551, 0.924) (0.565, 0.945) 0.707  (0.548, 0.912) (0.561, 0.943) 0.704 (0.545, 0.908) (0.547, 0.909) 
PLR (5) 0.717  (0.553, 0.931) (0.567, 0.950) 0.719  (0.556, 0.929) (0.569, 0.944) 0.721 (0.559, 0.930) (0.544, 0.928) 
Cox 0.774  (0.616, 0.973) (0.637, 0.944) 0.770 (0.613, 0.968) (0.632, 0.956) 0.768 (0.611, 0.966) (0.616, 0.940) 
       
Adjusted for treatment changes due to ISC only       
PLR (0) 0.665 (0.488, 0.907) (0.471, 1.267) 0.665 (0.490, 0.904) (0.417, 1.172) 0.666 (0.491, 0.902) (0.421, 1.278) 
PLR (3) 0.673 (0.500, 0.906) (0.431, 1.374)2 0.677 (0.508, 0.903) (0.432, 1.207) 0.674 (0.505, 0.898) (0.391, 1.189) 
PLR (5) 0.673 (0.497, 0.911) (0.391, 1.280)127 0.681 (0.506, 0.916) (0.421, 1.260)1 0.686 (0.510, 0.922) (0.398, 1.298)3 
Cox 0.491 (0.246, 0.981) (0.021, 1.930) 0.527 (0.333, 0.833) (0.021, 0.909) 0.605 (0.400, 0.915) (0.196, 17.318) 
       
Adjusted for treatment changes due to ISC/choice only       
PLR (0) 0.668 (0.488, 0.913) (0.450, 1.396) 0.667 (0.490, 0.909) (0.409, 1.197) 0.671 (0.493, 0.912) (0.409, 1.246) 
PLR (3)  0.677 (0.501, 0.915) (0.420, 1.331)1 0.681 (0.509, 0.910) (0.403, 1.302) 0.677 (0.507, 0.905) (0.380, 1.332) 
PLR (5) 0.676 (0.498, 0.919) (0.408, 1.263)106 0.683 (0.507,0.921) (0.408, 1.323)1 0.687 (0.510, 0.926) (0.382, 1.420)2 
Cox 0.492 (0.259, 0.933) (0.008, 1.206) 0.543 (0.350, 0.844) (0.026, 0.930) 0.603 (0.400, 0.908) (0.245, 5.652) 
       
Adjusted for all treatment changes (ISC/choice and UAEs)       
PLR (0) 0.599 (0.423, 0.850) (0.387, 1.224) 0.600 (0.424, 0.848) (0.404, 1.197) 0.588 (0.417, 0.829) (0.374, 1.182) 
PLR (3)  0.593 (0.420, 0.838) (0.409, 1.422)4 0.603 (0.435, 0.836) (0.429, 1.575)1 0.584 (0.421, 0.810) (0.402, 1.261)1 
PLR (5) 0.583 (0.408, 0.833) (0.415, 1.466)22 0.598 (0.426, 0.838) (0.417, 1.385) 0.587 (0.419, 0.822) (0.376, 1.567) 
Cox 0.388 (0.272, 0.552) (0.022, 0.690) 0.497 (0.370, 0.669) (0.163, 0.934) 0.529 (0.399, 0.700) (0.260, 0.809) 
 
* Note that none of these models contain time-varying covariates and therefore no weighting is applied; therefore these models correspond with those presented in Table 60. 
CIs in italics indicate invalid normal Cox regression CIs, while subscripts indicate the number of bootstrapped samples (out of a total of 200) which failed to converge due to overfitting. 
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Table 63 Treatment, seizure count, dose and AE models 
Treatment + seizures 
+ dose + AEs 
models: 
Month Fortnight Week 
Treatment 
effect 
95% CI 95% CI (BS) Treatment 
effect 
95% CI 95% CI (BS) Treatment 
effect 
95% CI 95% CI (BS) 
       
No adjustment for treatment changes (ITT)*        
PLR (0) 0.679 (0.516, 0.894) (0.527, 0.906) 0.673  (0.512, 0.887) (0.524, 0.901) 0.673 (0.512, 0.885) (0.516, 0.916) 
PLR (3) 0.714  (0.551, 0.924) (0.565, 0.945) 0.707  (0.548, 0.912) (0.561, 0.943) 0.704 (0.545, 0.908) (0.547, 0.909) 
PLR (5) 0.717  (0.553, 0.931) (0.567, 0.950) 0.719  (0.556, 0.929) (0.569, 0.944) 0.721 (0.559, 0.930) (0.544, 0.928) 
Cox 0.774  (0.616, 0.973) (0.637, 0.944) 0.770 (0.613, 0.968) (0.632, 0.956) 0.768 (0.611, 0.966) (0.616, 0.940) 
       
Adjusted for treatment changes due to ISC only       
PLR (0) 0.657 (0.482, 0.895) (0.455, 1.264) 0.658 (0.485, 0.895) (0.411, 1.068) 0.638 (0.470, 0.867) (0.410, 1.139) 
PLR (3) 0.661 (0.491, 0.890) (0.429, 1.253)2 0.668 (0.501, 0.891) (0.407, 1.054) 0.644 (0.482, 0.860) (0.415, 1.182) 
PLR (5) 0.658 (0.486, 0.892) (0.389, 1.323)126 0.669 (0.497, 0.900) (0.405, 1.077) 0.648 (0.482, 0.873) (0.416, 1.278)3 
Cox 0.386 (0.168, 0.884) (0.002, 1.661) 0.389 (0.222, 0.681) (0.0007, 0.886) 0.417 (0.249, 0.699) (0.003, 1.750)1 
       
Adjusted for treatment changes due to ISC/choice only       
PLR (0) 0.661 (0.483, 0.904) (0.445, 1.433) 0.661 (0.485, 0.901) (0.384, 1.146) 0.645 (0.474, 0.879) (0.446, 1.112) 
PLR (3)  0.667 (0.494, 0.902) (0.435, 1.343)1 0.672 (0.502, 0.899) (0.428, 1.176) 0.650 (0.486, 0.871) (0.432, 1.166)1 
PLR (5) 0.664 (0.488, 0.903) (0.441, 1.470)104 0.672 (0.498, 0.907) (0.395, 1.097) 0.654 (0.484, 0.882) (0.421, 1.269)3 
Cox 0.386 (0.187, 0.796) (0.002, 1.131) 0.414 (0.248, 0.692) (0.001, 0.964) 0.429 (0.267, 0.689) (0.014, 2.316) 
       
Adjusted for all treatment changes (ISC/choice and UAEs)       
PLR (0) 0.584 (0.410, 0.834) (0.375, 1.094) 0.592 (0.414, 0.846) (0.357, 1.160) 0.570 (0.398, 0.816) (0.298, 1.514) 
PLR (3)  0.576 (0.407, 0.816) (0.401, 1.204)4 0.584 (0.414, 0.823) (0.383, 1.128)1 0.551 (0.386, 0.786) (0.342, 1.155) 
PLR (5) 0.564 (0.394, 0.808)  0.570 (0.398, 0.817) (0.357, 1.154) 0.541 (0.374, 0.783) (0.326, 1.172) 
Cox 0.161 (0.077, 0.334) (0.0002, 0.414) 0.226 (0.140, 0.367) (0.000002, 0.619) 0.315 (0.214, 0.464) (0.008. 0.706) 
 
* Note that none of these models contain time-varying covariates and therefore no weighting is applied; therefore these models correspond with those presented in Table 60. 
CIs in italics indicate invalid normal Cox regression CIs, while subscripts indicate the number of bootstrapped samples (out of a total of 200) which failed to converge due to overfitting. 
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Table 64 Treatment only models 
  PLR (no splines) PLR (3 knots) PLR (5 knots) Cox RPSFTM  
No adjustment for treatment changes (ITT) 
 Month 0.68 (0.53, 0.91) 0.71 (0.57, 0.95) 0.72 (0.57, 0.95) 0.77 (0.64, 0.94)  
 Fortnight 0.67 (0.52, 0.90) 0.71 (0.56, 0.94) 0.72 (0.57, 0.94) 0.77 (0.63, 0.96) 0.79 (0.64, 0.98) 
 Week 0.67 (0.52, 0.92) 0.70 (0.55, 0.91) 0.72 (0.54, 0.93) 0.77 (0.62, 0.94)  
Adjusted for ISC treatment changes only      
 Month 0.70 (0.52, 0.99) 0.70 (0.52, 0.996) 0.70 (0.51, 0.99) 0.77 (0.62, 0.99)  
 Fortnight 0.67 (0.40, 1.11) 0.70 (0.55, 1.04) 0.70 (0.54, 0.998) 0.77 (0.64, 1.00) 0.88 (0.78, 0.99) 
 Week 0.70 (0.53, 0.99) 0.70 (0.55, 0.97) 0.70 (0.54, 0.96) 0.77 (0.62, 0.96)  
Adjusted for ISC/choice treatment changes only      
 Month 0.70 (0.51, 1.01) 0.70 (0.52, 0.99) 0.70 (0.51, 0.996) 0.77 (0.62, 0.99)  
 Fortnight 0.67 (0.40, 1.21) 0.70 (0.57, 1.07) 0.70 (0.55, 0.99) 0.77 (0.64, 0.996) 0.77 (0.61, 0.98) 
 Week 0.70 (0.54, 0.96) 0.70 (0.54, 0.96) 0.70 (0.53, 0.94) 0.77 (0.62, 0.96)  
Adjusted for all treatment changes       
 Month 0.64 (0.46, 0.89) 0.65 (0.48, 0.90) 0.64 (0.48, 0.90) 0.74 (0.59, 0.93)  
 Fortnight 0.60 (0.41, 1.23) 0.65 (0.48, 0.91) 0.65 (0.47, 0.88) 0.73 (0.58, 0.89) 0.76 (0.58, 0.98) 
 Week 0.64 (0.45, 0.88) 0.65 (0.47, 0.87) 0.65 (0.47, 0.88) 0.73 (0.55, 0.91)  
 
Table 65 Treatment and seizure models 
  PLR (no splines) PLR (3 knots) PLR (5 knots) Cox RPSFTM  
No adjustment for treatment changes (ITT)      
 Month 0.68 (0.53, 0.91) 0.71 (0.57, 0.95) 0.72 (0.57, 0.95) 0.77 (0.64, 0.94)  
 Fortnight 0.67 (0.52, 0.90) 0.71 (0.56, 0.94) 0.72 (0.57, 0.94) 0.77 (0.63, 0.96) 0.79 (0.64, 0.98) 
 Week 0.67 (0.52, 0.92) 0.70 (0.55, 0.91) 0.72 (0.54, 0.93) 0.77 (0.62, 0.94)  
Adjusted for ISC treatment changes only      
 Month 0.66 (0.45, 1.26) 0.68 (0.41, 1.09) 0.68 (0.39, 1.11) 0.61 (0.19, 0.92)  
 Fortnight 0.67 (0.40, 1.11) 0.68 (0.41, 1.25) 0.69 (0.39, 1.26) 0.61 (0.14, 0.91) 0.88 (0.78, 0.99) 
 Week 0.67 (0.38, 1.35) 0.68 (0.51, 0.90) 0.69 (0.38, 1.12) 0.66 (0.39, 1.15)  
Adjusted for ISC/choice treatment changes only      
 Month 0.67 (0.48, 1.39) 0.68 (0.40, 1.16) 0.68 (0.37, 1.11) 0.63 (0.22, 0.92)  
 Fortnight 0.67 (0.40, 1.21) 0.69 (0.42, 1.49) 0.69 (0.38, 1.25) 0.63 (0.27, 0.91) 0.77 (0.61, 0.98) 
 Week 0.67 (0.36, 1.08) 0.68 (0.38, 1.21) 0.69 (0.38, 1.22) 0.66 (0.40, 1.08)  
Adjusted for all treatment changes       
 Month 0.61 (0.42, 1.14) 0.60 (0.41, 1.34) 0.60 (0.39, 1.36) 0.58 (0.34, 0.92)  
 Fortnight 0.60 (0.41, 1.23) 0.61 (0.44, 1.07) 0.61 (0.40, 1.09) 0.53 (0.16, 0.89) 0.76 (0.58, 0.98) 
 Week 0.59 (0.37, 1.02) 0.60 (0.38, 0.99) 0.60 (0.37, 1.07)  0.55 (0.29, 0.82)  
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Table 66 Treatment, seizures and dose models 
  PLR (no splines) PLR (3 knots) PLR (5 knots) Cox RPSFTM  
No adjustment for treatment changes (ITT)      
 Month 0.68 (0.53, 0.91) 0.71 (0.57, 0.95) 0.72 (0.57, 0.95) 0.77 (0.64, 0.94)  
 Fortnight 0.67 (0.52, 0.90) 0.71 (0.56, 0.94) 0.72 (0.57, 0.94) 0.77 (0.63, 0.96) 0.79 (0.64, 0.98) 
 Week 0.67 (0.52, 0.92) 0.70 (0.55, 0.91) 0.72 (0.54, 0.93) 0.77 (0.62, 0.94)  
Adjusted for ISC treatment changes only      
 Month 0.67 (0.47, 1.27) 0.67 (0.43, 1.37) 0.67 (0.39, 1.28) 0.49 (0.02, 1.93)  
 Fortnight 0.67 (0.42, 1.17) 0.68 (0.43, 1.21) 0.68 (0.42, 1.26) 0.53 (0.02, 0.91) 0.88 (0.78, 0.99) 
 Week 0.67 (0.42, 1.28) 0.67 (0.39, 1.19) 0.69 (0.40, 1.30) 0.61 (0.20, 17.32)  
Adjusted for ISC/choice treatment changes only      
 Month 0.67 (0.45, 1.40) 0.68 (0.42, 1.33) 0.68 (0.41, 1.26) 0.49 (0.01, 1.21)  
 Fortnight 0.67 (0.41, 1.20) 0.68 (0.40, 1.30) 0.68 (0.41, 1.32) 0.54 (0.03, 0.93) 0.77 (0.61, 0.98) 
 Week 0.67 (0.41, 1.25) 0.68 (0.38, 1.33) 0.69 (0.38, 1.42) 0.60 (0.25, 5.65)  
Adjusted for all treatment changes       
 Month 0.60 (0.39, 1.22) 0.59 (0.41, 1.42) 0.58 (0.42, 1.47) 0.39 (0.02, 0.69)  
 Fortnight 0.60 (0.40, 1.20) 0.60 (0.43, 1.58) 0.60 (0.42, 1.39) 0.50 (0.16, 0.93) 0.76 (0.58, 0.98) 
 Week 0.59 (0.37, 1.18) 0.58 (0.40, 1.26) 0.59 (0.38, 1.57) 0.53 (0.26, 0.81)  
 
Table 67 Treatment, seizures, dose and AEs models 
 PLR (no splines) PLR (3 knots) PLR (5 knots) Cox RPSFTM  
No adjustment for treatment changes (ITT)      
 Month 0.68 (0.53, 0.91) 0.71 (0.57, 0.95) 0.72 (0.57, 0.95) 0.77 (0.64, 0.94)  
 Fortnight 0.67 (0.52, 0.90) 0.71 (0.56, 0.94) 0.72 (0.57, 0.94) 0.77 (0.63, 0.96) 0.79 (0.64, 0.98) 
 Week 0.67 (0.52, 0.92) 0.70 (0.55, 0.91) 0.72 (0.54, 0.93) 0.77 (0.62, 0.94)  
Adjusted for ISC treatment changes only      
 Month 0.66 (0.46, 1.26) 0.66 (0.43, 1.25) 0.66  (0.39, 1.32) 0.39 (0.002, 1.66)  
 Fortnight 0.66 (0.41, 1.07) 0.67 (0.41, 1.05) 0.67 (0.41, 1.08) 0.39 (0.0007, 0.89) 0.88 (0.78, 0.99) 
 Week 0.64 (0.41, 1.14) 0.64 (0.42, 1.18) 0.65 (0.42, 1.28) 0.42 (0.003, 1.75)  
Adjusted for ISC/choice treatment changes only      
 Month 0.66 (0.45, 1.43) 0.67 (0.44, 1.34) 0.66 (0.44, 1.47) 0.39 (0.002, 1.13)  
 Fortnight 0.66 (0.38, 1.15) 0.67 (0.43, 1.18) 0.67 (0.40, 1.10) 0.41 (0.001, 0.96) 0.77 (0.61, 0.98) 
 Week 0.65 (0.45, 1.11) 0.65 (0.43, 1.17) 0.65 (0.42, 1.27) 0.43 (0.01, 2.32)  
Adjusted for all treatment changes       
 Month 0.58 (0.38, 1.09) 0.58 (0.40, 1.20) 0.56 (NA) 0.16 (0.0002, 0.41)  
 Fortnight 0.59 (0.36, 1.16) 0.58 (0.38, 1.13) 0.57 (0.36, 1.15) 0.23 (0.000002, 0.62) 0.76 (0.58, 0.98) 
 Week 0.57 (0.30, 1.51) 0.55 (0.34, 1.16) 0.54 (0.33, 1.17) 0.32 (0.008, 0.706)  
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Figure 15 Treatment only models (BS CIs) 
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Figure 16  Treatment and seizures models (BS CIs) 
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Figure 17 Treatment, seizures and dose models (BS CIs) 
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Figure 18 Treatment, seizures, dose and AE models (BS CIs) 
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Table 68 Accounting for reasons for treatment changes in RPSFTM 
 HR (95% CI) Number (%) of treatment 
changes adjusted for  
[% of treatment arm] 
Number of ignored (censored) treatment changes  
(% of total number of IPCW treatment changes, m) 
  VPS (n=235) LTG (n=217) 
 
 VPS (m=108) LTG (m=105) 
No adjustment for 
switches  
0.794 (0.641, 0.983) 0 0 Switches between VPS and LTG 
(due to ISC, UAEs or choice) 
18 (16.7) 35 (33.3) 
Switch to other AED 8 (7.4) 8 (7.6) 
Additions 18 (16.7) 24 (22.9) 
Withdrawals 64 (59.3) 38 (36.2) 
   
        
Adjusted for switches due 
to ISC only 
0.877 (0.777, 0.990) 9 (8.3) 
[3.8] 
25 (23.8)  
[11.5] 
Switches between VPS and LTG 
(due to UAEs or choice) 
9 (8.3) 10 (9.5) 
Switch to other AED 8 (7.4) 8 (7.6) 
Additions 18 (16.7) 24 (22.9) 
Withdrawals 64 (59.3) 38 (36.2) 
   
       
Adjusted for switches due 
to ISC or choice only 
0.772 (0.608, 0.981) 11 (10.2)  
[4.7] 
25 (23.8)  
[11.5] 
Switches between VPS and LTG 
(due to UAEs) 
7 (6.5) 10 (9.5) 
Switch to other AED 8 (7.4) 8 (7.6) 
Additions 18 (16.7) 24 (22.9) 
Withdrawals 64 (59.3) 38 (36.2) 
   
       
Adjusted for all switches 
(due to ISC, choice or 
UAEs) 
0.756 (0.584, 0.980) 
 
18 (16.7) 
[7.7] 
35 (33.3)  
[16.1] 
Switch to other AED 8 (7.4) 8 (7.6) 
Additions 18 (16.7) 24 (22.9) 
Withdrawals 64 (59.3) 38 (36.2) 
 
 
